itraconazole profile

Itraconazole is a triazole antifungal medication. It works by interfering with the production of ergosterol, a vital component of fungal cell membranes. This disrupts the fungal cell wall, leading to cell death. It is used to treat a variety of fungal infections, including blastomycosis, histoplasmosis, coccidioidomycosis, paracoccidioidomycosis, aspergillosis, and candidiasis. Itraconazole is also used to prevent fungal infections in people with weakened immune systems. The synthesis of itraconazole involves a multi-step process starting from a commercially available starting material. The drug is orally administered and is well absorbed. Its importance lies in its broad spectrum of activity against various fungal pathogens, making it a valuable therapeutic option for treating severe fungal infections. Itraconazole is extensively studied due to its clinical efficacy, safety profile, and potential for new applications in treating other fungal infections and even certain types of cancer.'

Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	55283
CHEMBL ID	22587
CHEBI ID	6076
SCHEMBL ID	23934
MeSH ID	M0027131
PubMed CID	3793
CHEMBL ID	64391
CHEBI ID	94366
SCHEMBL ID	95627
SCHEMBL ID	16984893
MeSH ID	M0027131

Synonym
AC-542
AB01274818-01
AKOS015842738
itraconazole & nyotran(liposomal nystatin)
itraconazole & nyotran
CHEBI:6076 ,
onmel
2-(butan-2-yl)-4-{4-[4-(4-{[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3h-1,2,4-triazol-3-one
4-(4-{4-[4-({[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3h-1,2,4-triazol-3-one
sporanox
oriconazole
3h-1,2,4-triazol-3-one, 4-(4-(4-(4-((2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(1-methylpropyl)-
itraconazol [spanish]
r51211
itcz
4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-sec-butyl-1,2,4-triazol-3-one
3h-1,2,4-triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)
itz ,
itraconazole
sporanox(tm)
DB01167
itraconazole (jp17/usp)
itrizole (tn)
sporanox (tn)
D00350
intraconazole
chembl22587
bdbm50127138
2-butan-2-yl-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
304nug5gf4 ,
cis-itraconazole
pharmakon1600-01505756
nsc-759239
nsc759239
tox21_110854
dtxcid903180
cas-84625-61-6
dtxsid3023180 ,
itraconazolum
itraconazol
AKOS015961385
NCGC00274068-02
S2476
itraconazole [mart.]
itraconazole [green book]
(+/-)-1-sec-butyl-4-(p-(4-(p-(((2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-.delta.(sup 2)-1,2,4-triazolin-5-one
itraconazole [orange book]
itraconazole [vandf]
itraconazole (ema epar: veterinary)
itraconazole [who-dd]
fungitraxx
itraconazole [usp-rs]
itraconazole [ep monograph]
itraconazole [inci]
itraconazole [mi]
itraconazole [usp monograph]
itraconazole [usan]
suba-itraconazole component itraconazole
itraconazole [inn]
itraconazole component of suba-itraconazole
cladosal 100
itraconazole [ep impurity]
itraconazole [jan]
HY-17514
SCHEMBL23934
tox21_110854_1
NCGC00274068-01
KS-1268
1-(butan-2-yl)-4-{4-[4-(4-{[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1h-1,2,4-triazol-5-one
MLS006011958
smr001827898
4-(4-(4-(4-(((2r,4s)-2-((1h-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3h-1,2,4-triazol-3-one
AB01274818_02
AB01274818_03
itraconazole 2.0 mg/ml in dimethyl sulfoxide
SBI-0206914.P001
NCGC00274068-07
873066-43-4
SW219756-1
Q411229
Z1544404944
itraconazole (sporanox) ,
BRD-A23067620-001-01-7
EN300-122640
1-(butan-2-yl)-4-{4-[4-(4-{[(2r,4s)-2-(2,4-dichlorophenyl)-2-[(1h-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1h-1,2,4-triazol-5-one
AMY922
CCG-270391
A933954
gtpl11426
itraconazolo
itraconazole oral
3h-1,2,4-triazol-3-one, 4-
itraconazole (ep impurity)
itraconazole (usp monograph)
itraconazole (usp-rs)
itraconazole (mart.)
tolsura
lozanoc
itraconazole (ep monograph)
j02ac02
itrafungol
MLS001148245
HMS3393K14
AB00383031-14
itraconazolum [latin]
sempera
orungal
itrizole
r-51211
r 51211
MLS000759472
NCGC00089812-03
MLS000863291 ,
smr000058959
MLS000028582
HMS2051K14
HMS2090M20
I0732
AKOS000280875
2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
NCGC00018268-03
4-(4-(4-(4-((2-((1h-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-(sec-butyl)-1h-1,2,4-triazol-5(4h)-one
NCGC00018268-02
spherazole cr
sporonox
candistat
itrac
canditral
triasporin
r 51,211
traconal
spherazole ir
sporamelt
itralek
MLS001424065
HMS2235M11
CCG-100876
FT-0601621
HMS3370P13
CCG-220567
DL-427
SCHEMBL95627
AKOS022171690
NC00126
CHEMBL64391
itrazole
itraconazole, antibiotic for culture media use only
Q-201261
bdbm50011478
OPERA_ID_902
STL450986
2-(butan-2-yl)-4-{4-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3h-1,2,4-triazol-3-one
1217512-35-0
SCHEMBL16984893
itraconazole, united states pharmacopeia (usp) reference standard
2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-1,2,4-triazol-3-one
CHEBI:94366
itraconazole, >=98% (tlc)
itraconazole, european pharmacopoeia (ep) reference standard
(+/-)-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3h-1,2,4-triazol-3-one
itraconazole, pharmaceutical secondary standard; certified reference material
itraconazole for system suitability, european pharmacopoeia (ep) reference standard
J-015921
SR-01000003153-5
SR-01000003153-6
trans itraconazole
sr-01000003153
itraconzaole
HMS3713B16
4-(4-(4-(4-((2-((1h-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3h-1,2,4-triazol-3-one
4-(4-(4-(4-((2-((1h-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-sec-butyl-1h-1,2,4-triazol-5(4h)-one
Q27166205
2049588-24-9
1-(butan-2-yl)-4-{4-[4-(4-{[2-(2,4-dichlorophenyl)-2-[(1h-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1h-1,2,4-triazol-5-one
mfcd00941396
itraconazole,(s)
BCP28497
FT-0670576
O11835
NCGC00018268-05
NCGC00018268-06
nsc754771
nsc-754771
EN300-246240
SY057462
BI164594
CS-0242228
Z2194031989

Excerpt	Reference	Relevance
"Itraconazole is an antifungal drug that was recently found to possess potent antiangiogenic activity and anti-hedgehog (Hh) pathway activity. "	( Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. Aftab, BT; Head, S; Liu, JO; Nacev, BA; Rudin, CM; Shi, W, 2011)	3.25
"Itraconazole (ITZ) is an FDA-approved member of the triazole class of antifungal agents. "	( Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic. Chan, KA; DeBerardinis, AM; Hadden, MK; Pace, JR; Raccuia, DS; Sail, V; Tacheva-Grigorova, SK; Tran, R; Wechsler-Reya, RJ, 2016)	2.12

Excerpt	Reference	Relevance
" Two itraconazole patients stopped medication due to an adverse event, compared to four patients in the griseofulvin group."	( Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. Blomqvist, K; Brandt, H; Havu, V; Hollmen, A; Kohtamäki, K; Lehtonen, L; Piepponen, T; Turjanmaa, K, 1992)	0.28
" This is, however, a species-specific phenomenon which leads to secondary events at toxic doses, especially in long-term toxicity studies."	( Safety aspects of oral antifungal agents. Coussement, W; De Coster, R; Lampo, A; Marsboom, R; Van Cauteren, H; Vandenberghe, J; Vanparys, P, 1990)	0.28
" Adverse reactions possibly due to itraconazole were seen in 74 patients (39%)."	( Adverse events associated with itraconazole in 189 patients on chronic therapy. Denning, DW; Haq, Y; Stevens, DA; Tucker, RM, 1990)	0.28
" This species-specific phenomenon leads at toxic dose levels to secondary events, especially in the long-term toxicity studies."	( Toxicological profile and safety evaluation of antifungal azole derivatives. Coussement, W; De Coster, R; Lampo, A; Marsboom, R; Van Cauteren, H; Vandenberghe, J; Vanparys, P, 1989)	0.28
"Itraconazole pulse therapy was efficient and safe for the treatment of onychomycosis caused by dermatophytes, although a much higher daily dosage than the known continuous administration was used."	( Efficacy and safety of itraconazole pulse therapy: Brazilian multicentric study on toenail onychomycosis caused by dermatophytes. Campbell, I; Gontijo, B; Marques, SA; Ramos-e-Silva, M; Veloso, ST; Zaitz, C, 1998)	0.3
" During treatment, adverse events were recorded in 7 patients in the itraconazole group and 2 patients in the placebo group."	( Efficacy and safety of short-term itraconazole in tinea pedis: a double-blind, randomized, placebo-controlled trial. Avnstorp, C; Heremans, A; Nilsson, J; Svejgaard, E; Wanscher, B, 1998)	0.3
" Most adverse events occurred infrequently; major changes in liver function tests were not noted."	( Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. Abeck, D; Haneke, E; Ring, J, 1998)	0.3
" A possible adverse drug interaction with itraconazole and amphotericin B is postulated based on the mechanism of action of each drug."	( Hepatotoxicity possibly caused by amphotericin B. Gill, J; Ralph, ED; Sharpe, MD; Sprenger, HR, 1999)	0.3
"Amphotericin B therapy can be associated with many adverse effects, but reports of hepatotoxicity are rare."	( Hepatotoxicity possibly caused by amphotericin B. Gill, J; Ralph, ED; Sharpe, MD; Sprenger, HR, 1999)	0.3
" Adverse events were reported in 4 of the 27 itraconazole subjects; no adverse events were reported in the 25 palliative treatment subjects."	( The safety of itraconazole in the diabetic population. Albreski, DA; Gross, EG, 1999)	0.3
" From clinical trials including a total of 189 diabetic patients treated with itraconazole for various infections (mainly systemic infections and vaginal candidiasis), only one itraconazole-related adverse event was recorded; this was a case of aggravated diabetes in a renal transplant recipient who was also receiving cyclosporine."	( Safety of itraconazole in diabetic patients. De Doncker, P; Gupta, AK; Marynissen, G; Verspeelt, J, 1999)	0.3
"A 1-week intermittent itraconazole dosing regimen is a safe and effective treatment for onychomycosis."	( Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Li, RY; Wang, AP; Wang, DL; Wang, R, 1999)	0.3
" In addition, itraconazole is safe to use in diabetic patients with dermatomycosis or onychomycosis."	( Continuous itraconazole treatment for onychomycosis and dermatomycosis: an overview of safety. Doncker, PD; Gupta, A; Jacko, ML; Moskovitz, BL; Nolting, SK, )	0.13
" Adverse events are generally mild and transient."	( Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Gupta, A; Lambert, J; Revuz, J; Shear, N, )	0.13
" As expected in the patient population studied, all patients experienced some adverse events (mainly gastrointestinal)."	( Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Boogaerts, MA; Bosly, A; Cleeren, M; De Beule, K; Maertens, J; Michaux, JM; Van Der Geest, R; Van Hoof, A; Wostenborghs, R, 2001)	0.31
"The extent and consistency of adverse effects documented in this study support the recommendation that concurrent administration of vincristine and itraconazole should be avoided."	( Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Breatnach, F; Butler, K; Kamaluddin, M; McNally, P; O'Dell, E; O'Marcaigh, A; O'Meara, A; Scanlon, P; Webb, D, 2001)	0.31
" The most common adverse events are gastrointestinal upset, headache, and transient skin reaction."	( Hepatic safety of itraconazole. Baran, R; Chwetzoff, E; Del Rosso, J; Gupta, AK, )	0.13
"To determine rates of drug-induced, rare, serious adverse events affecting the liver, kidneys, skin, or blood, occurring within 45 days of completing a prescription or refill for itraconazole or fluconazole."	( Itraconazole and fluconazole and certain rare, serious adverse events. Bradbury, BD; Jick, SS, 2002)	0.31
"Itraconazole and fluconazole do not commonly cause rare, serious adverse events affecting the liver, kidneys, skin, or blood."	( Itraconazole and fluconazole and certain rare, serious adverse events. Bradbury, BD; Jick, SS, 2002)	0.31
"6%) discontinued treatment prematurely due to study drug-related adverse events."	( Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Chiou, CC; Dad, L; Groll, AH; Mickiene, D; Piscitelli, SC; Roden, M; Townley, E; Walsh, TJ; Wood, L, 2002)	0.31
" The oral solution also produces good rates of efficacy, but may be associated with a somewhat higher potential for gastrointestinal adverse events than the capsules."	( Efficacy and safety of itraconazole use in children. Cooper, EA; Ginter, G; Gupta, AK, 2003)	0.32
" Measurements included incidence of fungal colonization, superficial or systemic fungal infections requiring systemic therapy, adverse events, and mortality rate."	( Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. David Colby, W; Ghent, C; Grant, D; Horbay, GL; McDougal, J; Sharpe, MD, 2003)	0.32
" Adverse events were reported by 97% and 100% of the intraconazole and placebo groups, respectively, and one itraconazole and six placebo-group patients died within the study period."	( Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. David Colby, W; Ghent, C; Grant, D; Horbay, GL; McDougal, J; Sharpe, MD, 2003)	0.32
" Safety was assessed from biochemistry and haematology data and reported adverse events."	( Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. Brownlee, KG; Conway, SP; Cunliffe, H; Etherington, C; Peckham, DG; Whitehead, A, 2004)	0.32
" Adverse events were reported by 53% of subjects."	( Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. Brownlee, KG; Conway, SP; Cunliffe, H; Etherington, C; Peckham, DG; Whitehead, A, 2004)	0.32
" The dosage regimen was safe and well tolerated."	( Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. Brownlee, KG; Conway, SP; Cunliffe, H; Etherington, C; Peckham, DG; Whitehead, A, 2004)	0.32
" The frequency of adverse incident of A, B, C groups were 22."	( [Study on the compliance and safety of the oral antifungal agents for the treatment of onychomycosis]. Dai, XY; Hu, Y; Hua, HK; Qi, J; Sun, H; Wei, L; Yang, LJ; Zheng, Y, 2005)	0.33
" When treating onychomycosis with oral itraconazole, the results seemed to be just as safe as when using terbinafine."	( [Study on the compliance and safety of the oral antifungal agents for the treatment of onychomycosis]. Dai, XY; Hu, Y; Hua, HK; Qi, J; Sun, H; Wei, L; Yang, LJ; Zheng, Y, 2005)	0.33
" The relationship between liver adverse reaction and itraconazole treatment was evaluated."	( [Hepatic safety of itraconazole intravenous solution in treatment of invasive fungal infection]. Chen, S; Huang, YX; Lu, Q; Shi, GF; Weng, XH; Yang, FF; Zhang, WH; Zhang, YX; Zhu, LP, 2006)	0.33
" However, only in 2 patients with mild liver function test abnormality the liver adverse reaction could be associated with itraconazole treatment."	( [Hepatic safety of itraconazole intravenous solution in treatment of invasive fungal infection]. Chen, S; Huang, YX; Lu, Q; Shi, GF; Weng, XH; Yang, FF; Zhang, WH; Zhang, YX; Zhu, LP, 2006)	0.33
" The most common adverse events were hypokalemia (13."	( Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in china. Glasmacher, A; Hahn-Ast, C; Han, M; He, L; Li, R; Liang, D; Liao, W; Liekwok, WA; Shen, Z; Wang, A; Wu, S; Zhang, Y, 2006)	0.33
" Permanent discontinuation of study medication due to any adverse event was the primary safety parameter."	( Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Aulitzky, WE; Bammer, S; Binder, C; Böhme, A; Egerer, G; Ehninger, G; Glasmacher, A; Sandherr, M; Schuler, U; Schwerdtfeger, R; Silling, G; Wandt, H, 2007)	0.34
"Significantly fewer itraconazole patients discontinued treatment due to any adverse event (22."	( Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Aulitzky, WE; Bammer, S; Binder, C; Böhme, A; Egerer, G; Ehninger, G; Glasmacher, A; Sandherr, M; Schuler, U; Schwerdtfeger, R; Silling, G; Wandt, H, 2007)	0.34
" This study confirms the role of itraconazole as a useful and safe agent in empirical antifungal therapy of febrile neutropenic cancer patients."	( Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Aulitzky, WE; Bammer, S; Binder, C; Böhme, A; Egerer, G; Ehninger, G; Glasmacher, A; Sandherr, M; Schuler, U; Schwerdtfeger, R; Silling, G; Wandt, H, 2007)	0.34
" Study end-points were proven invasive fungal infection (IFI), survival, adverse reactions and graft-vs."	( Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Beilken, A; Grigull, L; Kuehlke, O; Linderkamp, C; Sander, A; Schmid, H; Schuster, FR; Seidemann, K; Sykora, KW; Welte, K, 2007)	0.34
"We estimated the absolute risks of treatment termination and incidence of adverse liver outcomes among all commonly used oral antifungal treatments for superficial dermatophytosis and onychomycosis."	( The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Chan, AK; Chang, CH; Kurth, T; Orav, JE; Young-Xu, Y, 2007)	0.34
"Oral antifungal therapy against superficial dermatophytosis and onychomycosis, including intermittent and continuous terbinafine, itraconazole, and fluconazole, was associated with a low incidence of adverse events in an immunocompetent population."	( The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Chan, AK; Chang, CH; Kurth, T; Orav, JE; Young-Xu, Y, 2007)	0.34
" Four patients discontinued ITCZ therapy because of adverse effects following the administration of 200 mg/day or 400 mg/day."	( [Correlations between drug plasma concentration and adverse effects in patients treated with itraconazole for pulmonary aspergilloma]. Hashiguchi, K; Higashiyama, Y; Kohno, S; Maesaki, S; Miyazaki, H; Miyazaki, Y; Sasaki, E; Tashiro, T; Tomiyama, Y; Tomono, K, 1999)	0.3
" Clinical efficacy and adverse reaction were record."	( [Clinical efficacy and safety of itraconazole injection/oral solution sequential therapy for treatment of invasive fungal infection in intensive care unit]. Qui, HB, 2008)	0.35
" (4) No severe adverse reaction was found."	( [Clinical efficacy and safety of itraconazole injection/oral solution sequential therapy for treatment of invasive fungal infection in intensive care unit]. Qui, HB, 2008)	0.35
"Itraconazole injection/oral sequential therapy is an effective and safe antibiotic for the treatment of IFI in ICU."	( [Clinical efficacy and safety of itraconazole injection/oral solution sequential therapy for treatment of invasive fungal infection in intensive care unit]. Qui, HB, 2008)	0.35
" Adverse effects were found in 58 patients (8."	( [A retrospective study of efficacy and safety of itraconazole for treatment of invasive fungal infection in hematologic diseases]. Huang, XJ; Ji, Y, 2008)	0.35
"Itraconazole is an effective and safe antifungal agent for patients with hematological disease or undergoing HSCT and is suitable for empirical antifungal therapy."	( [A retrospective study of efficacy and safety of itraconazole for treatment of invasive fungal infection in hematologic diseases]. Huang, XJ; Ji, Y, 2008)	0.35
" Mild adverse reactions were observed in 6 patients (8."	( Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan. Aoyama, Y; Hagihara, K; Hayashi, Y; Hino, M; Hirose, A; Koh, H; Kumura, T; Nakane, T; Nakao, Y; Nishiki Kosaka, S; Ohta, K; Okamoto, S; Sakamoto, E; Takeoka, Y; Terada, Y; Umemoto, Y; Yamamura, R, 2009)	0.35
" Drug discontinuation because of adverse events occurred in 15 patients (21%) receiving voriconazole and six (11%) receiving itraconazole (P=0."	( Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Alvarado, G; Blamble, D; Cortes, J; Faderl, S; Hernandez, M; Kantarjian, H; Koller, C; Mattiuzzi, GN; Pierce, S; Verstovsek, S; Xiao, L, 2011)	0.37
" Even if combined with coronary artery disease and/or cor pulmonale, the elderly patients who have chronic pulmonary diseases were safe when using the itraconazole injection in 14 days."	( [The clinical efficacy and cardiac safety of itraconazole injection in treatment of acute pulmonary invasive fungal infection in chronic pulmonary diseases in the elderly]. Gao, SL; Jia, W; Li, GH; Li, YC; Zhang, DR; Zhao, XY; Zhou, YL; Zhu, YQ, 2010)	0.36
" It is an effective and safe alternative treatment for cutaneous sporotrichosis, which can also lower the cost by decreasing the number of capsules."	( Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. Cai, Q; Huo, SS; Li, SS; Liu, YY; Song, Y; Yao, L; Zhong, SX; Zhou, JF, 2011)	0.37
" Clinical efficacy and adverse events were recorded."	( [The clinical efficacy and safety of itraconazole injection in treatment of invasive fungal infection in intensive care unit]. , 2010)	0.36
"Itraconazole injection was an effective and safe drug for the treatment of IFI in ICU."	( [The clinical efficacy and safety of itraconazole injection in treatment of invasive fungal infection in intensive care unit]. , 2010)	0.36
" The aim of this article is to review the metabolism of these two drugs, to analyze the published cases with severe triazole-enhanced vincristine neurotoxicity, to discuss the pathophysiological mechanisms of this adverse effect, and to contribute in understanding the differences in triazole-vincristine interaction severity."	( Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pana, ZD; Roilides, E, 2011)	0.37
" Drug-related adverse events occurred in 18."	( Efficacy and safety of intravenous itraconazole followed by oral itraconazole solution in the treatment of invasive pulmonary mycosis. Zhang, YY; Zhou, X, 2011)	0.37
"This study showed that in patients with invasive pulmonary mycosis, intravenous itraconazole followed by oral itraconazole solution therapy was safe and effective."	( Efficacy and safety of intravenous itraconazole followed by oral itraconazole solution in the treatment of invasive pulmonary mycosis. Zhang, YY; Zhou, X, 2011)	0.37
" Other adverse effects were reported but did not lead to the discontinuation of treatment, as follows: hepatic dysfunction, two patients; hypokalemia, nine patients."	( [An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis]. Fujii, H; Hayashi, M; Kaneda, T; Kaneko, M; Karino, T; Kida, Y; Suzuki, Y; Tada, K; Tomii, K; Tomioka, H, 2011)	0.37
" The incidence of adverse events was 22."	( Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort. Cheng, S; Huang, XJ; Jin, J; Shen, ZX; Zhou, JF; Zou, P, 2011)	0.37
" Adverse events occurred in 6 of the 17 patients (35."	( The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. Fujita, M; Harada, E; Ikegame, S; Kajiki, A; Matsumoto, T; Nakanishi, Y; Ouchi, H; Tao, Y; Uchino, J; Watanabe, K, 2012)	0.38
" Adverse effects occurred in 9 of 60 patients (15."	( Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care. Aikawa, N; Fujishima, S; Mikamo, H; Oda, S; Takesue, Y, 2012)	0.38
" Significant differences in incidence of withdrawal due to an adverse event (4."	( Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Chen, H; Chen, X; Han, M; Hu, J; Huang, H; Huang, X; Lai, Y; Liu, T; Wang, J; Wu, D; Zhu, H; Zou, P, 2012)	0.38
" Adverse events such as liver dysfunction and heart failure were observed in 9 of the 24 patients."	( Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. Ando, T; Kamei, K; Kurashima, A; Niki, Y; Oritsu, M; Yamamoto, T; Yoshida, K, 2012)	0.38
"To investigate spontaneous reporting relationships between representative antifungal agents and congestive heart failure (CHF)-related adverse events (AE) we performed multiple disproportionality analyses of the US FDA AERS database."	( A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. Hauben, M; Hung, EY, 2013)	0.39
"Tricyclic antidepressants, not influencing the P450 3A4 activity, are safe in combination with drugs of other groups used in the treatment of comorbid patients."	( [Preclinical investigation of pharmaceuticals impact against cytochrome P450 activity and prognosis of substrate affinity as means for providing substrate therapy safety]. Baĭchorov, IKh; Fomin, EV; Shikh, EV; Sizova, ZhM, 2013)	0.39
"Itraconazole injection was an effective and safe agent in targeted and diagnostic- driven antifungal therapy for immunocompromised or neutropenic febrile patients with hematological malignancies."	( [Efficacy and safety of intravenous itraconazole in different antifungal strategies for patients undergoing intensive chemotherapy or hematopoietic stem cell transplantation]. Huang, X; Ji, Y; Xu, L, 2014)	0.4
"21 adult asthmatics with SAFS (n = 11) and ABPA (n = 10) who had either failed itraconazole (n = 8), voriconazole proceeded by itraconazole (n = 5) or developed adverse events (AEs) to either agent (n = 7) were treated with 10mg of NAB (Fungizone) twice daily."	( Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). Chishimba, L; Denning, DW; Langridge, P; Niven, RM; Powell, G, 2015)	0.42
"Combination of itraconazole and SSKI is an effective treatment modality for RFC with relatively faster onset of action, low relapse rates, and minimal adverse effects."	( A prospective case series evaluating efficacy and safety of combination of itraconazole and potassium iodide in rhinofacial conidiobolomycosis. Dogra, S; Gupta, M; Kaur, RJ; Manhas, A; Narang, T; Saikia, UN, 2016)	0.43
" Grade 3 adverse events including hyperbilirubinemia (2 vs."	( Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. Choi, CW; Jang, JH; Jeong, SH; Kim, DY; Kim, JS; Kim, SH; Mun, YC; Park, JS, 2016)	0.43
"Itraconazole is safe and effective at a dose of 5 mg/kg per day in a short duration of therapy for superficial fungal infections and 10 mg/kg per day for systemic fungal infections in infants."	( Efficacy and safety of itraconazole use in infants. Chen, S; Feng, XW; Lama, J; Ran, X; Ran, YP; Sun, KY, 2016)	0.43
" Adverse events occurred in 53 subjects (33 in the miconazole group and 20 in the itraconazole group)."	( The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial. Chou, L; Guan, X; Han, Y; Hua, H; Lin, M; Liu, X; Liu, Y; Wang, Q; Wang, W; Yan, Z; Zhang, H; Zhu, S; Zhu, X, 2016)	0.43
" Physicians should be cautious about thrombocytopenic purpura occurring as a rare and serious adverse event of miconazole nitrate."	( The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial. Chou, L; Guan, X; Han, Y; Hua, H; Lin, M; Liu, X; Liu, Y; Wang, Q; Wang, W; Yan, Z; Zhang, H; Zhu, S; Zhu, X, 2016)	0.43
" In addition to commonly described adverse effects, there have been few reports of heart failure with its use."	( Cardiotoxicity with Itraconazole. Paul, V; Rawal, H, 2017)	0.46
" However, addition of emulsifiers to stabilize the formulation may cause toxic effects."	( Cytotoxicity screening of emulsifiers for pulmonary application of lipid nanoparticles. Corzo, C; Fröhlich, E; Öhlinger, K; Salar-Behzadi, S; Steiner, V, 2019)	0.51
"The tested emulsifiers showed overall low cytotoxicity with less pronounced adverse effects in human cells than in murine macrophages."	( Cytotoxicity screening of emulsifiers for pulmonary application of lipid nanoparticles. Corzo, C; Fröhlich, E; Öhlinger, K; Salar-Behzadi, S; Steiner, V, 2019)	0.51
" Being human cells, they appear more suitable for the screening of adverse effects in human lungs."	( Cytotoxicity screening of emulsifiers for pulmonary application of lipid nanoparticles. Corzo, C; Fröhlich, E; Öhlinger, K; Salar-Behzadi, S; Steiner, V, 2019)	0.51
"Oral itraconazole has variable pharmacokinetics and risks of adverse events associated with high plasma exposure."	( A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. Bedwell, P; Connor, L; Curran, AK; Hava, DL; Henderson, D; Johnson, P; Kane, K; Khan, N; Kramer, S; Layton, G; McKenzie, L; Perry, J; Roach, J; Singh, D; Swann, C; Tan, L, 2020)	0.56
"None of the adverse events considered as at least possibly related to study treatment were moderate or severe, and none were classed as serious."	( A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. Bedwell, P; Connor, L; Curran, AK; Hava, DL; Henderson, D; Johnson, P; Kane, K; Khan, N; Kramer, S; Layton, G; McKenzie, L; Perry, J; Roach, J; Singh, D; Swann, C; Tan, L, 2020)	0.56
"PUR1900 was safe and well-tolerated under the study conditions."	( A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. Bedwell, P; Connor, L; Curran, AK; Hava, DL; Henderson, D; Johnson, P; Kane, K; Khan, N; Kramer, S; Layton, G; McKenzie, L; Perry, J; Roach, J; Singh, D; Swann, C; Tan, L, 2020)	0.56
"This systematic review and network meta-analysis compared the efficacy (as per mycological cure) and adverse event rates of three oral antifungal medications in the treatment of dermatophyte toenail onychomycosis, namely terbinafine, itraconazole and fluconazole."	( The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. Bamimore, MA; Foley, KA; Gupta, AK; Piguet, V; Shear, NH; Stec, N, 2020)	0.56
" There were no significant differences in the likelihood of adverse events between any continuous and pulse regimens of terbinafine, itraconazole and fluconazole."	( The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. Bamimore, MA; Foley, KA; Gupta, AK; Piguet, V; Shear, NH; Stec, N, 2020)	0.56
" Our results indicate that in the treatment of dermatophyte toenail onychomycosis, the continuous and pulse regimens for terbinafine and itraconazole have similar efficacies and rates of adverse events."	( The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. Bamimore, MA; Foley, KA; Gupta, AK; Piguet, V; Shear, NH; Stec, N, 2020)	0.56
"To classify the most common adverse reactions with the oral onychomycosis medications terbinafine, itraconazole, and off-label fluconazole."	( Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. Lipner, SR; Wang, Y, 2021)	0.62
"The United States Food and Drug Administration Adverse Event Reporting (FAERS) database was analyzed for common adverse reactions with terbinafine, itraconazole, and off-label fluconazole."	( Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. Lipner, SR; Wang, Y, 2021)	0.62
"The most common adverse reaction with terbinafine was taste disturbance and the most common adverse events with itraconazole and fluconazole were drug interactions."	( Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. Lipner, SR; Wang, Y, 2021)	0.62
"Patients should be counseled that taste disturbance with terbinafine is the most common adverse event."	( Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. Lipner, SR; Wang, Y, 2021)	0.62
"The aim of the study was to determine whether it is safe to stop secondary prophylaxis in patients with talaromycosis after immune reconstitution with a sustained increase in CD4 count to ≥ 100 cells/µL after antiretroviral therapy (ART)."	( Is stopping secondary prophylaxis safe in HIV-positive talaromycosis patients? Experience from Myanmar. Ashley, E; Aung, Y; Deed, X; Hlaing, M; Mclean, A; Smithuis, F; Tun, N; Wilkins, E, 2020)	0.56
" Clinicians should be aware of pseudohyperaldosteronism as a possible adverse effect of itraconazole, and we recommend monitoring potassium levels and blood pressure in all patients receiving this drug over a longer period of time."	( Pseudohyperaldosteroism during itraconazole treatment: a hitherto neglected clinically significant side effect. Brandi, SL; Eldrup, E; Feltoft, CL; Serup, J, 2021)	0.62
" PK parameters, dose proportionality, adverse events and taste assessments (taste strips; dysgeusia questionnaire) were evaluated."	( First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. Baumann, S; Chang, X; Friedrich, C; Gashaw, I; Hummel, T; Klein, S; Thuß, U, 2022)	0.72
"The PK profile, particularly the long half-life, and favourable tolerability with no taste-related adverse events, supports the further development of eliapixant in disorders with underlying P2X3 receptor-mediated neuronal hypersensitisation."	( First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. Baumann, S; Chang, X; Friedrich, C; Gashaw, I; Hummel, T; Klein, S; Thuß, U, 2022)	0.72
"This study concluded that the test drugs (IHA and HK) were safe and effective in the treatment of PV."	( Evaluation of the efficacy and safety of Unani Formulations in Pityriasis Versicolor: A randomized controlled trial. Fatima, SH; Ismail, BA; Minhajuddin, A; Nawab, M; Rasheed Naikodi, MA, 2022)	0.72
" The primary endpoint was clinical cure at the end-of-treatment period [visit 4 (V4)] while secondary endpoints were clinical remission rates, partial remission rates, mycological cure, clinical relapse, and adverse events (AEs)."	( Efficacy and safety of miconazole muco-adhesive tablet versus itraconazole in oropharyngeal candidiasis: A randomized, multi-centered, double-blind, phase 3 trial. Chai, H; Chen, Q; Duan, N; Fan, Y; Fei, W; Guan, X; Hua, H; Jia, C; Jiang, L; Kong, H; Liu, J; Liu, Q; Lu, H; Lun, W; Luo, Z; Shen, X; Tang, G; Wang, H; Wang, W; Wang, Y; Xu, J; Yan, Z; Zhang, T; Zhao, J; Zhou, H, 2022)	0.72
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32

Excerpt	Reference	Relevance
" Based on the pharmacokinetic profile, 100 mg itraconazole daily was then compared with 500 mg ultramicronized griseofulvin daily using a fixed treatment schedule of 15 days in tinea corporis and/or cruris and 30 days in tinea pedis and/or manus."	( Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Cauwenbergh, G; De Doncker, P; Janssen, PA; Lachapelle, JM; Tennstedt, D, 1992)	0.28
" and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL."	( Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. Bradford, CR; Copplestone, JA; Prentice, AG; Warnock, DW, 1991)	0.28
"Orally active antifungals have different physicochemical and pharmacokinetic properties."	( Pharmacokinetics of oral antifungals and their clinical implications. Cauwenbergh, G; Heykants, J; Lavrijsen, K; Meuldermans, W; Van Peer, A; Woestenborghs, R, 1990)	0.28
"Itraconazole is an orally active triazole antifungal drug which has demonstrated a broad spectrum of activity and a favourable pharmacokinetic profile."	( Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Clissold, SP; Grant, SM, 1989)	0.28
" The pharmacokinetics of itraconazole in man are characterized by a good oral absorption, an extensive tissue distribution with tissue concentrations many times higher than in plasma, a relatively long elimination half-life of about one day and a biotransformation into a large number of metabolites."	( The clinical pharmacokinetics of itraconazole: an overview. Cauwenbergh, G; Heykants, J; Lavrijsen, K; Meuldermans, W; Van Cutsem, J; Van de Velde, V; Van Peer, A; Van Rooy, P; Woestenborghs, R, 1989)	0.28
" All data support dose-dependent pharmacokinetic behavior for itraconazole."	( Pharmacokinetics of itraconazole following oral administration to normal volunteers. Fetchick, R; Graybill, JR; Hardin, TC; Kuhn, JG; Rinaldi, MG; Woestenborghs, R, 1988)	0.27
" With fluconazole the pharmacokinetic parameters after food were essentially the same for the 2 races."	( Comparative pharmacokinetics of fluconazole and of itraconazole in Japanese and in German subjects. Albrecht, M; Laufen, H; Wildfeuer, A; Yeates, RA; Zimmermann, T, 1995)	0.29
"05; ANOVA) in the pharmacokinetic parameters of fluconazole (AUC, Cmax, Tmax) were found during the three days of the trial."	( Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. Lazo de la Vega, S; Pfaff, G; Volkow, P; Yeates, RA, 1994)	0.29
" Half-life of itraconazole ranges between 17 to 21 h and 99."	( Itraconazole: pharmacokinetics and indications. Arechavala, AI; Negroni, R, 1993)	0.29
" Single-dose terfenadine administration (120 mg) was accompanied by pharmacokinetic profiles and serial determination of the QTc interval for 12 hours."	( Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. Cantilena, LR; Honig, PK; Hull, R; Smith, JE; Wortham, DC; Zamani, K, 1993)	0.29
"Blood samples were obtained for pharmacokinetic analyses immediately before dosing and at regular intervals up to 96 hours after each dose."	( Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Cauwenbergh, GF; De Beule, KL; Heykants, JJ; Van de Velde, VJ; Van Peer, AP; Van Rooy, P; Woestenborghs, RJ, )	0.13
" The mean times to peak concentration for both the parent compound and its metabolite were significantly shorter under fasting than under nonfasting conditions."	( Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Cauwenbergh, GF; De Beule, KL; Heykants, JJ; Van de Velde, VJ; Van Peer, AP; Van Rooy, P; Woestenborghs, RJ, )	0.13
" The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113."	( [Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. Cavalier, A; Elkhaili, H; Jehl, F; Kaltenbach, G; Levêque, D; Monteil, H; Peter, JD; Salmon, J; Salmon, Y, 1996)	0.29
"Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng."	( Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Jalava, KM; Neuvonen, PJ; Olkkola, KT, 1996)	0.29
"Itraconazole has a statistically significant pharmacokinetic interaction with zopiclone but this is only of limited clinical importance, at least in young adults."	( Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Jalava, KM; Neuvonen, PJ; Olkkola, KT, 1996)	0.29
"Itraconazole treatment did not significantly change the peak concentration of astemizole (0."	( Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Lefebvre, RA; Van Peer, A; Woestenborghs, R, 1997)	0.3
"Since ceftriaxone and itraconazole are highly protein bound, are excreted via a biliary pathway, and are in vitro modulators of the efflux pump P glycoprotein, a pharmacokinetic interaction between these antimicrobial agents can be hypothesized."	( Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. Cavalier, A; Elkhaïli, H; Geisert, J; Jehl, F; Levêque, D; Monteil, H; Nobelis, P; Peter, JD; Salmon, J; Salmon, Y, 1997)	0.3
" Pharmacokinetic parameters determined at days 1 and 14 (the area under the concentration-time curve from 0 to 10 h, the maximum concentration of drug in plasma [Cmax], and the time to Cmax) were comparable in both groups."	( Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Ajana, F; Bazin, C; Chwetzoff, E; Datry, A; Le Moing, JP; Levron, JC; Reynes, J, 1997)	0.3
" The increases in digoxin Cmax and T(1/2) by itraconazole were not statistically significant."	( Itraconazole decreases renal clearance of digoxin. Jalava, KM; Neuvonen, PJ; Partanen, J, 1997)	0.3
" At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39."	( Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Barone, JA; Bierman, RH; Colaizzi, JL; Guarnieri, J; Hassell, AE; Jessen, L; Moskovitz, BL, )	0.13
" The pharmacokinetic and pharmacologic properties provide the basis of their activity and are related to their efficacy and safety in dermatophyte infections."	( Pharmacokinetics and pharmacology of terbinafine and itraconazole. Leyden, J, 1998)	0.3
" With concomitant omeprazole treatment, the mean AUC0-24 and Cmax of itraconazole were significantly reduced by 64% and 66%, respectively."	( Effect of omeprazole on the pharmacokinetics of itraconazole. Jaruratanasirikul, S; Sriwiriyajan, S, 1998)	0.3
" Plasma concentrations of itraconazole were measured by HPLC, and pharmacokinetic parameters; Cmax, Tmax, T1/2, AUC, and AUC corrected by human body surface area: AUC/S, were calculated."	( Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Hidaka, T; Ishizuka, T; Kawakami, M; Matsuki, Y; Nakamura, H; Suzuki, K, 1998)	0.3
"Grapefruit juice had no effect on any pharmacokinetic parameter of itraconazole."	( Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Hidaka, T; Ishizuka, T; Kawakami, M; Matsuki, Y; Nakamura, H; Suzuki, K, 1998)	0.3
"Coadministration of grapefruit juice did not affect any pharmacokinetic parameter of itraconazole while that of orange juice decreased the parameters of T1/2, AUC, and AUC/S of the drug."	( Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Hidaka, T; Ishizuka, T; Kawakami, M; Matsuki, Y; Nakamura, H; Suzuki, K, 1998)	0.3
" The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1."	( Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Belhabri, A; Chwetzoff, E; Fiere, D; Kranzhöfer, N; Le Moing, JP; Levron, JC; Michallet, M; Persat, F; Piens, MA; Prat, C, 1998)	0.3
"The effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, two inhibitors of HMG-CoA reductase with different pharmacokinetic properties, were studied."	( Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Kantola, T; Kivistö, KT; Neuvonen, PJ, 1998)	0.3
" Itraconazole had no significant effects on the pharmacokinetic parameters of levosimendan."	( The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Antila, S; Honkanen, T; Lehtonen, L; Neuvonen, PJ, 1998)	0.3
"10 ml/min per kg) and prolonged the elimination half-life (15."	( Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Furukori, H; Kaneko, S; Kondo, T; Nagasaki, T; Ohkubo, T; Otani, K; Sugawara, K; Yasui, N, 1998)	0.3
"05) and the Cmax by 57% (P<0."	( Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1999)	0.3
" Based on these results, the pharmacokinetic interaction between DGX and ITZ may be due not only to a reduction in the renal clearance but also to a reduction in the metabolic clearance of DGX by ITZ."	( Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. Hibino, J; Iga, T; Kotaki, H; Nishihara, K; Sawada, Y, 1999)	0.3
" The Medline electronic database from 1966 through 1998 was used to identify clinical studies of the pharmacokinetic effect of drugs on these three benzodiazepines."	( Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. Balian, JD; Flockhart, DA; Yuan, R, 1999)	0.3
"Concomitant administration of diclofenac reduced the partial clearance of quinidine by N-oxidation by 27%, while no effect was found for other pharmacokinetic parameters of quinidine."	( Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Brosen, K; Damkier, P; Hansen, LL, 1999)	0.3
"05), while it had no significant effect on other pharmacokinetic variables of the enantiomers."	( Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in healthy volunteers. Neuvonen, PJ; Olkkola, KT; Palkama, VJ, 1999)	0.3
"The objective of this study was to evaluate the pharmacodynamic activity of fluconazole, itraconazole, and amphotericin B against Candida albicans."	( Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Burgess, DS; Hardin, TC; Hastings, RW; Rinaldi, MG; Summers, KK, 2000)	0.31
"The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments."	( Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Komada, F; Nishiguchi, K; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y, 1999)	0.3
" Pharmacokinetic parameters [AUC(0-infinity), AUC(0-tn), peak concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2)] were determined for parent statins and major metabolites."	( Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P, 2000)	0.31
" However, itraconazole dramatically increased atorvastatin AUC (150%), Cmax (38%), and t1/2 (30%) (P < ."	( Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P, 2000)	0.31
" There were no significant changes in the pharmacokinetic parameters of the parent ropivacaine after ingestion of clarithromycin or itraconazole."	( Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Ahonen, J; Jokinen, MJ; Neuvonen, PJ; Olkkola, KT, 2001)	0.31
" Plasma cortisol concentrations were determined as a pharmacodynamic index."	( Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Archer, VC; Chosidow, O; Diquet, B; Lebrun-Vignes, B; Levron, JC; Puech, AJ; Warot, D, 2001)	0.31
" The pharmacokinetic interaction between methylprednisolone and itraconazole is probably related to inhibition of hepatic CYP3A4 activity by itraconazole."	( Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Archer, VC; Chosidow, O; Diquet, B; Lebrun-Vignes, B; Levron, JC; Puech, AJ; Warot, D, 2001)	0.31
" Pharmacokinetic sampling was performed after the first dose and for up to 120 h after the last dose, and antifungal efficacy was evaluated by standardized scoring of the oropharynx."	( Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Chiou, CC; Dad, L; Groll, AH; Mickiene, D; Piscitelli, SC; Roden, M; Townley, E; Walsh, TJ; Wood, L, 2002)	0.31
"The authors describe the development of a population pharmacokinetic model using NONMEM for itraconazole and its active metabolite hydroxyitraconazole in a Thai cohort of HIV-infected patients who were using itraconazole as an addition to their antiretroviral therapy."	( Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Beijnen, JH; Chuenyam, T; Huitema, AD; Koks, CH; Kroon, ED; Lange, JM; Sparidans, RW, 2003)	0.32
" Pharmacokinetic parameters were calculated by a non-compartmental model."	( Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. Burger, D; Cardiello, PG; Cooper, DA; Hoetelmans, R; Lange, JM; Mahanontharit, A; Phanuphak, P; Ruxrungtham, K; Samor, T, 2003)	0.32
" The time course of the pharmacodynamic effects of bromazepam on the central nervous system was assessed using a subjective rating of sedation, continuous number addition test and electroencephalography up to 21."	( The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Kotegawa, T; Kuwatani, K; Nakano, S; Oda, M; Ohtani, Y; Tsutsumi, K, 2003)	0.32
" The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32."	( The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Kotegawa, T; Kuwatani, K; Nakano, S; Oda, M; Ohtani, Y; Tsutsumi, K, 2003)	0.32
" Hence, the method is suitable for use in pharmacokinetic and bioavailability studies of itraconazole."	( Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. Nisar, UR; Wong, JW; Yuen, KH, 2003)	0.32
" We determined the extent of the pharmacokinetic interaction between cyclosporine and itraconazole oral solution in renal transplant recipients and the effect on daily drug costs."	( Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Capitano, B; Florea, NR; Hull, D; Leitz, GJ; Nicolau, DP; Nightingale, CH, 2003)	0.32
" Once at steady state, blood samples were collected over 12 hours for pharmacokinetic evaluation of cyclosporine, itraconazole, and hydroxy-itraconazole."	( Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Capitano, B; Florea, NR; Hull, D; Leitz, GJ; Nicolau, DP; Nightingale, CH, 2003)	0.32
" The aim of this study was to elucidate clinical effectiveness and pharmacokinetic profiles of a 6-month continuous itraconazole treatment at a daily dose of 100 mg."	( Clinical and pharmacokinetic studies of continuous itraconazole for the treatment of onychomycosis. Aragane, Y; Kawada, A; Tezuka, T, 2004)	0.32
" Dialysis had no effect on the half-life and clearance of ITC or OH-ITC."	( Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Finkel, KW; Leitz, GJ; Mohr, JF; Ostrosky-Zeichner, L; Rex, JH; Rodriguez, JR, 2004)	0.32
" The pharmacokinetic profile of intravenous midazolam was characterized before and after itraconazole administration (200 mg once daily for 4 days) and also after rifampin (INN, rifampicin) pretreatment (600 mg once daily for 10 days), with a washout period of 2 weeks in between."	( Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Cho, JY; Chung, JY; Hong, KS; Jang, IJ; Kim, JR; Lim, HS; Liu, KH; Oh, DS; Shin, JG; Shin, SG; Yi, SY; Yu, KS, 2004)	0.32
"The pharmacokinetic profiles of midazolam and of its hydroxy metabolites did not show differences between the genotype groups under basal and induced metabolic conditions."	( Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Cho, JY; Chung, JY; Hong, KS; Jang, IJ; Kim, JR; Lim, HS; Liu, KH; Oh, DS; Shin, JG; Shin, SG; Yi, SY; Yu, KS, 2004)	0.32
"We determined the steady-state intrapulmonary pharmacokinetic and pharmacodynamic parameters of orally administered itraconazole (ITRA), 200 mg every 12 h (twice a day [b."	( Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Conte, JE; Golden, JA; Kipps, J; McIver, M; Zurlinden, E, 2004)	0.32
" No statistically significant differences were observed in any of the pharmacokinetic parameters; peak concentrations, concentration peak times or elimination half-lives of lidocaine or monoethylglycinexylidide."	( Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2004)	0.32
" Studies compared the multiple-dose pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with 4 inhibitors of cytochrome P450-3A4 isoenzymes in healthy subjects."	( Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson, TA, 2004)	0.32
"1 ng ml h(-1)), and prolonged the elimination half-life (4."	( Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. Kaneko, S; Kondo, T; Ohkubo, T; Osanai, T; Yasui, N, 2004)	0.32
"To determine whether coadministration of the cytochrome P450 3A4 (CYP3A4) inhibitors itraconazole or grapefruit juice will modify the pharmacokinetic profile of telithromycin, and to assess the safety of telithromycin."	( Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Bhargava, VO; Leroy, B; Montay, G; Shi, J, 2005)	0.33
"Standard pharmacokinetic and safety measurements were performed."	( Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Bhargava, VO; Leroy, B; Montay, G; Shi, J, 2005)	0.33
" The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined."	( Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Azuma, J; Fukuda, T; Inaba, A; Koue, T; Kubo, M; Maune, H; Takeda, H, 2005)	0.33
"A population pharmacokinetic analysis of cyclosporine (CsA) was performed, and the influence of covariates on CsA oral clearance and relative bioavailability was investigated."	( Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Akhlaghi, F; Baheti, G; Rosenbaum, SE; Trull, AK, 2005)	0.33
" Consequently, we have used a previously published decision-making algorithm to determine whether clinical pharmacokinetic monitoring of itraconazole is warranted."	( Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Buchkowsky, SS; Ensom, MH; Partovi, N, 2005)	0.33
" The first study evaluated in vivo release of ITZ from subcutaneously injected controlled-release gel formulations and the second study compared pharmacokinetic parameters for two ITZ oral suspensions."	( Studies on itraconazole delivery and pharmacokinetics in mallard ducks (Anas platyrhynchos). Clemons, KV; Clifford, A; Craigmill, AL; Ina, JH; Laizure, SC; Nugent-Deal, JP; Stevens, DA; Sun, Y; Tell, LA; Woods, L, 2005)	0.33
"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194."	( Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Cha, IJ; Choi, YG; Hong, WS; Lee, SS; Nguyen, PM; Shin, JG; Shon, JH; Yoon, YR, 2005)	0.33
" Based on these findings, three clinical studies were carried out to investigate pharmacokinetic drug interactions in vivo with gefitinib."	( Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ, 2005)	0.33
" Data were analyzed by compartmental and noncompartmental pharmacokinetic methods."	( Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. Davis, JL; Papich, MG; Salmon, JH, 2005)	0.33
"94 L/kg) and a long half-life (11."	( Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. Davis, JL; Papich, MG; Salmon, JH, 2005)	0.33
" Itraconazole had no statistically significant effect on any of the pharmacokinetic or pharmacodynamic variables of atenolol."	( Effect of itraconazole on the pharmacokinetics of atenolol. Backman, JT; Lilja, JJ; Neuvonen, PJ, 2005)	0.33
"A single-institution, open-label prospective pharmacokinetic evaluation of the interaction between intravenous itraconazole and intravenous cyclosporin A and tacrolimus was conducted in allogeneic hematopoietic stem cell transplant recipients."	( Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Boyette, RM; Leather, H; Tian, L; Wingard, JR, 2006)	0.33
" The pharmacokinetics of haloperidol and its pharmacodynamic effects measured for QTc prolongation and neurologic side effects were evaluated after a single dose of 5 mg haloperidol following a pretreatment of placebo or itraconazole at 200 mg/d for 10 days in a randomized crossover manner."	( Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. Cha, IJ; Jung, HJ; Kim, KA; Park, JY; Shim, JC; Shin, JG; Shon, JH; Yoon, YR, 2006)	0.33
" Elimination half-life and renal clearance in the itraconazole phase were not altered significantly compared with those in the control phase."	( Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Shimizu, M; Sugawara, K; Tateishi, T; Uno, T, 2006)	0.33
" Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively)."	( Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Shimizu, M; Sugawara, K; Tateishi, T; Uno, T, 2006)	0.33
"The objective of the study was to characterise the population pharmacokinetic properties of itraconazole and its active metabolite hydroxy-itraconazole in a representative paediatric population of cystic fibrosis and bone marrow transplant (BMT) patients and to identify patient characteristics influencing the pharmacokinetics of itraconazole."	( Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Bell, SC; Charles, BG; Friberg, LE; Hennig, S; Miller, H; Wainwright, CE, 2006)	0.33
"The developed population pharmacokinetic model adequately described the pharmacokinetics of itraconazole and its active metabolite, hydroxy-itraconazole, in paediatric patients with either cystic fibrosis or undergoing BMT."	( Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Bell, SC; Charles, BG; Friberg, LE; Hennig, S; Miller, H; Wainwright, CE, 2006)	0.33
"The primary objective of the study was to estimate the population pharmacokinetic parameters for itraconazole and hydroxy-itraconazole, in particular, the relative oral bioavailability of the capsule compared with solution in adult cystic fibrosis patients, in order to develop new dosing guidelines."	( A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Bell, SC; Charles, BG; Duffull, SB; France, M; Hennig, S; Miller, H; Wainwright, CE; Waterhouse, TH, 2007)	0.34
" The pharmacokinetic profiles of ITZ-PM for itraconazole and its major metabolite, hydroxy-itraconazole, were comparable to those of the cyclodextrin formulations (Sporanox(R) Injection and Oral Solution) in rats and dogs."	( A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. Hwang, SJ; Kim, BO; Kim, SO; Seo, MH; Shim, M; Yi, Y; Yoon, HJ, 2007)	0.34
" Although elimination half-life differed significantly (16."	( Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Inoue, Y; Kaneko, S; Niioka, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2007)	0.34
" Nevirapine pharmacokinetic studies were carried out starting with the seventh dose of nevirapine in the nevirapine regimen (on days 7-10 or 28-31) and the combination regimen (on days 49-52)."	( Pharmacokinetic study of the interaction between itraconazole and nevirapine. Jaruratanasirikul, S; Sriwiriyajan, S, 2007)	0.34
"There was no significant difference in nevirapine pharmacokinetic parameters between the nevirapine and combination regimens."	( Pharmacokinetic study of the interaction between itraconazole and nevirapine. Jaruratanasirikul, S; Sriwiriyajan, S, 2007)	0.34
" In this study, we aim to predict the effect of the CYP3A4 inhibitors, itraconazole (ITZ) and its primary metabolite, hydroxyitraconazole (OH-ITZ) on the pharmacokinetics of the anesthetic, midazolam (MDZ) and its metabolites, 1' hydroxymidazolam (1OH-MDZ) and 1' hydroxymidazolam glucuronide (1OH-MDZ-Glu) using mechanistic whole body physiologically-based pharmacokinetic simulation models."	( Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Edginton, AN; Jang, IJ; Niederalt, C; Sevestre, M; Vossen, M; Willmann, S, 2007)	0.34
" The terminal half-life of itraconazole was 524 min."	( Pharmacokinetics, blood partition, and tissue distribution of itraconazole. Lee, JH; Lee, MG; Shin, JH, 2004)	0.32
" This study suggests that an important pharmacokinetic interaction between CIP and KTC or ITC is likely to occur when either of the two antifungal drugs is administered concomitantly with CIP."	( Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacin. Abou-Auda, HS; Al-Humayyd, MS; Mustafa, AA, 2008)	0.35
"The population pharmacokinetic parameters of aripiprazole in healthy Japanese males were estimated using a nonlinear mixed effects model (NONMEM) program."	( Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. Azuma, J; Fukuda, T; Funaki, T; Hashimoto, Y; Kayano, Y; Koue, T; Kubo, M; Takaai, M, 2007)	0.34
"Although administration of antifungal agents, such as itraconazole (ITC) solution, for prophylaxis is the most promising strategy for the treatment of haematological malignancies, little is known about the population pharmacokinetic (PK) parameters."	( Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. Fujimoto, Y; Horiike, S; Kanbayashi, Y; Matsumoto, Y; Nomura, K; Okamoto, K; Shimazaki, C; Shimizu, D; Shimura, K; Takagi, T; Taniwaki, M, 2008)	0.35
"Therapeutic drug monitoring of any pharmacologic agent should be considered when there is both significant pharmacokinetic variability and strong, clinically relevant, exposure-effect relationships."	( Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Andes, D; Smith, J, 2008)	0.35
" Large interindividual variations were observed in area under the concentration curve values among patients."	( Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies. Beijnen, JH; Bosch, TM; Huijgens, PC; Kessels, LW; Timmers, GJ; Veldkamp, AI; Wilhelm, AJ, 2008)	0.35
"The pharmacokinetic parameters of atorvastatin were measured after intravenous (2 mg/kg) and intragastric (10 mg/kg) administration of atorvastatin in rats, which were pretreated with cyclosporin A (5, 10, and 20 mg/kg) or itraconazole (5, 10, and 20 mg/kg)."	( Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats. Chen, XJ; Dong, J; Sun, YB; Wang, GJ; Wang, L; Yu, X, 2008)	0.35
"A rapid and highly sensitive liquid chromatography/electrospray ionization tandem mass spectrometric method (LC/ESI-MS/MS) for itraconazole determination in human plasma was validated and applied to pharmacokinetic and bioequivalence study in humans."	( A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. Kang, JS; Kim, DS; Lee, MH; Park, JH; Park, YS; Rhim, SY; Shaw, LM, 2009)	0.35
" It has been reported that physicochemical characteristics of these compounds are disparate, leading to different pharmacokinetic profiles."	( Comparison of the oral pharmacokinetics of fluconazole and itraconazole in Mexicans. Carrasco-Portugal, Mdel C; Flores-Murrieta, FJ; Landa, C, 2008)	0.35
" Blood concentrations of everolimus were measured up to 240 min, and pharmacokinetic parameters were calculated."	( Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. Inui, K; Katsura, T; Masuda, S; Sato, E; Yano, I; Yokomasu, A, 2009)	0.35
" This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers."	( Clinical pharmacokinetics of fexofenadine enantiomers. Miura, M; Uno, T, 2010)	0.36
" The most appropriate method for data analysis might be a semi-mechanistic population pharmacokinetic modelling approach."	( Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Kloft, C; Lehr, T; Schaefer, HG; Staab, A; Trommeshauser, D, 2010)	0.36
" First, pharmacokinetic models of itraconazole and tesofensine were developed in parallel."	( Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Kloft, C; Lehr, T; Schaefer, HG; Staab, A; Trommeshauser, D, 2010)	0.36
"This analysis presents a semi-mechanistic population pharmacokinetic approach that may be useful for the evaluation of DDI studies."	( Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Kloft, C; Lehr, T; Schaefer, HG; Staab, A; Trommeshauser, D, 2010)	0.36
" Plasma concentrations of oxycodone and its oxidative metabolites were measured for 48 h, and pharmacodynamic effects were evaluated."	( Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2010)	0.36
" Most of the pharmacokinetic changes in oral oxycodone were seen in the elimination phase, with modest effects by itraconazole on its peak concentration, which was increased by 45% (P=0."	( Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, M; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2010)	0.36
"Itraconazole is a potent inhibitor of cytochrome P450 (CYP) 3A with an elimination half-life of more than 30 hours."	( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010)	0.36
"We developed a pharmacokinetic model based on the assumption that both itraconazole and hydroxyitraconazole competitively and reversibly inhibit the first-pass metabolism and systemic elimination of triazolam."	( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010)	0.36
" Thus, we investigated whether a pharmacokinetic interaction occurs between the anti-fungal agent itraconazole and the anti-glycaemic drug metformin, as both drugs are commonly administered together to diabetic patients and are metabolized via hepatic CYP3A subfamily in rats."	( Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Choi, YH; Lee, BK; Lee, MG; Lee, U, 2010)	0.36
" Drug concentrations were analyzed using standard pharmacokinetic methods."	( Effects of compounding on pharmacokinetics of itraconazole in black-footed penguins (Spheniscus demersus). Mitchell, MA; Papich, MG; Russell, G; Smith, JA, 2010)	0.36
" Plasma concentrations of oxycodone and its oxidative metabolites were measured over 48 hours, and pharmacokinetic and pharmacodynamic parameters subsequently evaluated."	( Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2011)	0.37
"To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers."	( Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. Mahatthanatrakul, W; Ridtitid, W; Samaeng, M; Sriwiriyajan, S; Wongnawa, M, 2011)	0.37
"Ten healthy male volunteers were assigned into a 2-sequence, 3-period pharmacokinetic interaction study."	( Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. Mahatthanatrakul, W; Ridtitid, W; Samaeng, M; Sriwiriyajan, S; Wongnawa, M, 2011)	0.37
" The half-life and CL of itraconazole were not changed significantly."	( Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. Mahatthanatrakul, W; Ridtitid, W; Samaeng, M; Sriwiriyajan, S; Wongnawa, M, 2011)	0.37
" Pharmacokinetic parameters were determined using non-compartmental methods."	( Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Duvauchelle, T; Kennedy, SJ; Martin, P; Oliver, S; Read, J; Robertson, J, 2011)	0.37
"To set up a population pharmacokinetic (PPK) model of cyclosporine A (CsA) in Chinese allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients to provide reference for individualized medication in clinical practice."	( Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. Cheng, XL; Gao, Y; Li, ZD; Zhou, H, 2012)	0.38
"The pharmacokinetic variability of hydroxy-itraconazole (OH-ITZ), an active metabolite of itraconazole (ITZ), is not fully known."	( Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. Kawakami, J; Mino, Y; Naito, T; Watanabe, T; Yagi, T; Yamada, H; Yamada, T, 2013)	0.39
"The pharmacokinetic variability of OH-ITZ was associated with saturated metabolism to keto-ITZ, serum concentration of albumin, and renal function in immunocompromised patients."	( Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. Kawakami, J; Mino, Y; Naito, T; Watanabe, T; Yagi, T; Yamada, H; Yamada, T, 2013)	0.39
"5mg/kg for pharmacokinetic profile (lung and plasma concentration) determination in ICR CD-1 mice."	( Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. Amighi, K; Duret, C; Merlos, R; Sebti, T; Vanderbist, F; Wauthoz, N, 2014)	0.4
" Systolic and diastolic blood pressures and pulse rate were periodically recorded after nadolol administration as pharmacodynamic parameters."	( Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. Fukushima, T; Kimura, J; Misaka, S; Miyazaki, N; Ono, T; Shikama, Y; Yatabe, MS, 2013)	0.39
" When co-administered with voriconazole, pharmacokinetic parameters of imatinib were not significantly altered except for a 36."	( Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Han, A; Hu, G; Kan, X; Lin, G; Qiu, X; Wang, C; Wang, Z; Xu, T, 2014)	0.4
"A new approach for calculation of sample size in pediatric clinical pharmacokinetic studies was suggested based on desired precision for a pharmacokinetic parameter of interest."	( Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used? Aarons, L; Johnson, TN; Ogungbenro, K; Rostami-Hodjegan, A; Salem, F; Vajjah, P, 2014)	0.4
" Correlation of pharmacokinetic and pharmacodynamic (PK-PD) parameters with the in vivo bactericidal action of antimicrobial agents has progressed markedly in recent years."	( Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. Hagihara, M; Hamada, Y; Mikamo, H; Yamagishi, Y, 2013)	0.39
" For the pharmacokinetic analysis, average concentrations of high variability drug-itraconazole were used before (BO) and after sampling intervals optimization (AO)."	( Sampling intervals verification in pharmacokinetics studies. Bujalska-Zadrożny, M; Grabowski, T; Jaroszewski, JJ; Sasinowska-Motyl, M, 2014)	0.4
" Terbinafine increased the peak concentration (C max) of tramadol by 53 % (P < 0."	( Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Backman, JT; Hagelberg, NM; Laine, K; Neuvonen, PJ; Olkkola, KT; Saari, TI; Saarikoski, T; Scheinin, M, 2015)	0.42
"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15."	( Pharmacokinetics and bioavailability of itraconazole oral solution in cats. Cao, C; Li, W; Liang, C; Shan, Q; Wang, J; Zeng, Z; Zhang, X; Zhong, J, 2016)	0.43
" Empirical antifungal efficacy was assessed retrospectively in 159 transplantations, and a full pharmacokinetic study was prospectively conducted in six of these patients."	( Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. Ahn, HS; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, MS; Kim, SJ; Lee, JW; Park, JD; Park, KD; Shin, D; Shin, HY; Song, ES; Yu, KS, 2015)	0.42
" The purpose of the present study is to develop a physiologically based pharmacokinetic (PBPK) model for atorvastatin and its two primary metabolites, 2-hydroxy-atorvastatin acid and atorvastatin lactone, using in vitro and in vivo data."	( Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. Zhang, T, 2015)	0.42
" This study aimed to develop a population pharmacokinetic model for itraconazole and the active metabolite hydroxyitraconazole, in particular, quantifying the effects of food and formulation on oral absorption."	( Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Abuhelwa, AY; Foster, DJ; Hayes, D; Mudge, S; Upton, RN, 2015)	0.42
" A physiologically based pharmacokinetic model was developed to describe DDIs between domperidone and three different inhibitors of CYP3A4."	( A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Ravenstijn, P; Sensenhauser, C; Snoeys, J; Templeton, I, 2016)	0.43
"Physiologically based pharmacokinetic (PBPK) modeling for itraconazole has been challenging due to highly variable in vitro d ata used for 'bottom-up' model building."	( Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Budha, N; Chen, Y; Hop, CE; Jin, JY; Kenny, JR; Lu, T; Ma, F; Mao, J; Wong, H, 2016)	0.43
" The key parameters that govern the pharmacokinetic profile, including non-linear clearance (i."	( Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Budha, N; Chen, Y; Hop, CE; Jin, JY; Kenny, JR; Lu, T; Ma, F; Mao, J; Wong, H, 2016)	0.43
" The resulting interaction between these CYP3A4 substrates can be utilized clinically as a pharmacokinetic booster for prolonging saquinavir dosing regimen and/or decreasing saquinavir dose requirement in HIV/AIDS patients."	( A semi-mechanistic pharmacokinetic model of saquinavir combined with itraconazole in HIV-1-positive patients. Jenjob, A; Lohitnavy, M; Methaneethorn, J; Pankaew, A; Phuphuak, K; Sriarwut, T, 2015)	0.42
" Even though pharmacokinetic data regarding such interaction are available, they cannot be used for quantitative prediction."	( Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole. Chan-Im, D; Chiang-Ngernthanyakool, R; Lohitnavy, M; Methaneethorn, J; Phaohorm, S; Tongpeng, W, 2015)	0.42
"Published data involving pharmacokinetic of simvastatin, itraconazole, and pharmacokinetic interaction between simvastatin and itraconazole were selected from PubMed search."	( Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole. Chan-Im, D; Chiang-Ngernthanyakool, R; Lohitnavy, M; Methaneethorn, J; Phaohorm, S; Tongpeng, W, 2015)	0.42
"IVIVC was developed based on fed/fasted pharmacokinetic data from randomized cross-over trials, in vitro dissolution studies, and prior information about typical and between subject variability of GI pH and transit times."	( Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. Abuhelwa, AY; Foster, DJ; Hayes, D; Mudge, S; Upton, RN, 2016)	0.43
" Pharmacokinetic profiles for fasted itraconazole periods were described based on the in vitro dissolution model, in vivo disposition model, and the prior information on GI pH and transit times."	( Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. Abuhelwa, AY; Foster, DJ; Hayes, D; Mudge, S; Upton, RN, 2016)	0.43
"The results of this study suggest that vismodegib can be administered with acid-reducing agents and P-gp and CYP inhibitors without the risk of a clinically meaningful pharmacokinetic drug-drug interaction."	( A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Chandra, P; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Malhi, V; Williams, SJ, 2016)	0.43
" The aim of this study was to investigate the influence of itraconazole (ITCZ) on tacrolimus absorption, distribution and metabolism by developing a semi-physiological pharmacokinetic model of tacrolimus in mice."	( Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice. Bi, KS; Chen, XH; Lu, XF; Zhan, J; Zhou, Y, 2017)	0.46
"Rat is commonly used for pharmacokinetic screening during pharmaceutical lead optimization."	( Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. Gaud, N; Holenarsipur, VK; Kole, P; Kumar, A; Mandlekar, S; Matta, M; Sridhar, S, 2017)	0.46
"Therapeutic drug monitoring (TDM) may be required to achieve optimal clinical outcomes in the setting of significant pharmacokinetic variability, a situation that applies to a number of anti-mould therapies."	( Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. Hope, WW; Stott, KE, 2017)	0.46
" Pharmacokinetic parameters were determined with compartmental analysis."	( Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. Hasbach, AE; Langlois, DK; Papich, MG; Rosser, EJ, 2017)	0.46
" Despite some pharmacokinetic differences between itraconazole capsule and solution, formulation-specific dosages do not appear to be necessary."	( Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. Hasbach, AE; Langlois, DK; Papich, MG; Rosser, EJ, 2017)	0.46
"001% bath, itraconazole exceeded the MIC and declined with a disappearance half-life that markedly varied (14."	( THE PHARMACOKINETICS OF TOPICAL ITRACONAZOLE IN PANAMANIAN GOLDEN FROGS (ATELOPUS ZETEKI). Barrett, K; Boothe, D; Bronson, E; Rifkin, A; Visser, M, 2017)	0.46
" Dissolution tests by pH transition and pharmacokinetic study using male Sprague Dawley rats were conducted."	( Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods. Choi, HG; Choi, S; Kang, W; Kim, DW; Kim, KS; Kim, M; Kim, Y; Lee, ES; Lee, JW; Lim, C; Oh, KT; Sim, T, 2017)	0.46
"In recent years, physiologically based PharmacoKinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics."	( Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S, 2018)	0.48
"The accuracy of physiologically based pharmacokinetic (PBPK) model prediction in children, especially those younger than 2 years old, has not been systematically evaluated."	( Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Al-Huniti, N; Bui, KH; Cheung, SYA; Johnson, TN; Li, J; Xu, H; Zhou, D; Zhou, W, 2018)	0.48
"The aim of this study was to develop a population in vitro-in vivo pharmacokinetic model that simultaneously describe the absorption and accumulation kinetics of itraconazole (ICZ) and hydroxy-itraconazole (HICZ) in healthy subjects."	( Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. Abuhelwa, AY; Foster, DJR; Mudge, S; Upton, RN, 2018)	0.48
" Physiologically based pharmacokinetic (PBPK) modeling was conducted using a population-based simulator."	( Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. Al-Huniti, N; Chen, Y; Masson, E; Tang, W; Zhou, D; Zhou, W, 2018)	0.48
"16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19."	( Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Aluri, J; Boyd, P; Chang, MK; Ferry, J; Lai, WG; Nomoto, M; Rege, B; Schuck, E; Siu, YA; Yasuda, S; Zamora, CA, 2018)	0.48
" The objective of the present study was to develop a physiologically-based pharmacokinetic (PBPK) model for BMS-823778 and use the model to predict PK and drug-drug interaction (DDI) in virtual populations with multiple polymorphic genes."	( Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data. Gong, J; Humphreys, WG; Iacono, L; Iyer, RA; Zheng, M, 2018)	0.48
"Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a bottom-up approach is challenging, not only due to complex saturable pharmacokinetics (PK) and the presence of three metabolites exhibiting CYP3A4 inhibition, but also because of discrepancies in reported in vitro data."	( Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. Ericsson, H; Janzén, D; Kanebratt, KP; Lennernäs, H; Lundahl, A; Prieto Garcia, L, 2018)	0.48
" Risdiplam exhibited linear PK over the dose range with a multi-phasic decline with a mean terminal half-life of 40-69 h."	( A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Al Kotbi, N; Bergauer, T; Cleary, Y; Czech, C; Frances, N; Günther, A; Heinig, K; Jaber, B; Jordan, P; Khwaja, O; Kletzl, H; Marquet, A; Müller, L; Parkar, N; Poirier, A; Ratni, H; Sturm, S, 2019)	0.51
"An in vitro-in vivo (IVIV) pharmacokinetic model of itraconazole and hydroxyitraconazole was developed including data from an omeprazole interaction study with SUBA itraconazole."	( Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. Abuhelwa, AY; Foster, DJR; Mudge, S; Upton, RN, 2019)	0.51
" The physiologically based pharmacokinetic (PBPK) models were developed to investigate the influence of different triazoles on tamoxifen pharmacokinetics in this paper."	( Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen. Chen, L; Li, M; Li, N; Qi, F; Wang, N; Zhu, L, 2019)	0.51
"We previously verified a physiologically based pharmacokinetic (PBPK) model for mirabegron in healthy subjects using the Simcyp Simulator by incorporating data on the inhibitory effect on cytochrome P450 (CYP) 2D6 and a multi-elimination pathway mediated by CYP3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7 and butyrylcholinesterase (BChE)."	( Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K, 2019)	0.51
" This work by an International Consortium for Innovation and Quality in Pharmaceutical Development working group (WG) is to develop and verify a mechanistic ITZ physiologically-based pharmacokinetic model and provide recommendations for optimal DDI study design based on model simulations."	( Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model. Cabalu, TD; Callegari, E; Chen, Y; Einolf, H; Hall, SD; Liu, L; Parrott, N; Peters, SA; Schuck, E; Sharma, P; Tracey, H; Upreti, VV; Zheng, M; Zhu, AZX, 2019)	0.51
" The pharmacokinetic profile of PUR1900 suggests the potential to improve upon the efficacy and safety profile observed with oral itraconazole."	( A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. Bedwell, P; Connor, L; Curran, AK; Hava, DL; Henderson, D; Johnson, P; Kane, K; Khan, N; Kramer, S; Layton, G; McKenzie, L; Perry, J; Roach, J; Singh, D; Swann, C; Tan, L, 2020)	0.56
"A multicenter-based population pharmacokinetic model of ciclosporin was established."	( Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. Ding, XL; Liu, LN; Miao, LY; Tian, JX; Xue, L; Yan, HH; Zhang, JJ; Zhang, WJ; Zhang, WW, 2019)	0.51
" A physiologically based pharmacokinetic (PBPK) model incorporating the metabolites was developed to predict the effect of other strong and moderate CYP3A4 inhibitors and inducers."	( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020)	0.56
" Pharmacokinetic parameters were calculated using noncompartmental analysis, and safety was assessed."	( Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects. Irie, S; Ishizuka, H; Ishizuka, T; Kato, M; Kirigaya, Y; Nakatsu, T; Nishikawa, Y; Shimizu, T; Shiramoto, M; Uchimaru, H, 2020)	0.56
" Values for total clearance of compounds from plasma should be one of the most important pharmacokinetic parameters for predictions."	( Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data. Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N, 2020)	0.56
" To enable administering safe doses of molibresib to healthy volunteers, this 2-part randomized, open-label, crossover drug-drug interaction trial was conducted as an adaptive design study using physiologically based pharmacokinetic (PBPK) modeling and simulation to predict the lowest doses of molibresib that could be safely administered alone (10 mg) or with itraconazole and rifampicin (strong inhibitors and inducers of CYP3A and P-gp, respectively)."	( An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers. Collins, G; Ferron-Brady, G; Kremer, BE; Patel, A; Riddell, K; Schramek, D; Zhou, Y, 2021)	0.62
"Develop a physiologically based pharmacokinetic (PBPK) model of ivosidenib using in vitro and clinical PK data from healthy participants (HPs), refine it with clinical data on ivosidenib co-administered with itraconazole, and develop a model for patients with acute myeloid leukemia (AML) and apply it to predict ivosidenib drug-drug interactions (DDI)."	( Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Fan, B; Ke, A; Le, K; Prakash, C; Yang, H, 2020)	0.56
" We report on how 2 acumapimod clinical DDI studies and a physiologically-based pharmacokinetic (PBPK) model assessing how co-administration of a weak (azithromycin) and strong (itraconazole) CYP3A4 inhibitor affected acumapimod systemic exposure, informed decision making and supported concomitant use of CYP3A4 and P-gp inhibitors."	( A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor. Agyemang, A; Farrell, C; Moore, W; Parkin, J, 2021)	0.62
" It has been reported that sunitinib was mainly metabolized by CYP3A but its pharmacokinetic interactions have not been revealed."	( Effects of CYP3A inhibitors ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of sunitinib and its main metabolite in rats. Chen, RJ; Cheng, C; Cui, X; Huang, CK; Sun, W; Wang, J; Wang, Y; Wang, Z, 2021)	0.62
" We investigated whether the single-dose pharmacokinetic (PK) profile of pamiparib is altered by coadministration of a strong CYP3A inducer (rifampin) or a strong CYP3A inhibitor (itraconazole) in patients with solid tumors."	( The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study. Andreu-Vieyra, C; Bulat, I; Lin, C; Maglakelidze, M; Mu, S; Sahasranaman, S; Skarbova, V; Skrzypczyk-Ostaszewicz, A, 2021)	0.62
" A physiologically based pharmacokinetic (PBPK) model was constructed to predict plasma concentration-time profiles of selumetinib, and to evaluate the impact of coadministering moderate cytochrome P450 (CYP) 3A4/2C19 inhibitors/inducers."	( Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. Cohen-Rabbie, S; Freshwater, T; Jain, L; Schalkwijk, S; Tomkinson, H; Vishwanathan, K; Wild, M; Xu, S; Zhou, D; Zhou, L, 2021)	0.62
" Physiologically based pharmacokinetic (PBPK) modelling was performed to predict the drug-drug interaction (DDI) effect of cytochrome P450 (CYP)3A modulators on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment."	( Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment. Igawa, Y; Ishizuka, H; Ishizuka, T; Shimizu, T; Watanabe, A; Yamada, M, 2022)	0.72
"As one of the key components in model-informed drug discovery and development, physiologically-based pharmacokinetic (PBPK) modeling linked with in vitro-to-in vivo extrapolation (IVIVE) is widely applied to quantitatively predict drug-drug interactions (DDIs) on drug-metabolizing enzymes and transporters."	( Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition. De Zwart, L; Evers, R; Yamazaki, S, 2022)	0.72
"A new UPLC-MS/MS technique for the determination of ripretinib in beagle dog plasma was developed, and the pharmacokinetic effects of voriconazole and itraconazole on ripretinib in beagle dogs were studied."	( The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique. Geng, XN; Gou, KF; Qiu, XJ; Su, YD; Wang, HJ; Zhou, CY, 2021)	0.62
" The concentration of ripretinib was detected, and the pharmacokinetic parameters of ripretinib were calculated."	( The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique. Geng, XN; Gou, KF; Qiu, XJ; Su, YD; Wang, HJ; Zhou, CY, 2021)	0.62
" To predict the potential influence of different triazoles (voriconazole, fluconazole, and itraconazole) on the pharmacokinetics of crizotinib by modeling and simulation the physiologically based pharmacokinetic models were established and validated in virtual cancer subjects through Simcyp software based on the essential physicochemical properties and pharmacokinetic data collected."	( Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib. Chen, L; Chen, W; Li, L, 2022)	0.72
"Eliapixant had a long half-life (23."	( First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. Baumann, S; Chang, X; Friedrich, C; Gashaw, I; Hummel, T; Klein, S; Thuß, U, 2022)	0.72
" As SHR2554 is mainly metabolized by CYP3A4, it is helpful to conduct research on the effects of itraconazole, a strong inhibitor of CYP3A4-metabolizing enzymes, on the pharmacokinetic characteristics and safety of SHR2554."	( Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial. Cui, C; Deng, K; Huang, J; Wang, H; Xiang, Y; Yang, G; Yang, S; Yang, X; Zou, C; Zou, Y, 2023)	0.91
"We conducted a single-center, open-label pharmacokinetic study of itraconazole on SHR2554 in 18 healthy Chinese subjects."	( Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial. Cui, C; Deng, K; Huang, J; Wang, H; Xiang, Y; Yang, G; Yang, S; Yang, X; Zou, C; Zou, Y, 2023)	0.91
" Here, we investigate the pharmacokinetic drug-drug interaction potential of trilaciclib."	( Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W, 2022)	0.72
" Population pharmacokinetic modeling showed no significant effect of trilaciclib on topotecan clearance."	( Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W, 2022)	0.72
"A phase I open-label study assessed the effect of multiple oral doses of a potent CYP3A4 inhibitor (itraconazole) and inducer (rifampicin) on the pharmacokinetic profile of a single oral dose of senaparib, a novel, highly potent poly-(ADP-ribose) polymerase 1/2 inhibitor and CYP3A4 substrate, in Chinese healthy male volunteers (HMV)."	( Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study. Cai, SX; Hsieh, CY; Hu, X; Li, X; Liu, L; Liu, P; Liu, W; Shi, H; Xu, P; Xu, S; Zhang, H; Zhang, M; Zhang, Y, 2023)	0.91
" To consider an adult physiologically-based pharmacokinetic (PBPK) model for pediatric scaling, we assessed in vitro-derived cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) enzyme contributions to CBD clearance in human."	( Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling. Beers, JL; Edginton, AN; Jackson, KD; Yeung, CHT, 2023)	0.91
" Full pharmacokinetic curves were obtained on Days 7 and 14."	( Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation. Blijlevens, N; Brüggemann, RJM; Donnelly, JP; Jansen, AME; Ter Heine, R, 2023)	0.91
"This study provides information on the pharmacokinetic properties of the itraconazole NCF useful for development of this formulation."	( Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation. Blijlevens, N; Brüggemann, RJM; Donnelly, JP; Jansen, AME; Ter Heine, R, 2023)	0.91
" This study aimed to evaluate the utility of physiologically-based pharmacokinetic (PBPK) modeling in the prediction of gastric pH-mediated drug exposure by using itraconazole, a weak base, as a case."	( Prediction of gastric pH-mediated drug exposure using physiologically-based pharmacokinetic modeling: A case study of itraconazole. Lee, S; Yang, E; Yu, KS, 2023)	0.91
" Pharmacokinetic parameters were calculated using non-compartmental analysis."	( Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects. Feng, S; Fu, M; Gao, X; Li, X; Li, Y; Lin, H; Shen, K; Yu, G; Zhang, P; Zhang, Z, 2023)	0.91
" This project used physiologically based pharmacokinetic (PBPK) modeling to assess the DDI potential of inhaled PUR1900, using midazolam as a "victim drug."	( Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data. Bergagnini-Kolev, M; Curran, AK; Kane, K; Templeton, IE, 2023)	0.91
" Clinical pharmacokinetic drug-drug interaction (DDI) of ocedurenone with CYP3A inhibitor and inducer were investigated in healthy volunteers."	( Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo. Liu, J; McCabe, J; Tan, X; Wang, P; Yang, F; Zhang, J, 2023)	0.91
"The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments."	( Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Komada, F; Nishiguchi, K; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y, 1999)	0.86
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" This can be rationalized based on the interplay of the effects of lipophilicity on individual parameter values in pharmacokinetic equations."	( Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization. Geissler, WM; Madeira, M; Martin, IJ; Miller, RR; Raab, CE; Wood, HB, 2020)	0.56

Excerpt	Reference	Relevance
"Cilofungin, a lipopeptide antifungal agent, was tested for in vitro activity alone and in combination with ketoconazole, itraconazole, flucytosine and amphotericin B against 102 clinical isolates of Candida species."	( In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species. Cobbs, CG; Dismukes, WE; Lank, KM; Smith, KR, 1991)	0.28
"A randomized trial of amphotericin B (AB) alone and in combination with oral itraconazole (IZ) is carried out in two groups of 10 mucocutaneous leishmaniasis patients from Bolivia and Peru."	( A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Cardenas, F; Dedet, JP; Mendoza, C; Paredes, V; Rodriguez, LV, )	0.13
"Ten expressed human CYPs and human liver microsomes were used in the experiments for the identification of enzymes responsible for zonisamide metabolism and for the prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data, respectively."	( Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Kitada, M; Kiuchi, M; Nakamura, H; Nakasa, H; Ohmori, S; Ono, S; Tsutsui, M, 1998)	0.3
"We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide."	( Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Kitada, M; Kiuchi, M; Nakamura, H; Nakasa, H; Ohmori, S; Ono, S; Tsutsui, M, 1998)	0.3
" We investigated the antifungal activities of nikkomycin Z alone and in combination with fluconazole and itraconazole."	( In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Li, RK; Rinaldi, MG, 1999)	0.3
" In addition, special attention is needed for the detection of adverse drug reactions resulting from possible drug-drug interactions."	( Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Egberts, AC; Leufkens, HG; Meyboom, RH; Van Puijenbroek, EP, 1999)	0.3
" This approach might be a promising tool for the development of procedures for automated detection of possible drug-drug interactions in spontaneous reporting systems."	( Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Egberts, AC; Leufkens, HG; Meyboom, RH; Van Puijenbroek, EP, 1999)	0.3
" In contrast, there are no drug-drug contraindications with terbinafine."	( Drug interactions of the newer oral antifungal agents. Katz, HI, 1999)	0.3
" A physiologically-based pharmacokinetic model was used to predict the maximum in vivo drug-drug interaction."	( Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Ikeda, T; Inoue, S; Ishigam, M; Ito, K; Iwabuchi, H; Komai, T; Kondo, T; Sugiyama, Y; Takasaki, W; Uchiyama, M, 2001)	0.31
"The objectives of this review are to discuss the role of cytochrome P450 (CYP450) isoforms in drug metabolism, to explain differences in metabolism among the HMG-CoA reductase inhibitors (HMGs, statins), to review drug-drug and drug-food interaction studies dealing with the HMGs, to present case reports dealing with HMG-related myopathy, to discuss major clinical implications of these case reports and to express an opinion of use of HMGs in clinical practice."	( The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Bottorff, M; Worz, CR, 2001)	0.31
" These results showed that the encapsulated, enteric-coated bead formulation of didanosine can be concomitantly administered with drugs, such as the azole antifungal agents, whose bioavailability may be influenced by interaction with antacids."	( Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Damle, B; Hess, H; Kaul, S; Knupp, C, 2002)	0.31
" The method was applied to drug-drug interaction study of TZ with itraconazole (ITZ)."	( Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. Al-Dirbashi, OY; Kaddoumi, A; Nakashima, K; Nakashima, MN; Yamamoto, K, 2003)	0.32
" Amphotericin B was combined with flucytosine and ciprofloxacin, whereas itraconazole was combined with ciprofloxacin, levofloxacin, lomefloxacin and sulfadiazine."	( In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera. Afeltra, J; de Hoog, GS; Rijs, AJ; Verweij, PE; Vitale, RG, 2003)	0.32
"We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis."	( Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Beijnen, JH; Crommentuyn, KM; Huitema, AD; Mulder, JW; Schellens, JH; Sparidans, RW, 2004)	0.32
" Cytarabine metabolism was significantly decreased when combined with caspofungin or itraconazole."	( In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Colburn, DE; Giles, FJ; Oladovich, D; Smith, JA, 2004)	0.32
" We studied the activities of the combination of CAS and SMX against 31 Aspergillus isolates and compared them with that of SMX combined with amphotericin B (AMB) or itraconazole (ITC)."	( In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Osherov, N; Shadkchan, Y; Shalit, I; Yekutiel, A, 2004)	0.32
"To evaluate and compare the in vitro antifungal properties of lufenuron and nikkomycin Z against isolates of Coccidioides immitis and Aspergillus fumigatus when used singly and in combination with the azole antifungal agent itraconazole."	( Comparison of susceptibility of fungal isolates to lufenuron and nikkomycin Z alone or in combination with itraconazole. Davidson, AP; Hector, RF; Johnson, SM, 2005)	0.33
"This article reviews the in vitro metabolic and the in vivo pharmacokinetic drug-drug interactions with antifungal drugs, including fluconazole, itraconazole, micafungin, miconazole, and voriconazole."	( [Drug-drug interaction of antifungal drugs]. Niwa, T; Shiraga, T; Takagi, A, 2005)	0.33
" Consequently, azoles interact with a vast array of compounds."	( Drug-drug interactions of antifungal agents and implications for patient care. Amsden, JR; Gubbins, PO, 2005)	0.33
"Rhinotomy with removal of the flap combined with one-hour infusion of 2 per cent enilconazole and oral itraconazole resulted in satisfactory outcome in dogs with severe or recurrent aspergillosis."	( Surgical treatment of canine nasal aspergillosis by rhinotomy combined with enilconazole infusion and oral itraconazole. Claeys, S; Clercx, C; Hamaide, A; Lefebvre, JB; Schuller, S, 2006)	0.33
"This study was aimed to investigate the clinical features and therapy of Ph(+) acute lymphoblastic leukemia (Ph(+)ALL) combined with invasive aspergillosis."	( [Ph+ acute lymphoblastic leukemia combined with lung and brain invasive aspergillosis]. Huang, M; Liu, WL; Ran, D; Sun, HY; Zhang, YC; Zhou, JF, 2006)	0.33
" A potentially drug-drug interaction (DDI) occurred when the use of concomitant drugs were recorded within +/-30 days from the date of the first azoles prescription."	( Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. Caputi, AP; Cricelli, C; Galatti, L; Greco, A; Mazzaglia, G; Nicoletti, G; Schito, GC; Sessa, E; Spina, E, 2007)	0.34
"Although there is a presumed drug-drug interaction between itraconazole and nonnucleoside reverse-transcriptase inhibitors, the medical literature lacks such documentation."	( Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Andrade, RA; Hamill, RJ; Koo, HL, 2007)	0.34
"We describe drug-drug interactions (DDIs) encountered with antifungals in clinical practice."	( Drug-drug interactions with systemic antifungals in clinical practice. Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F, 2007)	0.34
" All treatment episodes with antifungal agent were examined and all prescribed concomitant medication identified for potential drug-drug interactions (PDDI)-serious events occurring during treatment were adjudicated for clinical DDI."	( Drug-drug interactions with systemic antifungals in clinical practice. Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F, 2007)	0.34
" In conclusion, posaconazole salvage therapy demonstrated greater efficacy and safety than HD-LPD/AMB alone or in combination with caspofungin in the salvage therapy of invasive aspergillosis in hematologic malignancy."	( Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Afif, C; Boktour, M; Hachem, RY; Hanna, HA; Jiang, Y; Kontoyiannis, DP; Raad, II; Torres, HA, 2008)	0.35
" Collections of individual case safety reports (ICSRs) related to suspected ADR incidents in clinical practice have proven to be very useful in post-marketing surveillance for pairwise drug--ADR associations, but have yet to reach their full potential for drug-drug interaction surveillance."	( A statistical methodology for drug-drug interaction surveillance. Bate, A; Edwards, IR; Norén, GN; Sundberg, R, 2008)	0.35
"The vitro antifungal activity of retigeric acid B (RAB), a pentacyclic triterpenoid from the lichen species Lobaria kurokawae, was evaluated alone and in combination with fluconazole, ketoconazole, and itraconazole against Candida albicans using checkerboard microdilution and time-killing tests."	( In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Cheng, A; Lou, H; Sun, L; Sun, S; Wu, X; Zhang, Y, 2009)	0.35
"For compounds with a long elimination half-life, the evaluation of a drug-drug interaction (DDI) study can be challenging."	( Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Kloft, C; Lehr, T; Schaefer, HG; Staab, A; Trommeshauser, D, 2010)	0.36
"In vitro investigation of pharmacokinetic drug-drug interactions (DDIs) has officially been part of the regulatory pathway for new drugs in the USA since the publication of an FDA guidance on the subject in 1997."	( The nasty surprise of a complex drug-drug interaction. Bode, C, 2010)	0.36
"To further explore the mechanism underlying the interaction between repaglinide and gemfibrozil, alone or in combination with itraconazole."	( Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Chen, W; Gan, J; Gao, L; Hong, Y; Humphreys, WG; Li, W; Rodrigues, AD; Shen, H; Tang, Y; Tian, Y; Zhang, H; Zhang, Y, 2010)	0.36
"Exposure to vandetanib, as assessed by AUC(504) in healthy subjects, was reduced by around 40% when a single dose was given in combination with the potent CYP3A4 inducer rifampicin."	( Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Duvauchelle, T; Kennedy, SJ; Martin, P; Oliver, S; Read, J; Robertson, J, 2011)	0.37
" Due to the difference in the IC50 values for CYP3A4 and CYP3A5, nonconcordant expression of CYP3A4 and CYP3A5 protein can significantly affect the observed magnitude of CYP3A-mediated drug-drug interactions in humans."	( Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Chang, SY; Grubb, MF; Isoherranen, N; Peng, CC; Rodrigues, AD; Shirasaka, Y; Thummel, KE, 2013)	0.39
" Finally, observed/predicted drug-drug interactions between antiretrovirals and antifungals are summarized along with clinical recommendations."	( Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK, 2014)	0.4
" Posaconazole is contraindicated in combination with either efavirenz or fosamprenavir."	( Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK, 2014)	0.4
" We treated one case of chromoblastomycosis by photodynamic therapy (PDT) of 5-aminolevulinic acid (ALA) irradiation combined with terbinafine 250 mg a day."	( Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro. Hamblin, MR; Hu, Y; Huang, X; Lu, S; Mylonakis, E; Xi, L; Zhang, J, 2015)	0.42
"Ketoconazole has been widely used as a strong cytochrome P450 (CYP) 3A (CYP3A) inhibitor in drug-drug interaction (DDI) studies."	( Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. Bello, A; Dresser, MJ; Heald, D; Komjathy, SF; Liu, L; O'Mara, E; Robertson, SM; Rogge, M; Stoch, SA, 2016)	0.43
" The model was used to predict the pharmacokinetic profiles and drug-drug interaction (DDI) effect for atorvastatin and its metabolites in different DDI scenarios."	( Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. Zhang, T, 2015)	0.42
"Domperidone is a dopamine receptor antagonist and a substrate of CYP3A4, hence there is a potential for CYP3A inhibition-based drug-drug interactions (DDI)."	( A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Ravenstijn, P; Sensenhauser, C; Snoeys, J; Templeton, I, 2016)	0.43
" Under-prediction of pharmacokinetics and drug-drug interactions (DDIs) following multiple doses of itraconazole has limited the use of PBPK model simulation to aid an itraconazole clinical DDI study design."	( Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Budha, N; Chen, Y; Hop, CE; Jin, JY; Kenny, JR; Lu, T; Ma, F; Mao, J; Wong, H, 2016)	0.43
"The mechanism of drug-drug interaction between saquinavir, a protease inhibitor used effectively for HIV/AIDS treatment, and itraconazole, an azole antifungal agent, is hypothesized to involve competitive inhibition at CYP3A4 enzyme, an important drug metabolizing enzyme in humans."	( A semi-mechanistic pharmacokinetic model of saquinavir combined with itraconazole in HIV-1-positive patients. Jenjob, A; Lohitnavy, M; Methaneethorn, J; Pankaew, A; Phuphuak, K; Sriarwut, T, 2015)	0.42
"The majority of hospitalized patients receiving mold-active triazoles are at risk of drug-drug interactions (DDIs)."	( Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. Andes, D; Azie, N; Franks, B; Harrington, R; Kelley, C; Khandelwal, N; Kristy, R; Lee, E; Spalding, J; Tan, RD; Wu, EQ; Yang, H, 2016)	0.43
" Preclinical studies of GTx-024 supported the evaluation of several potential drug-drug interactions in a clinical setting."	( Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Coss, CC; Dalton, JT; Jones, A, 2016)	0.43
"The results of this study suggest that vismodegib can be administered with acid-reducing agents and P-gp and CYP inhibitors without the risk of a clinically meaningful pharmacokinetic drug-drug interaction."	( A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Chandra, P; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Malhi, V; Williams, SJ, 2016)	0.43
" In this study, we examined the efficacy of laser treatment using self-controlled study programs involving a long-pulsed Nd:YAG 1064-nm laser combined with oral medication."	( Self-controlled Study of Onychomycosis Treated with Long-pulsed Nd:YAG 1064-nm Laser Combined with Itraconazole. Li, Y; Xu, J; Zhao, JY; Zhuo, FL, 2016)	0.43
" Muscle biopsy was compatible with statin-associated rhabdomyolysis, probably caused by a drug-drug interaction between simvastatin and itraconazole."	( Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole. Damkier, P; Dybro, AM; Hellfritzsch, M; Rasmussen, TB, 2016)	0.43
"The antifungal activity of tacrolimus in combination with antifungal agents against different fungal species has been previously reported."	( Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates. Alves, SH; Azevedo, MI; Denardi, LB; Kubiça, TF; Oliveira, V; Santurio, JM; Severo, LC, )	0.13
"To investigate the antitumor effect of arsenic trioxide (ATO) combined with itraconazole (ITRA) on human multiple myeloma NCI-H929 cells by synergistically inhibiting Hedgehog (HH) signaling pathway."	( [Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells]. Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD, 2016)	0.43
"ATO combined with ITRA significantly inhibited NCI-H929 cell proliferation as compared with a single administration."	( [Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells]. Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD, 2016)	0.43
"ATO combined with ITRA can more strongly suppress the growth of multiple myeloma NCI-H929 cells, as compared with a single administration."	( [Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells]. Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD, 2016)	0.43
"The efficacy and safety of amorolfine 5% nail lacquer in combination with systemic antifungal agents in the treatment of the onychomycosis were evaluated."	( Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review. Feng, X; Ran, Y; Xiong, X, 2017)	0.46
" Menthol in combination with itraconazole or nystatin exhibited the synergistic effects against all species of Candida tested."	( Synergistic anticandidal activity of menthol in combination with itraconazole and nystatin against clinical Candida glabrata and Candida krusei isolates. Khosravi, AR; Sharifzadeh, A; Shokri, H; Tari, PS, 2017)	0.46
"In this study, impact of a polymorphism of CYP2C19 on drug-drug interaction (DDI) was examined for etizolam."	( Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19. Furihata, K; Hisaka, A; Iwatsubo, T; Kusayama, S; Mori, A; Moritoyo, T; Motohashi, K; Ogoe, K; Suzuki, H; Yamamoto, T, 2017)	0.46
"To explore the effect of arsenic trioxide combined with itraconazole on proliferation and apoptosis of KG1a cells and its potential mechanism."	( [Synergistic Killing Effects of Arsenic Trioxide Combined with Itraconazole on KG1a Cells]. Fan, JX; Guo, KY; Li, YM; Wu, JW; Xiao, WT; Ye, YB; Zeng, YJ; Zhen, R, 2017)	0.46
"Arsenic trioxide combined with itraconazole can inhibit the KG1a cell proliferation and induce apoptosis, which may be related with the inhibition of Hh signaling pathway and upregulation of both Caspase-3 and BAX protein expression, and provided experimental data of arsenic trioxide combined with itraconazole for the treatment of refractory AML."	( [Synergistic Killing Effects of Arsenic Trioxide Combined with Itraconazole on KG1a Cells]. Fan, JX; Guo, KY; Li, YM; Wu, JW; Xiao, WT; Ye, YB; Zeng, YJ; Zhen, R, 2017)	0.46
" It has been demonstrated to be informative and helpful to quantify the modification in drug exposure due to specific physio-pathological conditions, age, genetic polymorphisms, ethnicity and particularly drug-drug interactions (DDIs)."	( Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S, 2018)	0.48
" We assessed three drug-drug interactions of avatrombopag as a victim with dual or selective CYP2C9/3A inhibitors and inducers."	( Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Aluri, J; Boyd, P; Chang, MK; Ferry, J; Lai, WG; Nomoto, M; Rege, B; Schuck, E; Siu, YA; Yasuda, S; Zamora, CA, 2018)	0.48
" Herein, we aimed to evaluate the effect of ITC in combination with the mAb-anti-Ly6G in an experimental model of pulmonary PCM."	( Itraconazole in combination with neutrophil depletion reduces the expression of genes related to pulmonary fibrosis in an experimental model of paracoccidioidomycosis. Arango, JC; González, A; Pino-Tamayo, PA; Puerta-Arias, JD; Salazar-Peláez, LM, 2018)	0.48
" A combination of in vitro data, clinical pharmacokinetic data, and drug-drug interaction (DDI) data of osimertinib in oncology patients were used to develop the physiologically based pharmacokinetic (PBPK) model and verify the DDI data of osimertinib."	( Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. Ballard, P; Pilla Reddy, V; Sharma, P; Vishwanathan, K; Walker, M, 2018)	0.48
"9-ms 1064-nm Nd:YAG laser alone or combined with itraconazole for treatment of toenail onychomycosis."	( [Effect of 0.9-ms 1064-nm Nd:YAG laser combined with itraconazole for treatment of toenail onychomycosis]. Han, X; Hu, YQ; Hu, YX; Hunag, SY; Liu, KX; Lu, Y; Mao, ZH; Wu, Z; Yang, YM; Zhong, ZM; Zhou, ST; Zhou, XY, 2018)	0.48
" The patients in group A were treated with laser alone, and those in group B were treated with laser combined with itraconazole."	( [Effect of 0.9-ms 1064-nm Nd:YAG laser combined with itraconazole for treatment of toenail onychomycosis]. Han, X; Hu, YQ; Hu, YX; Hunag, SY; Liu, KX; Lu, Y; Mao, ZH; Wu, Z; Yang, YM; Zhong, ZM; Zhou, ST; Zhou, XY, 2018)	0.48
" Given the scarcity of options for sporotrichosis treatment and the promising activity of diphenyl diselenide (PhSe)2 against a diversity of fungal pathogens, this study aimed to evaluate the in vitro susceptibility of Sporothrix brasiliensis to (PhSe)2 alone and in combination with itraconazole (ITC)."	( Antifungal activity of diphenyl diselenide alone and in combination with itraconazole against Sporothrix brasiliensis. Klafke, GB; Mattei, AS; Mendes, JF; Poester, VR; Ramis, IB; Sanchotene, KO; Xavier, MO, 2019)	0.51
" The overall objective of this study is to provide a comprehensive mechanistic PBPK model for itraconazole in order to increase the confidence in its drug-drug interaction (DDI) predictions."	( Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. Ericsson, H; Janzén, D; Kanebratt, KP; Lennernäs, H; Lundahl, A; Prieto Garcia, L, 2018)	0.48
" Using drugs with potential to be repurposed, combined with 5-fluorouracil, the aim of this project was to investigate whether this combination led to therapeutic benefits, comparing with the isolated drugs."	( Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations. Correia, A; Gärtner, F; Silva, D; Vale, N; Vilanova, M, 2018)	0.48
"Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug-drug interaction (DDI) studies."	( Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model. Cabalu, TD; Callegari, E; Chen, Y; Einolf, H; Hall, SD; Liu, L; Parrott, N; Peters, SA; Schuck, E; Sharma, P; Tracey, H; Upreti, VV; Zheng, M; Zhu, AZX, 2019)	0.51
" Accordingly, the drug-drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical studies."	( Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. Bairlein, M; Denner, K; Fricke, R; Gieschen, H; Graudenz, K; Korjamo, T; Koskinen, M; Prien, O; von Bühler, CJ; Wilkinson, G; Zurth, C, 2019)	0.51
"We treated 5 refractory and complex cases of chromoblastomycosis with 5-aminolevulinic acid photodynamic therapy (ALA-PDT) combined with oral antifungal drugs."	( Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro. Chen, X; Hu, Y; Liu, K; Lu, Y; Mao, Z; Qi, X; Sun, H; Wu, Z; Yang, Y; Zhou, X, 2019)	0.51
"These results provide the basis for the development of a new therapeutic approach, and ALA-PDT combined with oral antifungal drugs constitutes a promising alternative method for the treatment of refractory and complex cases of chromoblastomycosis."	( Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro. Chen, X; Hu, Y; Liu, K; Lu, Y; Mao, Z; Qi, X; Sun, H; Wu, Z; Yang, Y; Zhou, X, 2019)	0.51
" An integrated in silico, in vitro, and clinical approach including a clinical drug interaction study as well as a bespoke physiologically based pharmacokinetic (PBPK) model was used to assess the drug-drug interaction (DDI) risk."	( Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations. Cahn, AP; Georgiou, A; Harrell, AW; Hessel, EM; Marotti, M; Patel, A; Riddell, K; Taskar, KS; Taylor, M; Tracey, H; Wilson, R, 2020)	0.56
"Cyclodextrins are widely used pharmaceutical excipients, particularly for insoluble compounds dosed orally, such as the oral solution of itraconazole, which is frequently used in clinical drug-drug interaction studies to inhibit cytochrome P450 3A."	( Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study. Chen, JZ; Chen, Y; Chiang, PC; Chinn, LW; Durk, MR; Jones, NS; Liu, J; Mao, C; Nagapudi, K; Plise, EG; Wong, S, 2020)	0.56
"In this study, we aimed to develop and validate a sensitive and simple ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the quantification of gilteritinib in plasma and to investigate whether CYP3A4 inhibitors (fluconazole and itraconazole) could influence the pharmacokinetics of gilteritinib from a drug-drug interaction study in rats."	( An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug-Drug Interaction Study. Chen, D; Chen, Z; Wang, Q; Ye, XY, 2020)	0.56
" The validated UPLC-MS/MS method was successfully applied to a drug-drug interaction study between gilteritinib and CYP3A4 inhibitors (fluconazole and itraconazole) in rats."	( An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug-Drug Interaction Study. Chen, D; Chen, Z; Wang, Q; Ye, XY, 2020)	0.56
" Consequently, the potential of iberdomide as a victim of drug-drug interactions (DDI) was evaluated in a clinical study with healthy subjects."	( Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects. Atsriku, C; Gaudy, A; Liu, L; MacGorman, K; Palmisano, M; Surapaneni, S; Xue, Y; Ye, Y, 2021)	0.62
"6 mg) and when administered with the CYP3A and P-gp inhibitor itraconazole (200 mg twice daily on day 1 and 200 once daily on days 2 through 9)."	( Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects. Atsriku, C; Gaudy, A; Liu, L; MacGorman, K; Palmisano, M; Surapaneni, S; Xue, Y; Ye, Y, 2021)	0.62
"Develop a physiologically based pharmacokinetic (PBPK) model of ivosidenib using in vitro and clinical PK data from healthy participants (HPs), refine it with clinical data on ivosidenib co-administered with itraconazole, and develop a model for patients with acute myeloid leukemia (AML) and apply it to predict ivosidenib drug-drug interactions (DDI)."	( Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Fan, B; Ke, A; Le, K; Prakash, C; Yang, H, 2020)	0.56
" Concerns about drug-drug interactions (DDIs) have meant patients receiving drugs that inhibit CYP3A4 were ineligible for acumapimod trials."	( A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor. Agyemang, A; Farrell, C; Moore, W; Parkin, J, 2021)	0.62
"This drug-drug interaction study determined whether the metabolism and distribution of the Polo-like kinase 1 inhibitor, volasertib, is affected by co-administration of the P-glycoprotein and cytochrome P-450 3A4 inhibitor, itraconazole."	( Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors. Chizhikov, E; Fritsch, H; Lang, I; Liptai, B; Liu, D; Taube, T, 2020)	0.56
" Due to its widespread use and CYP3A4-mediated metabolism, there is concern regarding drug-drug interactions (DDIs), particularly a suboptimal LNG exposure when co-administered with CYP3A4 inducers, potentially leading to unintended pregnancies."	( Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H, 2021)	0.62
"To assess the pharmacokinetic of itraconazole capsule formulation and its active metabolite, hydroxyitraconazole, in adults with HIV diagnosed with talaromycosis in an endemic area, and to evaluate the drug-drug interaction between itraconazole/hydroxyitraconazole (ITC/OH-ITC) and efavirenz."	( Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. Chaiwarith, R; Chindamporn, A; Cressey, TR; Kaewpoowat, Q; Sirisanthana, T; Worasilchai, N; Yasri, S, 2021)	0.62
" The clinical impact of this drug-drug interaction on talaromycosis treatment or prophylaxis in the era of potent ART needs further evaluation."	( Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. Chaiwarith, R; Chindamporn, A; Cressey, TR; Kaewpoowat, Q; Sirisanthana, T; Worasilchai, N; Yasri, S, 2021)	0.62
" In vitro experiments proved that terbinafine combined with itraconazole achieves better antifungal effects."	( Terbinafine Hydrochloride Combined With Itraconazole for Fungal Skin Diseases: A Randomized Controlled Trial. Chen, C; Lai, H; Liao, W; Liu, S; Zhang, D, )	0.13
"Terbinafine combined with itraconazole achieves better therapeutic effects in fungal skin diseases."	( Terbinafine Hydrochloride Combined With Itraconazole for Fungal Skin Diseases: A Randomized Controlled Trial. Chen, C; Lai, H; Liao, W; Liu, S; Zhang, D, )	0.13
" The current study aims to understand the drug-drug interaction (DDI) risk of milademetan as a CYP3A substrate during its early clinical development."	( Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan. Abutarif, M; Hong, Y; Ishizuka, H; Ishizuka, T; LaCreta, F; Lee, M; Tachibana, M; Watanabe, A, 2021)	0.62
" This model was built based on physiochemical data and clinical in vivo drug-drug interaction (DDI) studies with itraconazole and fluconazole, and verified against data from an in vivo rifampicin DDI study and an absolute bioavailability study."	( Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. Cohen-Rabbie, S; Freshwater, T; Jain, L; Schalkwijk, S; Tomkinson, H; Vishwanathan, K; Wild, M; Xu, S; Zhou, D; Zhou, L, 2021)	0.62
"We investigated savolitinib pharmacokinetics (PK) when administered alone or in combination with rifampicin, itraconazole or famotidine, and investigated midazolam PK when administered with or without savolitinib in healthy males."	( Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam. Burke, W; Cantarini, M; Frewer, P; Goldwater, R; Han, D; Hara, I; Li, Y; Ren, S; Scarfe, G; Schalkwijk, S; Vishwanathan, K, 2022)	0.72
" Photodynamic therapy combined with oral itraconazole was administered, and the patient recovered in a short time."	( Photodynamic therapy combined with itraconazole against a case of cutaneous blastomycosis. Cheng, QH; Ding, W; He, Y; Huang, XQ; Lei, X; Wu, JJ; Zhang, XJ, 2021)	0.62
" As such, this 2-part clinical drug-drug interaction study was conducted to assess the effect of itraconazole (a strong CYP3A4 inhibitor), rifampicin (a strong CYP3A4 inducer), rabeprazole, and omeprazole (both proton pump inhibitors) on the pharmacokinetics of belumosudil."	( A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors. Alabanza, A; Lohmer, L; Patel, J; Schueller, O; Singh, N; Willson, A, 2022)	0.72
" albicans isolates and to evaluate the inhibitory activity of eucalyptol on Candida biofilm, alone and in combination with antifungal agents."	( Anti-biofilm properties of eucalyptol in combination with antifungals against Candida albicans isolates in patients with hematological malignancy. Abolghasemi, S; Falahati, M; Farahyar, S; Ghasemi, R; Keymaram, M; Khalandi, H; Lotfali, E; Mahmoudi, S; Raiesi, O; Sadeghi, F; Shamsaei, S, 2022)	0.72
" Here, we investigate the pharmacokinetic drug-drug interaction potential of trilaciclib."	( Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W, 2022)	0.72
"Overall, the drug-drug interaction and safety profiles of trilaciclib in these studies support its continued use in patients with extensive-stage small-cell lung cancer."	( Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W, 2022)	0.72
" Understanding potential drug-drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies."	( Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers. Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L, 2022)	0.72
" Here, we report the results from 2 drug-drug interaction studies."	( Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects. Chen, J; Gu, J; Hackling, M; Prince, W; Shah, B; Stringer, R; Woessner, R; Zhang, Y, 2022)	0.72
" It is metabolized via cytochrome P450 (CYP) 3A, but little is known about the drug-drug interactions of JNJ-56136379 when combined with drugs that inhibit or are metabolized by CYP3A."	( Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir). Biermer, M; Biewenga, J; Hillewaert, V; Kakuda, TN; Nangosyah, J; Palmer, M; Rasschaert, F; Snoeys, J; Talloen, W; Vandenbossche, J; Yogaratnam, J, 2022)	0.72
" Based on nonclinical in vitro characterization of gepotidacin metabolism, two phase I studies were conducted in healthy participants to investigate clinical drug-drug interactions (DDIs)."	( Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters. Barth, A; Brimhall, DB; Dumont, EF; Nguyen, D; Perry, CR; Shabbir, S; Srinivasan, M; Swift, B; Thomas, S; Zamek-Gliszczynski, MJ, 2023)	0.91
" Considering the possibility of combination therapy in patients with NSCLC, we investigated the drug-drug interaction (DDI) potential of SH-1028 both in vitro and in clinical trials."	( Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials. Ding, J; Ding, Y; He, C; Li, X; Liu, B; Liu, Y; Shan, R; Wang, Y; Wang, Z; Xie, J; Xu, Y; Zhou, H; Zhu, M, 2023)	0.91
" Phase I studies investigated the drug-drug interactions of futibatinib with itraconazole (a dual P-gp and strong CYP3A inhibitor), rifampin (a dual P-gp and strong CYP3A inducer), or midazolam (a sensitive CYP3A substrate) in healthy adult participants."	( Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib. Benhadji, KA; Gao, L; He, Y; Hunt, A; Mina, M; Sonnichsen, D; Takenaka, T; Yamamiya, I, 2023)	0.91
"Itraconazole is a potent inhibitor of cytochrome P450 3A4 (CYP3A4), associated with numerous drug-drug interactions (DDI)."	( Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data. Bergagnini-Kolev, M; Curran, AK; Kane, K; Templeton, IE, 2023)	0.91
" Clinical pharmacokinetic drug-drug interaction (DDI) of ocedurenone with CYP3A inhibitor and inducer were investigated in healthy volunteers."	( Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo. Liu, J; McCabe, J; Tan, X; Wang, P; Yang, F; Zhang, J, 2023)	0.91
" This study is aimed to evaluate the in vitro activity of doxycycline combined with antifungal therapy against dominant Mucorales pathogens."	( In vitro combination with doxycycline plus antifungals against clinical Mucorales pathogens. Liang, G; Liu, W; Pathakumari, B; Song, G; Zhang, M; Zheng, H, 2023)	0.91
"The vitro antifungal activity of retigeric acid B (RAB), a pentacyclic triterpenoid from the lichen species Lobaria kurokawae, was evaluated alone and in combination with fluconazole, ketoconazole, and itraconazole against Candida albicans using checkerboard microdilution and time-killing tests."	( In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Cheng, A; Lou, H; Sun, L; Sun, S; Wu, X; Zhang, Y, 2009)	0.54
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38

Excerpt	Reference	Relevance
" Variable interpatient bioavailability and detrimental drug interactions with p450 enzyme-inducing agents are well documented."	( Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Denning, DW; Law, D; Moore, CB, 1994)	0.29
" The bioavailability (90% confidence intervals) of itraconazole relative to that after the full meal, was 54% (41-77%) on an empty stomach and 86% (65-102%) after a light meal."	( Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Laufen, H; Pfaff, G; Wildfeuer, A; Yeates, RA; Zimmermann, T, 1994)	0.29
" This itraconazole-cyclodextrin solution was well absorbed and was effective in the treatment of experimental invasive aspergillosis; it demonstrates the potential of this class of agents in improving therapy for invasive aspergillosis."	( Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis. Fothergill, AW; Patterson, TF; Rinaldi, MG, 1993)	0.29
" The improved effectiveness of these agents is probably related to their rapid penetration into the nails and prolonged bioavailability at the site of infection."	( New approaches to the treatment of onychomycosis. De Doncker, P; Roseeuw, D, 1993)	0.29
"Our findings suggest that the higher bioavailability of this new formulation of itraconazole may be of benefit in seriously ill patients who are not able to ingest adequate quantities of food."	( Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Cauwenbergh, GF; De Beule, KL; Heykants, JJ; Van de Velde, VJ; Van Peer, AP; Van Rooy, P; Woestenborghs, RJ, )	0.13
" In addition, a comparative evaluation of the oral bioavailability of itraconazole was made in volunteers after intake of Funazol and Sporanox."	( Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. Arrese, JE; De Doncker, P; Jacqmin, P; Pierard, GE; Pierard-Franchimont, G; Van de Velde, V, 1995)	0.29
" The systemic bioavailability of desmethylastemizole was also increased."	( Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Lefebvre, RA; Van Peer, A; Woestenborghs, R, 1997)	0.3
"Thirty-three healthy individuals participated in an open-label, randomized, three-way crossover study designed to compared the bioavailability of a single 200-mg oral dose of itraconazole when administered alone or after treatment with ranitidine, both with and without coadministration of a cola beverage."	( Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. Klausner, M; Lange, D; Pavao, JH; Wu, J, 1997)	0.3
"To determine the disposition of itraconazole in cats after single IV and oral dosing (as a solution or capsule) and multiple oral (capsule) dosing, and to establish bioavailability after oral administration of the solution."	( Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Boothe, DM; Calvin, J; Dvorak, J; Herring, I; Way, N, 1997)	0.3
"864 micrograms/ml, MRT was 48 +/- 17 hours, and bioavailability was 78."	( Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Boothe, DM; Calvin, J; Dvorak, J; Herring, I; Way, N, 1997)	0.3
"Oxybutynin has low oral bioavailability due to an extensive presystemic metabolism."	( Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Aranko, K; Juhakoski, A; Lukkari, E; Neuvonen, PJ, 1997)	0.3
"The oral bioavailability of buspirone is very low as a result of extensive first-pass metabolism."	( Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Kantola, T; Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1997)	0.3
" In conclusion, the oral solution of itraconazole generates effective levels in plasma and saliva in HIV-infected patients; its relative bioavailability is not modified by the stage of HIV infection."	( Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Ajana, F; Bazin, C; Chwetzoff, E; Datry, A; Le Moing, JP; Levron, JC; Reynes, J, 1997)	0.3
" The bioavailability of fluconazole is much less varied although validation of compliance is a situation where obtaining serum concentrations may provide additional information."	( Therapeutic drug monitoring of systemic antifungal therapy. Gore, SJ; Graybill, JR; Hardin, TC; Summers, KK, 1997)	0.3
"The bioavailability of itraconazole from an extemporaneously prepared suspension was compared with its bioavailability from the commercially available capsules."	( Relative bioavailability of itraconazole from an extemporaneously prepared suspension and from the marketed capsules. Bowman, JL; Buice, RG; Christensen, KJ; Gubbins, PO; Gurley, BJ, 1998)	0.3
" The oral bioavailability of the solubilizer hydroxypropyl-beta-cyclodextrin was less than 1% in the majority of the patients."	( Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Cornu, G; De Beule, K; de Repentigny, L; Jacqmin, P; Leclerc, JM; Ratelle, J; Sokal, EM, 1998)	0.3
"To evaluate the effect of food on the bioavailability of itraconazole (ITR) hydroxypropyl-beta-cyclodextrin (HP-beta-CD) solution under multiple-dose to steady-state conditions, and to determine the pharmacokinetics of ITR solution at steady state."	( Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Barone, JA; Bierman, RH; Colaizzi, JL; Guarnieri, J; Hassell, AE; Jessen, L; Moskovitz, BL, )	0.13
"The bioavailability of ITR and OH-ITR is enhanced when ITR oral solution is given in the fasted state; this was true for both single and multiple dosing to steady state."	( Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Barone, JA; Bierman, RH; Colaizzi, JL; Guarnieri, J; Hassell, AE; Jessen, L; Moskovitz, BL, )	0.13
"Omeprazole affects itraconazole kinetics, leading to a reduction in bioavailability and Cmax."	( Effect of omeprazole on the pharmacokinetics of itraconazole. Jaruratanasirikul, S; Sriwiriyajan, S, 1998)	0.3
" Itraconazole has recently undergone reformulation as a solution, which gives significant added advantages in bioavailability and increases the practical applications."	( Itraconazole: managing mycotic complications in immunocompromised patients. Graybill, JR, 1998)	0.3
" This work shows a good bioavailability of itraconazole oral solution during the early phase after allogeneic BMT, but more data are needed for the late phases."	( Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Belhabri, A; Chwetzoff, E; Fiere, D; Kranzhöfer, N; Le Moing, JP; Levron, JC; Michallet, M; Persat, F; Piens, MA; Prat, C, 1998)	0.3
" Ten (50%) patients in the itraconazole group were taking concomitant medications that could potentially affect the bioavailability of itraconazole."	( Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis. Clumeck, N; De Vroey, C; De Wit, S; O'Doherty, E, )	0.13
"The extensive interindividual variability in oral bioavailability of itraconazole prompted an assessment of the bioequivalence of two formulations marketed in Brazil, namely, Sporanox (reference) and Traconal (test)."	( Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study. Bozza, FA; Ponte, CG; Struchiner, CJ; Suarez-Kurtz, G; Vicente, FL, 1999)	0.3
"Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%."	( Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 1999)	0.3
" Therapeutic itraconazole monitoring by plasma concentrations measurement is justified by its dose-dependent pharmacokinetics, drug interactions, and frequent bioavailability modifications observed in immunocompromised patients."	( [Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring]. Cheymol, G; Poirier, JM, 1999)	0.3
" Itraconazole has a broader spectrum of activity but the capsules give erratic bioavailability in neutropenic patients."	( A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Morgenstern, GR; Prentice, AG; Prentice, HG; Ropner, JE; Schey, SA; Warnock, DW, 1999)	0.3
" Since the bioavailability of itraconazole is reduced in these patients, a satisfactory dosing regimen remains to be defined."	( Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Glasmacher, A; Hahn, C; Marklein, G; Molitor, E; Sauerbruch, T; Schmidt-Wolf, IG, 1999)	0.3
"The role of itraconazole in anti-fungal prophylaxis has been limited by the low bioavailability of the capsule formulation but the bioavailability of the oral solution is much improved."	( Antifungal prophylaxis with itraconazole oral solution in neutropenic patients. Kibbler, CC, 1999)	0.3
" When given orally, its absorption was low, with a mean absolute bioavailability of 16."	( Absorption, first-pass metabolism, and disposition of itraconazole in rats. Jun, H; Kang, E; Lee, KC; Lee, KH; Shin, BS; Yoo, SD, 2000)	0.31
" Fluconazole and itraconazole are widely used in chemoprophylaxis because of their favourable oral bioavailability and safety profiles."	( Current management of fungal infections. Meis, JF; Verweij, PE, 2001)	0.31
" The enhanced absorption and bioavailability of itraconazole from these new formulations make them ideal for the treatment of systemic fungal infections in a wide range of patient populations."	( Pharmacology of itraconazole. De Beule, K; Van Gestel, J, 2001)	0.31
" The recent development of an itraconazole oral solution and an intravenous itraconazole solution has increased the options for the use of this drug and increased the oral bioavailability in a variety of at-risk patients."	( Clinical experience with itraconazole in systemic fungal infections. Boogaerts, M; Maertens, J, 2001)	0.31
" These formulations have improved the solubility of itraconazole, leading to enhanced absorption and bioavailability compared with the original capsule formulation, without having an impact on the tolerability profile of itraconazole."	( Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. de Beule, K; van der Geest, R; Willems, L, 2001)	0.31
" Itraconazole-cyclodextrin is well absorbed even in the presence of chemotherapy-induced neutropenia."	( The use of itraconazole as prophylaxis against invasive fungal infection in blood and marrow transplant recipients. Boyle, BM; McCann, SR, 2000)	0.31
"This open-label, two-way crossover study was undertaken to determine whether the enteric formulation of didanosine influences the pharmacokinetics of itraconazole or fluconazole, two agents frequently used to treat fungal infections that occur with HIV infection, and whose bioavailability may be influenced by changes in gastric pH."	( Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Damle, B; Hess, H; Kaul, S; Knupp, C, 2002)	0.31
" This formulation has a higher bioavailability and leads to higher local concentrations in the oral cavity which are advantages over the solid capsule formulation."	( Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. Beijnen, JH; Bult, A; Koks, CH; Meenhorst, PL, 2002)	0.31
"Oral itraconazole solution has adequate bioavailability in liver transplant recipients for effective antifungal prophylaxis."	( Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Busuttil, RW; Winston, DJ, 2002)	0.31
" General considerations that may be associated with recurrent infections are, a genetic predisposition and suboptimal bioavailability of drug, resulting in insufficient concentration at the target site."	( Onychomycosis: strategies to improve efficacy and reduce recurrence. Baran, R; Gupta, AK; Summerbell, R, 2002)	0.31
" The results suggest that cocrystals of drug molecules have the possibility of achieving the higher oral bioavailability common for amorphous forms of water-insoluble drugs while maintaining the long-term chemical and physical stability that crystal forms provide."	( Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. Almarsson, O; Guzmán, HR; MacPhee, JM; Morissette, SL; Moulton, B; Peterson, ML; Remenar, JF, 2003)	0.32
" Hence, the method is suitable for use in pharmacokinetic and bioavailability studies of itraconazole."	( Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. Nisar, UR; Wong, JW; Yuen, KH, 2003)	0.32
" The extent of absolute oral bioavailability (F) was 34."	( Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. Choi, KY; Kim, YC; Lee, MG; Shin, JH, 2004)	0.32
" Two of the first nine patients, in whom bioavailability was compromised due to significant vomiting and/or diarrhoea, died of probable or proven invasive aspergillus."	( A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. Brown, M; Grigg, AP; Roberts, AW; Slavin, MA; Szer, J, 2004)	0.32
" The mean bioavailability of itraconazole was comparable after administration of the HPMC solid dispersion, compared to Sporanox, while it was lower after administration of the Eudragit E100 or Eudragit E100-PVPVA64 dispersions."	( Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Bouche, MP; Brewster, ME; Daems, T; de Hoon, J; Depre, M; Peeters, J; Prinsen, P; Six, K; Van den Mooter, G; Van Hecken, A; Verreck, G, 2005)	0.33
"The findings are in line with the hypothesis that the determination of the bioavailability of highly variable CYP3A substrates might be improved by simultaneous non-interfering phenotyping."	( Simultaneous itraconazole bioequivalence assessment and CYP3A phenotyping in South American subjects. Bellocq, B; del Campo, MJ; Estevez-Carrizo, FE; Leal, C; Ruiz, S; Siri, MT, 2005)	0.33
"A population pharmacokinetic analysis of cyclosporine (CsA) was performed, and the influence of covariates on CsA oral clearance and relative bioavailability was investigated."	( Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Akhlaghi, F; Baheti, G; Rosenbaum, SE; Trull, AK, 2005)	0.33
"The objective of this study was to elucidate the feasibility to improve the solubility and bioavailability of poorly water-soluble itraconazole via solid dispersions by using supercritical fluid (SCF)."	( Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Hwang, SJ; Jun, SW; Kim, MS; Lee, S; Nam, K; Park, JS; Woo, JS, 2005)	0.33
" Bioavailability after administration of capsules relative to solution was 33."	( Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. Davis, JL; Papich, MG; Salmon, JH, 2005)	0.33
" These results demonstrate that the SEDDS of itraconazole composed of Transcutol, Pluronic L64 and tocopherol acetate greatly enhanced the bioavailability of itraconazole after the dose, particularly not influenced by food intake or not."	( A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. Hong, JY; Kim, CK; Kim, JK; Park, JS; Song, YK, 2006)	0.33
" BCS class II compounds are poorly soluble but highly permeable, exhibiting bioavailability that is limited by dissolution."	( Cryogenic liquids, nanoparticles, and microencapsulation. Chen, X; Hu, J; Johnston, KP; McConville, JT; Overhoff, KA; Purvis, T; Rogers, TL; Sinswat, P; Vaughn, JM; Williams, RO, 2006)	0.33
" The bioavailability of the liquid formulation was significantly lower when the solution was given by a feeding tube."	( Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Besuden, M; Bode, U; Fleischhack, G; Glasmacher, A; Hasan, C; Kreutzberg, S; Lampe, D; Simon, A; Vezmar, S, 2007)	0.34
" The ultimate goals were to determine the relative bioavailability between the two oral formulations (capsules vs oral solution) and to optimise dosing regimens in these patients."	( Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Bell, SC; Charles, BG; Friberg, LE; Hennig, S; Miller, H; Wainwright, CE, 2006)	0.33
"The objectives of this retrospective study were to examine the relationship between the bioavailability of itraconazole and the type of food consumed and to determine the effects of food consumption on the pharmacokinetic parameters following a single oral dose of itraconazole in healthy volunteers."	( Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. Baek, MS; Choi, BK; Kwon, KI; Park, IS; Yun, HY, 2006)	0.33
"The primary objective of the study was to estimate the population pharmacokinetic parameters for itraconazole and hydroxy-itraconazole, in particular, the relative oral bioavailability of the capsule compared with solution in adult cystic fibrosis patients, in order to develop new dosing guidelines."	( A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Bell, SC; Charles, BG; Duffull, SB; France, M; Hennig, S; Miller, H; Wainwright, CE; Waterhouse, TH, 2007)	0.34
" The relative bioavailability for itraconazole capsules was 82% compared with the solution."	( A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Bell, SC; Charles, BG; Duffull, SB; France, M; Hennig, S; Miller, H; Wainwright, CE; Waterhouse, TH, 2007)	0.34
" It was anticipated that the semisolid dosage forms would be industrially applicable to improving the bioavailability of poorly water-soluble drugs."	( Characterization of itraconazole semisolid dosage forms prepared by hot melt technique. Ji, CW; Lee, BJ; Park, ES; Sah, H; Shim, SY, 2006)	0.33
" The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine."	( Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Inoue, Y; Kaneko, S; Niioka, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2007)	0.34
" Due to the biopharmaceutical differences of SES in terms of efficient solubilization, easy dispersibility and higher lymphatic transport, the in vivo bioavailability of SES was about twice greater than that of SD in rats."	( In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Lee, BJ; Park, MJ; Ren, S, 2007)	0.34
"The main objective of this study was to improve the inclusion formation between itraconazole and beta-cyclodextrin and thus enhance dissolution amount and bioavailability characteristics of itraconazole."	( Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with beta-cyclodextrin using supercritical carbon dioxide. Al-Marzouqi, AH; Hamza, AA; Hassan, HA; Jobe, B; Ramadan, GA, 2007)	0.34
" When administered as oral solutions, the itraconazole:HBenBCD formulation provided higher oral bioavailability than the Sporanox oral solution."	( Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations. Buchanan, CM; Buchanan, NL; Edgar, KJ; Klein, S; Little, JL; Ramsey, MG; Ruble, KM; Wacher, VJ; Wempe, MF, 2007)	0.34
" After loading itraconazole into OMS, its oral bioavailability was compared with the crystalline drug and the marketed product Sporanox in rabbits and dogs."	( Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Aerts, CA; Annaert, P; Augustijns, P; Jammaer, JA; Martens, JA; Mellaerts, R; Mols, R; Van den Mooter, G; Van Humbeeck, J, 2008)	0.35
" This study was designed to compare the oral bioavailability and food-effect of SMEDDS of itraconazole (ITRA-GSMP capsule containing 50mg itraconazole) to that of the currently marketed formulation (Sporanox capsule containing 100mg itraconazole)."	( Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Hong, JY; Kim, CK; Lim, SJ; Song, YK; Woo, JS, 2008)	0.35
" Although itraconazole co-administration is known to increase the bioavailability of a racemic mixture of fexofenadine, little is known about the stereoselective inhibition of P-gp activity by itraconazole."	( The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Miura, M; Suzuki, T; Tateishi, T; Uno, T, 2008)	0.35
" Clearance, volume of distribution and the absorption rate constant were 12."	( Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. Fujimoto, Y; Horiike, S; Kanbayashi, Y; Matsumoto, Y; Nomura, K; Okamoto, K; Shimazaki, C; Shimizu, D; Shimura, K; Takagi, T; Taniwaki, M, 2008)	0.35
"2, w/w) yielded improved bioavailability in mice."	( High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Johnston, KP; McConville, JT; Miller, DA; Tam, J; Williams, RO; Yang, W; Zhou, J, 2008)	0.35
" The effect of medium composition on the intrinsic dissolution rate of itraconazole was evaluated as this drug has extremely poor solubility and its bioavailability is affected by food."	( In vitro evaluation of the dissolution behaviour of itraconazole in bio-relevant media. Dyas, AM; Ford, JL; Ghazal, HS; Hutcheon, GA, 2009)	0.35
" However, the efficacy and bioavailability of these drugs have been limited by their poor aqueous solubility and dissolution rate."	( Physicochemical properties of antifungal drug-cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques. Adem, A; Al-Marzouqi, AH; Elwy, HM; Shehadi, I, 2009)	0.35
"8 by minimizing undissolved excess surface area may be expected to be beneficial for raising bioavailability by gastrointestinal delivery."	( Highly supersaturated solutions from dissolution of amorphous itraconazole microparticles at pH 6.8. Johnston, KP; Matteucci, ME; Miller, MA; Paguio, JC; Williams, RO, )	0.13
"Amorphous engineered particle compositions of itraconazole (ITZ) and potential concentration enhancing polymers, cellulose acetate phthalate (CAP) and polyvinyl acetate phthalate (PVAP), were produced by ultra-rapid freezing to investigate the effect of these polymers on the bioavailability of ITZ solid dispersions."	( Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. DiNunzio, JC; McGinity, JW; Miller, DA; Williams, RO; Yang, W, )	0.13
" These results suggest that oral solution itraconazole significantly interacts with calcineurin inhibitors with a wide interindividual variability in allogeneic HSCT recipients, which could partly be explained by the variable bioavailability of oral solution itraconazole."	( Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Aisa, Y; Ikeda, Y; Kato, J; Mori, T; Nakamura, Y; Okamoto, S, 2009)	0.35
" Oral bioavailability was determined using a Sprague-Dawley rat model."	( Fusion processing of itraconazole solid dispersions by kinetisol dispersing: a comparative study to hot melt extrusion. Brough, C; DiNunzio, JC; McGinity, JW; Miller, DA; Williams, RO, 2010)	0.36
" Oral bioavailability of the 30/70 dispersion was, although lower compared to the marketed Sporanox formulation, significantly enhanced compared to the crystalline drug."	( Itraconazole/TPGS/Aerosil200 solid dispersions: characterization, physical stability and in vivo performance. Augustijns, P; Froyen, L; Houthoofd, K; Martens, JA; Mols, R; Van den Mooter, G; Van Eerdenbrugh, B; Van Humbeeck, J; Van Speybroeck, M, 2009)	0.35
"001), with an enormous reduction in the oral bioavailability of ebastine and significantly reduced histamine-induced skin reactions."	( Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. Cha, IJ; Lee, SS; Liu, KH; Shin, JG; Shon, JH; Yeo, CW, 2010)	0.36
"The effect of supersaturation on bioavailability of inhaled nebulized aerosols is compared for amorphous versus crystalline nanoparticulate dispersions."	( Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Johnston, KP; Williams, RO; Yang, W, 2010)	0.36
" To enhance the oral bioavailability of such compounds, pharmaceutical formulations target the creation of a supersaturated solution."	( Growth of itraconazole nanofibers in supersaturated simulated intestinal fluid. Aerts, A; Augustijns, P; Caremans, TP; Martens, JA; Mellaerts, R; Van den Mooter, G; Vermant, J, 2010)	0.36
" Oral bioavailability of lead formulations was also assessed in animal models."	( Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol Dispersing. Brough, C; DiNunzio, JC; Hughey, JR; McGinity, JW; Miller, DA; Williams, RO, 2010)	0.36
" Co-administration of Icz with CsA resulted in significant increases of oral bioavailability of CsA."	( Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine in cats. Kamishina, H; Katayama, M; Katayama, R, 2010)	0.36
"The purpose of this study is to compare the bioavailability of two itraconazole (CAS 84625-61-6) capsule formulations."	( Bioequivalence study of two formulations of 100 mg capsule of itraconazole. Quantification by tandem mass spectrometry. Donaduzzi, CM; dos Santos, MB; Favreto, WA; Manfio, JL; Pugens, AM; Weich, A, 2010)	0.36
" A simple formulation of 1:2 (w/w) ITZ/HPMC-P dispersion in a capsule was compared to crystalline ITZ in a capsule in a dog bioavailability study, with the dispersion being significantly more bioavailable."	( A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. Byrn, S; Campbell, C; Engers, D; Gent, P; Hossack, S; Ivanisevic, I; Jimenez-Novoa, J; Newman, A; Templeton, A; Teng, J; Thomson, J, 2010)	0.36
" The dissolution, bioavailability in rats and stability of solid dispersions were evaluated."	( Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability. Balakrishnan, P; Choi, HG; Lee, MK; Oh, DH; Park, YJ; Xuan, JJ; Yang, HJ; Yeo, WH; Yong, CS, 2010)	0.36
"This system is envisioned to increase bioavailability of ITZ by improving aqueous dispersibility and increasing antifungal penetration, thereby increasing antifungal activity of the entrapped drug."	( Itraconazole-loaded poly(lactic-co-glycolic) acid nanoparticles for improved antifungal activity. Damann, K; Leonardi, C; Patel, NR; Sabliov, CM, 2010)	0.36
" Therefore, SDs obtained by MW technique using vitamin E TPGS as carrier provide a promising way to increase the dissolution rate and solubility of poorly bioavailable drugs."	( Characterization of solid dispersions of itraconazole and vitamin E TPGS prepared by microwave technology. De Zordi, N; Macchiavelli, S; Moneghini, M; Princivalle, F; Solinas, D, 2010)	0.36
"Nanosizing techniques are important tools for improving the bioavailability of water insoluble drugs."	( Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Hirvonen, J; Kiesvaara, J; Laaksonen, T; Laru, J; Liu, P; Peltonen, L; Rong, X; van Veen, B, 2011)	0.37
"The objective of this study was to enhance the oral bioavailability of itraconazole (ITZ) with dried drug nanosuspensions."	( Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Chen, H; Mou, D; Wan, J; Xu, H; Yang, X, 2011)	0.37
" In particular, the analogues 30d, 30c, 31c, and 36d exhibited much higher solubility and bioavailability than that of itraconazole."	( Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability. Cao, X; He, H; Liu, X; Liu, Y; Liu, Z; Yang, Y, 2011)	0.37
"Rapid flocculation of nanoparticle dispersions of a poorly water soluble drug, itraconazole (Itz), was utilized to produce amorphous powders with desirable dissolution properties for high bioavailability in rats."	( Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. DiNunzio, J; Johnston, KP; Ludher, BS; Matteucci, ME; Miller, MA; Williams, RO, 2012)	0.38
" However, the oral bioavailability of both compounds varies widely, and dose-serum concentration relationships are poorly defined for these analytes."	( Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection. Buckner, SL; Ceesay, MM; Flanagan, RJ; Morgan, PE; Pagliuca, A, 2011)	0.37
" Fluconazole and voriconazole are well absorbed and exhibit high oral bioavailability, whereas the oral bioavailability of itraconazole and posaconazole is lower and more variable."	( Triazole antifungal agents in invasive fungal infections: a comparative review. Lass-Flörl, C, 2011)	0.37
"The poor solubility of itraconazole (ITR) results in its variable oral absorption and bioavailability and has also proven to be a major setback in developing an efficient oral delivery system."	( Preparation and cyclodextrin assisted dissolution rate enhancement of itraconazolium dinitrate salt. Bansal, G; Jana, AK; Kumar, N; Kumar, S, 2013)	0.39
"The objective of the present study was to enhance solubility and bioavailability of itraconazole by a combined use of membrane emulsification and spray drying solidification technique."	( Enhanced solubility and oral bioavailability of itraconazole by combining membrane emulsification and spray drying technique. Choi, HG; Choi, YK; Kim, JO; Kim, JW; Marasini, N; Poudel, BK; Yang, KY; Yong, CS, 2012)	0.38
" This study shows the utility of an itraconazole-succinic acid cocrystal for improving itraconazole bioavailability while also demonstrating the potential for CO(2) to replace traditional liquid antisolvents in cocrystal preparation, thus making cocrystal production more environmentally benign and scale-up more feasible."	( Formation of itraconazole-succinic acid cocrystals by gas antisolvent cocrystallization. Gupta, RB; Ober, CA, 2012)	0.38
" The PBPK modelling predicted that the bioavailability of itraconazole is likely to be increased after oral administration of ternary complex formulations, especially when itraconazole is formulated as a ternary complex comprising HP-β-CD or HBen-β-CD and Soluplus®."	( Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole. Buchanan, CM; Dressman, JB; Klein, S; Taupitz, T, 2013)	0.39
"Miconazole and itraconazole possess adequate membrane permeability, but only slight water solubility, which limits their bioavailability and antifungal effect."	( Formulation and drying of miconazole and itraconazole nanosuspensions. Cerdeira, AM; Gander, B; Mazzotti, M, 2013)	0.39
" PL increased the systemic bioavailability of ITZ (determined by the AUCplasma to AUClung ratio) as a consequence of their wetting and absorption enhancement effect."	( Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. Amighi, K; Duret, C; Merlos, R; Sebti, T; Vanderbist, F; Wauthoz, N, 2014)	0.4
" The relative bioavailability values with their 95% confidence limit were calculated to be 98."	( Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension. Lin, X; Luo, Q; Tang, X; Tian, B; Yang, S; Yu, H; Zhang, K; Zhang, Y, 2013)	0.39
" While newer antifungal agents are now available, itraconazole is an orally bioavailable agent with broad-spectrum antifungal activity."	( Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Hope, WW; Lestner, J, 2013)	0.39
" The low aqueous solubility hinders their clinical translations due to low bioavailability and dissolution-limited absorption of orally-administered drugs."	( A nanosystem for water-insoluble drugs prepared by a new technology, nanoparticulation using a solid lipid and supercritical fluid. Kim, KS; Lee, ES; Oh, KT; Oh, YT; Park, JW; Youn, YS; Yun, JM, 2013)	0.39
" The SEDDS based on PEGylated bile acids provide a controlled release system with significant improvement of the bioavailability of itraconazole in rats, as demonstrated by the pharmacokinetic studies."	( PEGylated bile acids for use in drug delivery systems: enhanced solubility and bioavailability of itraconazole. Hildgen, P; Le Dévédec, F; Leclair, G; Strandman, S; Zhu, XX, 2013)	0.39
" Due to the suppression of gastric acid secretion, they can significantly alter the intragastric pH conditions and are thus likely to affect the bioavailability of coadministered drugs requiring an acidic gastric environment for dissolution and subsequent absorption."	( Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data. Fotaki, N; Klein, S, 2013)	0.39
" The SNESD-loaded tablet displayed significantly increased oral bioavailability in healthy human volunteers compared with the reference Sporanox® capsule."	( Formulation and in vivo human bioavailability of dissolving tablets containing a self-nanoemulsifying itraconazole solid dispersion without precipitation in simulated gastrointestinal fluid. Choe, JS; Lee, BJ; Oh, KT; Piao, ZZ; Rhee, YS, 2014)	0.4
"In order to investigate the influence of drug physicochemical properties on bioavailability of water insoluble drug nanosuspensions, five drug nanosuspensions were prepared using high pressure homogenization."	( Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions. Cheng, J; Cun, D; Fang, L; Li, W; Liu, J; Quan, P; Xiang, R; Zhang, Y, 2014)	0.4
" The in vivo study showed that the NS formulation has a similar systemic bioavailability to Sporanox® while providing a sustained plasma level (> 100 ng/mL) for up to 24 hours after intravenous administration."	( Development of PLGA-based itraconazole injectable nanospheres for sustained release. Bian, X; Hsiao, CH; John, J; Liang, D; Liang, S; Wei, X; Xie, H, 2013)	0.39
"Our newly developed PLGA-ITZ-NS has shown great sustained release and comparable bioavailability with Sporanox®, therefore having the potential to be an alternative injectable formulation of ITZ."	( Development of PLGA-based itraconazole injectable nanospheres for sustained release. Bian, X; Hsiao, CH; John, J; Liang, D; Liang, S; Wei, X; Xie, H, 2013)	0.39
"The aim of the study is to increase the bioavailability of itraconazole (ITRA) using nanosized cocrystals prepared via wet milling of ITRA in combination with dicarboxylic acids."	( Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs. Adriaensens, P; Carleer, R; De Beer, T; De Smet, L; Remon, JP; Saerens, L; Van Bocxlaer, J; Vervaet, C, 2014)	0.4
" The objective of this study was to formulate solid oral nanocrystal delivery systems of itraconazole, and thus enhance the oral bioavailability of the very poorly soluble drug."	( Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption. Häkkinen, MR; Hirvonen, J; Ilkka, J; Järvinen, K; Kiesvaara, J; Kovalainen, M; Laaksonen, T; Laru, J; Oksala, O; Peltonen, L; Rönkkö, S; Sarnes, A, 2014)	0.4
"Amorphous drug nanoparticles have recently emerged as a promising bioavailability enhancement strategy of poorly soluble drugs attributed to the high supersaturation solubility generated by the amorphous state and fast dissolution afforded by the nanoparticles."	( Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles. Cheow, WS; Hadinoto, K; Kiew, TY; Yang, Y, 2014)	0.4
" In conclusion, the nanosuspension approach is feasible to improve the oral absorption of a BCS Class II drug in a tablet formulation and capable of achieving oral bioavailability equivalent to other well established oral absorption enhancement method."	( Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation. Li, LC; Mao, S; Ni, R; Sun, W; Zhang, X, 2015)	0.42
" It has a nephrotoxic effect and low bioavailability in patients who suffer from renal insufficiency, and its poor solubility in water makes ITR largely unavailable."	( Bioadhesive tablets containing cyclodextrin complex of itraconazole for the treatment of vaginal candidiasis. Açma, A; Aksu, B; Cevher, E; Mülazımoğlu, L; Sinani, G; Zloh, M, 2014)	0.4
"Itraconazole (ITR) is an antifungal drug with a limited bioavailability due to its poor aqueous solubility."	( Heat induced evaporative antisolvent nanoprecipitation (HIEAN) of itraconazole. Mugheirbi, NA; Paluch, KJ; Tajber, L, 2014)	0.4
" In vitro dissolution and in vivo bioavailability studies of the nano-amorphous powders were performed."	( Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole. Burgess, DJ; Kumar, S; Shen, J, 2014)	0.4
"The objectives of the present study were to formulate and optimize different sized liquid and solid nanocrystalline formulations and evaluate their in vitro and in vivo performance to determine the effect of particle size on the oral bioavailability of solid nanocrystalline formulations."	( In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole. Burgess, DJ; Jog, R; Kumar, S; Sadrieh, N; Shen, J; Zolnik, B, 2015)	0.42
" The recent approval of a solid oral tablet formulation of posaconazole with improved bioavailability and once-daily dosing has significantly improved the clinical utility of this agent."	( Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Dolton, MJ; McLachlan, AJ, 2014)	0.4
"The tunable particle size, surface charge, and favourable encapsulation efficiency with a sustained drug release profile of PLHNs suggesting that it could be promising system envisioned to increase the bioavailability by improving intestinal permeability through lymphatic uptake, M cell of payer's patch or paracellular pathway which was proven by confocal microscopy."	( Formulation and optimization of itraconazole polymeric lipid hybrid nanoparticles (Lipomer) using Box Behnken design. Dalwadi, C; Gajra, B; Patel, R, 2015)	0.42
" In conclusion, ITZ-loaded-TPP NPs significantly improved ITZ bioavailability by increasing its aqueous dispersibility and extending the duration of drug release, thereby improving the antifungal efficacy of the ITZ agent."	( Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles. Chen, H; Hu, B; Hu, Y; Li, S; Qiu, L; Wu, X; Zheng, Y, 2015)	0.42
" The capsular preparation often does not allow for accurate dosing, the oral solution is difficult to administer and poorly tolerated, and the bioavailability of compounded formulations has been shown to be poor in other species."	( Alternate-day dosing of itraconazole in healthy adult cats. Dirikolu, L; Kubier, A; Middleton, SM; Mitchell, MA; Papich, MG; Rubin, SI, 2016)	0.43
"The aim of this study was to describe the pharmacokinetics and bioavailability of itraconazole (ITR) oral solution in healthy cats."	( Pharmacokinetics and bioavailability of itraconazole oral solution in cats. Cao, C; Li, W; Liang, C; Shan, Q; Wang, J; Zeng, Z; Zhang, X; Zhong, J, 2016)	0.43
" The absolute bioavailability of ITR oral solution after oral administration was 52."	( Pharmacokinetics and bioavailability of itraconazole oral solution in cats. Cao, C; Li, W; Liang, C; Shan, Q; Wang, J; Zeng, Z; Zhang, X; Zhong, J, 2016)	0.43
" In vivo pharmacokinetic showed significant enhancement in C max and AUC0-t with relative bioavailability of 225%."	( Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. Desai, J; Fadke, J; Thakkar, H, 2015)	0.42
"This research aimed to develop a supercritical fluid (SCF) technique for preparing a particulate form of itraconazole (ITZ) with good dissolution and bioavailability characteristics."	( Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs. Daintree, LS; Ding, S; Han, J; Ledger, DM; Qi, J; Wang, B; Wu, W; Yin, X; Zhao, W, 2015)	0.42
"For the solubility and bioavailability of poorly soluble active pharmaceutical ingredients (APIs) to be improved, the transformation of crystalline APIs to the amorphous state has often been shown to be advantageous."	( Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach. Ji, Y; Paus, R; Sadowski, G; Vahle, L, 2015)	0.42
" Moreover calcitriol strongly synergizes with itraconazole (ITZ) in Smo inhibition, which did not result from elevated calcitriol bioavailability due to ITZ-mediated 24-hydroxylase inhibition but rather from a direct interaction of the compounds at the level of Smo."	( A Functional and Putative Physiological Role of Calcitriol in Patched1/Smoothened Interaction. Adamski, J; Dittmann, K; Hahn, H; Linder, B; Uhmann, A; Weber, S, 2015)	0.42
" The relative bioavailability of SUBA-itraconazole compared to that of Sporanox was 173% and was 21% less variable between subjects."	( Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Abuhelwa, AY; Foster, DJ; Hayes, D; Mudge, S; Upton, RN, 2015)	0.42
"Itraconazole (ITR), an antifungal agent has poor bioavailability due to low aqueous solubility."	( Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. Dhande, RD; Khunt, A; Patel, AA; Thakkar, HP, 2015)	0.42
" Due to the unique attributes of the KinetiSol® dispersing (KSD) technology, PVAL has been enabled for this application and it is the aim of this paper to investigate various grades for improvement of the solubility and bioavailability of poorly water soluble active pharmaceutical ingredients."	( Use of Polyvinyl Alcohol as a Solubility-Enhancing Polymer for Poorly Water Soluble Drug Delivery (Part 1). Brough, C; Keen, JM; Kucera, SA; Lubda, D; Miller, DA; Williams, RO, 2016)	0.43
" Our previous study revealed that the 88% hydrolyzed grade of PVAL was optimal for itraconazole (ITZ) amorphous compositions with regard to solid-state properties, non-sink dissolution performance, and bioavailability enhancement."	( Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for Poorly Water-Soluble Drug Delivery (Part 2). Brough, C; Ellenberger, D; Lubda, D; Miller, DA; Williams, RO, 2016)	0.43
"A biodegradable porous starch (BPS) was developed in order to improve dissolution and oral bioavailability of Itraconazole as a poorly water-soluble antifungal drug."	( Biodegradable Porous Starch Spheres as a Novel Carrier for Enhancement of Dissolution Rate and Oral Bioavailability of Itraconazole. Ali, MT; Amin, P; Fule, R; Moravkar, K; Pawar, J; Sathaye, S; Seervi, M, 2017)	0.46
" A proof of concept study showed that the optimized method is applicable to test the bioavailability of drug formulations containing ITZ."	( Sampling only ten microliters of whole blood for the quantification of poorly soluble drugs: Itraconazole as case study. Evrard, B; Fillet, M; Kok, MGM; Nys, G; Thiry, J, 2017)	0.46
" When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively."	( Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. Gaud, N; Holenarsipur, VK; Kole, P; Kumar, A; Mandlekar, S; Matta, M; Sridhar, S, 2017)	0.46
" Ethylcellulose (EC) coated and uncoated minitablets prepared with the 30% drug load dispersion were delivered orally to rats and exhibited sustained release characteristics, with overall bioavailability greater for the uncoated minitablets compared to the EC-coated minitablets, similar to the rank order observed in our in vitro dissolution experiments."	( Mucoadhesive amorphous solid dispersions for sustained release of poorly water soluble drugs. LaFountaine, JS; McGinity, JW; Miller, DA; Prasad, LK; Williams, RO, 2017)	0.46
" When Sporanox and itraconazole/AFFINISOL High Productivity HPMCAS SDDs were dosed in rats, the maximum absorption rate for each formulation rank-ordered with membrane flux in vitro."	( Impact of Drug-Rich Colloids of Itraconazole and HPMCAS on Membrane Flux in Vitro and Oral Bioavailability in Rats. Brodeur, TJ; Friesen, DT; Goodwin, AK; Grass, ME; Morgen, MM; Stewart, AM; Vodak, DT, 2017)	0.46
" However, marked differences in bioavailability have been reported in other species."	( Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. Hasbach, AE; Langlois, DK; Papich, MG; Rosser, EJ, 2017)	0.46
"The mean relative bioavailability of the capsule was 85% that of the solution, but drug absorption was variable, and overall drug concentrations were similar between formulations."	( Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. Hasbach, AE; Langlois, DK; Papich, MG; Rosser, EJ, 2017)	0.46
" Its variable and unpredictable oral bioavailability make it difficult to determine the optimal dosing regimen."	( Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. Allegra, S; Carcieri, C; Cusato, J; D'Avolio, A; De Francia, S; De Nicolò, A; Di Perri, G; Fatiguso, G; Favata, F; Pirro, E, 2017)	0.46
"Solid dispersion formulations have attracted attention to improve solubility and bioavailability of water-insoluble drugs."	( Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods. Choi, HG; Choi, S; Kang, W; Kim, DW; Kim, KS; Kim, M; Kim, Y; Lee, ES; Lee, JW; Lim, C; Oh, KT; Sim, T, 2017)	0.46
" After the oral administration of crystalline ITZ to high-fat meal-fed rats, the oral bioavailability of ITZ was 14-fold higher than that in fasted rats."	( Avoidance of food effect on oral absorption profile of itraconazole by self-micellizing solid dispersion approach. Kobayashi, K; Kojo, Y; Matsunaga, S; Onoue, S; Sato, H; Seto, Y; Suzuki, H, 2017)	0.46
"Itraconazole is a fungicide drug which has low bioavailability due to its poor water solubility."	( Application of hydroxypropyl methylcellulose as a protective agent against magnesium stearate induced crystallization of amorphous itraconazole. Balogh, A; Démuth, B; Farkas, A; Galata, DL; Hirsch, E; Marosi, G; Mensch, J; Nagy, B; Nagy, ZK; Pataki, H; Szabó, E; Verreck, G; Vigh, T, 2018)	0.48
" A newer formulation of oral itraconazole with improved bioavailability was commenced."	( Treatment of disseminated histoplasmosis in advanced HIV using itraconazole with increased bioavailability. Cronin, K; Mangalore, RP; McMahon, JH; Moso, MA; Young, K, 2018)	0.48
" Areas covered: A detailed analysis of the manufacturing process of itraconazole with emphasis on pelletization and parameters affecting the dissolution and bioavailability is presented."	( Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses. Gupta, A; Khurana, A; Sardana, K, 2019)	0.51
" These findings may be useful for improving the bioavailability of several drugs by effective absorption from the upper small intestine, with floating gastric retention system."	( Fabrication of Zero-Order Sustained-Release Floating Tablets via Fused Depositing Modeling 3D Printer. Ishikawa, T; Itai, S; Iwao, Y; Kimura, SI; Kondo, H, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first-pass metabolism by cytochrome P450 (CYP) 3A4."	( Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction. Backman, JT; Elonen, E; Neuvonen, M; Neuvonen, PJ; Niemi, M; Olkkola, AM; Tapaninen, T; Tornio, A, 2020)	0.56
" ITR has an unpredictable bioavailability and quality variation among brands is known to affect clinical outcome."	( An exploratory pilot analysis of the optimal pellet number in 100 mg of itraconazole capsule to maximize the surface area to satisfy the Noyes-Whitney equation. Khurana, A; Panesar, S; Sardana, K; Singh, A, 2021)	0.62
"0 L and the bioavailability (F) was 81."	( Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. Ding, XL; Liu, LN; Miao, LY; Tian, JX; Xue, L; Yan, HH; Zhang, JJ; Zhang, WJ; Zhang, WW, 2019)	0.51
" An absolute bioavailability study informed the hepatic and gastric availability."	( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020)	0.56
" Since ITZ is only weakly soluble in water, its bioavailability is limited."	( Cholesterol Reduces Partitioning of Antifungal Drug Itraconazole into Lipid Bilayers. Bunker, A; Dzieciuch-Rojek, M; Kepczynski, M; Poojari, C; Róg, T; Zak, A, 2020)	0.56
"Molibresib (GSK525762), an orally bioavailable small molecule with 2 major equipotent active metabolites, is being developed for the treatment of cancers."	( An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers. Collins, G; Ferron-Brady, G; Kremer, BE; Patel, A; Riddell, K; Schramek, D; Zhou, Y, 2021)	0.62
" A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking."	( Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital. Abbotsford, J; Blyth, CC; Bowen, AC; Foley, DA; Goff, Z; Yeoh, DK, 2021)	0.62
"Spray dried dispersions (SDDs) have the potential to dramatically improve the oral bioavailability of drugs with poor water solubility."	( The effects of spray drying, HPMCAS grade, and compression speed on the compaction properties of itraconazole-HPMCAS spray dried dispersions. Alayoubi, A; Ashraf, M; Das, S; Feng, X; Hoag, SW; Honick, M; Muller, FX; Polli, JE; Zidan, A, 2020)	0.56
"Nadolol is a hydrophilic and nonselective β-adrenoceptor blocker with a bioavailability of 30%, relatively longer half-life, negligible metabolism, and predominant renal excretion."	( Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P-Glycoprotein. Kuroda, J; Misaka, S; Shimazaki, S; Shimomura, K, 2021)	0.62
" The current standard treatment by systemic administration is limited by inadequate local bioavailability and systemic toxic effects."	( Inhaled Antifungal Agents for the Treatment and Prophylaxis of Pulmonary Mycoses. Lam, JKW; Liao, Q, 2021)	0.62
" Our center has recently changed from posaconazole to a highly bioavailable formulation of itraconazole (SUBA®-itraconazole) at substantially reduced cost, but safety and toxicity require further assessment."	( A novel highly bio-available itraconazole formulation (SUBA®-Itraconazole) for anti-fungal prophylaxis in lung transplant recipients. Boan, P; Lavender, M; Musk, M; Whitmore, TJ; Wrobel, J; Yaw, M, 2021)	0.62
" This model was built based on physiochemical data and clinical in vivo drug-drug interaction (DDI) studies with itraconazole and fluconazole, and verified against data from an in vivo rifampicin DDI study and an absolute bioavailability study."	( Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. Cohen-Rabbie, S; Freshwater, T; Jain, L; Schalkwijk, S; Tomkinson, H; Vishwanathan, K; Wild, M; Xu, S; Zhou, D; Zhou, L, 2021)	0.62
" Itraconazole, a broad-spectrum tri azole antifungal agent, is poorly absorbed in the intestines after oral absorption and makes it difficult to achieve a stable serum drug concentration."	( Efficacy of Intravenous Itraconazole Versus Liposomal Amphotericin B as Empirical Antifungal Therapy in Hematological Malignancy with Persistent Fever and Neutropenia: Study Protocol for a Multicenter, Prospective, Randomized Non-inferiority Trial. Hidaka, M; Kaneko, Y; Miyazaki, Y; Nagai, H; Saito, AM; Sawamura, M; Tanaka, S; Uike, N; Yoshida, I; Yoshida, S, 2021)	0.62
" The comparison of the in vitro data with published in vivo data revealed that the model successfully predicted the effect of food intake as well as of modified gastric pH conditions on the bioavailability of itraconazole from this formulation."	( Application of tiny-TIM as a mechanistic tool to investigate the in vitro performance of different itraconazole formulations under physiologically relevant conditions. Fischer, PL; Koziolek, M; Lenz, V; López Mármol, Á; Sauer, K; Schwöbel, D; Wahl, A, 2022)	0.72
" We report a case of a woman in fifties with post-COVID-19 respiratory failure who successfully underwent lung transplantation, followed by improved bioavailability of ITCZ tablets when given with acidic lemon beverages."	( Improved absorption of itraconazole tablet by co-administration with lemon beverages in a lung transplant recipient: A case report. Date, H; Katada, Y; Matsumura, K; Nagao, M; Nakagawa, S; Ohsumi, A; Sugimoto, M; Terada, T; Umemura, K; Yonezawa, A, 2022)	0.72
"Solubility and dissolution rate are essential for the oral absorption and bioavailability of poorly soluble drugs."	( Combination of co-crystal and nanocrystal techniques to improve the solubility and dissolution rate of poorly soluble drugs. Bodmeier, R; Huang, Z; Staufenbiel, S, 2022)	0.72
" There is a scarcity of studies on the bioavailability of various itraconazole brands available in the market."	( Correlation of plasma levels of itraconazole with treatment response at 4 weeks in chronic dermatophytosis: Results of a randomised controlled trial. Bhalavi, H; Dogra, S; Mehta, H; Narang, T; Rudramurthy, SM; Sachdeva, N; Shafiq, N; Shaw, D, 2023)	0.91
" Plasma levels of the three drugs were however similar, indicating that factors other than serum bioavailability are at play in determining response of chronic dermatophyte infections to oral itraconazole."	( Correlation of plasma levels of itraconazole with treatment response at 4 weeks in chronic dermatophytosis: Results of a randomised controlled trial. Bhalavi, H; Dogra, S; Mehta, H; Narang, T; Rudramurthy, SM; Sachdeva, N; Shafiq, N; Shaw, D, 2023)	0.91
"The current study aimed to improve the processability and oral bioavailability of itraconazole (ITZ) via spherical agglomeration."	( Processability and Oral Bioavailability Improvement of Itraconazole by Particle Engineering Technique. Kapalatiya, H; Patel, D; Singh, AD; Wairkar, S, 2022)	0.72
" In this work, AmB and ITR have been formulated within granules to elicit an enhanced pharmacological effect, while enhancing the oral bioavailability of AmB."	( Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses. Bolás-Fernández, F; Chamorro-Sancho, MJ; Fernández-García, R; Healy, AM; Jiménez-Cebrián, A; O'Connell, P; Paloma Ballesteros, M; Raposo, R; Serrano, DR; Slowing, K; Walsh, D, 2023)	0.91
"Solubility of the drug is an important property of the drug as it affects the release, absorption, dissolution rate and ultimately bioavailability of the drug."	( Comparative assessment of solubility enhancement of itroconazole by solid dispersion and co-crystallization technique: Investigation of simultaneous effect of media composition on drug dissolution. Barethiya, V; Dixit, G; Hiradeve, S; Kale, S; Karodadeo, GR; Kohale, N; Kumar, V; Lahane, A; Rajbhar, K; Rarokar, NR; Thakre, V, 2023)	0.91
"Along with the increasing demand for candidate-enabling formulations comes the need for appropriate in vitro bioavailability forecasting."	( In vitro dissolution/permeation tools for amorphous solid dispersions bioavailability forecasting I: Experimental design for PermeaLoop™. Bauer-Brandl, A; Brandl, M; Henriques, J; Nunes, PD; Paiva, AM; Pinto, JF, 2023)	0.91
"Esaxerenone was estimated to have high bioavailability (85."	( Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers. Fukae, M; Ishizuka, H; Kastrissios, H; Shimizu, T; Wada, R; Yoshihara, K, 2023)	0.91
" Super bioavailability (SUBA) itraconazole was initially not tolerated."	( [Recurrent tinea corporis generalisata due to Terbinafine-resistant Trichophyton rubrum strain : Long-term treatment with super bioavailability itraconazole]. Burmester, A; Ebert, A; Monod, M; Nenoff, P; Schaller, M; Stahl, M; Uhrlaß, S, 2023)	0.91
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" In particular, the analogues 30d, 30c, 31c, and 36d exhibited much higher solubility and bioavailability than that of itraconazole."	( Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability. Cao, X; He, H; Liu, X; Liu, Y; Liu, Z; Yang, Y, 2011)	0.84
" Moreover, pharmacokinetic studies in SD rats showed that A33 exhibited favourable pharmacokinetic properties, with a bioavailability of 77."	( Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives. Cheng, M; Su, X; Sun, N; Sun, Y; Tian, L; Yin, W; Zhang, C; Zhao, D; Zhao, L; Zhao, S; Zheng, Y, 2021)	0.62
" Moreover, pharmacokinetic studies in SD rats showed that compound 22a exhibited pharmacokinetic properties with a bioavailability of 15."	( Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents. Cheng, M; Cui, H; Jiang, H; Liu, L; Su, X; Sun, Y; Wu, T; Yin, W; Zhang, Y; Zhao, D; Zhao, L, 2022)	0.72

Excerpt	Relevance	Reference
" Cure of the toenails was observed in 79% of the patients treated with the 200 mg dosage and in 26% of those treated with 100 mg at 6 months after therapy."	( Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. Cauwenbergh, G; De Doncker, P; Heykants, J; Roseeuw, D; Van Cutsem, J; Van de Velde, V; Willems, J; Willemsen, M; Woestenborghs, R, 1992)	0.28
" The proper duration and dosage and the combination of antifungal drugs have not been clearly defined."	( [Primary Aspergillus endocarditis. Apropos of a case and review of the international literature]. Cajot, MA; Gosselin, B; Goullard, L; Koussa, A; Marquette, F; Pol, A; Roux, JP; Soots, G; Warembourg, H, 1992)	0.28
" In this open non-comparative clinical trial, itraconazole was given orally in the dosage of 100 mg per day for 14 consecutive days."	( Treatment of dermatophytosis with new systemic antifungal agent, itraconazole. Noppakun, N; Phuphaibool, K, 1992)	0.28
" Liposomal Amphotericin B allowing higher dosage by lower toxicity appears effective as salvage treatment especially in aspergillosis which also responds to Itraconazole available as oral formulation so far."	( Antifungal treatment strategy in leukemia patients. Büchner, T; Roos, N, 1992)	0.28
" In vivo, subchronic intraperitoneal dosing with 40 mg/kg ketoconazole or itraconazole to mice had no effect on the antibody response to SRBC as measured by the number of splenic IgM and IgG plaque-forming cells and did not significantly affect the DTH response to oxazolone."	( Lack of immunosuppression by ketoconazole and itraconazole. Aerts, F; Cools, M; Van Wauwe, J, 1992)	0.28
" Patients were classified in terms of severity and received itraconazole at the dosage of 200 to 400 mg per day until previously described criteria of cure have been reached."	( Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Bordignon, GF; Cauwenbergh, G; Fillus, JN; Lameira, RP; Purim, KS; Queiroz-Telles, F; Van Cutsem, J, 1992)	0.28
" The trial also aimed at a possible improvement of the therapy of toxoplasmosis in regard to safety and dosing easiness."	( [Itraconazole action on Toxoplasma gondii]. Amato Neto, V; Braz, LM; Camargo, ME; Jamra, LM, )	0.13
" However, 600 mg/day may be approaching the upper limits of acceptable dosing for long-term treatment."	( High-dose itraconazole in the treatment of severe mycoses. Dunn, JF; Fetchick, RJ; Graybill, JR; Hardin, TC; Rinaldi, MG; Sharkey, PK, 1991)	0.28
" In those treated for two months or longer, the mean total serum IgE level fell from 2,462 U/ml (CI, 752 to 4,202 U/ml) to 502 U/ml (CI, 123 to 880 U/ml) during each course, and the mean daily steroid dosage was decreased to a mean of 24 mg/day (CI, 11 to 37 mg/day)."	( Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Denning, DW; Lewiston, NJ; Stevens, DA; Van Wye, JE, 1991)	0.28
" However, the wide variation within and between patients suggests that an ITRA-PEL dosage of 400 mg/day may ensure earlier and more consistent therapeutic levels."	( Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. Bradford, CR; Copplestone, JA; Prentice, AG; Warnock, DW, 1991)	0.28
" The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections."	( Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. Gollapudi, S; Gupta, S; Kim, J, 1991)	0.28
" The same results could not be achieved with the same concentration or dosage of either ketoconazole or fluconazole."	( Oral and parenteral treatment with itraconazole in various superficial and systemic experimental fungal infections. Comparisons with other antifungals and combination therapy. Van Cutsem, J, 1990)	0.28
" The feasibility of one-day therapy was assessed in a clinical study in which three different dosage regimens were compared in a total of 552 patients with acute vulvovaginal candidosis: 200 mg twice daily for one day; 200 mg once daily for two days; and 200 mg once daily for three days."	( Itraconazole: a single-day oral treatment for acute vulvovaginal candidosis. Wesel, S, 1990)	0.28
" The fixed schedules indicated by pharmacokinetics and clinical studies are one 100 mg capsule daily for 15 days in cases of tinea corporis and tinea cruris and the same dosage for 30 days in cases of tinea pedis and tinea manuum."	( Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. Bonifaz, A; Saul, A, 1990)	0.28
" In order to prevent a mycotic infection in these immunocompromised patients, itraconazole, a new broad-spectrum antimycotic drug of the azole group, was given in an oral dosage of 100 mg day-1 (mean duration of prophylactic treatment 24 months)."	( Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients. König, HJ; Mühldorfer, SM, 1990)	0.28
" Treatment of invasive aspergillosis required a higher dosage (about 5 mg/kg) and prolonged administration."	( Experience with itraconazole in cryptococcosis and aspergillosis. Almaviva, M; Cristina, S; De Maria, R; Ferrazzi, P; Fiocchi, R; Langer, M; Negri, C; Scoccia, S; Tortorano, AM; Viviani, MA, 1989)	0.28
"We have studied the influence of food and dose (50, 100, 200 mg) on the oral systemic availability of the broad spectrum antifungal itraconazole and the pharmacokinetics after repeated dosing of 100 mg in six healthy volunteers."	( The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Gasparini, R; Gauwenbergh, G; Heykants, J; Van Peer, A; Woestenborghs, R, 1989)	0.28
" There is a clear need to obtain quick information on itraconazole plasma levels in order to adapt dosage during prophylactic treatment in immunocompromised patients."	( Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Boogaerts, MA; De Beule, K; Demuynck, H; Verbist, L; Verhoef, GE; Zachee, P, 1989)	0.28
" Two dosage regimens were tested--200 mg twice a day for 1 day and 200 mg twice a day for 2 days."	( Itraconazole in the treatment of acute vaginal candidiasis. Barnard, PG; Bloch, B; Burger, GD; Meyer, JS; Parkes, JR; Smythe, E, 1988)	0.27
" This study could not demonstrate any significant effect of renal dysfunction and hemodialysis or continuous ambulatory peritoneal dialysis treatment upon the pharmacokinetics of itraconazole, and firm conclusions concerning dosing in such patients should await confirmation of our data in a larger patient population."	( Itraconazole pharmacokinetics in patients with renal dysfunction. Boelaert, J; Daneels, R; De Beule, K; Heykants, J; Matthys, E; Schurgers, M; van Peer, A; Woestenborghs, R, 1988)	0.27
"Male Wistar rats were dosed with miconazole, ketoconazole and itraconazole by gastric intubation once daily for up to 7 days."	( Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolizing enzymes of male rats at high doses. Heykants, J; Lavrijsen, K; Meuldermans, W; Thijs, D; Van Houdt, J, 1986)	0.27
" The pharmacologic profiles, mechanisms of action, pharmacokinetics, clinical indications for use, dosage recommendations, side effects, and drug interactions for these agents are presented."	( The pharmacology of agents used in the treatment of pulmonary mycoses. Borgers, M; Cauwenbergh, G; Vanden Bossche, H, 1986)	0.27
" It appears that a dosage of 50 mg of itraconazole daily is not adequate for the treatment of these mycoses."	( Itraconazole in the treatment of superficial mycoses: an open trial of 40 cases. Arias, I; Bonifáz, A; Saúl, A, )	0.13
" Since the larger dosage induces a faster response, it should be evaluated further."	( Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages. Borghys, A; De Veylder, H; Degreef, H; Duprez, K; Mariën, K; Verhoeve, L, )	0.13
" The dosage was 100 mg daily for four to six weeks."	( Itraconazole in the treatment of tinea corporis: a pilot study. Nuijten, ST; Schuller, JL, )	0.13
" The difference between these rates was not significant, but the groups were small and the difference in dosage may ultimately be meaningful in terms of rates of cure."	( Itraconazole in pityriasis versicolor. Estrada, RA, )	0.13
" The sexual partners of one-half of the women were treated with the same dosage of itraconazole; the other men received placebo."	( Itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner. Calderón-Márquez, JJ, )	0.13
" Almost 50% were women with vaginal candidosis; a dosage of 200 mg per day for three days appeared to be optimal for their treatment."	( Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Cauwenbergh, G; De Dier, AM; De Doncker, P; Goyvaerts, H; Schuermans, V; Stoops, K, )	0.13
" Itraconazole was administered at a daily dosage of 50 mg for six months in the majority of these cases."	( Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Galimberti, RL; Koren, F; Negroni, R; Palmieri, O; Tiraboschi, IN, )	0.13
" Dosage was 100-200 mg per day, and duration of treatment was based on response."	( Itraconazole for deep mycoses: preliminary experience in Mexico. De Ovando, F; Lavalle, P; Reynoso, S; Suchil, P, )	0.13
" We used the Michaelis-Menten model for calculating dosing rates under steady-state conditions."	( [Therapeutic drug monitoring of itraconazole--a report of experiences]. Kreutzberg, S; Lampe, D; Prümke, HJ, 1994)	0.29
" With oral itraconazole at a dosage of 100 mg d(-1) for 15 months (total dose 45."	( Successful treatment of chromoblastomycosis with itraconazole. Yu, R, )	0.13
" In all cases, increasing the itraconazole dosage increased its prophylactic efficacy."	( Prophylaxis of Candida and Aspergillus infections with oral administration of itraconazole. Van Cutsem, J, )	0.13
" Well-defined dose-response curves reflecting impairment of mitochondrial function by the antifungal agents were obtained."	( Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Bhakdi, S; Jahn, B; Martin, E; Stueben, A, 1995)	0.29
" Thus serum concentrations of itraconazole suitable for antifungal prophylaxis can be attained in neutropenic patients, with the administration of an oral solution in a dosage of 5 mg/kg as either an od or bd schedule, following pre-autograft high-dose cytotoxic chemotherapy."	( Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. Johnson, SA; Oliver, DA; Phillips, MJ; Prentice, AG; Warnock, DW, 1994)	0.29
" Amphotericin B is often considered as the gold standard treatment despite its high toxicity particularly with high dosage (1-1."	( [Curative treatment of invasive aspergillosis]. Dupont, B, 1994)	0.29
" Consequently an individual itraconazole adjusting dosage is necessary to ensure adequate clinical antifungal activity."	( Determination of itraconazole and its active metabolite in plasma by column liquid chromatography. Cheymol, G; Descamps, P; Lebot, M; Levy, M; Poirier, JM, 1994)	0.29
" Itraconazole was given at a dosage of 200-400 mg day-1 for periods ranging from 14 to 488 days."	( Itraconazole in the treatment of aspergillosis: a study of 16 cases. Ambroise-Thomas, P; Brion, JP; Bru, JP; Delormas, P; Goût, JP; Lebeau, B; Michallet, M; Pelloux, H; Pinel, C; Pison, C, )	0.13
"Nail surfaces of toe-nail fragments were analysed by optical profilometry in patients treated with two different dosages of itraconazole: 200 mg continuous dosing for 12 weeks, or a pulse-dose regimen of 1 week per month of 400 mg itraconazole daily for 3-4 months."	( Acquired nail beading in patients receiving itraconazole--an indicator of faster nail growth? A study using optical profilometry. Doncker, PD; Pierard, GE, 1994)	0.29
" Twelve healthy male volunteers received each of 4 dosing regimens: 200 mg itraconazole alone, 200 mg itraconazole and famotidine, 100 mg fluconazole alone, and 100 mg fluconazole and famotidine."	( Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Hudson, M; Lim, SG; Pounder, RE; Sawyerr, AM; Sercombe, J, 1993)	0.29
" Delayed-type hypersensitivity (DTH) reaction to SRBC, phagocyte activity and circulating leukocytes also were significantly decreased in mice dosed at 40 and 80 mg/kg ICZ."	( The effects of itraconazole on the immune responses in ICR mice. Ahn, YK; Kim, JH, 1994)	0.29
" In the treatment of allergic bronchopulmonary aspergillosis, itraconazole has been reported to prompt a reduction in corticosteroid dosage in selected patients."	( Treatment of aspergillosis with itraconazole. Hardin, TC; Jennings, TS, 1993)	0.29
" Consistent therapy with itraconazole (Sempera) dosed at 3 mg/kg body weight per day over a period of 4 weeks led to a permanent cure."	( [Trichophyton soudanense as the pathogen of tinea corporis et capitis]. Bröcker, EB; Ebert, J; Schwinn, A; Wever, S, 1995)	0.29
" Shorter, higher dosage itraconazole treatment regimens (200 or 400 mg/day for 1 week) are also beneficial in dermatomycoses."	( Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Bryson, HM; Goa, KL; Haria, M, 1996)	0.29
"Blood samples were obtained for pharmacokinetic analyses immediately before dosing and at regular intervals up to 96 hours after each dose."	( Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Cauwenbergh, GF; De Beule, KL; Heykants, JJ; Van de Velde, VJ; Van Peer, AP; Van Rooy, P; Woestenborghs, RJ, )	0.13
" The fact that the solution was also well tolerated and was not associated with clinically significant changes in any laboratory value further underscores the potential utility of this dosing form."	( Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Cauwenbergh, GF; De Beule, KL; Heykants, JJ; Van de Velde, VJ; Van Peer, AP; Van Rooy, P; Woestenborghs, RJ, )	0.13
" The pits received daily during three weeks oral itraconazole at a dosage of 200 mg at the beginning of the meal, then during the next two weeks oral itraconazole combined with an intravenous administration of rifampin at a dosage of 10 mg/kg/day."	( [Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. Cavalier, A; Elkhaili, H; Jehl, F; Kaltenbach, G; Levêque, D; Monteil, H; Peter, JD; Salmon, J; Salmon, Y, 1996)	0.29
" The dependence of this interaction on the time interval of their ingestion and the possibility of avoiding the interaction by a correct daily dosing was studied."	( The effect of ingestion time interval on the interaction between itraconazole and triazolam. Neuvonen, PJ; Olkkola, KT; Varhe, A, 1996)	0.29
" A sensitivity analysis assessing alternative dosing regimens and a rank order stability analysis investigating the effects of length of treatment, success rates, relapse rates, and drug acquisition costs on overall results were also conducted."	( Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Marchetti, A; McGhan, WF; Neugut, AI; Piech, CT; Smith, BT, )	0.13
" More studies should be performed to determine the most appropriate dosage and the optimal duration of itraconazole treatment in children."	( Disseminated histoplasmosis in children: the role of itraconazole therapy. Arango, M; Espinal, D; Franco, L; Gómez, I; Restrepo, A; Tobón, AM; Trujillo, H, 1996)	0.29
" One patient was given a lower dosage of 100 mg, one capsule daily."	( Itraconazole therapy for onychomycosis: case reports. Kirshbaum, BA, 1996)	0.29
" These observations suggest that itraconazole intermittent dosing is a highly effective therapy for the treatment of onychomycosis caused by dermatophyte organisms, because it provides a high cure rate after only a short course of therapy."	( Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. Del Rosso, JQ, 1996)	0.29
" Firstly, the purpose of the study, the comparator drugs, their dosage regimens and the time frame of the analysis were defined."	( Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. De Doncker, P; Dubois, DJ; Eggleston, A; Gupta, AK; Haneke, E; Tormans, G; Van Doorslaer, EK; Van Rossem, K, 1996)	0.29
" Complete healing was achieved after re-treatment with itraconazole for 20 weeks at the same dosage in combination with topical amorolfine and local hyperthermia."	( [Diagnosis, clinical aspects and therapy of early chromoblastomycosis in a case example]. de Hoog, GS; Gründer, K; Köhn, FM; Mayser, P; Qadripur, S; Schill, WB, 1996)	0.29
"We treated 36 patients with this drug given as continuous dosing (100 or 200 mg/ day) for 6 to 20 weeks or as a 1-week pulse dosing (200 mg twice daily for 1 week per month) for two to four pulses."	( Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. Baran, RL; De Doncker, PR; Decroix, J; Degreef, HJ; Gupta, AK; Havu, V; Piérard, GE; Roseeuw, DI; Rosen, T; Scher, RK, 1997)	0.3
"Our purpose was to compare the effectiveness and tolerability of intermittent dosing of itraconazole ("pulse therapy") with placebo in fingernail onychomycosis."	( A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. Aly, R; Daniel, CR; DeVillez, R; Elewski, BE; Jacko, M; Moskovitz, BL; Odom, RB; Oleka, N; Scher, RK; Zaias, N, 1997)	0.3
" To assess plasma and tissues concentrations after oral dosing in reptiles, a 23."	( Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. Alvarado, TP; Bennett, CL; Gamble, KC, 1997)	0.3
"To determine the disposition of itraconazole in cats after single IV and oral dosing (as a solution or capsule) and multiple oral (capsule) dosing, and to establish bioavailability after oral administration of the solution."	( Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Boothe, DM; Calvin, J; Dvorak, J; Herring, I; Way, N, 1997)	0.3
" For the multiple oral dosing study, MRT (at last dose: 81."	( Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Boothe, DM; Calvin, J; Dvorak, J; Herring, I; Way, N, 1997)	0.3
"The oral itraconazole solution is preferred to capsules; a 24-hour dosing interval should be sufficient; 10 mg/kg given daily should generate therapeutic concentrations in most cats; steady-state concentrations may take up to 3 weeks to achieve; and cats appear to tolerate itraconazole well."	( Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Boothe, DM; Calvin, J; Dvorak, J; Herring, I; Way, N, 1997)	0.3
" Increased duration and/or dosage improved the efficacy of nikkomycin Z, with 10 days of each dose curing 50 to 90% of the animals."	( Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Clemons, KV; Stevens, DA, 1997)	0.3
"For tinea pedis and manuum, the recommended dosage is itraconazole 200 mg twice daily for 1 week (n = 220)."	( Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. Doncker, PD; Gupta, AK; Heremans, A; Marynissen, G; Stoffels, P, 1997)	0.3
") treatment was directly followed by repeated administrations of an oral solution of itraconazole at a dosage of either 200 mg once daily or 200 mg twice daily (b."	( Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Colardyn, F; De Beule, K; Decruyenaere, J; Groen, K; Jaqmin, P; Van Peer, A; Vandewoude, K; Vogelaers, D; Woestenborghs, R, 1997)	0.3
" ITZ treatment was continued again at the same dosage for 3 months until the antigen titer was negative (< 8)."	( A case of feline cryptococcosis treated with itraconazole. Hasegawa, A; Kano, R; Nakamura, Y; Tsujimoto, H; Watari, T, 1997)	0.3
" After 14 days, each subject was given the dosage form that he or she did not previously receive, and testing was repeated."	( Relative bioavailability of itraconazole from an extemporaneously prepared suspension and from the marketed capsules. Bowman, JL; Buice, RG; Christensen, KJ; Gubbins, PO; Gurley, BJ, 1998)	0.3
" The patients were treated with itraconazole at a dosage of 5 mg/kg of body weight once daily for 2 weeks."	( Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Cornu, G; De Beule, K; de Repentigny, L; Jacqmin, P; Leclerc, JM; Ratelle, J; Sokal, EM, 1998)	0.3
" Concomitant use of potent inhibitors of CYP3A with simvastatin should be avoided or its dosage should be greatly reduced."	( Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Kantola, T; Kivistö, KT; Neuvonen, PJ, 1998)	0.3
"The bioavailability of ITR and OH-ITR is enhanced when ITR oral solution is given in the fasted state; this was true for both single and multiple dosing to steady state."	( Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Barone, JA; Bierman, RH; Colaizzi, JL; Guarnieri, J; Hassell, AE; Jessen, L; Moskovitz, BL, )	0.13
" This has proved an effective and safe regimen which requires only 50% of the medication used for continuous dosing schedules."	( Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. De Doncker, P; Haneke, E; Heremans, A; Tajerbashi, M, 1998)	0.3
" In addition, the short treatment times (< 3 months) and intermittent dosing schedules are likely to enhance compliance and reduce the costs of therapy."	( Onychomycosis: pathogenesis, diagnosis, and management. Elewski, BE, 1998)	0.3
"Itraconazole, even at a small dosage of 100 mg daily, greatly elevated plasma concentrations of lovastatin and its active metabolite, lovastatin acid."	( Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Kantola, T; Kivistö, KT; Neuvonen, PJ, 1998)	0.3
" During the 1-week pulse of active therapy, itraconazole (5 mg/kg/day) was dosed as follows: more than 40 kg, 200 mg per day (two capsules per day); 20 to 40 kg, 100 mg per day (one capsule per day); and 10 to 19 kg, 50 mg per day (one half of a capsule per day)."	( Treatment of tinea capitis with itraconazole capsule pulse therapy. Adam, P; Alexis, M; De Doncker, P; Gupta, AK; Hofstader, SL; Raboobee, N; Solomon, R; Summerbell, RC, 1998)	0.3
" For patients administered concomitant cyclosporine, ketoconazole, and diltiazem, the dosage of cyclosporine, if it is administered alone, should be 20% to achieve the same blood concentrations."	( Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. McLachlan, AJ; Tett, SE, 1998)	0.3
"The efficacy and safety of an intermittent itraconazole dosing regimen was investigated in 354 patients with toenail onychomycosis, from 98 dermatology centres."	( An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. De Doncker, P; Ginter, G, )	0.13
" The dosage regimen was 3 mg/kg per day given once daily in a fasting state with each pulse lasting 1 week."	( Itraconazole oral solution for the treatment of tinea capitis. Adam, P; Gupta, AK; Solomon, RS, 1998)	0.3
" Five cats treated at the highest dosage of itraconazole vomited or became anorectic."	( Efficacy of oral administration of itraconazole to cats with dermatophytosis caused by Microsporum canis. Mancianti, F; Pedonese, F; Zullino, C, 1998)	0.3
"Itraconazole pulse therapy was efficient and safe for the treatment of onychomycosis caused by dermatophytes, although a much higher daily dosage than the known continuous administration was used."	( Efficacy and safety of itraconazole pulse therapy: Brazilian multicentric study on toenail onychomycosis caused by dermatophytes. Campbell, I; Gontijo, B; Marques, SA; Ramos-e-Silva, M; Veloso, ST; Zaitz, C, 1998)	0.3
" This information would then be useful in determining the efficacy of itraconazole administered by means of intermittent pulse dosing in the treatment of tinea capitis."	( Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. De Doncker, P; Groen, K; Gupta, AK; Woestenborghs, R, 1998)	0.3
" Zolpidem-induced benzodiazepine agonist effects (increased electrocardiographic beta activity, digit-symbol substitution test impairment, and delayed recall) during the first 4 hours after dosage were enhanced by ketoconazole but not by itraconazole or fluconazole."	( Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Counihan, M; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Roth-Schechter, B; Shader, RI; von Moltke, LL, 1998)	0.3
" Oral steroid dosing requirements and acute episodes of ABPA for days with vs days without itraconazole were compared."	( Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Esrig, S; Moss, RB; Nepomuceno, IB, 1999)	0.3
" Short course and pulse dosing are particularly exciting options that may decrease cost and lower the risk of adverse side effects."	( The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis. Friedlander, SF, 1999)	0.3
" The recent move to once-daily dosing means that criteria for therapeutic drug monitoring need to be redefined."	( The therapeutic monitoring of antimicrobial agents. Barclay, ML; Begg, EJ; Kirkpatrick, CJ, 1999)	0.3
" First, the purpose of the study, the comparator drugs and their dosage regimens were defined."	( Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Gupta, AK, 1998)	0.3
"The purpose of this study was to compare the efficacy of different dosage regimens in the management of onychomycosis with itraconazole and to determine the results of a further 1-week intermittent pulse treatment in non-cured patients."	( A comparison among four regimens of itraconazole treatment in onychomycosis. Chen, J; Liao, W; Wen, H; Wu, J; Yao, Z, 1999)	0.3
"To evaluate the efficacy and safety of a 1-week intermittent itraconazole dosing schedule for onychomycosis."	( Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Li, RY; Wang, AP; Wang, DL; Wang, R, 1999)	0.3
"A 1-week intermittent itraconazole dosing regimen is a safe and effective treatment for onychomycosis."	( Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Li, RY; Wang, AP; Wang, DL; Wang, R, 1999)	0.3
"In this open, randomized, parallel-group, the efficacy and safety of itraconazole pulse therapy (1 week 400 mg daily, 3 months) was evaluated in comparison with continuous terbinafine dosing (250 mg daily, 3 months) for the treatment of toenail onychomycosis."	( Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Kejda, J, 1999)	0.3
" The itraconazole was given once daily in a fasting state at a dosage of 3 mg/kg/day as a pulse lasting 1 week."	( Itraconazole oral solution for the treatment of tinea capitis using the pulse regimen. Adam, P; Aly, R; Gupta, AK; Soloman, R, 1999)	0.3
" Itraconazole was given from the start of chemotherapy in one of six different dosing regimens."	( Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Glasmacher, A; Hahn, C; Marklein, G; Molitor, E; Sauerbruch, T; Schmidt-Wolf, IG, 1999)	0.3
" All three benzodiazepines were susceptible to drug interactions, but oral dosing of midazolam and triazolam resulted in greater alterations in the pharmacokinetic parameters than alprazolam due to their larger presystemic extraction."	( Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. Balian, JD; Flockhart, DA; Yuan, R, 1999)	0.3
" Forty patients were randomly assigned to receive either itraconazole cyclodextrin solution or itraconazole capsules, both at a dosage of 100 mg bd for 15 days."	( Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules. Bagg, J; Cross, LJ; Oliver, D; Warnock, D, 2000)	0.31
"A tablet dosage form containing solid dispersions of itraconazole (Asd tablets) was prepared by using the spray-drying and wet granulation methods."	( Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Jun, H; Jung, JY; Kang, E; Lee, KH; Lee, SH; Park, JW; Yoo, SD, 2000)	0.31
" Since the bioavailability of itraconazole is reduced in these patients, a satisfactory dosing regimen remains to be defined."	( Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Glasmacher, A; Hahn, C; Marklein, G; Molitor, E; Sauerbruch, T; Schmidt-Wolf, IG, 1999)	0.3
" The optimal dosage and end point of treatment need to be ascertained after a larger study."	( Itraconazole pulse therapy in chromoblastomycosis. Kumarasinghe, MP; Kumarasinghe, SP, )	0.13
"The boosted oral antifungal treatment (BOAT) is introduced as a novel approach improving the efficacy of oral treatment with the itraconazole pulse dosing regimen."	( The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Arrese, JE; Piérard, GE; Piérard-Franchimont, C, 2000)	0.31
" One patient treated with the lowest dosage for the shortest term had a recurrence after 1 month and needed a second 30-day course of itraconazole at a higher dosage."	( Improved outcome of pulmonary aspergillosis in heart transplant recipients with early diagnosis and itraconazole treatment. Andreana, A; Cione, P; Cotrufo, M; Cuccurullo, S; De Vivo, F; Maiello, C; Marra, C; Mormone, G; Sarnataro, G; Tripodi, MF; Utili, R; Zampino, R, 2000)	0.31
" When problems are known to arise, they can often be overcome or minimised by varying the dosage regimens, or by drug monitoring."	( The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Drake, L; Gupta, AK; Lambert, J; Shear, N; Yaniv, R, 2000)	0.31
" The 2-, 6-, and 20-mg/kg dosages of POC maintained plasma drug levels above the MICs for the entire 24-h dosing interval."	( Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Avila, N; Bacher, J; Candelario, M; Field-Ridley, A; Groll, AH; Petraitiene, R; Petraitis, V; Piscitelli, S; Sein, T; Walsh, TJ, 2001)	0.31
" A newly recognized phenomenon known as the post-antifungal effect implies that antifungals, even at sub-therapeutic concentrations, may suppress the virulent attributes of yeasts, especially intra-orally where topical drug levels fluctuate dramatically during dosing intervals."	( Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis. Ellepola, AN; Samaranayake, LP, 2000)	0.31
" The patient failed to respond to treatment with a conventional dosage of a lipid formulation of amphotericin B (lifoAmB; 5 mg/kg/day) given alone or in combination with itraconazole, and he responded only to an aggressive strategy that included a very high dosage of lifoAmB (15 mg/kg/day) given in combination with itraconazole as well as a rapid reduction in immunosuppression."	( Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Andersson, BS; Kontoyiannis, DP; Lewis, RE; Raad, II, 2001)	0.31
" Intermittent pulse dosing with itraconazole is as safe and effective as short-term continuous therapy but more economical and convenient."	( Treating onychomycosis. Bassler, M; Rodgers, P, 2001)	0.31
" The CSA dosing interval over time was significantly prolonged in group 2 compared to group 1 or the control group (p< or =0."	( Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients. Gordon, SM; Haug , MT; Maurer, JR; Mehta, AC; Qu, A; Schilz, RJ; Shermock, KM; Wimberley, SL, 2001)	0.31
"ICZ capsules administered in a fed state with a cola resulted in greater random levels of ICZ, a decrease in cost/d of CSA, and a prolongation of CSA dosing interval."	( Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients. Gordon, SM; Haug , MT; Maurer, JR; Mehta, AC; Qu, A; Schilz, RJ; Shermock, KM; Wimberley, SL, 2001)	0.31
" The area under the curve (AUC) of simvastatin after concomitant dosing with itraconazole was predicted to increase ca."	( Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Ikeda, T; Inoue, S; Ishigam, M; Ito, K; Iwabuchi, H; Komai, T; Kondo, T; Sugiyama, Y; Takasaki, W; Uchiyama, M, 2001)	0.31
" Ternary polyoxyethylene [21] stearyl ether/ oil and water form liquid crystalline system cream, which has a potential as dosage form for 1% itraconazole as topical dermal drug delivery."	( Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. Nesseem, DI, 2001)	0.31
" Prophylactic measures to avoid fungal contamination must be performed during hospitalization; patients should be taught how to avoid contamination, not only during the first period after transplantation, when high dosage immunosuppressive drugs are given, but also later when a normal lifestyle is resumed."	( Fungal skin infections in organ transplant recipients. Mantovani, L; Virgili, A; Zampino, MR, 2002)	0.31
" Use of prednisone was discontinued, the dosage of methotrexate was decreased, and use of oral itraconazole 400 mg/day was instituted."	( Disseminated cutaneous sporotrichosis treated with itraconazole. Bell, K; Rosen, T; Stalkup, JR, 2002)	0.31
"2 years), at a dosage of 400 mg daily for 1 week a month for 6 months."	( Systemic itraconazole in the yellow nail syndrome. Iorizzo, M; Piraccini, BM; Tosti, A, 2002)	0.31
"To avoid severe myopathy, cyclosporine levels should be monitored sooner than weekly intervals and statins should be discontinued or their dosage should be reduced, as long as azoles need to be prescribed in transplant recipients."	( Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Alivizatos, PA; Chilidou, D; Manginas, A; Vlahakos, DV; Zamanika, C, 2002)	0.31
" These agents differ in their dosing regimen, efficacy, adverse events profile, potential for drug interaction, and cost."	( Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Amaya, K; Arikian, S; Casciano, J; Doyle, J; Haspel, M; Kahler, K; Shear, N, 2003)	0.32
" If the combination is considered necessary, repaglinide dosage should be greatly reduced and blood glucose concentrations carefully monitored."	( Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M, 2003)	0.32
" These studies suggested that an HPbetaCD-based, emulsified wax cream formulation was a useful and effective dosage form for treating vaginal candidiasis."	( A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. Brewster, ME; De Proost, E; Delaet, U; Francois, M; Peeters, J; Putteman, P; Snoeckx, E; Wouters, F, 2003)	0.32
"The application of electrostatic spinning to pharmaceutical applications resulted in dosage forms with useful and controllable dissolution properties."	( Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Brewster, ME; Chun, I; Peeters, J; Rosenblatt, J; Verreck, G, 2003)	0.32
" Five Kemp's ridley sea turtles (Lepidochelys kempi) receiving itraconazole at several dosages in a rehabilitation program had blood collected within 24 hr to estimate dosing frequency."	( Steady-state plasma concentrations of itraconazole after oral administration in Kemp's ridley sea turtles, Lepidochelys kempi. Hunter, RP; Manire, CA; Pennick, GJ; Rhinehart, HL; Rinaldi, MG; Sutton, DA, 2003)	0.32
"Current dosing regimens for itraconazole are effective, safe, and versatile for use in superficial fungal infections in children, particularly tinea capitis."	( Efficacy and safety of itraconazole use in children. Cooper, EA; Ginter, G; Gupta, AK, 2003)	0.32
" Posttransplantation, renal transplant recipients received itraconazole solution 200 mg twice daily and cyclosporine, dosed to achieve target concentrations."	( Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Capitano, B; Florea, NR; Hull, D; Leitz, GJ; Nicolau, DP; Nightingale, CH, 2003)	0.32
" Tacrolimus levels and dosage requirements were compared before and during azole therapy."	( Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Boyle, GJ; Gandhi, S; Kurland, G; Law, YM; Mahnke, CB; Michaels, M; Miller, SA; Pigula, FA; Sutton, RM; Venkataramanan, R; Webber, SA, 2003)	0.32
" Studies included in this meta-analysis required a standard accepted dosage regimen, treatment duration and follow-up period."	( Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Gupta, AK; Johnson, AM; Ryder, JE, 2004)	0.32
" The dosage regimen was safe and well tolerated."	( Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. Brownlee, KG; Conway, SP; Cunliffe, H; Etherington, C; Peckham, DG; Whitehead, A, 2004)	0.32
" The dosage of itraconazole was reduced when it was used in combination with lopinavir/ritonavir."	( Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Beijnen, JH; Crommentuyn, KM; Huitema, AD; Mulder, JW; Schellens, JH; Sparidans, RW, 2004)	0.32
" Two hours after dosing they received another 240 ml of the beverage."	( Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Fincher, TK; Franks, AM; Gubbins, PO; Gurley, BJ; McConnell, SA; Penzak, SR; Saccente, M; Williams, DK, 2004)	0.32
" In all children, the dosage of itraconazole was adjusted according to body weight, with 5 mg/kg/day given in a continuous regimen either as a capsule (116 patients) or an oral suspension (47 patients)."	( Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort. Ginter-Hanselmayer, G; Gupta, A; Smolle, J, )	0.13
" Each patient received a daily dosage of 400 mg of itraconazole for a minimum of 3 months."	( Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Armijos, RX; Calvopina, M; Cooper, PJ; Davidson, RN; Guevara, AG; Hashiguchi, Y, 2004)	0.32
" The clinical implication of this study is that no lidocaine dosage adjustments are necessary if it is used to prepare the airway prior to endoscopic procedures or intubation in patients using itraconazole or other inhibitors of CYP3A4."	( Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2004)	0.32
" These data highlight the species-specific differences in antifungal pharmacodynamics between mold-active agents that could be relevant for the development of in vitro susceptibility breakpoints and antifungal dosing in vivo."	( In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Klepser, ME; Lewis, RE; Wiederhold, NP, 2005)	0.33
" Although the symptoms worsened when the prednisone dosage was gradually reduced, her growth retardation and increased weight decided us to stop prednisone treatment."	( [Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis]. Dompeling, E; Hendriks, JJ; Jöbsis, Q; van Hoorn, JH, 2005)	0.33
" Clinical studies have suggested minimum bioavailable dosage and minimum trough blood levels for effective prophylaxis against systemic fungal infection."	( Making sense of itraconazole pharmacokinetics. Glasmacher, A; Prentice, AG, 2005)	0.33
" Exposure to gefitinib is increased by coadministration with CYP3A4 inhibitors, but since gefitinib is known to have a good tolerability profile, a dosage reduction is not recommended."	( Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ, 2005)	0.33
" Thus, this system may provide a useful dosage form for oral water-insoluble drug without food effect."	( A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. Hong, JY; Kim, CK; Kim, JK; Park, JS; Song, YK, 2006)	0.33
" Tacrolimus levels and dosage requirements were compared during and after itraconazole therapy."	( Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. Bakal, I; Kramer, MR; Ollech, A; Ollech, JE; Sahar, G; Saute, M; Shitrit, D, 2005)	0.33
"Both oral itraconazole and terbinafine are effective in the treatment of onychomycosis when administered in the pulse dosage form."	( An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Mishra, K; Mishra, M; Panda, P; Sengupta, S; Tripathy, S, )	0.13
" Plasma concentrations of perospirone and ID-15036 up to 10 hours after perospirone dosing were measured by high-performance liquid chromatography (HPLC)."	( Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Koyama, T; Kusumi, I; Masui, T; Takahashi, Y, 2006)	0.33
" After several regimen changes, the patient received oral itraconazole 200 mg every 12 hours and sirolimus at a dosage of 7 mg/day on days 76-80 and 5 mg/day on days 81 and 82."	( Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Abidi, MH; Dieterle, N; Garnick, JJ; Ibrahim, RB; Peres, E; Said, A, 2006)	0.33
"The objective of this study was to determine and compare the lung and serum concentrations in mice following oral and pulmonary dosing of amorphous nanoparticulate itraconazole (ITZ) compositions as well as the Sporanox oral solution (itraconazole/Janssen)."	( Single dose and multiple dose studies of itraconazole nanoparticles. Burgess, D; Johnston, KP; McConville, JT; Peters, JI; Talbert, RL; Vaughn, JM; Williams, RO, 2006)	0.33
"To study the efficacy of the 1-pulse dosing regimen of two generic products of itraconazole (Itracon and Itra) in comparison with the innovative product (Sporal) for the treatment of tinea pedis."	( A comparison of the efficacy between two itraconazole generic products and the innovative itraconazole in the treatment of tinea pedis. Chaichalotornkul, J; Hoharitanon, S; Sindhupak, W, 2005)	0.33
" A separate dosing uniformity study was also performed to qualify use of the chamber."	( Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Burgess, DS; Frei, BL; Johnston, KP; McConville, JT; Overhoff, KA; Peters, JI; Sinswat, P; Talbert, RL; Vaughn, JM; Williams, RO, 2006)	0.33
" Rats were pretreated with PB (75 mg/kg for 4 days) prior to itraconazole or fluconazole dosing (20 and 200 mg/kg for 4 days)."	( Involvement of phenobarbital and SKF 525A in the hepatotoxicity of antifungal drugs itraconazole and fluconazole in rats. Ahmad Bustamam, A; Hasiah, AH; Israf, DA; Khairi, HM; Somchit, N; Sulaiman, MR; Wong, CW; Zuraini, A, 2006)	0.33
" Orally dosed itraconazole (ITZ) compositions, formed by SFL, produce higher serum levels of the drug compared to the commercial product, Sporanox oral solution."	( Cryogenic liquids, nanoparticles, and microencapsulation. Chen, X; Hu, J; Johnston, KP; McConville, JT; Overhoff, KA; Purvis, T; Rogers, TL; Sinswat, P; Vaughn, JM; Williams, RO, 2006)	0.33
" The minimal inhibitory concentration (MIC) values calculated from dose-response curves on agar diffusion-test (Kadłubowski's method), were also examined by analysing the variation (mean x +/- standard error, median Me, mode Mo, Min-Max)."	( [Susceptibility to itraconazole and miconazole of fungi strains isolated from the vaginal ontocenosis]. Horwatt-Bozyczko, E; Kołtuńska, M; Kurnatowska, A, 2001)	0.31
" The ultimate goals were to determine the relative bioavailability between the two oral formulations (capsules vs oral solution) and to optimise dosing regimens in these patients."	( Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Bell, SC; Charles, BG; Friberg, LE; Hennig, S; Miller, H; Wainwright, CE, 2006)	0.33
"The primary objective of the study was to estimate the population pharmacokinetic parameters for itraconazole and hydroxy-itraconazole, in particular, the relative oral bioavailability of the capsule compared with solution in adult cystic fibrosis patients, in order to develop new dosing guidelines."	( A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Bell, SC; Charles, BG; Duffull, SB; France, M; Hennig, S; Miller, H; Wainwright, CE; Waterhouse, TH, 2007)	0.34
" Simulations from the final model showed that a dosing schedule of 500 mg twice daily for both formulations provided the highest chance of target success."	( A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Bell, SC; Charles, BG; Duffull, SB; France, M; Hennig, S; Miller, H; Wainwright, CE; Waterhouse, TH, 2007)	0.34
" From oral dosing of rats, it was determined that the two extrudate formulations performed similarly in vivo as confirmed by their statistically equivalent AUC values."	( Hot-melt extrusion for enhanced delivery of drug particles. McConville, JT; McGinity, JW; Miller, DA; Williams, RO; Yang, W, 2007)	0.34
"The objective of this study was to formulate itraconazole semisolid dosage forms and characterize their physicochemical properties."	( Characterization of itraconazole semisolid dosage forms prepared by hot melt technique. Ji, CW; Lee, BJ; Park, ES; Sah, H; Shim, SY, 2006)	0.33
" ITZ-IV at daily doses of 10, 20, or 40 mg/kg was as effective as the intraperitoneal administration of amphotericin B (AMPH) at a dosage of 1 mg/kg daily in improving survival."	( Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice. Abe, S; Ishibashi, H; Ono, Y; Otani, H; Tansho, S; Torii, S; Yamaguchi, H, 2006)	0.33
" However, a higher daily dosage of itraconazole might have an inhibitory effect."	( Pharmacokinetic study of the interaction between itraconazole and nevirapine. Jaruratanasirikul, S; Sriwiriyajan, S, 2007)	0.34
" After repeated dosing for 1 week, both SES and SD increased the areas of Peyer's patch region in intestinal tissues but no distinct histopathological damage of the intestine was observed except the hepatocytes."	( In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Lee, BJ; Park, MJ; Ren, S, 2007)	0.34
"The goal of this research was to evaluate an intravenous itraconazole nanosuspension dosage form, relative to a solution formulation, in the rat."	( Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Barker, K; Cook, C; Gass, J; Glosson, J; Kipp, J; Papadopoulos, P; Rabinow, B; Sun, CS; White, R; Wielgos, T; Wong, J; Wood, K, 2007)	0.34
" No food effects were observed with the itraconazole:HBenBCD solid dosage forms."	( Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations. Buchanan, CM; Buchanan, NL; Edgar, KJ; Klein, S; Little, JL; Ramsey, MG; Ruble, KM; Wacher, VJ; Wempe, MF, 2007)	0.34
" Treatment arms with the same regimen in terms of drug, type (continuous or intermittent), and dosage were combined to estimate the risk of an outcome of interest."	( The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Chan, AK; Chang, CH; Kurth, T; Orav, JE; Young-Xu, Y, 2007)	0.34
" Eight healthy volunteers received Sporanox or ITRA-GSMP capsule in the fasted state or after a high-fat diet on four separate dosing occasions with a 2-week washout period."	( Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Hong, JY; Kim, CK; Lim, SJ; Song, YK; Woo, JS, 2008)	0.35
" Nineteen patients were treated with itraconazole 200 mg once daily for 12 weeks, and 17 patients were treated with terbinafine for 12 weeks in a dosage according to their body weight, respectively."	( Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients. Ginter-Hanselmayer, G; Smolle, J; Weger, W, 2008)	0.35
" The solid dosage form Sporanox again failed to achieve a similar extent of absorption enhancement (0."	( Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Annaert, P; Augustijns, P; Kayaert, P; Martens, JA; Mellaerts, R; Mols, R; Van den Mooter, G; Van Humbeeck, J, 2008)	0.35
" In order to prepare an effective solid dosage form for a nanosuspension, it is imperative that the spray-dried nanoparticles should go back to their original particle size when reconstituted in an aqueous system."	( Conversion of nanosuspensions into dry powders by spray drying: a case study. Chaubal, MV; Popescu, C, 2008)	0.35
" Upon addition to water, ITZ formed a colloidal dispersion suitable for nebulization, which demonstrated optimal aerodynamic properties for deep lung delivery and high lung and systemic levels when dosed to mice."	( High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Johnston, KP; McConville, JT; Miller, DA; Tam, J; Williams, RO; Yang, W; Zhou, J, 2008)	0.35
" The influence of solubilizers on the aqueous solubility of the itraconazole, ketoconazole and miconazole was investigated in order to enhance their solubility for a possible parenteral dosage form."	( Aqueous solvent system for the solubilization of azole compounds. Antal, I; Klebovich, I; Kovács, K; Ludányi, K; Stampf, G, 2009)	0.35
" Posaconazole and itraconazole were the most active in vitro with MICs falling well below the achievable serum levels typically observed with standard dosing regimens."	( Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Fothergill, AW; Rinaldi, MG; Sutton, DA, 2009)	0.35
" Our data suggests that survival and microbiological response depend more on drug dosing than on the trailing phenotype of the isolates."	( Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. Chen, E; Leitz, GJ; Odabasi, Z; Ostrosky-Zeichner, L; Paetznick, VL; Rex, JH; Rodriguez, JR, 2010)	0.36
" Based on these distinctions, it is important to carry out local studies in order to establish dosage regimens according the characteristics of each population."	( Comparison of the oral pharmacokinetics of fluconazole and itraconazole in Mexicans. Carrasco-Portugal, Mdel C; Flores-Murrieta, FJ; Landa, C, 2008)	0.35
" We found that the current dosage regimen of IV-ITZ (200 mg/day) was appropriate to obtain therapeutic trough concentrations for neutropenic patients in Korea."	( Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. Chae, H; Choi, JH; Choi, SM; Kim, S; Lee, DG; Park, SH; Shin, WS; Yim, DS; Yoo, JH, 2009)	0.35
" Building on this data, a final steady-state trial was performed with the use of a 7 mg/kg oral dosage twice a day of commercial capsules given in fish to a group of 15 penguins."	( Evaluation of oral itraconazole administration in captive Humboldt penguins (Spheniscus humboldti). Abou-Madi, N; Bunting, EM; Cox, S; Fox, H; Kollias, GV; Martin-Jimenez, T, 2009)	0.35
" One study used daily dosing and the rest used once-weekly dosing."	( Efficacy of fluconazole for the treatment of onychomycosis. Brown, SJ, 2009)	0.35
" However, fluconazole may be preferred in patients unable to tolerate other oral antifungal agents due to the dosing regimen, adverse effect profile, and drug interactions."	( Efficacy of fluconazole for the treatment of onychomycosis. Brown, SJ, 2009)	0.35
" The antihistamine response after ebastine dosing would be decreased following rifampin pretreatments."	( Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. Cha, IJ; Lee, SS; Liu, KH; Shin, JG; Shon, JH; Yeo, CW, 2010)	0.36
"In this case, dosing recommendations of itraconazole 200 mg daily with lopinavir/ritonavir were appropriate."	( Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir. Hills-Nieminen, C; Houston, S; Hughes, CA; Shafran, SD, 2009)	0.35
"The dose of itraconazole was reduced to 200 mg daily as recommended by current guidelines, and therapeutic drug monitoring of both itraconazole and lopinavir concentrations confirmed that no further dosage adjustments were necessary."	( Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir. Hills-Nieminen, C; Houston, S; Hughes, CA; Shafran, SD, 2009)	0.35
" In the persistently neutropenic model with A1163, aminocandin, CAS and micafungin (2-10mg/kg) were all effective at prolonging survival, with some impact on reducing culture burdens, even with alternate-day dosing (4mg/kg)."	( Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. Denning, DW; Morrissey, G; Sharp, A; Warn, PA, 2010)	0.36
" Single-dose 24-h pharmacokinetic studies were conducted in Sprague-Dawley rats following inhalation of the nebulized colloidal dispersions (equivalent to 20mgITZ/mL dispersion in 5mL) in a nose-only dosing apparatus."	( Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Johnston, KP; Williams, RO; Yang, W, 2010)	0.36
" The aim of the presently reported study was the evaluation of the antimycotic action of two azole compounds--miconazole and itraconazole (Janssen) against 205 Candida strains isolated from the various biological specimens of two groups of patients--hospitalized (group 1) and examined in outpatient clinic (group 2); differentiation of species and codes of these strains; analysis of dose-response curves and parameters of polygons of the azoles minimal inhibitory concentrations (MIC)."	( [Susceptibility to miconazole and itraconazole of Candida strains isolated from hospitalized and outpatient clinic patients]. Kurnatowska, AK; Kwaśniewska, J, 2009)	0.35
" Conscious dogs, instrumented with a high-fidelity pressure transducer in the left ventricle, were placed in a sling for dosing and cardiac monitoring."	( Nanosuspension formulation of itraconazole eliminates the negative inotropic effect of SPORANOX in dogs. Cook, C; Gass, J; McKee, J; Rabinow, B, 2010)	0.36
" In this study, the effect of multiple dosing of Icz on the pharmacokinetics of CsA in three healthy cats was investigated."	( Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine in cats. Kamishina, H; Katayama, M; Katayama, R, 2010)	0.36
" Although separating their dosages by 24 hours has been shown to reduce the interaction, an appropriate dosage interval remains to be determined."	( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010)	0.36
" Subsequently, we simulated the plasma concentration profiles of triazolam administered after itraconazole therapy with various dosing intervals."	( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010)	0.36
"The model could explain and simulate the interaction between itraconazole-triazolam using a variety of dosage intervals between the administrations."	( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010)	0.36
" The complex was formulated as a capsule dosage form and drug release was evaluated."	( Comparative study of itraconazole-cyclodextrin inclusion complex and its commercial product. Ahmed, SM; Alanazi, FK; Alhamed, SS; Alsarra, IA; Bosela, AA; Mowafy, HA; Neau, SH, 2010)	0.36
" The present retrospective pharmacokinetic-pharmacodynamic (PK-PD) analysis was designed to find any factors affecting clinical outcome of ITCZ treatment, and was performed to evaluate the appropriateness of the current dosage regimen in ICU patients."	( Pharmacokinetic-pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units. Hagihara, M; Hasegawa, T; Kasai, H; Kato, T; Mikamo, H; Umemura, T, 2011)	0.37
" Plasma clearance of the commercial itraconazole solution was more rapid than the clearance published for other species, possibly warranting more frequent dosing in black-footed penguins."	( Effects of compounding on pharmacokinetics of itraconazole in black-footed penguins (Spheniscus demersus). Mitchell, MA; Papich, MG; Russell, G; Smith, JA, 2010)	0.36
" Therefore, when administering ITCZ-OS, which is more rapidly absorbed in the digestive tract compared to its conventional dosage forms, to patients with blood disease, the blood concentration of ITCZ should be measured to maintain its efficacy and safety."	( Clinical significance of measuring the blood concentration of itraconazole oral solution in the field of hematology. Kawano, K; Kobayashi, H; Nakagawa, S; Ohta, S; Shimoeda, S; Yamato, S, 2010)	0.36
" Tacrolimus levels and dosage requirements were compared during and after azole therapy."	( Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. Amital, A; Fuks, L; Kramer, MR; Shitrit, D, )	0.13
" In contrast, the other three strains resistant to 8 mg/L itraconazole in vitro were refractory to the therapy, even at the highest itraconazole dosage (40 mg/kg)."	( Correlation of in vitro activity and in vivo efficacy of itraconazole intravenous and oral solubilized formulations by testing Candida strains with various itraconazole susceptibilities in a murine invasive infection. Shimogawara, K; Uchida, K; Yamaguchi, H, 2011)	0.37
" The dosage of itraconazole should be reduced and its therapeutic outcome should be monitored closely when these two agents are concomitantly administered."	( Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. Mahatthanatrakul, W; Ridtitid, W; Samaeng, M; Sriwiriyajan, S; Wongnawa, M, 2011)	0.37
" Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment."	( Anidulafungin: when and how? The clinician's view. George, J; Reboli, AC, 2012)	0.38
" The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine."	( Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Hagelberg, NM; Laine, K; Neuvonen, PJ; Olkkola, KT; Peltoniemi, MA; Reponen, P; Saari, TI; Turpeinen, M, 2011)	0.37
" Suggestions for dosing regimens and laboratory monitoring are given."	( Systemic drugs in patients with skin diseases. Byekova, Y; Elewski, B; Hughey, L, 2011)	0.37
"In this study, the potential of wet granulation of ordered mesoporous silica (OMS) material was evaluated to assess the risk of premature drug release during processing and to improve the bulk powder flow properties and compactibility for the development of an immediate release oral dosage form."	( Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen. Backhuijs, F; Martens, JA; Van den Mooter, G; Vialpando, M, 2012)	0.38
" Response rates to griseofulvin are similar to rates seen in the 1970s, but require higher dosing and conversion to crushed tablets in partial responders."	( Treatment outcomes for tinea capitis in a skin of color population. Alexis, A; Bhanusali, D; Coley, M; Silverberg, JI; Silverberg, NB, 2012)	0.38
" Serum concentrations were lower, with a maximum concentration of 104ng/ml at 4h after dosing and a terminal half-life of 10."	( Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. Rundfeldt, C; Scherliess, H; Steckel, H; Wlaź, P; Wyska, E, 2013)	0.39
" According to the close drug monitoring, all 10 patients experienced supratherapeutic levels of CsA even with a preemptive CsA dosage reduction and prompt dose adjustment."	( Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population. Chen, RL; Chen, ZZ; Fu, DH; Hu, JD; Li, J; Luo, XF; Qiu, HQ; Wu, XM; Yang, T; Yuan, XH; Zheng, XY, )	0.13
" Additional therapy with itraconazole leads to the decrease of total IgE to the limits recommended for proper omalizumab dosing (30-1500 kUA/l)."	( Itraconazole as 'bridge therapy' to anti-IgE in a patient with severe asthma with fungal sensitisation. Badiu, I; Bussolino, C; Pizzimenti, S; Rolla, G, 2013)	0.39
"The influence of dosing regimens on the recurrence rates of onychomycosis has not been investigated."	( Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. Cooper, EA; Gupta, AK; Paquet, M, )	0.13
"To compare recurrence rates for toenail dermatophyte onychomycosis between four dosing regimens."	( Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. Cooper, EA; Gupta, AK; Paquet, M, )	0.13
" Itraconazole (ITRA) is an antifungal commonly used in birds, but administration requires repeated oral dosing and the safety margin is narrow."	( A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension. Jeżewska-Witkowska, G; Rundfeldt, C; Steckel, H; Witkowski, A; Wlaź, P; Wyska, E, 2013)	0.39
"This paper presents the chemometrically assisted optimization and validation of the RP-HPLC method intended for the quantitative analysis of itraconazole and its impurities in pharmaceutical dosage forms."	( Chemometrically assissted optimization and validation of RP-HPLC method for the analysis of itraconazole and its impurities. Ivanović, D; Jančić Stojanović, B; Jovanović, M; Kasagić, I; Malenović, A; Rakić, T, 2013)	0.39
"Itraconazole, approved for treatment of toenail fungal infection onychomycosis, provides antifungal activity at a dosage requiring once-daily (QD) administration of 2 100-mg capsules for 12 weeks."	( Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Bulger, L; Maddin, S; Quiring, J, 2013)	0.39
"This phase 3, randomized, placebo-controlled trial investigated the noninferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsules dosed QD for 12 weeks, with a 40-week follow-up period."	( Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. Bulger, L; Maddin, S; Quiring, J, 2013)	0.39
" Itraconazole (ITZ) was selected as the model compound for the development of an oral dosage form for enhanced release."	( Agglomeration of mesoporous silica by melt and steam granulation. part II: screening of steam granulation process variables using a factorial design. Albertini, B; Martens, JA; Passerini, N; Rombaut, P; Van Den Mooter, G; Vander Heyden, Y; Vialpando, M, 2013)	0.39
" The poorly water-soluble compound, itraconazole (ITZ), was selected for the development of an immediate-release oral dosage form."	( Agglomeration of mesoporous silica by melt and steam granulation. Part I: a comparison between disordered and ordered mesoporous silica. Albertini, B; Bergers, D; Martens, JA; Passerini, N; Rombaut, P; Van Den Mooter, G; Vialpando, M, 2013)	0.39
" However, the optimal dosage of antifungal agents based on PK-PD properties has not been clearly established."	( Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. Hagihara, M; Hamada, Y; Mikamo, H; Yamagishi, Y, 2013)	0.39
"The aims of the present study were to prepare new dual-mode floating gastroretentive tablets (DF-GRT) containing itraconazole (ITR) and to evaluate influence of the dosage forms on pharmacokinetic parameters of ITR."	( Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. Ha, JM; Kim, JY; Park, CW; Park, ES; Rhee, YS, 2014)	0.4
"The mean 6β-hydroxycortisol/cortisol ratio was reduced by 68% from baseline (P < 0·05) after the 1st pulse dosing, but the inhibitory effect appeared to be resolved before the next pulse dosing and at 3 months post-treatment."	( Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis. Atsuda, K; Echizen, H; Inamoto, N; Kubo, H; Machida, M; Ono, N; Saito, H; Shibata, S; Shinozaki, K; Takahashi, H; Wada, N, 2014)	0.4
" Nanocrystal suspensions were prepared by a rapid wet milling technique, after which the suspensions were transformed into solid dosage forms by both freeze drying and granulating."	( Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption. Häkkinen, MR; Hirvonen, J; Ilkka, J; Järvinen, K; Kiesvaara, J; Kovalainen, M; Laaksonen, T; Laru, J; Oksala, O; Peltonen, L; Rönkkö, S; Sarnes, A, 2014)	0.4
" The most widely used chemotherapeutic treatment is itraconazole, although the dosage commonly used can be harmful to some individuals and species."	( Reduced itraconazole concentration and durations are successful in treating Batrachochytrium dendrobatidis infection in amphibians. Brannelly, LA, 2014)	0.4
" The dosage of anti-F."	( Association of IgG immunoglobulin and subclasses level with the severity of chromoblastomycosis due to Fonsecaea pedrosoi and therapeutic response to itraconazole. Azevedo, CD; Azevedo, FS; Bouillet, LE; Bruña-Romero, O; Marques, SG; Nascimento, FR; Pinto, MC; Silva, LA; Stoianoff, MA, 2014)	0.4
" Limited published information exists regarding tacrolimus dosing when transitioning from voriconazole to itraconazole."	( Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study. Enderby, CY; Heckman, MG; Keller, CA; Thomas, CS, 2014)	0.4
"Tacrolimus dosage adjustments were not necessary when converting from voriconazole to itraconazole."	( Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study. Enderby, CY; Heckman, MG; Keller, CA; Thomas, CS, 2014)	0.4
" Recent advances in our knowledge of azole exposure-response relationships, therapeutic drug monitoring and individualized dosing strategies are reviewed as follows."	( Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Dolton, MJ; McLachlan, AJ, 2014)	0.4
" The recent approval of a solid oral tablet formulation of posaconazole with improved bioavailability and once-daily dosing has significantly improved the clinical utility of this agent."	( Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Dolton, MJ; McLachlan, AJ, 2014)	0.4
" Plasma concentrations of triazoles and their major metabolites at 12h after dosing were determined."	( Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. Kawakami, J; Mino, Y; Naito, T; Yamada, T, 2015)	0.42
"The main goal of the current work was to investigate the possible use of flexographic printing for the conversion of nanosuspensions into solid dosage forms."	( Fabrication of drug-loaded edible carrier substrates from nanosuspensions by flexographic printing. Genina, N; Kolakovic, R; Laaksonen, T; Määttänen, A; Palo, M; Peltonen, J; Salonen, J; Sandler, N, 2015)	0.42
" The most successful treatment option for eumycetomas offers itraconazole in a dosage of 200 mg twice daily."	( Eumycetoma and actinomycetoma--an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy. Fahal, AH; Nenoff, P; Reinel, D; Schöfer, H; van de Sande, WW, 2015)	0.42
" Interestingly although not approved as a treatment option, Itraconazole was effective in the seven cases it was used to treat cryptococcosis, with a dosage range of 100-400 mg/d and duration from 3 to 6 months."	( Systemic Review of Published Reports on Primary Cutaneous Cryptococcosis in Immunocompetent Patients. Chen, J; Du, L; Gu, J; Liao, W; Yang, Y; Zhu, Y, 2015)	0.42
"The current available formulations of itraconazole are not ideal for dosing in cats."	( Alternate-day dosing of itraconazole in healthy adult cats. Dirikolu, L; Kubier, A; Middleton, SM; Mitchell, MA; Papich, MG; Rubin, SI, 2016)	0.43
"The aim of this article is to investigate the role of amphiphilic block copolymer-based polymeric micelles of itraconazole for the management of fungal keratitis to overcome the limitations of the conventional dosage form."	( Zero order delivery of itraconazole via polymeric micelles incorporated in situ ocular gel for the management of fungal keratitis. Jaiswal, M; Kumar, M; Pathak, K, 2015)	0.42
" A dose-response curve was generated for itraconazole and clarithromycin (maximal concentration 100 μM) and compared to that of Zosuquidar, a highly specific known P-gp inhibitor."	( Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells. Bleier, BS; Han, X; Hoang, JD; Lam, A; Singleton, A, 2015)	0.42
"Both itraconazole and clarithromycin demonstrated a dose-response curve for P-gp inhibition similar to that of Zosuquidar."	( Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells. Bleier, BS; Han, X; Hoang, JD; Lam, A; Singleton, A, 2015)	0.42
"The objective of the present work was to formulate tablet dosage form of itraconazole with enhanced bioavailability."	( Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. Desai, J; Fadke, J; Thakkar, H, 2015)	0.42
" Various factors considered in the recommendations include the choice of itraconazole dosage form, administration in the fasted or fed state, the dose and duration of itraconazole administration, the timing of substrate and itraconazole coadministration, and measurement of itraconazole and metabolite plasma concentrations, among others."	( Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. Bello, A; Dresser, MJ; Heald, D; Komjathy, SF; Liu, L; O'Mara, E; Robertson, SM; Rogge, M; Stoch, SA, 2016)	0.43
" The activities of the benznidazole/itraconazole combinations were compared with the results from those receiving the same dosage of each individual drug."	( Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease. Assíria Fontes Martins, T; Bahia, MT; Caldas, IS; Caldas, S; da Silva do Nascimento, ÁF; de Andrade, IM; de Figueiredo Diniz, L; Mazzeti, AL; Ribeiro, I, 2015)	0.42
" We further formulated the amorphous solid dispersions into tablet dosage forms and evaluated their performance in a bio-relevant dissolution media."	( Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions. Lang, B; Liu, S; McGinity, JW; Williams, RO, 2016)	0.43
" The aim of this study was to establish the optimal dosage and administration of immunosuppressants and antifungal agents."	( [Optimization of Immunosuppression and the Prevention of Fungal Infection in Autoimmune Diseases]. Mino, Y, 2015)	0.42
" The resulting interaction between these CYP3A4 substrates can be utilized clinically as a pharmacokinetic booster for prolonging saquinavir dosing regimen and/or decreasing saquinavir dose requirement in HIV/AIDS patients."	( A semi-mechanistic pharmacokinetic model of saquinavir combined with itraconazole in HIV-1-positive patients. Jenjob, A; Lohitnavy, M; Methaneethorn, J; Pankaew, A; Phuphuak, K; Sriarwut, T, 2015)	0.42
" Model application can be of advantage for dosing adjustment to avoid serious adverse effects resulted from concomitant use of both drugs."	( Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole. Chan-Im, D; Chiang-Ngernthanyakool, R; Lohitnavy, M; Methaneethorn, J; Phaohorm, S; Tongpeng, W, 2015)	0.42
" Continuous dosing may be required to fully inhibit the HH pathway and achieve clinical response."	( Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. Ally, MS; Atwood, SX; Bailey-Healy, I; Beachy, PA; Chang, AL; Colevas, AD; Kim, J; Oro, A; Ransohoff, K; Rezaee, M; Sarin, K; Tang, JY, 2016)	0.43
" In short, the quantification of BNZ and ITZ by analysis of mixtures had shown to be efficient and cost-effective alternative for determination of these drugs in a pharmaceutical dosage form."	( Simultaneous determination of benznidazole and itraconazole using spectrophotometry applied to the analysis of mixture: A tool for quality control in the development of formulations. Cunha-Filho, MS; Infante, CM; Pinho, LA; Sá-Barreto, LC, 2016)	0.43
"The purpose of this study was to assess the feasibility of a multicompartmental in vitro dissolution apparatus, gastrointestinal simulator (GIS), in assessing the drug dissolution of 2 commercially available oral dosage forms for itraconazole (ICZ)."	( The Evaluation of In Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media. Amidon, GE; Amidon, GL; Matsui, K; Tsume, Y, 2016)	0.43
" The objective of the present study was to better understand the best choice of rodent model for evaluating the pharmacokinetic and efficacy of this orally administered modified release ITZ dosage form against invasive Aspergillus fumigatus."	( Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection. Huang, S; Kirkpatrick, WR; Maincent, JP; Najvar, LK; Patterson, TF; Peters, JI; Wiederhold, NP; Williams, RO, 2017)	0.46
" In patients whose blood concentration decreases after the switch, the development of GVHD should be monitored and tacrolimus dosage should be readjusted to maintain an appropriate blood concentration."	( Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Akashi, K; Ikesue, H; Masuda, S; Matsukawa, K; Miyamoto, T; Shiratsuchi, M; Suetsugu, K; Tsuchiya, Y; Uchida, M; Watanabe, H; Yamamoto-Taguchi, N, 2017)	0.46
" Based on the in vitro and in vivo results, further investigations in larger animals are a logical next step where fluid volumes, pH, and transit times are more favorable for the evaluated dosage forms."	( Mucoadhesive amorphous solid dispersions for sustained release of poorly water soluble drugs. LaFountaine, JS; McGinity, JW; Miller, DA; Prasad, LK; Williams, RO, 2017)	0.46
" The delivery of TDM as a future standard of care will require real-time measurement of drug concentrations at the bedside and algorithms for dosage adjustment."	( Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. Hope, WW; Stott, KE, 2017)	0.46
"There is more research required to broaden the knowledge on the downstream processing of nanosuspensions into solid oral dosage forms, especially for coated nanosuspensions onto beads as carriers."	( Downstream drug product processing of itraconazole nanosuspension: Factors influencing drug particle size and dissolution from nanosuspension-layered beads. Low, A; Möschwitzer, JP; Parmentier, J; Tan, EH, 2017)	0.46
" When Sporanox and itraconazole/AFFINISOL High Productivity HPMCAS SDDs were dosed in rats, the maximum absorption rate for each formulation rank-ordered with membrane flux in vitro."	( Impact of Drug-Rich Colloids of Itraconazole and HPMCAS on Membrane Flux in Vitro and Oral Bioavailability in Rats. Brodeur, TJ; Friesen, DT; Goodwin, AK; Grass, ME; Morgen, MM; Stewart, AM; Vodak, DT, 2017)	0.46
" Its variable and unpredictable oral bioavailability make it difficult to determine the optimal dosing regimen."	( Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. Allegra, S; Carcieri, C; Cusato, J; D'Avolio, A; De Francia, S; De Nicolò, A; Di Perri, G; Fatiguso, G; Favata, F; Pirro, E, 2017)	0.46
"There has been limited research done on the downstream processing of nanosuspensions into solid oral dosage forms."	( Downstream drug product processing of itraconazole nanosuspension: Factors influencing tablet material properties and dissolution of compacted nanosuspension-layered sugar beads. Low, A; Möschwitzer, JP; Parmentier, J; Tan, EH, 2017)	0.46
" SMSD technology could be an efficacious dosage option for the consistent oral absorption and clinical outcomes of ITZ."	( Avoidance of food effect on oral absorption profile of itraconazole by self-micellizing solid dispersion approach. Kobayashi, K; Kojo, Y; Matsunaga, S; Onoue, S; Sato, H; Seto, Y; Suzuki, H, 2017)	0.46
" Using an in vivo estimation of the pharmacodynamic target and a previously published pharmacokinetic model, the probability of target attainment (PTA) was determined for a range of isavuconazole MICs using three dosing regimens (I, 200 mg once daily; II, 300 mg once daily; and III, 400 mg once daily)."	( Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Brüggemann, RJM; Buil, JB; Meis, JF; Melchers, WJG; Mouton, JW; Verweij, PE; Wasmann, RE; Zoll, J, 2018)	0.48
" The PTA for isolates with an isavuconazole MIC of 1 mg/L was 92%-99% for 90% effective concentration (EC90) for the three dosing regimens."	( Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Brüggemann, RJM; Buil, JB; Meis, JF; Melchers, WJG; Mouton, JW; Verweij, PE; Wasmann, RE; Zoll, J, 2018)	0.48
"The formulation factors relevant to developing immediate and controlled release dosage forms containing poorly soluble drugs dispersed in amorphous systems are poorly understood."	( Development of Itraconazole Tablets Containing Viscous KinetiSol Solid Dispersions: In Vitro and In Vivo Analysis in Dogs. Hughey, JR; Keen, JM; LaFountaine, JS; McGinity, JW; Miller, DA, 2018)	0.48
"The poor attainment of target levels with current recommended dosing in children <12 years of age suggests that higher empiric doses are needed in this age group."	( Itraconazole Dosing and Drug Monitoring at a Tertiary Children's Hospital. Boast, A; Cranswick, N; Curtis, N; Gwee, A; Leong, YH, 2019)	0.51
"Current dosing regimens of reported drugs are effective and safe for use in tinea capitis in children."	( Tinea capitis in children: a systematic review of management. Friedlander, SF; Gupta, AK; Mays, RR; Piguet, V; Piraccini, BM; Shear, NH; Tosti, A; Versteeg, SG, 2018)	0.48
" To evaluate the efficacy and safety of different cycles of itraconazole pulse therapy, determine the optimal dosage and number of cycles for onychomycosis."	( An exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosis. Li, X; Shi, Y; Tao, Y; Xu, H; Yu, J; Zhang, L, 2018)	0.48
" Performance of the model was validated using prespecified acceptance criteria against different dosing regimens, formulations for 29 PK, and DDI studies with midazolam and other CYP3A4 substrates."	( Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. Ericsson, H; Janzén, D; Kanebratt, KP; Lennernäs, H; Lundahl, A; Prieto Garcia, L, 2018)	0.48
" Such thermodynamic based solubility data of ITRA will be of immense help in solubilization, synthesis, process development, preformualtion, and dosage form development in pharmaceuticals."	( Solubilization and determination of solution thermodynamic properties of itraconazole in different solvents at different temperatures. Jagdale, SK; Nawale, RB, 2019)	0.51
"Using patient-derived glioblastoma stem cell (GSC) cultures from 15 GBM patients, we described stem cell properties of individual cultures, determined the dose-response relationships of the drugs in the CUSP9, and assessed the efficacy the CUSP9 combination with TMZ in concentrations clinically achievable."	( The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019)	0.51
"4 mg/lb], PO, q 24 h, with or without a loading dosage protocol) and itraconazole (approx 10 mg/kg [4."	( Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. Benaím, G; Estep, JS; Luis Concepción, J; Madigan, R; Majoy, S; Márquez, ME; Mogollón-Mendoza, AC; Paniz-Mondolfi, AE; Pérez Alvarez, A; Ritter, K; Rodriguez-Morales, AJ; Silva, SC; Zao, CL, 2019)	0.51
"Solid dosage forms of amorphous solid dispersions (ASDs) have rarely been assessed for their crushability, although it might possibly be a more frequent practice than thought to facilitate oral administration in several clinical conditions (e."	( The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics. Appeltans, B; Pas, T; Van den Mooter, G; Verbert, S, 2020)	0.56
"These results provided a new perspective for designing topical dosage forms for the treatment of onychomycosis."	( Effect of monoterpenes on ex vivo transungual delivery of itraconazole for the management of onychomycosis. Abdollahi, D; Afshar, M; Jafariazar, Z, 2020)	0.56
" The current PBPK model, which considers changes in unbound potency-adjusted active species, can be used to inform dosing recommendations when abemaciclib is coadministered with CYP3A4 perpetrators."	( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020)	0.56
"Cyclodextrins are widely used pharmaceutical excipients, particularly for insoluble compounds dosed orally, such as the oral solution of itraconazole, which is frequently used in clinical drug-drug interaction studies to inhibit cytochrome P450 3A."	( Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study. Chen, JZ; Chen, Y; Chiang, PC; Chinn, LW; Durk, MR; Jones, NS; Liu, J; Mao, C; Nagapudi, K; Plise, EG; Wong, S, 2020)	0.56
" ECG data were collected on multiple days during repeat dosing treatment regimens, thereby allowing the capture of QT data across a wide range of drug concentrations in each study participant and encompassing both "therapeutic" and "supra-therapeutic" exposures."	( PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration. Bentley, D; Derks, M; Diack, C; Jaminion, F; Wandel, C; Wang, K, 2020)	0.56
"The administration of conventional dosage forms of itraconazole (ITZ) for cutaneous candidiasis treatment is limited by its poor aqueous solubility and the deep location ofCandida albicans(CA) in this disease."	( Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis. Anjani, QK; Donnelly, RF; Paredes, AJ; Permana, AD; Utomo, E; Volpe-Zanutto, F, 2020)	0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)	0.72
" Plasma concentrations of ITZ and OH-ITZ at 12 h after dosing were determined at steady state."	( Associations between plasma hydroxylated metabolite of itraconazole and serum creatinine in patients with a hematopoietic or immune-related disorder. Imoto, Y; Kawakami, J; Miyadera, Y; Naito, T; Ono, T, 2021)	0.62
" Although the clinical practices of nebulised parenteral amphotericin B and voriconazole formulations (off-label use) are reported to show promising therapeutic effects with few adverse effects, there is no consensus about the dosage regimen (e."	( Inhaled Antifungal Agents for the Treatment and Prophylaxis of Pulmonary Mycoses. Lam, JKW; Liao, Q, 2021)	0.62
" According to our study, resveratrol can reduce the dosage to 1/64 of ketoconazole as well as itraconazole."	( The synergistic antifungal activity of resveratrol with azoles against Candida albicans. Gao, L; Song, F; Wan, Y; Wang, J; Wang, L; Zhang, L; Zhang, X, 2021)	0.62
"7 mg/L were achieved on empiric dosing in 49% and 68% respectively."	( A novel highly bio-available itraconazole formulation (SUBA®-Itraconazole) for anti-fungal prophylaxis in lung transplant recipients. Boan, P; Lavender, M; Musk, M; Whitmore, TJ; Wrobel, J; Yaw, M, 2021)	0.62
" The model was also used to extrapolate pharmacokinetic exposures from older children with different body surface area to guide dosing in younger children."	( Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. Cohen-Rabbie, S; Freshwater, T; Jain, L; Schalkwijk, S; Tomkinson, H; Vishwanathan, K; Wild, M; Xu, S; Zhou, D; Zhou, L, 2021)	0.62
" The model was also verified by the observed pharmacokinetics after multiple oral dosing and by the effect of hepatic impairment on esaxerenone pharmacokinetics."	( Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment. Igawa, Y; Ishizuka, H; Ishizuka, T; Shimizu, T; Watanabe, A; Yamada, M, 2022)	0.72
" We have summarized the most appropriate dosing regimens of posaconazole, fosravuconazole, voriconazole, and oteseconazole (VT-1161) to treat onychomycosis and superficial fungal infections."	( Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. Gupta, AK; Talukder, M; Venkataraman, M, 2022)	0.72
" In clinic, adverse drug reactions and toxicity related to crizotinib should be carefully monitored, and therapeutic drug monitoring for crizotinib is recommended to guide dosing and optimize treatment when coadministered with voriconazole, fluconazole, or itraconazole."	( Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib. Chen, L; Chen, W; Li, L, 2022)	0.72
" When a 200-mg single oral dose of belumosudil was coadministered with both rabeprazole and omeprazole, parent and metabolite exposures were largely reduced, suggesting that belumosudil dosage should be increased when given with PPIs."	( A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors. Alabanza, A; Lohmer, L; Patel, J; Schueller, O; Singh, N; Willson, A, 2022)	0.72
"Limited research has been performed on the downstream processing of nano-co-crystal suspensions into solid oral dosage forms."	( Incorporation of itraconazole nano-co-crystals into multiparticulate oral dosage forms. Bodmeier, R; Huang, Z; Staufenbiel, S, 2022)	0.72
" Understanding potential drug-drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies."	( Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers. Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L, 2022)	0.72
" However, the dosage of venetoclax is fixed, irrespective of body surface area (BSA) or weight."	( Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia. Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T, 2022)	0.72
" Most responders did not follow the strategies of voriconazole dosage based on CYP2C19 genotyping."	( A survey to describe common practices on antifungal monitoring among Spanish clinicians. Gómez-López, A; Martín-Gómez, MT; Salavert Lletí, M, 2023)	0.91
" Interestingly, a substantial reduction in plasma itraconazole concentration was observed during TPE, which was attributed to an insufficient delay between the dosing of itraconazole and TPE initiation."	( Effect of Therapeutic Plasma Exchange on Itraconazole Pharmacokinetics: A Case Study. Girgis, L; Kocic, D; Marriott, DJE; Reuter, SE; Seah, V; Sreeharan, T; Stocker, SL, 2023)	0.91
" The dog was initially treated with oral itraconazole at a dosage of 10 mg/kg once daily."	( Cutaneous protothecosis in a dog successfully treated with oral itraconazole in pulse dosing. Bacher, LH; Baldasso, G; de Farias, MR; Gmyterco, VC; Jagielski, T; Ribeiro, MG, 2023)	0.91
"This report highlights the refractoriness of skin infections by Prototheca wickerhamii with therapies proposed in the literature and suggests a new treatment option with oral itraconazole in pulse dosing for long-term disease control successfully performed in a dog with skin lesions."	( Cutaneous protothecosis in a dog successfully treated with oral itraconazole in pulse dosing. Bacher, LH; Baldasso, G; de Farias, MR; Gmyterco, VC; Jagielski, T; Ribeiro, MG, 2023)	0.91
" These present studies provided valuable information that helps inform SHR0302 dosing instructions and concomitant medication precautions."	( Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects. Feng, S; Fu, M; Gao, X; Li, X; Li, Y; Lin, H; Shen, K; Yu, G; Zhang, P; Zhang, Z, 2023)	0.91
" We found that an agent's dosage was associated with its efficacy; for example, the 1-year odds of mycological cure with terbinafine 250 mg daily for 24 weeks (SUCRA = 92."	( Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study. Bamimore, MA; Gupta, AK; Venkataraman, M, 2023)	0.91
"14); however, a statistically significant difference was noted for OD dosing over BD dosing in achieving clinical cure rates (p<0."	( Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial. Barkate, H; Bhushan, S; Chakraborty, D; Choudhary, A; Das, A; De, A; Dhoot, D; Doshi, Y; Gadkari, R; Gonsalves, N; J, D; Kamat, S; Lahiri, K; Mahadkar, N; Saraswat, A; Sarda, A; Shah, B; Shenoy, MM; Yadav, S, 2023)	0.91
" over the 12-h dosing interval and for 24 h following the last dose."	( Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Conte, JE; Golden, JA; Krishna, G; Little, E; McIver, M; Zurlinden, E, 2009)	0.35
" Increasing the standard dosing regimen may have some effect and may be clinically useful if no alternatives are available."	( Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Brüggemann, RJ; Mavridou, E; Melchers, WJ; Mouton, JW; Verweij, PE, 2010)	0.36

Role	Description
P450 inhibitor	An enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor	An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of xenobiotic-transporting ATPase (EC 3.6.3.44).
Hedgehog signaling pathway inhibitor	Any pathway inhibitor that inhibits the Hedgehog signalling pathway.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
triazoles	An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
dioxolane
N-arylpiperazine
dichlorobenzene	Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
cyclic ketal	A ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
conazole antifungal drug	Any conazole antifungal agent that has been used for the treatment of fungal infections in animals or humans.
triazole antifungal drug	Any triazole antifungal agent that has been used for the treatment of fungal infections in humans or animals.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	6.0070	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	1.4334	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
Fumarate hydratase	Homo sapiens (human)	Potency	29.5659	0.0030	8.7949	48.0869	AID1347053
GALC protein	Homo sapiens (human)	Potency	0.6310	28.1838	28.1838	28.1838	AID1159614
GLI family zinc finger 3	Homo sapiens (human)	Potency	1.5059	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	5.6319	0.0002	21.2231	8,912.5098	AID1259243; AID1259247
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	2.9849	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	2.4926	0.0010	22.6508	76.6163	AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	0.6918	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.8333	0.0013	10.1577	42.8575	AID1259252
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	1.5916	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	2.3914	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	4.5728	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	8.4120	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	2.9849	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	5.5679	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
polyprotein	Zika virus	Potency	29.5659	0.0030	8.7949	48.0869	AID1347053
activating transcription factor 6	Homo sapiens (human)	Potency	7.5624	0.1434	27.6121	59.8106	AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	6.0070	19.7391	45.9784	64.9432	AID1159509
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	3.7827	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	5.9553	0.0420	27.3789	61.6448	AID743210
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	2.0755	0.0006	27.2152	1,122.0200	AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	3.7578	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	10.9640	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	10.5909	0.0023	19.5956	74.0614	AID651631
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	3.7578	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	10.9640	0.0123	8.9648	39.8107	AID1645842
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	6.3096	0.0447	17.8581	100.0000	AID485341
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	7.9433	0.6310	35.7641	100.0000	AID504339
TDP1 protein	Homo sapiens (human)	Potency	2.4519	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	1.9732	0.1800	13.5574	39.8107	AID1460
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	2.5119	0.0013	7.7625	44.6684	AID914; AID915
67.9K protein	Vaccinia virus	Potency	14.1254	0.0001	8.4406	100.0000	AID720580
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	19.9526	0.7079	36.9043	89.1251	AID504333
IDH1	Homo sapiens (human)	Potency	2.9093	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	1.5849	0.0355	20.9770	89.1251	AID504332
beta-2 adrenergic receptor	Homo sapiens (human)	Potency	15.8489	0.0058	6.0263	32.6427	AID492947
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	2.0596	0.0041	9.9848	25.9290	AID504444
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	14.1254	0.0398	16.7842	39.8107	AID1454
geminin	Homo sapiens (human)	Potency	4.8470	0.0046	11.3741	33.4983	AID624296; AID624297
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	44.6684	0.0316	22.3146	100.0000	AID588579
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	7.8997	0.0056	12.3677	36.1254	AID624032; AID624044
lamin isoform A-delta10	Homo sapiens (human)	Potency	4.4668	0.8913	12.0676	28.1838	AID1487
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	4.4668	0.3162	12.7657	31.6228	AID881
Alpha-synuclein	Homo sapiens (human)	Potency	2.2387	0.5623	9.3985	25.1189	AID652106
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	4.4668	0.0063	8.2350	39.8107	AID881
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	28.1838	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	18.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Tyrosine-protein kinase Fyn	Homo sapiens (human)	IC50 (µMol)	3.8900	0.0002	1.6789	8.6800	AID625185
ATP-dependent translocase ABCB1	Mus musculus (house mouse)	IC50 (µMol)	0.7000	0.0640	4.0126	10.0000	AID150754; AID681128
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	1.6660	0.0002	2.3185	10.0000	AID150752; AID150755; AID679463; AID681122; AID681127
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	0.4256	0.0001	1.7536	10.0000	AID1180169; AID1783793; AID54923; AID625251
ATP-dependent translocase ABCB1	Mus musculus (house mouse)	IC50 (µMol)	0.2000	0.2000	4.7130	10.0000	AID150753; AID681119
C-X-C chemokine receptor type 1	Homo sapiens (human)	IC50 (µMol)	8.5038	0.0010	2.0227	10.0000	AID729310; AID729311; AID729312
Cruzipain	Trypanosoma cruzi	IC50 (µMol)	101.5000	0.0002	2.0450	8.0000	AID484274; AID484275
Vasopressin V2 receptor	Homo sapiens (human)	IC50 (µMol)	6.3988	0.0000	1.1213	7.0000	AID729307; AID729308; AID729309
C-C chemokine receptor type 4	Homo sapiens (human)	IC50 (µMol)	5.7620	0.2000	4.5424	10.0000	AID729298; AID729313; AID729314; AID729315
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	40.0000	0.0009	1.9014	10.0000	AID1138338
Lanosterol 14-alpha demethylase	Homo sapiens (human)	IC50 (µMol)	3.6000	0.0500	1.4390	4.0000	AID322753
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	2.0000	0.0040	1.9666	10.0000	AID1873196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 144	Mycobacterium tuberculosis CDC1551	Kd	30.2000	0.3600	2.5990	5.3000	AID1799791
Steroid C26-monooxygenase	Mycobacterium tuberculosis CDC1551	Kd	30.2000	0.1000	2.5967	6.1000	AID1799791
Steroid C26-monooxygenase	Mycobacterium tuberculosis CDC1551	Kd	30.2000	0.3600	2.5990	5.3000	AID1799791
Sterol 14-alpha demethylase	Aspergillus fumigatus Af293	Kd	1.0100	1.0100	3.0300	4.7900	AID575747
14-alpha sterol demethylase	Aspergillus fumigatus	Kd	0.0310	0.0310	0.8482	4.0300	AID575755
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
heat shock protein HSP 90-alpha isoform 2	Homo sapiens (human)	AC50	0.1950	0.1950	3.6679	18.6960	AID540270
HSP40, subfamily A [Plasmodium falciparum 3D7]	Plasmodium falciparum 3D7	AbsAC1000_uM	0.1290	0.1290	4.1169	11.3160	AID540271
heat shock protein 90, putative	Plasmodium falciparum 3D7	AC50	0.1950	0.1950	4.9920	98.5000	AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to singlet oxygen	Tyrosine-protein kinase Fyn	Homo sapiens (human)
neuron migration	Tyrosine-protein kinase Fyn	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
heart process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
calcium ion transport	Tyrosine-protein kinase Fyn	Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
axon guidance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
learning	Tyrosine-protein kinase Fyn	Homo sapiens (human)
feeding behavior	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of cell shape	Tyrosine-protein kinase Fyn	Homo sapiens (human)
gene expression	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of gene expression	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of neuron projection development	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein ubiquitination	Tyrosine-protein kinase Fyn	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein catabolic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
forebrain development	Tyrosine-protein kinase Fyn	Homo sapiens (human)
T cell costimulation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of protein ubiquitination	Tyrosine-protein kinase Fyn	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of protein catabolic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase Fyn	Homo sapiens (human)
response to ethanol	Tyrosine-protein kinase Fyn	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ephrin receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite morphogenesis	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
activated T cell proliferation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
modulation of chemical synaptic transmission	Tyrosine-protein kinase Fyn	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
leukocyte migration	Tyrosine-protein kinase Fyn	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to hydrogen peroxide	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein targeting to membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendritic spine maintenance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein localization to nucleus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of glutamate receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of dendritic spine maintenance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
response to amyloid-beta	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to amyloid-beta	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to L-glutamate	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to glycine	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein localization to membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of calcium ion import across plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
dendritic cell chemotaxis	C-X-C chemokine receptor type 1	Homo sapiens (human)
cell surface receptor signaling pathway	C-X-C chemokine receptor type 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	C-X-C chemokine receptor type 1	Homo sapiens (human)
receptor internalization	C-X-C chemokine receptor type 1	Homo sapiens (human)
interleukin-8-mediated signaling pathway	C-X-C chemokine receptor type 1	Homo sapiens (human)
chemokine-mediated signaling pathway	C-X-C chemokine receptor type 1	Homo sapiens (human)
calcium-mediated signaling	C-X-C chemokine receptor type 1	Homo sapiens (human)
immune response	C-X-C chemokine receptor type 1	Homo sapiens (human)
neutrophil chemotaxis	C-X-C chemokine receptor type 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	C-X-C chemokine receptor type 1	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Vasopressin V2 receptor	Homo sapiens (human)
renal water retention	Vasopressin V2 receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
activation of adenylate cyclase activity	Vasopressin V2 receptor	Homo sapiens (human)
hemostasis	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of gene expression	Vasopressin V2 receptor	Homo sapiens (human)
telencephalon development	Vasopressin V2 receptor	Homo sapiens (human)
response to cytokine	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of intracellular signal transduction	Vasopressin V2 receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V2 receptor	Homo sapiens (human)
calcium ion homeostasis	Alpha-synuclein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Alpha-synuclein	Homo sapiens (human)
microglial cell activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of receptor recycling	Alpha-synuclein	Homo sapiens (human)
positive regulation of neurotransmitter secretion	Alpha-synuclein	Homo sapiens (human)
negative regulation of protein kinase activity	Alpha-synuclein	Homo sapiens (human)
fatty acid metabolic process	Alpha-synuclein	Homo sapiens (human)
neutral lipid metabolic process	Alpha-synuclein	Homo sapiens (human)
phospholipid metabolic process	Alpha-synuclein	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial membrane organization	Alpha-synuclein	Homo sapiens (human)
adult locomotory behavior	Alpha-synuclein	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-synuclein	Homo sapiens (human)
response to iron(II) ion	Alpha-synuclein	Homo sapiens (human)
regulation of phospholipase activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
regulation of glutamate secretion	Alpha-synuclein	Homo sapiens (human)
regulation of dopamine secretion	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle exocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle priming	Alpha-synuclein	Homo sapiens (human)
regulation of transmembrane transporter activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of microtubule polymerization	Alpha-synuclein	Homo sapiens (human)
receptor internalization	Alpha-synuclein	Homo sapiens (human)
protein destabilization	Alpha-synuclein	Homo sapiens (human)
response to magnesium ion	Alpha-synuclein	Homo sapiens (human)
negative regulation of transporter activity	Alpha-synuclein	Homo sapiens (human)
response to lipopolysaccharide	Alpha-synuclein	Homo sapiens (human)
negative regulation of monooxygenase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Alpha-synuclein	Homo sapiens (human)
response to type II interferon	Alpha-synuclein	Homo sapiens (human)
cellular response to oxidative stress	Alpha-synuclein	Homo sapiens (human)
SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
positive regulation of SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
regulation of locomotion	Alpha-synuclein	Homo sapiens (human)
dopamine biosynthetic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial ATP synthesis coupled electron transport	Alpha-synuclein	Homo sapiens (human)
regulation of macrophage activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of endocytosis	Alpha-synuclein	Homo sapiens (human)
negative regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
positive regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle endocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle transport	Alpha-synuclein	Homo sapiens (human)
positive regulation of inflammatory response	Alpha-synuclein	Homo sapiens (human)
regulation of acyl-CoA biosynthetic process	Alpha-synuclein	Homo sapiens (human)
protein tetramerization	Alpha-synuclein	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Alpha-synuclein	Homo sapiens (human)
neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of serotonin uptake	Alpha-synuclein	Homo sapiens (human)
regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
negative regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
excitatory postsynaptic potential	Alpha-synuclein	Homo sapiens (human)
long-term synaptic potentiation	Alpha-synuclein	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
response to interleukin-1	Alpha-synuclein	Homo sapiens (human)
cellular response to copper ion	Alpha-synuclein	Homo sapiens (human)
cellular response to epinephrine stimulus	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber organization	Alpha-synuclein	Homo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinone	Alpha-synuclein	Homo sapiens (human)
positive regulation of glutathione peroxidase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of hydrogen peroxide catabolic process	Alpha-synuclein	Homo sapiens (human)
regulation of synaptic vesicle recycling	Alpha-synuclein	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein localization to cell periphery	Alpha-synuclein	Homo sapiens (human)
negative regulation of chaperone-mediated autophagy	Alpha-synuclein	Homo sapiens (human)
regulation of presynapse assembly	Alpha-synuclein	Homo sapiens (human)
amyloid fibril formation	Alpha-synuclein	Homo sapiens (human)
synapse organization	Alpha-synuclein	Homo sapiens (human)
chemical synaptic transmission	Alpha-synuclein	Homo sapiens (human)
tolerance induction	C-C chemokine receptor type 4	Homo sapiens (human)
chemotaxis	C-C chemokine receptor type 4	Homo sapiens (human)
inflammatory response	C-C chemokine receptor type 4	Homo sapiens (human)
response to bacterium	C-C chemokine receptor type 4	Homo sapiens (human)
homeostasis of number of cells	C-C chemokine receptor type 4	Homo sapiens (human)
positive regulation of positive chemotaxis	C-C chemokine receptor type 4	Homo sapiens (human)
chemokine-mediated signaling pathway	C-C chemokine receptor type 4	Homo sapiens (human)
interneuron migration	C-C chemokine receptor type 4	Homo sapiens (human)
cell chemotaxis	C-C chemokine receptor type 4	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	C-C chemokine receptor type 4	Homo sapiens (human)
immune response	C-C chemokine receptor type 4	Homo sapiens (human)
calcium-mediated signaling	C-C chemokine receptor type 4	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
steroid biosynthetic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
cholesterol biosynthetic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
sterol metabolic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
negative regulation of protein catabolic process	Lanosterol 14-alpha demethylase	Homo sapiens (human)
negative regulation of protein secretion	Lanosterol 14-alpha demethylase	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
enzyme binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
alpha-tubulin binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau-protein kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
growth factor receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
disordered domain specific binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Mus musculus (house mouse)
interleukin-8 receptor activity	C-X-C chemokine receptor type 1	Homo sapiens (human)
G protein-coupled receptor activity	C-X-C chemokine receptor type 1	Homo sapiens (human)
chemokine receptor activity	C-X-C chemokine receptor type 1	Homo sapiens (human)
protein binding	C-X-C chemokine receptor type 1	Homo sapiens (human)
interleukin-8 binding	C-X-C chemokine receptor type 1	Homo sapiens (human)
C-C chemokine receptor activity	C-X-C chemokine receptor type 1	Homo sapiens (human)
C-C chemokine binding	C-X-C chemokine receptor type 1	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V2 receptor	Homo sapiens (human)
protein binding	Vasopressin V2 receptor	Homo sapiens (human)
peptide binding	Vasopressin V2 receptor	Homo sapiens (human)
fatty acid binding	Alpha-synuclein	Homo sapiens (human)
phospholipase D inhibitor activity	Alpha-synuclein	Homo sapiens (human)
SNARE binding	Alpha-synuclein	Homo sapiens (human)
magnesium ion binding	Alpha-synuclein	Homo sapiens (human)
transcription cis-regulatory region binding	Alpha-synuclein	Homo sapiens (human)
actin binding	Alpha-synuclein	Homo sapiens (human)
protein kinase inhibitor activity	Alpha-synuclein	Homo sapiens (human)
copper ion binding	Alpha-synuclein	Homo sapiens (human)
calcium ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Alpha-synuclein	Homo sapiens (human)
phospholipid binding	Alpha-synuclein	Homo sapiens (human)
ferrous iron binding	Alpha-synuclein	Homo sapiens (human)
zinc ion binding	Alpha-synuclein	Homo sapiens (human)
lipid binding	Alpha-synuclein	Homo sapiens (human)
oxidoreductase activity	Alpha-synuclein	Homo sapiens (human)
kinesin binding	Alpha-synuclein	Homo sapiens (human)
Hsp70 protein binding	Alpha-synuclein	Homo sapiens (human)
histone binding	Alpha-synuclein	Homo sapiens (human)
identical protein binding	Alpha-synuclein	Homo sapiens (human)
alpha-tubulin binding	Alpha-synuclein	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
tau protein binding	Alpha-synuclein	Homo sapiens (human)
phosphoprotein binding	Alpha-synuclein	Homo sapiens (human)
molecular adaptor activity	Alpha-synuclein	Homo sapiens (human)
dynein complex binding	Alpha-synuclein	Homo sapiens (human)
cuprous ion binding	Alpha-synuclein	Homo sapiens (human)
chemokine receptor activity	C-C chemokine receptor type 4	Homo sapiens (human)
protein binding	C-C chemokine receptor type 4	Homo sapiens (human)
C-C chemokine receptor activity	C-C chemokine receptor type 4	Homo sapiens (human)
C-C chemokine binding	C-C chemokine receptor type 4	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
iron ion binding	Lanosterol 14-alpha demethylase	Homo sapiens (human)
sterol 14-demethylase activity	Lanosterol 14-alpha demethylase	Homo sapiens (human)
heme binding	Lanosterol 14-alpha demethylase	Homo sapiens (human)
oxidoreductase activity	Lanosterol 14-alpha demethylase	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Lanosterol 14-alpha demethylase	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
nucleus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase Fyn	Homo sapiens (human)
endosome	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fyn	Homo sapiens (human)
actin filament	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
postsynaptic density	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perikaryon	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell body	Tyrosine-protein kinase Fyn	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear endoplasmic reticulum	Tyrosine-protein kinase Fyn	Homo sapiens (human)
glial cell projection	Tyrosine-protein kinase Fyn	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Mus musculus (house mouse)
plasma membrane	C-X-C chemokine receptor type 1	Homo sapiens (human)
secretory granule membrane	C-X-C chemokine receptor type 1	Homo sapiens (human)
external side of plasma membrane	C-X-C chemokine receptor type 1	Homo sapiens (human)
endosome	Vasopressin V2 receptor	Homo sapiens (human)
endoplasmic reticulum	Vasopressin V2 receptor	Homo sapiens (human)
Golgi apparatus	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
membrane	Vasopressin V2 receptor	Homo sapiens (human)
endocytic vesicle	Vasopressin V2 receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Vasopressin V2 receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
platelet alpha granule membrane	Alpha-synuclein	Homo sapiens (human)
extracellular region	Alpha-synuclein	Homo sapiens (human)
extracellular space	Alpha-synuclein	Homo sapiens (human)
nucleus	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
mitochondrion	Alpha-synuclein	Homo sapiens (human)
lysosome	Alpha-synuclein	Homo sapiens (human)
cytosol	Alpha-synuclein	Homo sapiens (human)
plasma membrane	Alpha-synuclein	Homo sapiens (human)
cell cortex	Alpha-synuclein	Homo sapiens (human)
actin cytoskeleton	Alpha-synuclein	Homo sapiens (human)
membrane	Alpha-synuclein	Homo sapiens (human)
inclusion body	Alpha-synuclein	Homo sapiens (human)
axon	Alpha-synuclein	Homo sapiens (human)
growth cone	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle membrane	Alpha-synuclein	Homo sapiens (human)
perinuclear region of cytoplasm	Alpha-synuclein	Homo sapiens (human)
postsynapse	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber	Alpha-synuclein	Homo sapiens (human)
protein-containing complex	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
axon terminus	Alpha-synuclein	Homo sapiens (human)
neuronal cell body	Alpha-synuclein	Homo sapiens (human)
plasma membrane	C-C chemokine receptor type 4	Homo sapiens (human)
neuronal cell body	C-C chemokine receptor type 4	Homo sapiens (human)
external side of plasma membrane	C-C chemokine receptor type 4	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
endoplasmic reticulum membrane	Lanosterol 14-alpha demethylase	Homo sapiens (human)
membrane	Lanosterol 14-alpha demethylase	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2253)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1799791	Binding Assay from Article 10.1074/jbc.M110.164293: \\Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.\\	2010	The Journal of biological chemistry, Dec-03, Volume: 285, Issue:49	Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID371226	Antimicrobial activity against Candida albicans ATCC 24433 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID581866	Antifungal activity against Candida albicans isolated from HSCT recipient 301 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1076027	Antifungal activity against Candida sp. clinical isolate 12341 derived from urine by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID555576	Antimicrobial activity against Candida pelliculosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555614	Antimicrobial activity against Aspergillus glaucus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID467286	Antifungal activity against Candida tropicalis by serial dilution method after 24 hrs	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Discovery of highly potent novel antifungal azoles by structure-based rational design.
AID606218	Antifungal activity against Fonsecaea compacta by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID584394	Antifungal activity against 8 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx after 12 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1157297	Antifungal activity against Microsporum gypseum Cmccfmza assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID555620	Antimicrobial activity against Fusarium verticillioides by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID554716	Antimicrobial activity against Candida krusei NZCDC 90.147 after 48 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID581898	Antifungal activity against Candida glabrata isolated from HSCT recipient 002 with acute or chronic GVHD mouth after 116 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID582253	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525542	Antimicrobial activity against Fonsecaea pedrosoi isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID563412	Antifungal activity against Aspergillus tubingensis isolate CM-3654 obtained from blood culture after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID563413	Antifungal activity against Aspergillus tubingensis isolate CM-4000 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID515014	Antifungal activity against Candida kefyr by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID532162	Antifungal activity against Candida glabrata by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID531249	Antifungal activity against Candida tropicalis assessed as resistant isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID1473925	AUC in human at 200 mg, po QD for 1 to 2 weeks after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID249331	Minimum inhibitory concentration against Microsporum species (n=38)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID1413326	Antifungal activity against Candida pseudotropicalis YOGI	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID1872520	Antifungal activity against Cryptococcus neoformans TIMM 1855 by 96-well microplate method	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1604175	Antileishmanial activity against Leishmania amazonensis MHOM/BR/75/Josefa intracellular amastigotes infected in CF-1 macrophages assessed as reduction in parasite viability after 72 hrs by optical microscopic method	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing.
AID725869	Antifungal activity against Rhizomucor pusillus RHMI1 after 48 hrs by broth microdilution test	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID323599	Antifungal activity against Candida sp. bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID424635	Antimicrobial activity against azole-resistant Candida albicans isolate CA16 cotreated with calcineurin signaling inhibitor Tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1357638	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID1204554	Antifungal activity against Candida albicans Strain 24 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID545670	Ratio of intracellular to extracellular drug uptake in alveolar macrophages of New Zealand white rabbit infected with Mycobacterium bovis at 1 ug/ml	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID1067048	Antifungal activity against Candida albicans SC5314 after 24 hrs by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID527135	Antifungal activity against Trichophyton rubrum LMGO 4218 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID1872498	Antifungal activity against Candida albicans	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID555579	Antimicrobial activity against Candida intermedia by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID341560	AUC (0 to 24 hrs) in children of >6-12 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID518602	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID405051	Antifungal activity against Sporothrix schenckii PGAC0016 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1689212	Antifungal activity against fluconazole-resistant Candida auris 381 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID555618	Antimicrobial activity against Fusarium proliferatum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1157293	Antifungal activity against Candida glabrata 537 assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID1254070	Antibacterial activity against Streptococcus mutans 3065 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID29344	Ionisation constant (pKa)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1419495	Antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2876 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID532146	Antifungal activity against Rhizopus oryzae	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555622	Antimicrobial activity against Paecilomyces lilacinus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1413331	Antifungal activity against resistant Candida albicans ATCC 64124	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID519450	Antimicrobial activity against Aspergillus fumigatus ATCC 2004305 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID555569	Antimicrobial activity against Candida glabrata by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1598000	Antifungal activity against Microsporum gypseum after 7 days by NCCLS protocol based method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.
AID525140	Antifungal activity against Fusarium moniliforme clade 2 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1877280	Antifungal activity against Candida albicans CPCC400616 assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID283337	Antifungal activity against Rhizopus spp after 48 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID584593	Antifungal activity against 56 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID468519	Antifungal activity against Candida albicans ATCC 10231 after 24 to 72 hrs by NCCLS method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis and antimicrobial activities of 3-O-alkyl analogues of (+)-catechin: improvement of stability and proposed action mechanism.
AID581901	Antifungal activity against Candida glabrata isolated from HSCT recipient 497 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID609309	Antifungal activity against Aspergillus flavus JLC 40437 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID575479	Antifungal activity against 10'7 CFU/ml Candida albicans B2630 infected in vulvovaginitis rat model assessed as fungal burden at 5 mg/kg administered tropically twice daily measured after 3 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID432803	Antifungal activity against Sporothrix albicans after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID532561	Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 0.5 ug/ml (Rvb = 0.144%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID555807	Antimicrobial activity against Rhizopus oryzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555809	Antimicrobial activity against Cunninghamella bertholletiae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID480477	Antifungal activity against Candida krusei after 24 hrs by serial dilution method	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
AID519064	Antifungal activity against Candida parapsilosis assessed as resistant isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID547564	Antifungal activity against Candida tropicalis after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID555571	Antimicrobial activity against Candida guilliermondii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1674374	Half life in human	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID1411888	Antifungal activity against Candida krusei ATCC 14243 by M27-A3 guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID48960	Tested in vitro for the minimum inhibitory concentration (MIC) against Candida albicans ATCC 64550	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Synthesis of Sordaricin analogues as potent antifungal agents against Candida albicans.
AID1609928	Antifungal activity against Candida glabrata assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID1419498	Antifungal activity against ITC and FLC-resistant Candida albicans ATCC 1237 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID542417	Antimicrobial activity against Aspergillus terreus clinical isolate after 48 hrs by EUCAST test	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID1204522	Antifungal activity against Candida lipolytica by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID584392	Antifungal activity against 19 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1413328	Antifungal activity against Candida rugosa 95-967	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID555628	Antimicrobial activity against Fusarium equiseti by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID245443	Minimum inhibitory concentration against Candida albicans V-01-191 evaluated by in vitro agar diffusion and microbroth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID1493827	Antifungal activity against Candida albicans SC5314 after 24 hrs by spectrophotometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.
AID341547	Clearance in children of >6-12 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID584397	Antifungal activity against 14 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx after 12 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532323	Antifungal activity against Candida guilliermondii by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID582231	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID680076	TP_TRANSPORTER: inhibition of Azidopine photoaffinity labelling in membranes from MDR1-expressing LLC-PK1 cells	1999	Biological & pharmaceutical bulletin, Dec, Volume: 22, Issue:12	Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
AID1917560	Induction of apoptosis in human A549 cells assessed as viable cells at 30 uM incubated for 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 98.2%)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID563387	Antifungal activity against Aspergillus niger isolate CM-3236 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID245680	In vitro minimal inhibitory concentration against Candida albicans with percentage of resistant strains %R = 25 (MIC > 64 ug/mL) at a range of 0.062-0.25 ug/mL	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
AID736604	Antifungal activity against caspofungin-resistant Candida glabrata R assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID518597	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, Q88H mutant gene and by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID542418	Antimicrobial activity against Aspergillus terreus environmental isolate after 48 hrs by EUCAST test	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.
AID484274	Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-100	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID519466	Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from AIDS patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID322855	Antifungal activity against azole-resistant Aspergillus fumigatus V27/28-CM3273 isolate from patient by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1493833	Antifungal activity against Microsporum gypseum Cmccfmza after 24 hrs by spectrophotometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.
AID323594	Antifungal activity against Candida albicans bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID555615	Antimicrobial activity against Aspergillus spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID609303	Antifungal activity against Candida krusei JLC 30386 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID1595046	Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID555568	Antimicrobial activity against Candida tropicalis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555797	Antimicrobial activity against Alternaria alternata by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID582797	Antifungal activity against Candida albicans isolate 14 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID405064	Antifungal activity against Sporothrix schenckii P3287 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID468517	Antifungal activity against Candida krusei IFO 1664 after 24 to 72 hrs by NCCLS method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis and antimicrobial activities of 3-O-alkyl analogues of (+)-catechin: improvement of stability and proposed action mechanism.
AID532158	Antifungal activity against Curvularia lunata	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID531471	Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring Tandem repeat-L98H (TR) mutation in cyp51A gene after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID564271	Antifungal activity against Candida albicans isolate 177 after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID405009	Antifungal activity against Sporothrix schenckii P0019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID406952	Antifungal activity against Candida albicans ATCC 10261 at 35 degC after 48 to 96 hrs by broth microdilution test	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID419079	Antifungal activity against Candida albicans ATCC 64550	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID549310	Antifungal activity against Rhizopus oryzae after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID555799	Antimicrobial activity against Exophiala dermatitidis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID581873	Antifungal activity against Candida glabrata isolated from neutropenic subject 1187 with AML or MDS stool receiving antifungal drug after 22 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563582	Metabolic stability in healthy human plasma assessed as compound recovery at 3 mg/kg QD	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.
AID532338	Antifungal activity against Rhizopus oryzae by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532545	Antifungal activity against wild-type Saccharomyces cerevisiae BY4741 assessed as accumulation of lanosterol at 8 ug/ml (Rvb = 17+/- 1.22 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID547546	Antifungal activity against Cryptococcus gattii after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID563608	Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as ergosterol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID406950	Antifungal activity against Candida parapsilosis ATCC 22019 at 35 degC after 48 hrs by broth microdilution test	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID1309056	Antifungal activity against Aspergillus flavus ATCC MYA-3631 after 48 hrs by CLSI M38-A2 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID555607	Antimicrobial activity against Aspergillus nidulans by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1872522	Antifungal activity against Aspergillus flavus SANK 18497 by 96-well microplate method	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID283339	Antifungal activity against Syncephalastrum spp after 48 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID678776	TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse	1998	Antimicrobial agents and chemotherapy, Jul, Volume: 42, Issue:7	P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier.
AID484276	Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 1% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1877282	Antifungal activity against Cryptococcus neoformans CGMCC 2.3161 assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID535620	Antifungal activity against Candida tropicalis T26 blood stream isolate harboring Fks1p LLTLSLRDP mutant protein	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID555611	Antimicrobial activity against Aspergillus ustus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID341558	AUC (0 to 24 hrs) in infants of 0.6-2 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID531234	Antifungal activity against Candida albicans after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID392422	Antifungal activity against Aspergillus fumigatus AF98003	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Synthesis and structure-activity relationships of 2-phenyl-1-[(pyridinyl- and piperidinylmethyl)amino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID609891	Antifungal activity against Candida tropicalis by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID1059366	Antifungal activity against Candida albicans after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID555595	Antimicrobial activity against Trichosporon jirovecii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555802	Antimicrobial activity against Cladosporium spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532126	Antifungal activity against Candida glabrata	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID609314	AUC (0 to t) in rat at 10 mg/kg, po administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID546076	Antifungal activity against Candida rugosa isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID555818	Antifungal activity against cdr1/cdr1 deficient Candida albicans STY19 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID1889407	Cardiotoxicity in zebrafish embryos assessed as pericardial edema at 0.25 uM treated at 6 hpf and measured at 120 hpf by stereomicroscopic analysis	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Unraveling the anti-virulence potential and antifungal efficacy of 5-aminotetrazoles using the zebrafish model of disseminated candidiasis.
AID551209	Antifungal activity against Trichophyton rubrum by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID563415	Antifungal activity against Aspergillus foetidus isolate CM-4002 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID519433	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4420 obtained from nail of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID249335	Minimum inhibitory concentration against Trichophyton tonsurans (n=18)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID284106	Antifungal activity against Candida neoformans IM 031631 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID582254	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving fluconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1634359	Antifungal activity against Cryptococcus neoformans cgmcc 2.3161 assessed as inhibition of visible microbe growth by broth microdilution method	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents.
AID405099	Antimicrobial activity against Rhizomucor sp. after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID555798	Antimicrobial activity against Alternaria infectoria by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID565554	Antifungal activity against Rhizopus microsporus UTHSC 04-3294 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1204548	Antifungal activity against Candida albicans Strain 18 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID555823	Ratio of MIC50 for Candida albicans 5674 to MIC50 for cdr1/cdr1/cdr2/cdr2 deficient Candida albicans STY31	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID584414	Antifungal activity against 16 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 31 days after 28 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1265815	Antifungal activity against azole-resistant Candida albicans ATCC 64124 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID555601	Antimicrobial activity against Trichosporon mycotoxinivorans by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID566883	Antifungal activity against Aspergillus fumigates by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID547568	Antifungal activity against Candida dubliniensis after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID480478	Antifungal activity against Cryptococcus neoformans after 72 hrs by serial dilution method	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
AID1067045	Antifungal activity against Aspergillus fumigatus by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID294853	Antifungal activity against Trichophyton rubrum after 7 days by microbroth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID125941	In vitro evaluation of minimum inhibitory concentration against Microsporum canis 47	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID1743171	Antifungal activity against Epidermophyton floccosum	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID701472	Antifungal activity against Candida spp	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	The biology and chemistry of antifungal agents: a review.
AID1595048	Antifungal activity against Candida albicans assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID341569	AUC (0 to 24 hrs) in human at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID547566	Antifungal activity against Candida parapsilosis after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID519047	Antifungal activity against Candida krusei after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1634361	Antifungal activity against Aspergillus fumigatus cgmcc 3.7795 assessed as inhibition of visible microbe growth by broth microdilution method	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents.
AID532157	Antifungal activity against Sporothrix schenckii	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1546100	Antimicrobial activity against Escherichia coli after 24 hrs by agar disk diffusion method	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Current scenario of tetrazole hybrids for antibacterial activity.
AID555566	Antimicrobial activity against Candida albicans by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID546075	Antifungal activity against Candida guilliermondii isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID1204547	Antifungal activity against Candida albicans Strain 17 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID518609	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, L358L, E427K, C454C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID285855	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.12 ug/ml by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID555592	Antimicrobial activity against Trichosporon inkin by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID415954	Antimicrobial activity against Microsporum gypseum by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID405016	Antifungal activity against Sporothrix schenckii P25013 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID492161	Antimicrobial activity against Candida albicans ATCC 66029 at 100 ug/well after 24 hrs at 30 degC by agar diffusion assay	2010	Journal of natural products, Jul-23, Volume: 73, Issue:7	Cellular localization of clathridimine, an antimicrobial 2-aminoimidazole alkaloid produced by the Mediterranean calcareous sponge Clathrina clathrus.
AID1061739	Antimicrobial activity against Candida glabrata by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID302122	Antifungal activity against fluconazole-resistant Candida albicans 0511655 after 24 hrs	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID322543	Antifungal activity against Trichophyton mentagrophytes after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID563397	Antifungal activity against Aspergillus niger isolate CM-4213 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID341577	AUC (0 to 24 hrs) in children of >6-12 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID555801	Antimicrobial activity against Hortaea werneckii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID480480	Antifungal activity against Aspergillus fumigatus after 7 days by serial dilution method	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
AID484275	Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-100	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID575480	Antifungal activity against azole-resistant Aspergillus fumigatus isolate R13 harboring Cyp51A TR/L98H mutant gene assessed as inhibition of fungal growth at 4 mg/l relative to control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID525544	Antimicrobial activity against Fonsecaea nubica isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID701459	Antifungal activity against Trichophyton rubrum	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	The biology and chemistry of antifungal agents: a review.
AID1076023	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1689214	Antifungal activity against fluconazole-resistant Candida auris 384 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID1411889	Antifungal activity against Candida glabrata ATCC 34138 by M27-A3 guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID1872499	Antifungal activity against Candida tropicalis	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID531236	Antifungal activity against Candida parapsilosis after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID602933	Antifungal activity against Aspergillus fumigatus by broth microdilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID1898159	Antifungal activity against Candida albicans 12#
AID322549	Antifungal activity against Microsporum canis after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID518596	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, S52T mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1817557	Antifungal activity against Aspergillus fumigatus ATCC 204305 assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.
AID322552	Antifungal activity against Microsporum sp. after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID284105	Antifungal activity against Candida neoformans IM 972751 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID1783793	Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID278905	Antifungal activity against Scedosporium apiospermum isolates at 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates.
AID525601	Antibacterial activity against Fluconazole resistant Candida albicans DSY3706 containing tac1delta/delta ERG11-1/ERG11-1 genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID531239	Antifungal activity against Candida lusitaniae after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID532954	Antifungal activity against Candida albicans isolate V4 with CAI genotype by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
AID1557075	Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID283330	Antifungal activity against Cunninghamella spp after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID420660	Antifungal activity against Candida albicans ATCC 76615 after 24 hrs by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID563406	Antifungal activity against Aspergillus tubingensis isolate CM-4005 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID509111	Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse survival at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID563414	Antifungal activity against Aspergillus tubingensis isolate CM-4001 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID581872	Antifungal activity against Candida glabrata isolated from neutropenic subject 1187 with AML or MDS stool after 22 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525597	Antibacterial activity against Fluconazole resistant Candida albicans DSY3752 containing (TAC1-5/TAC1-5 ERG11-1/ERG11-1) genotype by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID1783769	Antifungal activity against Candida tropicalis GIM2.183 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID555586	Antimicrobial activity against Saccharomyces cerevisiae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID50136	Minimum concentration required to inhibit the growth of Candida kefyr	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID1204549	Antifungal activity against Candida albicans Strain 19 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID564266	Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as obtusifoliol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID283329	Antifungal activity against Absidia spp after 48 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID519464	Antimicrobial activity against Cryptococcus neoformans var. grubii by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID729315	Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID547545	Antifungal activity against Cryptococcus neoformans after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID729305	Inhibition of vasopressin V2 receptor (unknown origin) assessed as change in intracellular calcium levels incubated with compound treated with Tween-80 by fluorometric analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID575455	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 50 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated con	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID405019	Antifungal activity against Sporothrix schenckii P20825 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID406951	Antifungal activity against Candida albicans ATCC 10261 at 35 degC after 48 hrs by broth microdilution test	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID532552	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 1 ug/ml (Rvb = 0.157%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID518404	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220V mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID440319	Antifungal activity against Aspergillus niger isolated from patient sputum after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID1783066	Antifungal activity against fluconazole-sensitive Candida albicans 0304103 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID558028	Antifungal activity against voriconalzole-resistant Aspergillus fumigatus isolate by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
AID1658274	Thermodynamic solubility in 0.001N HCl by HPLC analysis
AID1556211	Antifungal activity against Candida tropicalis CGMCC 2.3739 assessed as inhibition of visible microbial growth by NCCLS protocol based method	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents.
AID45502	In vivo Evaluation of minimum inhibitory concentration against Candida albicans 406	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID1071689	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Antifungal ether diglycosides from Matayba guianensis Aublet.
AID549323	Antifungal activity against Rhizomucor variabilis after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID519054	Antifungal activity against Penicillium marneffei after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID555577	Antimicrobial activity against Candida coliculosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532143	Antifungal activity against Absidia corymbifera	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID341554	Cmax in human at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID532160	Antifungal activity against Rhinocladiella aquaspersa	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID537735	Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID575493	Antifungal activity against azole-resistant Aspergillus fumigatus isolate T22 harboring Cyp51A TR/L98H mutation assessed as inhibition of fungal growth at 4 mg/l relative to control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID575458	Antifungal activity against 5 x 10'6 CFU/ml Trichophyton mentagrophytes B70554 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID37717	In vitro evaluation of minimum inhibitory concentration against Aspergillus niger 18	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID555813	Antimicrobial activity against Exophiala jeanselmei by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID527137	Antifungal activity against Trichophyton rubrum LMGO 08 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID546069	Antifungal activity against Candida krusei isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID294851	Antifungal activity against Cryptococcus neoformans ATCC BLS108 after 72 hrs by micro-broth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID525141	Antifungal activity against Fusarium moniliforme clade 3 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID508312	Antifungal activity against Aspergillus fumigatus isolate V28-77 harboring M220I mutation in Cyp51A protein by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1204539	Antifungal activity against Candida albicans Strain 9 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID531254	Antifungal activity against Candida albicans assessed as susceptible dose-dependent isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID39704	In vitro evaluation of minimum inhibitory concentration against Aspergillus fumigatus 33	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID436738	Antifungal activity against multidrug-resistant Candida albicans after 24 hrs by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID371229	Antimicrobial activity against Candida albicans ATCC 64550 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID1524622	Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID555590	Antimicrobial activity against Trichosporon asahii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID432799	Antifungal activity against Sporothrix brasiliensis after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID1223574	Inhibition of CYP3A4.16 (unknown origin)-mediated testosterone 6beta-hydroxylation incubated for 10 mins prior to NADPH addition measured after 20 mins by HPLC-UV analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID1754263	Antifungal activity against Cryptococcus neoformans ATCC 32609 by microplate reader assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID527133	Antifungal activity against Microsporum canis LMGO 22 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1898170	Antifungal activity against Candida tropicalis ATCC750
AID1076028	Antifungal activity against Candida sp. clinical isolate 300 derived from urine by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID150753	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID262546	Antifungal activity against Candida albicans	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID341561	AUC (0 to 24 hrs) in adolescents of >12-16 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID531253	Antifungal activity against Candida lusitaniae assessed as resistant isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID554714	Antimicrobial activity against Candida krusei NZCDC 89.102 after 48 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID563395	Antifungal activity against Aspergillus niger isolate CM-3672 obtained from cutaneous layer of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1689210	Antifungal activity against Candida albicans ATCC 10231 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID1076031	Antifungal activity against Candida albicans ATCC 66027 by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID532347	Antifungal activity against Fusarium solani by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID518613	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A L252L mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID747171	Antimicrobial activity against Candida tropicalis ATCC 750 by broth dilution method	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Synthesis and antimicrobial activity of novel amphiphilic aromatic amino alcohols.
AID581878	Antifungal activity against Candida glabrata isolated from HSCT recipient 186 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID753510	Antidermatophytic activity against Epidermophyton floccosum isolate after 7 days by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID584403	Antifungal activity against 1 day cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID725871	Antifungal activity against Scedosporium sp. SCSP1 after 48 hrs by broth microdilution test	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID1413325	Antifungal activity against Cryptococcus neoformans 94-2586	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID551211	Antifungal activity against Microsporum gypseum by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID440320	Antifungal activity against Aspergillus niger isolated from patient nasal swab after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID1770938	Antifungal activity against Candida albicans CPCC400616 assessed as fungal growth inhibition by CLSI protocol based method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID555587	Antimicrobial activity against Yarrowia lipolytica by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555600	Antimicrobial activity against Trichosporon domesticum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1301916	Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID519439	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3303 obtained from skin of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563419	Antifungal activity against Aspergillus tubingensis isolate CM-4899 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID37564	Antifungal activity against Aspergillus nidulans CABI 0160037 strain	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity.
AID531247	Antifungal activity against Candida albicans assessed as resistant isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID531470	Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring M220V, M220K, M220T and M220I mutation in cyp51A gene after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID1155872	Antifungal activity against Candida albicans assessed as growth inhibition after 24 hrs by serial dilution method	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.
AID532042	Antifungal activity against Lichtheimia ramosa clinical isolate after 48 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID1138338	Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay	2014	Journal of medicinal chemistry, May-08, Volume: 57, Issue:9	Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.
AID555795	Antimicrobial activity against Scedosporium apiospermum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID37585	Antifungal activity against Aspergillus niger IMI17454 strain.	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity.
AID555817	Antifungal activity against cdr2/cdr2 deficient Candida albicans STY7 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID555584	Antimicrobial activity against Candida zeylanoides by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID515008	Antifungal activity against Candida albicans SC5314 after 24 hrs by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID420665	Antifungal activity against Candida krusei by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID555619	Antimicrobial activity against Fusarium oxysporum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1783067	Antifungal activity against fluconazole-sensitive Candida albicans 7781 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1770932	Fungicidal activity against Candida albicans ATCC SC5314 assessed as inhibition of visible fungal growth measured after 48 hrs	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID361270	Binding affinity to recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric equilibrium binding titration method	2007	The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9	Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.
AID549326	Antifungal activity against Actinomucor spp. after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1689221	Antifungal activity against Cryptococcus neoformans NR41298 assessed as reduction in fungal growth incubated for 48 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID532556	Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 4 ug/ml (Rvb = 0.144%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID249314	In vitro concentration causing 50% inhibition of Candida albicans with percentage of resistant strains %R = 25 (MIC > 64 ug/mL) at a range of 0.062-0.25 ug/mL	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
AID1783775	Antifungal activity against Candida albicans GIM2.194 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1284002	Antifungal activity against Mucor hiemalis ATCC 8690 by M38-A protocol-based microdilution method	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.
AID1301923	Antiproliferative activity against HUVEC assessed as inhibition of VEGF induced cell proliferation using methyl-[3H]thymidine after 36 hrs	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID518610	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, E427K mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID532342	Antifungal activity against Cunninghamella species by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID606217	Antifungal activity against Trichophyton rubrum after 7 days by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID1557083	Antifungal activity against Candida guilliermondii T-47 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID405010	Antifungal activity against Sporothrix schenckii P0019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID284100	Antifungal activity against Candida neoformans IM 983040 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID415951	Antimicrobial activity against Candida parapsilosis by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID606214	Antifungal activity against Candida tropicalis by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID405011	Antifungal activity against Sporothrix schenckii P0019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID533028	Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as planktonic cell on CFBE41o cell after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID584389	Antifungal activity against 1 day cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522129	Antimicrobial activity against wild type Candida glabrata TG11 by colorimetric microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata.
AID1872496	Antifungal activity against Candida parapsilosis	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872507	In vivo antifungal activity against Candida albicans infected in CDF1 mouse treated po or iv 2 hrs after infection twice daily for 2 days measured on day 10	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID424631	Antimicrobial activity against azole-susceptible Candida albicans isolate CA14 co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID584418	Antifungal activity against 62 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID559692	Antimicrobial activity against Mycocladus corymbiferus after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID294854	Antifungal activity against Fonsecaea compacta after 7 days by micro-broth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID28235	Unbound fraction (plasma)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID48819	Tested in vitro for the minimum inhibitory concentration (MIC) against Candida tropicalis ATCC750	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Synthesis of Sordaricin analogues as potent antifungal agents against Candida albicans.
AID285869	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 1 ug/ml by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID204351	Minimum concentration required to inhibit the growth of Sporothrix schenck ii	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID554720	Antimicrobial activity against Saccharomyces cerevisiae isolate AD overexpressing Candida krusei ERG11C after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID520618	Antifungal activity against Candida parapsilosis by microdilution AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1204523	Antifungal activity against Candida pseudotropicalis by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID341579	Cmax in adolescents of >12-16 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID531464	Antifungal activity against Candida parapsilosis assessed as susceptible dose-dependent isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID582232	Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID729313	Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID555612	Antimicrobial activity against Aspergillus niveus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1284001	Antifungal activity against Rhizopus oryzae ATCC 10329 by M38-A protocol-based microdilution method	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.
AID405075	Antifungal activity against Sporothrix schenckii isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID314996	Antifungal activity against Aspergillus fumigatus AF98003	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Design, synthesis, and evaluation of 1-(N-benzylamino)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.
AID525591	Antibacterial activity against Fluconazole resistant Candida albicans DSY296 overexpressing multidrug transporter gene CDR1 and CDR2 and containing ERG11 G464S mutation by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID610070	Antifungal activity against Candida parapsilosis JLC 30275 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID525592	Antibacterial activity against Fluconazole resistant Candida albicans DSY3083 containing tac1delta/delta genotype by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID1357632	Antifungal activity against Candida krusei ATCC 20298 after 48 hrs by microbroth dilution assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID554933	Increase in ERG11 mRNA expression in Candida krusei B2399 at 2 times MIC concentration after 1 hr by hot-phenol extraction based Northern blotting	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID1076029	Antifungal activity against Candida sp. clinical isolate 178 derived from high vaginal swabs by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID341548	Apparent volume of distribution in children of >6-12 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1549141	Antifungal activity against azole-sensitive Cryptococcus neoformans H99 after 72 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID1898177	Antifungal activity against Candida auris BS12372
AID572692	Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP51 at pH7.5	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID1820637	Antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal growth by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents.
AID1204531	Antifungal activity against Candida albicans Strain 1 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID419076	Antifungal activity against Aspergillus fumigatus SANK 10569	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID531238	Antifungal activity against Candida krusei after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID249333	Minimum inhibitory concentration against Trichophyton species (n=80)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID527145	Antifungal activity against Cryptococcus gattii LMGO L1 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID44970	Antifungal activity against Candida albicans NCPF 3179 strain; na = not active	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity.
AID508311	Antifungal activity against Aspergillus fumigatus isolate AZN 8196 harboring wild type Cyp51A protein by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1817568	Antifungal activity against pan-azole resistant Aspergillus fumigatus SR47013 harbouring Cyp51A Y121F mutant assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.
AID729309	Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID322547	Antifungal activity against Trichophyton sp. after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID371235	Antimicrobial activity against Aspergillus fumigatus ATCC 6430 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID319757	Antimicrobial activity against Fonsecaea compacta isolates	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID322857	Antifungal activity against azole-resistant Aspergillus fumigatus V34/75-CM3276 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID405059	Antifungal activity against Sporothrix schenckii P14036 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID340965	Antifungal activity against sKloeckera apiculata isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID519430	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4370 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID582250	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving fluconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID319754	Antimicrobial activity against Aspergillus fumigatus isolates	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID48248	Compound was tested for inherent antifungal geometric minimum inhibitory concentration (GMMIC) against Candida albicans and Candida tropicalis in serial dilution from 64 to 0.0313 ug/mL	2002	Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13	Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.
AID1419505	Antifungal activity against Aspergillus terreus ATCC MYA-3633 incubated for 48 hrs by CLSI M38-A2 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID736601	Antifungal activity against fluconazole-resistant Candida glabrata isolate 6258 assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID575375	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 25 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated cont	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID575376	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 25 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated con	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID555803	Antimicrobial activity against Cladophialophora bantiana by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID419073	Antifungal activity against Candida glabrata ATCC 90030	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID1917556	Cytotoxicity against human L02 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID285868	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.5 ug/ml by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID319751	Antimicrobial activity against Cryptococcus parapsilosis isolates	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID323069	Antifungal activity against Cryptococcus neoformans IM 042074 by micro-broth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID575366	Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in lung at 50 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID424626	Antimicrobial activity against azole-resistant Candida albicans isolate CA135 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID610068	Antifungal activity against Candida albicans JLC 31374 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID1419494	Antifungal activity against Candida albicans ATCC 64124 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID729307	Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID285866	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.12 ug/ml by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID532152	Antifungal activity against Scedosporium apiospermum	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532388	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 4 ug/ml (Rvb = 0.157%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID547569	Antifungal activity against Candida guilliermondii after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID322548	Antifungal activity against Epidermophyton floccosum after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID519052	Antifungal activity against Fusarium sp. after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID440326	Antifungal activity against Aspergillus flavus isolated from patient sputum after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID566888	Antifungal activity against Cladophialophora carrionii by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1917558	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 30 uM incubated for 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 0.316%)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID1284000	Antifungal activity against Trichosporon cutaneum ATCC 28592 by M38-A protocol-based microdilution method	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.
AID405092	Antimicrobial activity against Rhizopus sp. after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID532350	Antifungal activity against Curvularia lunata by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID535617	Antifungal activity against Candida tropicalis T7 blood stream isolate	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID532159	Antifungal activity against Bipolaris australiensis	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532137	Antifungal activity against Geotrichum candidum	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID340951	Antifungal activity against Candida albicans isolates from animals by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID1413330	Antifungal activity against Candida albicans ATCC 10231	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID531233	Antifungal activity against Candida tropicalis after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID566884	Antifungal activity against Aspergillus flavus by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1783063	Antifungal activity against fluconazole-resistant Candida tropicalis 3890 assessed as inhibition of fungal growth incubated for 48 hrs by two-fold serial microdilution method	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID549312	Antifungal activity against Mucor circinelloides after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID26380	Dissociation constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID582242	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID768336	Antifungal activity against Aspergillus flavus ATCC 204304 after 48 hrs	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID584416	Antifungal activity against 1 day cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405101	Antimicrobial activity against Cunninghamella sp. after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID532145	Antifungal activity against Rhizopus microsporus var. oligosporus	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID48959	Tested in vitro for the minimum inhibitory concentration (MIC) against Candida albicans ATCC 24433	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Synthesis of Sordaricin analogues as potent antifungal agents against Candida albicans.
AID559694	Antimicrobial activity against Rhizopus microsporus after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID609313	Tmax in rat at 10 mg/kg, po administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID424632	Antimicrobial activity against azole-susceptible Candida albicans isolate CA129 co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1491242	Antifungal activity against Candida albicans ATCC SC5314 by broth microdilution method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.
AID575367	Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in kidney at 50 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated contro	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID285852	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.015 ug/ml by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID518608	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, M172V, L358L, E427K, C454C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID546070	Antifungal activity against Candida parapsilosis isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID1301921	Antiangiogenic activity against HUVEC assessed as inhibition of total tube junctions at 1 uM after 16 hrs by inverted microscopy	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID1877283	Antifungal activity against Candida parapsilosis GIM2.190 assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID425136	Antimicrobial activity against azole-susceptible Candida albicans isolate CA14 assessed as log reduction in colony count at 1 ug/ml co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by XTT assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID278901	Antifungal activity against Scedosporium aurantiacum corneal isolate CNM-CM-2923 at 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates.
AID582239	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID176380	Efficacy against Candida albicans CY3003 on day 14th after peroral administration in rat	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.
AID371231	Antimicrobial activity against Candida glabrata ATCC 90030 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID319756	Antimicrobial activity against Microsporum gypseum isolates	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID1411893	Antifungal activity against Trichosporon cutaneum ATCC 28592 by M38-A guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID555598	Antimicrobial activity against Rhodotorula glutinis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID484387	Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 2.5 uM by dynamic light scattering assay in presence of 1% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID555575	Antimicrobial activity against Candida famata by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID322859	Antifungal activity against azole-resistant Aspergillus fumigatus V34/77-CM3278 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID294850	Antifungal activity against Candida tropicalis after 7 days by micro-broth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID405048	Antifungal activity against Sporothrix schenckii P26187 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID525543	Antimicrobial activity against Fonsecaea monophora isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID340963	Antifungal activity against Cryptococcus neoformans ATCC 90112 by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID1141106	Antimicrobial activity against Candida albicans ATCC 537Y after 48 hrs by two-fold broth microdilution method	2014	Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10	Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.
AID535619	Antifungal activity against Candida tropicalis T19 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID575476	Antifungal activity against 10'7 CFU/ml Candida albicans B2630 infected in vulvovaginitis rat model assessed as fungal burden at 10 mg/kg, po SID	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID1595071	Antifungal activity against Aspergillus flavus NCIM 524 assessed as reduction in fungal cell growth incubated for 3 to 4 days by disk diffusion method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID1770936	Anti-biofilm activity in Candida albicans CPCC400616 assessed as inhibition of biofilm formation incubated for 3 hrs by XTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID415950	Antimicrobial activity against Cryptococcus neoformans by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID532153	Antifungal activity against Penicillium marneffei	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID603347	Antifungal activity against Microsporum gypseum clinical isolate by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID633997	Antifungal activity against Saccharomyces cerevisiae ATCC 24657 assessed as growth inhibition at 90.7 uM after 24 hrs by spectrophotometric bioassay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID575464	Antifungal activity against 5 x 10'6 CFU/ml Candida glabrata B63155 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID546072	Antifungal activity against Candida glabrata isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID532156	Antifungal activity against Fusarium oxysporum	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID405068	Antifungal activity against Candida krusei ATCC 6258 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID519440	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3305 obtained from skin of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID509390	Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in lung at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID532328	Antifungal activity against Trichosporon asahii by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID509120	Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in spleen at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID510637	Antifungal activity against Trichophyton rubrum ATCC 28188 after 24 hrs by AFSTEUCAST assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID555581	Antimicrobial activity against Candida metapsilosis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1411887	Antifungal activity against Candida utilis ATCC 9226 by M27-A3 guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID575205	Antifungal activity against Cunninghamella echinulata UTHSC 03-3725 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID322544	Antifungal activity against Trichophyton tonsurans after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID283206	Antimicrobial activity against polyene-resistant Candida glabrata 21229 isolate by E-test	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
AID557813	Antifungal activity against Aspergillus fumigatus isolate by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
AID484291	Colloidal aggregation in phosphate buffer at 50 uM by transmission electron microscopy in presence of 0.5% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID533026	Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as planktonic cell on 16HBE cell after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID518598	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, N125I mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID624628	Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID555602	Antimicrobial activity against Trichosporon spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID620355	Antifungal activity against Geotrichum candidum RCMB 052006 at 30 ug/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID1204557	Antifungal activity against Candida albicans Strain 27 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID584400	Antifungal activity against 35 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 165 days after 138 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID424627	Antimicrobial activity against azole-resistant Candida albicans isolate CA137 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID519449	Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-4518 obtained from nail of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1204553	Antifungal activity against Candida albicans Strain 23 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID249384	In vitro concentration causing 90% inhibition of Candida albicans with percentage of resistant strains %R = 25 (MIC > 64 ug/mL) at a range of 0.062-0.25 ug/mL	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
AID527136	Antifungal activity against Trichophyton rubrum LMGO 06 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID424633	Antimicrobial activity against azole-resistant Candida albicans isolate CA10 co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1511963	Inhibition of Hedgehog signaling pathway in Sufu-deficient mouse MEF cells assessed as decrease in Gli1 mRNA expression by q-PCR analysis relative to control	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties.
AID246930	Effective dose was measured in guinea pig infected with Microsporum canis on 21st day	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID549049	Antifungal activity against Candida albicans CA132 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID341557	Half life in human at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1595073	Antifungal activity against Penicillium marneffei assessed as reduction in fungal cell growth incubated for 3 to 4 days by disk diffusion method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID581893	Antifungal activity against Candida albicans isolated from HSCT recipient 042 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID584386	Antifungal activity against 29 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS pharynx after 48 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID322551	Antifungal activity against Microsporum cookei after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID582240	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID736603	Antifungal activity against voriconazole-resistant Candida glabrata clinical isolate 724 assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID49980	Minimum concentration required to inhibit the growth of Candida glabrata	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID609322	Clearance in rat at 10 mg/kg, iv administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID566891	Antifungal activity against Exophiala xenobiotica by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID555583	Antimicrobial activity against Candida pintolopesii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID565550	Antifungal activity against Rhizopus microsporus IHEM 13311 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID575470	Cmax in plasma of guinea pig infected with 10'6 CFU Microsporum canis B68128 at 20 mg/kg, po administered 2 hrs before infection for 5 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID1911626	Antifungal activity against Aspergillus fumigatus AF293 assessed as fungal growth inhibition by broth microdilution assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Development of Lipo-γ-AA Peptides as Potent Antifungal Agents.
AID1180169	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Design and optimization of highly-selective fungal CYP51 inhibitors.
AID555811	Antimicrobial activity against Rhizomucor spp.by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID519469	Antimicrobial activity against Cryptococcus albidus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID518603	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing wild type cyp51A gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID575204	Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID555580	Antimicrobial activity against Candida inconspicua by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID531252	Antifungal activity against Candida krusei assessed as resistant isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID565075	Antimicrobial activity against Blastoschizomyces capitatus by microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy.
AID415953	Antimicrobial activity against Trichophyton rubrum by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID602931	Antifungal activity against Cryptococcus neoformans BLS108 after 72 hrs by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID405074	Antifungal activity against Aspergillus flavus ATCC 204304 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID729311	Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID555627	Antimicrobial activity against Hormographiella aspergillata by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1351937	Ratio of MIC for Candida albicans ATCC 90028 in presence of ergosterol to MIC for Candida albicans ATCC 90028 in absence of ergosterol	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	New 1,5 and 2,5-disubstituted tetrazoles-dependent activity towards surface barrier of Candida albicans.
AID1898171	Antifungal activity against Candida krusei 463
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID436740	Antifungal activity against Candida albicans after 24 hrs by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID532955	Antifungal activity against Candida albicans isolate V5 with CAI genotype by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
AID1059363	Antifungal activity against Candida krusei after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID285854	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.06 ug/ml by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID532352	Antifungal activity against Rhinocladiella aquaspersa by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID555800	Antimicrobial activity against Aureobasidium pullulans by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID119043	The compound was tested in vivo for anti-candida activity in mice model 2 (dose 1 mg/kg, fluconazole-treated group); not tested	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID73614	In vitro antifungal activity against 6 filamentous fungi	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID1877317	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID532154	Antifungal activity against Penicillium species	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519283	Antifungal activity against Candida krusei ATCC 6258 by WIDERYST method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID1301917	Inhibition of hedgehog pathway in mouse MERP MB cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by qPCR method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID555630	Antimicrobial activity against Hormographiella verticillata by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532128	Antifungal activity against Candida krusei	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID582800	Antifungal activity against Candida albicans isolate 488 harboring ERG3 H243N, T330A, A351V and ERG11 D225G, E266D, E391G, V488I mutant genes by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID648414	Antifungal activity against recultured Trichophyton mentagrophytes by serial plate dilution method	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID532550	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID1783771	Antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID1898174	Antifungal activity against Candida krusei 467
AID563390	Antifungal activity against Aspergillus tubingensis isolate CM-3507 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID582228	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1911625	Antifungal activity against Mucor racemosus R715 assessed as fungal growth inhibition by broth microdilution assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Development of Lipo-γ-AA Peptides as Potent Antifungal Agents.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1413336	Antifungal activity against sensitive Candida parapsilosis	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID1546102	Antimicrobial activity against Klebsiella pneumoniae after 24 hrs by agar disk diffusion method	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Current scenario of tetrazole hybrids for antibacterial activity.
AID555330	Antimicrobial activity against Candida krusei ATCC 6258 by EUCAST broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID323597	Antifungal activity against Candida parapsilosis bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID532952	Antifungal activity against Candida albicans isolate V2 with CAI genotype by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
AID1609924	Antifungal activity against fluconazole-resistant Candida albicans CaR assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID1392807	Antifungal activity against Candida albicans ATCC SC5314 after 24 hrs by serial dilution method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
AID1609927	Antifungal activity against Candida tropicalis GIM 2.183 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID584601	Antifungal activity against 16 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID565556	Antifungal activity against Rhizopus microsporus UTHSC 01-983 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID555603	Antimicrobial activity against Aspergillus fumigatus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1204527	Antifungal activity against Mucor hiemalis ATCC 8690 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1223578	Ratio of Ki for CYP3A4.16 (unknown origin) to Ki for CYP3A4.1 (unknown origin)	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID524737	Antimicrobial activity against Fusarium solani after 48 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID1415218	Anti-angiogenic activity against HUVEC after 24 hrs by scintillation counting based [3H]-thymidine incorporation assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition.
AID520619	Antifungal activity against Candida orthopsilosis by microdilution AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID1419496	Antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-90819 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID1674373	Fraction unbound in human	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID424621	Antimicrobial activity against azole-susceptible Candida albicans isolate CA14 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID582230	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID584419	Antifungal activity against 85 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID446450	Antifungal activity against Aspergillus fumigatus AF98003	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.
AID581895	Antifungal activity against Candida albicans isolated from HSCT recipient 928 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1917554	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID1917566	Induction of mitochondrial membrane potential loss in human A549 cells assessed as assessed as proportion of MMP decreased cells at 30 uM and measured after 24 hrs by JC-1 staining based flow cytometry assay (Rvb = 7.50%)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID28236	Unbound fraction (tissues)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID555609	Antimicrobial activity against Aspergillus versicolor by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1309047	Antifungal activity against Candida albicans ATCC 64124 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1901385	Antifungal activity against Candida albicans assessed as inhibition of fungal growth measured after 48 hrs in presence of exogenous ergosterol by M27-A3 based broth microdilution	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Tetrazole derivatives bearing benzodiazepine moiety-synthesis and action mode against virulence of Candida albicans.
AID532528	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 2 ug/ml (Rvb = 0.157%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID555133	Antimicrobial activity against Candida glabrata by EUCAST broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID425156	Antimicrobial activity against azole-resistant Candida albicans isolate CA10 assessed as log reduction in colony count at 1 ug/ml co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by time killing test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID609315	AUC (0 to t) in rat at 10 mg/kg, iv administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID405111	Antimicrobial activity against Absidia corymbifera assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID1059354	Antifungal activity against Candida tropicalis clinical isolate after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID563394	Antifungal activity against Aspergillus niger isolate CM-3641 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID565555	Antifungal activity against Rhizopus microsporus UTHSC 07-371 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID118899	In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg for 5 days.(percent protection for 100% mortality with untreated group); not tested	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID634076	Fungistatic activity against Saccharomyces cerevisiae ATCC 24657 assessed as cell proliferation at 90.7 uM after 24 hrs by agar plate bioassay relative to control	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID563411	Antifungal activity against Aspergillus niger isolate CM-3551 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1061741	Antimicrobial activity against Candida parapsilosis by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID529668	Antimicrobial activity against Paecilomyces lilacinus by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Susceptibility testing and molecular classification of Paecilomyces spp.
AID554719	Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Candida albicans ERG11A after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID322858	Antifungal activity against azole-resistant Aspergillus fumigatus V34/76-CM3277 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID519049	Antifungal activity against Candida tropicalis after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID546074	Antifungal activity against Candida dubliniensis isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID609306	Antifungal activity against Aspergillus fumigatus JLC 30506 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID547567	Antifungal activity against Candida krusei after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID1076034	Antifungal activity against Candida tropicalis ATCC 66029 by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID532327	Antifungal activity against Trichosporon inkin by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID581864	Antifungal activity against 29 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool after 48 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID262550	Antifungal activity against Aspergillus fumigatus	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID285875	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID565397	Antifungal activity against Rhizopus microsporus FMR 3542 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID214273	Minimum concentration required to inhibit the growth of Trichophyton mentagrophytes	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID283232	Reduction of fungal burden in Coccidioides immitis Silveira infected po dosed CD1 mouse brain, spinal cord, lung, kidney administered twice daily after 3 days of infection measured after 5 days relative to control	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID581904	Antifungal activity against Candida glabrata isolated from HSCT recipient 491 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531241	Antifungal activity against Candida glabrata assessed as susceptible isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID278904	Antifungal activity against Scedosporium aurantiacum bronchial aspirate isolate CNM-CM-4183 at 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates.
AID581903	Antifungal activity against Candida glabrata isolated from HSCT recipient 807 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID48806	Minimum inhibitory concentration of compound for antifungal activity against Candida tropicalis	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID283202	Susceptibility of polyene-resistant Candida glabrata 21229 isolate at 8 ug by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
AID736606	Antifungal activity against fluconazole-resistant Candida albicans clinical isolate 5.O.A assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID549328	Antifungal activity against Apophysomyces spp. after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1061740	Antimicrobial activity against Cryptococcus neoformans after 72 hrs by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID405113	Antimicrobial activity against Apophysomyces elegans assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID519053	Antifungal activity against Paecilomyces variotii after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID322542	Antifungal activity against Trichophyton rubrum after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID118760	In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/kg at various time intervals. (percent protection for 100% mortality with fluconazole-treated group.)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID582249	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525598	Antibacterial activity against Fluconazole resistant Candida albicans DSY296 overexpressing multidrug transporter gene CDR1 and CDR2 and containing ERG11 G464S mutation by EUCAST standards based broth microdilution method relative to wildtype sCandida alb	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID519055	Antifungal activity against Penicillium sp. after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID323598	Antifungal activity against Candida tropicalis bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID527144	Antifungal activity against Candida krusei LMGO 174 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID609896	Antifungal activity against Aspergillus fumigatus by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID1609931	Antifungal activity against fluconazole-resistant Candida albicans 632 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID532127	Antifungal activity against Candida parapsilosis	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519060	Antifungal activity against Candida tropicalis assessed as susceptible isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID581869	Antifungal activity against Candida glabrata isolated from neutropenic subject 1102 with AML or MDS stool receiving antifungal drug after 26 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1301922	Inhibition of hedgehog pathway in mouse Shh-Light2 cells after 46 hrs by luciferase reporter gene assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID582217	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID467288	Antifungal activity against Trichophyton rubrum by serial dilution method after 7 days	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Discovery of highly potent novel antifungal azoles by structure-based rational design.
AID519467	Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from non-AIDS patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID341563	Cmax in infants of 0.6-2 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1420568	Inhibition of Smo-mediated hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium after 48 hrs by Gli-Renilla luciferase reporter gene assay	2018	Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19	Current trends in Hedgehog signaling pathway inhibition by small molecules.
AID522127	Antimicrobial activity against Candida glabrata TG172 containing deltacrz1 mutant by colorimetric microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata.
AID1180173	Antifungal activity against Trichophyton rubrum by broth macrodilution method	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Design and optimization of highly-selective fungal CYP51 inhibitors.
AID1911624	Antifungal activity against Mucor racemosus MZ140 assessed as fungal growth inhibition by broth microdilution assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Development of Lipo-γ-AA Peptides as Potent Antifungal Agents.
AID521787	Antifungal activity against Candida albicans after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID519465	Antimicrobial activity against Cryptococcus neoformans var. grubii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID405031	Antifungal activity against Sporothrix schenckii P24223 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID545165	Antimicrobial activity against Candida albicans isolate C after 48 hrs by EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID19468	Partition coefficient (logP)	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID582251	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID467287	Antifungal activity against Cryptococcus neoformans by serial dilution method after 72 hrs	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Discovery of highly potent novel antifungal azoles by structure-based rational design.
AID285863	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.015 ug/ml by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID527132	Antifungal activity against Microsporum gypseum LMGO 533 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID519065	Antifungal activity against Candida tropicalis assessed as resistant isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID572693	Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP51 in presence of 0.5 M NaCl at pH7.5	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1595047	Antifungal activity against Candida krusei assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID405021	Antifungal activity against Sporothrix schenckii P30019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID405045	Antifungal activity against Sporothrix schenckii SSA29 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID284101	Antifungal activity against Candida neoformans IM 972724 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID531250	Antifungal activity against Candida parapsilosis assessed as resistant isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID532134	Antifungal activity against Cryptococcus neoformans var. gattii	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID549321	Antifungal activity against Rhizomucor pusillus after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID283335	Antifungal activity against Rhizomucor spp after 48 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID581891	Antifungal activity against Candida albicans isolated from HSCT recipient 462 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID563398	Antifungal activity against Aspergillus tubingensis isolate CM-4264 obtained from blood culture after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID582218	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID665067	Antifungal activity against Candida albicans after 24 hrs by serial dilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.
AID48962	Tested in vitro for the minimum inhibitory concentration (MIC) against Candida albicans TIMM3164	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Synthesis of Sordaricin analogues as potent antifungal agents against Candida albicans.
AID518606	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, L358L, E427K, C454C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID679612	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM, Itraconazole: 100 uM) in MDR1-expressing LLC-PK1 cells	1999	Biological & pharmaceutical bulletin, Dec, Volume: 22, Issue:12	Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
AID555866	Antimicrobial activity against Beauveria bassiana by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID549319	Antifungal activity against Rhizopus microsporus after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID546079	Antifungal activity against Candida lipolytica isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID176382	Efficacy against Candida tropicalis CY5042 on day 14th after peroral administration in rat	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.
AID1265816	Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2876 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID555608	Antimicrobial activity against Aspergillus sydowii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID575495	Antifungal activity against azole-susceptible Aspergillus fumigatus isolate CM-237 by EUCAST microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID602930	Antifungal activity against Candida kefyr by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID283331	Antifungal activity against Cunninghamella spp after 48 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1898164	Antifungal activity against Candida albicans 20#
AID341134	Antifungal activity against Saccharomycopsis guttulata isolates from feeding stuff by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID563388	Antifungal activity against Aspergillus niger isolate CM-3257 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID150756	Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1204519	Antifungal activity against Candida albicans ATCC 10231 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1877279	Antifungal activity against Candida albicans ATCC SC5314 assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID566877	Antifungal activity against Candida albicans by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1204544	Antifungal activity against Candida albicans Strain 14 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID546068	Antifungal activity against Candida albicans isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID1898165	Antifungal activity against Candida albicans 28#
AID541567	AUC (0 to 24 hrs) in healthy human alveolar cell at 200 mg, po every 12 hrs for 5 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID249332	Minimum inhibitory concentration against Trichophyton rubrum (n=14)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID554709	Antimicrobial activity against Candida krusei NZCDC 89.221 after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID245478	Minimum inhibitory concentration against Aspergillus fumigatus LSI-11 evaluated by in vitro agar diffusion and microbroth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID416040	Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID531251	Antifungal activity against Candida guilliermondii assessed as resistant isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID405049	Antifungal activity against Sporothrix schenckii P26187 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID119044	The compound was tested in vivo for anti-candida activity in mice model 2 (dose 1 mg/kg, untreated group); not tested	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID518400	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G54W mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID532046	Antifungal activity against Lichtheimia ornata clinical isolate after 48 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID519429	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4330 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID125957	In vitro evaluation of minimum inhibitory concentration against Microsporum gypseum 22	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID527140	Antifungal activity against Candida albicans LMGO 102 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID532125	Antifungal activity against Candida albicans	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID532322	Antifungal activity against Candida tropicalis by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID283231	Reduction of fungal burden in Coccidioides immitis Silveira infected CD1 mouse brain, spinal cord and lungs administered after 3 days of infection at 25 mg/kg, po bid after 12 days relative to control	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID405066	Antifungal activity against Candida krusei ATCC 6258 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID546073	Antifungal activity against Candida tropicalis isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID1594793	Antifungal activity against Histoplasma capsulatum G217B after 10 to 14 days by microscopic method	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Secondary Metabolites of Onygenales Fungi Exemplified by Aioliomyces pyridodomos.
AID555567	Antimicrobial activity against Candida parapsilosis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID554715	Antimicrobial activity against Candida krusei NZCDC 89.221 after 48 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID555135	Antimicrobial activity against Candida albicans by EUCAST broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID1754264	Antifungal activity against clinical strain Candida tropicalis by microplate reader assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID1484674	Antileishmanial activity against wild type Leishmania major LV39 Rho/SU/59/P promastigote forms after 48 hrs	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID341581	AUC (0 to 24 hrs) in adolescents of >12-16 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID563611	Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as ergosta 5,7-dienol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID549329	Antifungal activity against Apophysomyces spp. after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID555597	Antimicrobial activity against Ustilago spp by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID527141	Antifungal activity against Candida parapsilosis ATCC 22019 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID405095	Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID283328	Antifungal activity against Absidia spp after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID566890	Antifungal activity against Exophiala oligosperma by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID609304	Antifungal activity against Cryptococcus neoformans JLC 50122 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID575068	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 20 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID525599	Antibacterial activity against Fluconazole resistant Candida albicans DSY3083 containing tac1delta/delta genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID509548	Antagonist activity at hedgehog receptor	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Modulators of the hedgehog signaling pathway.
AID214268	In vitro evaluation of minimum inhibitory concentration against Trichophyton mentagrophytes 23	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID606219	Antifungal activity against Microsporum gypseum after 7 days by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID1204542	Antifungal activity against Candida albicans Strain 12 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID532548	Antifungal activity against wild-type Saccharomyces cerevisiae BY4741 assessed as accumulation of ergosterol at 8 ug/ml (Rvb = 57+/- 1.00 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID419072	Antifungal activity against fluconazole-resistant Candida albicans TIMM3164	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID283234	Antifungal activity against Coccidioides immitis by broth macrodilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID563399	Antifungal activity against Aspergillus tubingensis isolate CM-4296 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1254068	Antibacterial activity against Staphylococcus aureus 209 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID725876	Antifungal activity against Aspergillus fumigatus ASFU7 after 48 hrs by M38 method	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID725872	Antifungal activity against Aspergillus fumigatus ASFU23 after 48 hrs by M38 method	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID564270	Antifungal activity against Candida albicans isolate 14 after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID91481	Binding constant against human serum albumin (HSA)	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Cheminformatic models to predict binding affinities to human serum albumin.
AID289592	Antifungal activity against Trichophyton mentagrophytes by serial plate dilution method	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis of some bioactive 2-bromo-5-methoxy-N'-[4-(aryl)-1,3-thiazol-2-yl]benzohydrazide derivatives.
AID1330312	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction in BAPTA-induced Ca2+ depletion-stimulated SOCE activity at 100 uM preincubated for 15 mins followed by BAPTA addition in presence of extracellular Ca2+	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID582234	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID519468	Antimicrobial activity against Cryptococcus gattii by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID583000	Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene in reverse orientation without doxycycline-regulatable promoter by broth dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID582226	Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID150754	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID531237	Antifungal activity against Candida guilliermondii after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID323070	Antifungal activity against Cryptococcus neoformans IM 983036 by micro-broth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID609890	Antifungal activity against Candida albicans Y0109 by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID1301913	Inhibition of hedgehog pathway in mouse ASZ cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by qPCR method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID1175555	Antimicrobial activity against Aspergillus niger SNB-AF1 after 24 hrs	2015	Journal of natural products, Jan-23, Volume: 78, Issue:1	Antibacterial ilicicolinic acids C and D and ilicicolinal from Neonectria discophora SNB-CN63 isolated from a termite nest.
AID634072	Antifungal activity against Saccharomyces cerevisiae ATCC 24657 assessed as growth at 90.7 uM after 48 hrs by agar plate bioassay relative to control	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID525602	Antibacterial activity against Fluconazole resistant Candida albicans DSY3606 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-5) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID249329	Minimum inhibitory concentration against Candida species (n=24)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID521969	Antibacterial activity against Fluconazole resistant Candida albicans DSY3608 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-1) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID582238	Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531244	Antifungal activity against Candida guilliermondii assessed as susceptible isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID603259	Antifungal activity against Candida albicans ATCC Y0109 after 24 hrs by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID50131	In vitro evaluation of minimum inhibitory concentration against Candida guilliermondii 26	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID622012	Inhibition of VEGFR2 glycosylation in human HUVEC cells at 2 uM after 24 hrs by Western blot analysis	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.
AID532335	Antifungal activity against Absidia corymbifera by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID436741	Antifungal activity against Cryptococcus neoformans after 72 hrs by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID543973	Half life in human at 15 mg, po pretreated with itraconazole at 200 mg, po qd for 4 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID405055	Antifungal activity against Sporothrix schenckii PJRC002 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1689222	Antifungal activity against Cryptococcus neoformans NR41300 assessed as reduction in fungal growth incubated for 48 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID405012	Antifungal activity against Sporothrix schenckii PSSA81 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID525541	Antimicrobial activity against Fonsecaea isolates after 72 hrs by CLSI M38-A2 protocol method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
AID1783777	Antifungal activity against Candida parapsilosis GIM2.190 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID549325	Antifungal activity against Cunninghamella spp. after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1557082	Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID405093	Antimicrobial activity against Rhizopus arrhizus after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID1493829	Antifungal activity against Candida glabrata 537 after 24 hrs by spectrophotometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.
AID554722	Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Saccharomyces cerevisiae ERG11 to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID532320	Antifungal activity against Candida krusei by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID610067	Antifungal activity against Candida albicans JLC 30364 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID554721	Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Candida krusei ERG11g after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID1059364	Antifungal activity against Candida parapsilosis after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID603260	Antifungal activity against Candida parapsilosis clinical isolate by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID563613	Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as 14 -Methylergosta-8,24(28)-dien-3beta,6alpha-diol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID1309057	Antifungal activity against Aspergillus nidulans ATCC 38163 after 48 hrs by CLSI M38-A2 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1557079	Antifungal activity against Candida glabrata ATCC 2001 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1898179	Antifungal activity against Candida auris D12
AID1689226	Antifungal activity against Aspergillus fumigatus NR 35303 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID1223571	Inhibition of CYP3A4.1 (unknown origin)-mediated testosterone 6beta-hydroxylation incubated for 10 mins prior to NADPH addition measured after 20 mins by HPLC-UV analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID322863	Antifungal activity against azole-resistant Aspergillus fumigatus V48/27-CM3936 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID341565	AUC (0 to 24 hrs) in infants of 0.6-2 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1917561	Antiproliferative activity against human A549 cells assessed as inhibition of clone formation at 10 uM incubated for 1 day followed by culture in new medium for 7 days by crystal violet staining based assay relative to control	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID37739	Compound was tested for inherent antifungal geometric minimum inhibitory concentration (GMMIC) against Aspergillus in serial dilution from 64 to 0.0313 ug/mL	2002	Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13	Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.
AID1357636	Antifungal activity against Cryptococcus neoformans ATCC 24067 after 72 hrs by microbroth dilution assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID582799	Antifungal activity against Candida albicans isolate 12 harboring ERG3 W332R mutant gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID1898168	Antifungal activity against Candida parapsilosis 700
AID1413329	Antifungal activity against Candida tropicalis 95-41	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID729308	Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID581899	Antifungal activity against Candida glabrata isolated from HSCT recipient 002 with acute or chronic GVHD mouth receiving antifungal drug after 116 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID584600	Antifungal activity against 16 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID609311	Solubility of the compound in water at pH 7.4	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID582219	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID582224	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID497819	Antifungal activity against Fusarium sp. clinical isolates after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of thimerosal against ocular pathogenic fungi.
AID1917555	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID564272	Antifungal activity against Candida albicans isolate 108 harboring erg11 and erg5 double mutant after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID584401	Antifungal activity against 60 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID436739	Antifungal activity against Candida tropicalis after 24 hrs by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID622013	Ratio of itraconazole IC50 to compound IC50 for antiproliferative activity against mouse Ptch+/- p53-/- medulloblastoma cells isolated from allografts in nude Harlan mouse after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.
AID341580	Tmax in adolescents of >12-16 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID405109	Antimicrobial activity against Rhizomucor sp. assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID546078	Antifungal activity against Candida kefyr isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID245449	Minimum inhibitory concentration against Candida glabrata ATCC 90030 evaluated by in vitro agar diffusion and microbroth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID634074	Fungistatic activity against Saccharomyces cerevisiae ATCC 24657 assessed as cell proliferation at 90.7 uM after 24 hrs by spectrophotometric bioassay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID432800	Antifungal activity against Sporothrix schenckii after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID1877315	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID519470	Antimicrobial activity against Cryptococcus albidosimilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID582227	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531872	Antifungal activity against Scedosporium apiospermum isolated from voriconazole treated scedosporiosis patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
AID283332	Antifungal activity against Mucor spp after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID432801	Antifungal activity against Sporothrix globosa after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID753515	Antidermatophytic activity against Trichophyton mentagrophytes var. erinacei NCPF 375 after 7 days by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID532332	Antifungal activity against Aspergillus flavus by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID584588	Antifungal activity against -2 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID249266	Minimum inhibitory concentration against Microsporum species (n=38)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID555599	Antimicrobial activity against Cryptococcus laurentii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID519051	Antifungal activity against Curvularia species after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID532527	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 16 ug/ml (Rvb = 0.157%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID648418	Antifungal activity against Aspergillus fumigatus NCIM 902 by serial plate dilution method	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID323073	Antifungal activity against Cryptococcus neoformans IM 031631 by micro-broth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID424625	Antimicrobial activity against azole-resistant Candida albicans isolate CA16 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1059350	Fungicidal activity against Candida albicans clinical isolate by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID1877304	Antibiofilm activity against FLC-resistant Candida albicans CPCC400616 assessed as assessed as inhibition of biofilm formation measured at 3 hrs by XTT reduction assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID575496	Antifungal activity against Aspergillus niger isolate	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID323074	Antifungal activity against Cryptococcus neoformans IM 031706 by micro-broth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID341572	Tmax in children of >2-6 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1428258	Antifungal activity against Syncephalastrum racemosum 005004 assessed as zone of inhibition at 30 ug/ml	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID1411890	Antifungal activity against Candida parapsilosis ATCC 22019 by M27-A3 guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID555134	Antimicrobial activity against Candida glabrata by CLSI M27-A2 broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID532341	Antifungal activity against Mucor species by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID563417	Antifungal activity against Aspergillus tubingensis isolate CM-4352 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID565401	Antifungal activity against Rhizopus microsporus IHEM 9503 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1898176	Antifungal activity against Candida auris 791
AID515010	Antifungal activity against Cryptococcus neoformans after 72 hrs by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID582225	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532147	Antifungal activity against Rhizopus species	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID322865	Antifungal activity against azole-resistant Aspergillus fumigatus V49/77-CM4050 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID555591	Antimicrobial activity against Rhodotorula mucilaginosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1411894	Antifungal activity against Rhizopus oryzae ATCC 10329by M38-A guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID509098	Antifungal activity against Fonsecaea monophora CBS 269.37	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID549044	Antifungal activity against Candida albicans CA1 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID532560	Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 1 ug/ml (Rvb = 0.144%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID543974	Tmax in human at 15 mg, po pretreated with itraconazole at 200 mg, po qd for 4 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID323595	Antifungal activity against Candida glabrata bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID603346	Antifungal activity against Fonsecaea compacta clinical isolate by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID405023	Antifungal activity against Sporothrix schenckii P30019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID555621	Antimicrobial activity against Paecilomyces variotii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532140	Antifungal activity against Aspergillus flavus	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID549316	Antifungal activity against Cunninghamella bertholletiae after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID302758	Solubility by shake flask method	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Poorly soluble marketed drugs display solvation limited solubility.
AID322861	Antifungal activity against azole-resistant Aspergillus fumigatus V41/26-CM3820 isolate from patient with pulmonary fibrosis by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID701455	Antifungal activity against Cryptococcus neoformans	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	The biology and chemistry of antifungal agents: a review.
AID747169	Antimicrobial activity against Candida glabrata ATCC 18804 by broth dilution method	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Synthesis and antimicrobial activity of novel amphiphilic aromatic amino alcohols.
AID405022	Antifungal activity against Sporothrix schenckii P30019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405077	Antifungal activity against Sporothrix schenckii isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID582802	Antifungal activity against Candida albicans isolate 1008 harboring ERG3 K97E, L193P, V237A, A351V, A353T and ERG11 E266D mutant genes by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID405038	Antifungal activity against Sporothrix schenckii P24255 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID341553	Half life in adolescents of >12-16 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID340953	Antifungal activity against Candida glabrata isolates from feeding stuffs by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID546080	Antifungal activity against Candida pulcherrima isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID563612	Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as 14 -Methylergosta-8,24(28)-dien-3beta,6alpha-diol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID1904357	Antifungal activity against Candida albicans CPCC400616 assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID1164090	Antifungal activity against Candida albicans ATCC 18804 by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Synthesis and biological evaluation of a new series of N-acyldiamines as potential antibacterial and antifungal agents.
AID1743167	Antifungal activity against Trichophyton gypseum	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID624626	Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID424628	Antimicrobial activity against azole-susceptible Candida albicans isolate CA5 co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID610071	Antifungal activity against Candida krusei JLC 30366 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID619761	Antifungal activity against Candida albicans RCMB 052002 at 30 mg/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID1820640	Antifungal activity against Cryptococcus neoformans GIM 2.209 assessed as inhibition of fungal growth by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents.
AID549052	Antifungal activity against Candida albicans CA137 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID1204520	Antifungal activity against Candida tropicalis ATCC 13803 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1917553	Inhibition of hedgehog signalling pathway in human A549 cells assessed as reduction in Gli gene expression incubated for 24 hrs by qPCR analysis	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID510636	Antifungal activity against Trichophyton mentagrophytes ATCC 24198 after 24 hrs by AFSTEUCAST assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID406959	Antifungal activity against dermatophytes at 28 degC after 7 days by broth microdilution test	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID555624	Antimicrobial activity against Scopulariopsis brevicaulis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1059349	Fungicidal activity against Candida tropicalis clinical isolate by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID1301914	Antiproliferative activity against HUVEC assessed as inhibition of VEGF induced cell proliferation after 72 hrs by MTS assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID555804	Antimicrobial activity against Scytalidium hyalinum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1204543	Antifungal activity against Candida albicans Strain 13 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID555810	Antimicrobial activity against Rhizopus microsporus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID415955	Antimicrobial activity against Aspergillus fumigatus by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID1589575	Substrate activity at BCRP in human Caco2 cells assessed as efflux ratio by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
AID527138	Antifungal activity against Trichophyton mentagrophytes LMGO 1931 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID655584	Antifungal activity against Candida tropicalis by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID1223573	Inhibition of CYP3A4.7 (unknown origin)-mediated testosterone 6beta-hydroxylation incubated for 10 mins prior to NADPH addition measured after 20 mins by HPLC-UV analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID519423	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3134 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID531235	Antifungal activity against Candida glabrata after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID531874	Antifungal activity against Scedosporium prolificans isolated from voriconazole treated scedosporiosis patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
AID1428256	Antifungal activity against Aspergillus fumigatus RCMB 002006 assessed as zone of inhibition at 30 ug/ml	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID575751	Antimicrobial activity against sterol 14-alpha demethylase isoenzyme B-deficient Aspergillus fumigatus CEA10	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID341582	Half life in adolescents of >12-16 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID555629	Antimicrobial activity against Fusarium reticulatum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID582216	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID49633	Minimum concentration required to inhibit the growth of Candida albicans 2	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID602929	Antifungal activity against Candida parapsilosis by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID1689211	Antifungal activity against fluconazole-resistant Candida albicans NR29448 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID1204551	Antifungal activity against Candida albicans Strain 21 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID582246	Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531246	Antifungal activity against Candida lusitaniae assessed as susceptible isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID1419502	Antifungal activity against Candida parapsilosis ATCC 22019 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID436742	Antifungal activity against Trichophyton rubrum after 7 days by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID341578	Half life in children of >6-12 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID555625	Antimicrobial activity against Trichoderma spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1254074	Antibacterial activity against Pseudomonas aeruginosa 2004 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID1254071	Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID582221	Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405107	Antimicrobial activity against Mucor sp. after assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID284099	Antifungal activity against Candida neoformans ATCC 32264 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID1477763	Antifungal activity against drug resistant Candida albicans DF2672R after 24 hrs by two fold serial dilution method	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Semisynthesis and Biological Evaluation of Xanthone Amphiphilics as Selective, Highly Potent Antifungal Agents to Combat Fungal Resistance.
AID1689217	Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID176376	Efficacy against Aspergillosis fumigatus CY1003 on day 14th after peroral administration in rat	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.
AID665072	Antifungal activity against Trichophyton rubrum by serial dilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.
AID565552	Antifungal activity against Rhizopus microsporus UTHSC R-3466 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID545671	Ratio of intracellular to extracellular drug uptake in RBC of New Zealand white rabbit infected with Mycobacterium bovis at 1 ug/ml	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID1589583	Permeability of the compound after 5 hrs by PAMPA	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
AID1872506	In vivo antifungal activity against Candida albicans infected in CDF1 mouse treated po or iv immediately after infection measured on day 7	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1609926	Antifungal activity against Candida albicans GIM 2.194 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID555593	Antimicrobial activity against Trichosporon ovoides by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555596	Antimicrobial activity against Cryptococcus albidus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1164092	Antifungal activity against Candida glabrata ATCC 90030 by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Synthesis and biological evaluation of a new series of N-acyldiamines as potential antibacterial and antifungal agents.
AID1549138	Antifungal activity against azole-resistant Candida albicans 7781 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID519422	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-1290 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID524736	Antimicrobial activity against Fusarium verticillioides after 48 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID532537	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as accumulation of ergosterol at 8 ug/ml (Rvb = 54+/- 0.82 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID547353	Antifungal activity against Candida lusitaniae after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID214430	Minimum inhibitory concentration of compound for antifungal activity against Trichophyton rubrum	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID701462	Antifungal activity against Candida parapsilosis	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	The biology and chemistry of antifungal agents: a review.
AID655581	Antifungal activity against Candida albicans Y0109 after 24 hrs by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID1754262	Antifungal activity against Candida albicans ATCC 76615 by microplate reader assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID619767	Antifungal activity against Syncephalastrum racemosum RCMB 052003 at 30 mg/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID753514	Antidermatophytic activity against Trichophyton mentagrophytes var. erinacei isolate after 7 days by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID1309051	Antifungal activity against Candida albicans ATCC MYA-1237 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1076022	Cytotoxicity against human HT1080 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID405067	Antifungal activity against Candida krusei ATCC 6258 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1674377	Unbound AUC at steady state in human administered as single dose	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID549047	Antifungal activity against Candida albicans CA4 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID1904362	Antifungal activity against Candida krusei GIM 2.1 assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID442519	Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by microbroth dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.
AID340959	Antifungal activity against Candida parapsilosis ATCC 22013 by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID581879	Antifungal activity against Candida glabrata isolated from HSCT recipient 186 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID415948	Antimicrobial activity against Candida krusei by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID581870	Antifungal activity against Candida glabrata isolated from neutropenic subject 1318 with AML or MDS stool after 36 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID554727	Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 0.36 nM	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID509122	Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in brain at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID519436	Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-4063 obtained from bronchoalveolar aspirate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519427	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3583 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID214426	Minimum concentration required to inhibit the growth of Trichophyton rubrum	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID519046	Antifungal activity against Candida glabrata after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID725870	Antifungal activity against Rhizomucor pusillus RHPU1 after 48 hrs by broth microdilution test	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID533030	Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as planktonic cell on polystyrene after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID1076030	Antifungal activity against Candida sp. clinical isolate 11972 derived from high vaginal swabs by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID283226	Effect on fungal burdens in Coccidioides immitis Silveira infected CD1 mouse brain administered after 3 days of infection at 50 mg/kg, po bid after 12 days	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID532330	Antifungal activity against Aspergillus fumigatus by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1689828	Antifungal activity against Fusarium sp. assessed as reduction in microbial growth after 24 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID341562	AUC (0 to 24 hrs) in human at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1556210	Antifungal activity against Cryptococcus neoformans CGMCC 2.3161 assessed as inhibition of visible microbial growth by NCCLS protocol based method	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents.
AID622014	Inhibition of hedgehog signaling pathway in mouse Ptch+/- p53-/- medulloblastoma cells assessed as inhibition of receptor-mediated Gli1 transcriptional activity at antiproliferative IC90 concentration after 24 hrs by RT-PCR analysis relative to control	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.
AID1689219	Antifungal activity against Candida krusei CAB 396420 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID1484676	Antileishmanial activity against Leishmania major LV39 Rho/SU/59/P promastigote forms harboring C14DM null mutant after 48 hrs	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID55045	Minimum concentration required to inhibit the growth of Cryptococcus neoformans	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID565404	Antifungal activity against Rhizopus microsporus IHEM 5234 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID406960	Antifungal activity against dermatophytes at 35 degC after 48 to 96 hrs by broth microdilution test	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID341566	Half life in infants of 0.6-2 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1415219	Inhibition of human liver microsome CYP3A4 at 1 uM expressed in baculosomes using fluorogenic-DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition.
AID554708	Antimicrobial activity against Candida krusei NZCDC 89.102 after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID532044	Antifungal activity against Lichtheimia corymbifera clinical isolate after 48 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID546071	Antifungal activity against Clavispora lusitaniae isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID729312	Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID1204534	Antifungal activity against Candida albicans Strain 4 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID405025	Antifungal activity against Sporothrix schenckii P14954 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID575207	Antifungal activity against Cunninghamella echinulata FMR 10973 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID555613	Antimicrobial activity against Aspergillus sclerotiorum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID541563	Cmax in healthy human lung epithelial lining fluid assessed as hydroxyitraconazole at 200 mg, po every 12 hrs for 5 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID480476	Antifungal activity against Candida parapsilosis after 24 hrs by serial dilution method	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
AID1663762	Antifungal activity against Paracoccidioides brasiliensis Pb18	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Synthesis and antifungal activity of new hybrids pyrimido[4,5-d]pyridazinone-N-acylhydrazones.
AID555582	Antimicrobial activity against Candida orthopsilosis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555605	Antimicrobial activity against Aspergillus flavus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1877314	Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID1309054	Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1419503	Antifungal activity against Aspergillus flavus ATCC MYA-3631 incubated for 48 hrs by CLSI M38-A2 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID519057	Antifungal activity against Candida glabrata assessed as susceptible isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1898167	Antifungal activity against Candida parapsilosis 90018
AID371234	Antimicrobial activity against Cryptococcus neoformans TIMM 1855 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID619763	Antifungal activity against Aspergillus fumigatus RCMB 002003 at 30 mg/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID1689220	Antifungal activity against Candida krusei ATCC 34135 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID405076	Antifungal activity against Sporothrix schenckii isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1413327	Antifungal activity against Candida lusitaniae 95-767	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID555572	Antimicrobial activity against Candida lusitaniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID584591	Antifungal activity against 176 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575489	Antifungal activity against azole-resistant Aspergillus fumigatus isolate T18 harboring Cyp51A TR/L98H mutation assessed as inhibition of fungal growth at 4 mg/l relative to control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID1428259	Antifungal activity against Candida albicans RCMB 0005003 assessed as zone of inhibition at 30 ug/ml	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID549046	Antifungal activity against Candida albicans CA3 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID1059362	Antifungal activity against Candida dubliniensis after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID467289	Antifungal activity against Aspergillus fumigatus by serial dilution method after 7 days	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Discovery of highly potent novel antifungal azoles by structure-based rational design.
AID634073	Antifungal activity against Saccharomyces cerevisiae ATCC 24657 assessed as growth at 90.7 uM after 48 hrs by spectrophotometric bioassay relative to control	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID555578	Antimicrobial activity against Candida norvegensis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1334850	Anti-fungal activity against Aspergillus fumigatus CGMCC 3.7795 by broth microdilution method	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.
AID1604174	Antileishmanial activity against Leishmania amazonensis MHOM/BR/75/Josefa promastigotes assessed as reduction in parasite viability after 72 hrs by Neubauer chamber counting method	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing.
AID519050	Antifungal activity against Aspergillus sp. after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID55176	Minimum inhibitory concentration of compound for antifungal activity against Cryptococcus neoformans	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID1357637	Antifungal activity against Paracoccidioides brasiliensis Pb18 after 7 days by microbroth dilution assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID584410	Antifungal activity against -3 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID624629	Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID679901	TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.1 uM, Itraconazole: 100 uM) in MDR1-expressing LLC-PK1 cells	1999	Biological & pharmaceutical bulletin, Dec, Volume: 22, Issue:12	Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
AID341743	Toxicity in human at risk for fungal infection assessed as occurrence of adverse events at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1783070	Antifungal activity against fluconazole-sensitive Candida albicans 9770 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1689225	Antifungal activity against Cryptococcus gattii NR43209 assessed as reduction in fungal growth incubated for 48 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID532041	Antifungal activity against Lichtheimia ramosa clinical isolate after 24 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID1556208	Antifungal activity against Candida albicans CPCC 400523 assessed as inhibition of visible microbial growth by NCCLS protocol based method	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents.
AID575755	Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme B expressed in Escherichia coli assessed as tight binding affinity constant	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID563410	Antifungal activity against Aspergillus tubingensis isolate CM-3177 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1419493	Antifungal activity against Candida albicans ATCC 10231 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID515009	Antifungal activity against Candida albicans Y0109 after 24 hrs by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID563391	Antifungal activity against Aspergillus tubingensis isolate CM-3585 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1204559	Antifungal activity against Candida albicans Strain 29 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1128929	Antifungal activity against Aspergillus fumigatus assessed as total growth inhibition by micro-broth dilution method	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Imidazolylchromanones containing non-benzylic oxime ethers: synthesis and molecular modeling study of new azole antifungals selective against Cryptococcus gattii.
AID278903	Antifungal activity against Scedosporium aurantiacum ear swab isolate CNM-CM-2846 at 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates.
AID532333	Antifungal activity against Aspergillus niger by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1689824	Antifungal activity against Aspergillus fumigatus ASFU77 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID1076025	Antifungal activity against Candida sp. clinical isolate 12810 derived from blood by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID519549	Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-2280 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID405096	Antimicrobial activity against Mucor sp. after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID532558	Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 8 ug/ml (Rvb = 0.144%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID602932	Antifungal activity against Trichophyton rubrum by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID1415222	Binding affinity to NPC1 in HUVEC assessed as increase in cholesterol accumulation in late endosome/lysosome at 0.2 uM after 14 hrs by filipin staining-based confocal microscopy	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition.
AID424630	Antimicrobial activity against azole-susceptible Candida albicans isolate CA12 co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID581905	Antifungal activity against Candida glabrata isolated from HSCT recipient 491 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1820639	Antifungal activity against Candida tropicalis GIM 2.183 assessed as inhibition of fungal growth by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents.
AID563400	Antifungal activity against Aspergillus niger isolate CM-4316 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID531463	Antifungal activity against Candida tropicalis assessed as susceptible dose-dependent isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID555610	Antimicrobial activity against Aspergillus ochraceus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID468520	Antifungal activity against Candida tropicalis IFO 10241 after 24 to 72 hrs by NCCLS method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis and antimicrobial activities of 3-O-alkyl analogues of (+)-catechin: improvement of stability and proposed action mechanism.
AID1597998	Antifungal activity against Cryptococcus neoformans after 72 hrs by NCCLS protocol based method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.
AID581867	Antifungal activity against Candida albicans isolated from HSCT recipient 301 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1204550	Antifungal activity against Candida albicans Strain 20 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1334851	Anti-fungal activity against Candida tropicalis CGMCC 2.3739 by broth microdilution method	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.
AID283338	Antifungal activity against Syncephalastrum spp after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID1204533	Antifungal activity against Candida albicans Strain 3 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID405037	Antifungal activity against Sporothrix schenckii P24255 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1061743	Antimicrobial activity against Candida albicans Y0109 after 24 hrs by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID278902	Antifungal activity against Scedosporium aurantiacum sputum isolate CNM-CM-2631 at 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates.
AID1689224	Antifungal activity against Cryptococcus gattii NR43210 assessed as reduction in fungal growth incubated for 48 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID1743166	Antifungal activity against Trichophyton rubrum	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID405102	Antimicrobial activity against Apophysomyces elegans after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID484285	Colloidal aggregation in fed state simulated intestinal fluid assessed as critical aggregation concentration by UV-visible spectrophotometry in presence of 3% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID753511	Antidermatophytic activity against Epidermophyton floccosum RSKK 3027 after 7 days by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID681119	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID341570	Half life in human at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1904360	Antifungal activity against Candida parapsilosis GIM 2.190 assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID1357631	Antifungal activity against Candida albicans ATCC 18804 after 48 hrs by microbroth dilution assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID582243	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID581886	Antifungal activity against Saccharomyces cerevisiae isolated from HSCT recipient 513 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1411891	Antifungal activity against Mucor hiemalis ATCC 8690 by M38-A guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID1204535	Antifungal activity against Candida albicans Strain 5 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID220225	The compound was tested in vitro for antifungal activity against 10 yeasts.	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID204352	Minimum inhibitory concentration of compound for antifungal activity against Sporothrix schenck ii	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID1474172	Antifungal activity against Candida tropicalis cgmcc 2.3739 by broth microdilution assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents.
AID549313	Antifungal activity against Mucor circinelloides after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1904358	Antifungal activity against Candida tropicalis CGMCC 2.3739 assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID555796	Antimicrobial activity against Scedosporium prolificans by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1059357	Fungicidal activity against Candida krusei by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID575483	Antifungal activity against azole-resistant Aspergillus fumigatus isolate T11 harboring Cyp51A TR/L98H mutant gene assessed as inhibition of fungal growth at 4 mg/l relative to control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID484289	Binding affinity to beta-lactamase AmpC at 200 uM after 30 mins by SDS-PAGE	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID581882	Antifungal activity against Candida glabrata isolated from HSCT recipient 975 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID545674	Ratio of cellular uptake in alveolar macrophages to plasma of healthy human at 10 doses of 200 mg/kg, twice daily	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID582222	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID609895	Antifungal activity against Trichophyton rubrum by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID1413332	Antifungal activity against sensitive Candida albicans MYA-2876	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID1392810	Antifungal activity against Candida tropicalis cgmcc 2.3739 after 24 hrs by serial dilution method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
AID468518	Antifungal activity against Candida lusitaniae ATCC 42720 after 24 to 72 hrs by NCCLS method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis and antimicrobial activities of 3-O-alkyl analogues of (+)-catechin: improvement of stability and proposed action mechanism.
AID736599	Antifungal activity against anidulafungin-resistant Candida parapsilosis isolate 22019 assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID440321	Antifungal activity against Aspergillus fumigatus isolated from patient sputum after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID582255	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1856367	Antifungal activity against Aspergillus fumigatus ATCC 46645 assessed as inhibition of conidial and mycelial growth incubated for 5 days by CLSI protocol based microbroth dilution method
AID555812	Antimicrobial activity against Saksenaea vasiformis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID405018	Antifungal activity against Sporothrix schenckii P20825 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID249339	Minimum inhibitory concentration against Epidermophyton floccosum (n=12)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID405098	Antimicrobial activity against Mucor circinelloides after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID581862	Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405053	Antifungal activity against Sporothrix schenckii PGAC0016 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID549318	Antifungal activity against Rhizopus microsporus after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID581865	Antifungal activity against Candida albicans isolated from HSCT recipient 262 with acute or chronic GVHD mouth receiving antifungal drug after 115 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1428257	Antifungal activity against Geotrichum candidum 052008 assessed as zone of inhibition at 30 ug/ml	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID575471	Tmax in guinea pig infected with 10'6 CFU Microsporum canis B68128 at 20 mg/kg, po administered 2 hrs before infection for 5 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID555623	Antimicrobial activity against Acremonium sp.by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1770943	Antifungal activity against Candida krusei GIM2.1 assessed as fungal growth inhibition by CLSI protocol based method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID555617	Antimicrobial activity against Fusarium solani by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532139	Antifungal activity against Aspergillus terreus	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID582229	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID729306	Inhibition of vasopressin V2 receptor (unknown origin) assessed as change in intracellular calcium levels treated with centrifuged compound solution by fluorometric analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID405020	Antifungal activity against Sporothrix schenckii P20825 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID519048	Antifungal activity against Candida parapsilosis after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID518604	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID518605	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, E427K, C454C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID551212	Antifungal activity against Aspergillus fumigatus by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID405100	Antimicrobial activity against Absidia corymbifera after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID283334	Antifungal activity against Rhizomucor spp after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID302124	Antifungal activity against fluconazole-resistant Candida albicans 18 after 24 hrs	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID1820638	Antifungal activity against Candida albicans GIM 2.194 assessed as inhibition of fungal growth by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents.
AID1634358	Antifungal activity against Candida albicans CPCC 400523 assessed as inhibition of visible microbe growth by broth microdilution method	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents.
AID555604	Antimicrobial activity against Aspergillus terreus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID533029	Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as biofilm on polystyrene after 24 to 48 hrs by XTT assay	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID283336	Antifungal activity against Rhizopus spp after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID535618	Antifungal activity against Candida tropicalis T3 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
AID555574	Antimicrobial activity against Candida rugosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID323596	Antifungal activity against Candida krusei bloodstream isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID555570	Antimicrobial activity against Candida krusei by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555806	Antimicrobial activity against Mycocladus corymbiferus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID575194	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 25 mg/kg, po bid administered 1 day after infection for 7 days relative to untreated control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID555588	Antimicrobial activity against Galactomyces geotrichum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID581875	Antifungal activity against Candida glabrata isolated from neutropenic subject 1497 with AML or MDS pharynx receiving antifungal drug after 61 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID582233	Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1204540	Antifungal activity against Candida albicans Strain 10 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID525600	Antibacterial activity against Fluconazole resistant Candida albicans DSY3604 containing tac1delta/delta ERG11-1/ERG11-5 genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID262549	Antifungal activity against Cryptococcus neoformans	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID554712	Antimicrobial activity against Candida krusei IFO0011 after 48 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID531096	Binding affinity to Candida albicans CYP56 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	CYP56 (Dit2p) in Candida albicans: characterization and investigation of its role in growth and antifungal drug susceptibility.
AID555815	Antifungal activity against tac1/tac1 deficient Candida albicans SZY31 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID581880	Antifungal activity against Candida glabrata isolated from HSCT recipient 474 with acute or chronic GVHD mouth after 124 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID555616	Antimicrobial activity against Penicillium spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555585	Antimicrobial activity against Dipodascus capitatus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1524623	Antibacterial activity against Streptococcus mutans 3289 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID681126	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID319755	Antimicrobial activity against Trichophyton rubrum isolates	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID519431	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4387 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID533027	Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as biofilm on CFBE41o cell after 24 to 48 hrs by XTT assay	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID340962	Antifungal activity against sCandida stellata isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID1597999	Antifungal activity against Trichophyton rubrum after 7 days by NCCLS protocol based method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.
AID340966	Antifungal activity against Rhodotorula sp. isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID1595044	Antifungal activity against Cryptococcus neoformans LA314 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID509110	Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in OF1 mouse assessed as increase in mouse survival at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID566880	Antifungal activity against Candida krusei by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID416041	Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID211473	In vitro evaluation of minimum inhibitory concentration against Torulopsis glabrata 78	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID1157291	Antifungal activity against Candida albicans SC5314 assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID547565	Antifungal activity against Candida glabrata after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID1067047	Antifungal activity against Cryptococcus neoformans after 72 hrs by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID1419501	Antifungal activity against Candida krusei ATCC 6258 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID555594	Antimicrobial activity against Trichosporon dermatis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1157292	Antifungal activity against Candida parapsilosis 22019 assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID584402	Antifungal activity against 88 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1128930	Antifungal activity against Exophiala dermatitidis assessed as total growth inhibition by micro-broth dilution method	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Imidazolylchromanones containing non-benzylic oxime ethers: synthesis and molecular modeling study of new azole antifungals selective against Cryptococcus gattii.
AID302125	Antifungal activity against fluconazole-resistant Candida albicans 25 after 24 hrs	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID518614	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A S400I mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1534780	Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID1901384	Antifungal activity against Candida albicans assessed as inhibition of fungal growth measured after 48 hrs by M27-A3 based broth microdilution	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Tetrazole derivatives bearing benzodiazepine moiety-synthesis and action mode against virulence of Candida albicans.
AID555821	Ratio of MIC50 for Candida albicans 5674 to MIC50 for cdr1/cdr1 deficient Candida albicans STY19	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID532043	Antifungal activity against Lichtheimia corymbifera clinical isolate after 24 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID284104	Antifungal activity against Candida neoformans IM 00319 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID49636	Minimum concentration required to inhibit the growth of Candida albicans 4	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID1254075	Antibacterial activity against Salmonella typhimurium 2421 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID1877284	Antifungal activity against Candida glabrata clinical isolate assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID554951	Inhibition of Candida krusei Abc1g expressed in Saccharomyces cerevisiae isolate ADdelta assessed as fractional inhibitory concentration index at 2.5 ug/ml after 48 hrs by checkerboard susceptibility assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID1484675	Antileishmanial activity against Leishmania major LV39 Rho/SU/59/P promastigote forms harboring c14dm-/+C14DM mutant after 48 hrs	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.
AID47892	In vitro evaluation of minimum inhibitory concentration against Candida parapsilosis 61	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID49988	Tested in vitro for the minimum inhibitory concentration (MIC) against Candida glabrata ATCC 90030	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Synthesis of Sordaricin analogues as potent antifungal agents against Candida albicans.
AID1301919	Antiangiogenic activity against HUVEC assessed as inhibition of total tube length at 1 uM after 16 hrs by inverted microscopy	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID405050	Antifungal activity against Sporothrix schenckii P26187 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1770934	Anti-biofilm activity in Candida albicans CPCC400616 assessed as inhibition of biofilm formation incubated for 18 hrs by XTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID1357634	Antifungal activity against Candida tropicalis ATCC 750 after 48 hrs by microbroth dilution assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID532349	Antifungal activity against Sporothrix schenckii by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID509396	Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse serum at 50 mg/kg, po bid administered 1 day after infection measured on day 6 after 4 hrs of last treatment	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID549311	Antifungal activity against Rhizopus oryzae after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID560241	Antifungal activity against Candida albicans by checkerboard method in presence of itraconazole	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID563615	Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant assessed as lanosterol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID289590	Antifungal activity against Penicillium marneffei by serial plate dilution method	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis of some bioactive 2-bromo-5-methoxy-N'-[4-(aryl)-1,3-thiazol-2-yl]benzohydrazide derivatives.
AID480475	Antifungal activity against Candida tropicalis after 24 hrs by serial dilution method	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
AID620357	Antifungal activity against Syncephalastrum racemosum RCMB 005003 at 30 ug/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID532138	Antifungal activity against Aspergillus fumigatus	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID575463	Antifungal activity against 5 x 10'6 CFU/ml Candida albicans B2630 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID609308	Antifungal activity against Aspergillus flavus JLC 30784 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID283333	Antifungal activity against Mucor spp after 48 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
AID581888	Antifungal activity against Candida albicans isolated from HSCT recipient 031 with acute or chronic GVHD mouth after 109 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405027	Antifungal activity against Sporothrix schenckii MRSS4 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1067043	Antifungal activity against Trichophyton rubrum by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID1334849	Anti-fungal activity against Cryptococcus neoformans CGMCC 2.3161 by broth microdilution method	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.
AID340964	Antifungal activity against Pichia anomala isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID519281	Antifungal activity against Candida krusei ATCC 6258 by AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID1330310	Inhibition of Orai1-mediated store operated Ca2+ entry in human MDA-MB-231 cells assessed as reduction of SERCA inhibition-induced ER release at 100 uM preincubated for 15 mins followed by CPA addition by PBX-based FLIPR assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID1898175	Antifungal activity against Candida glabrata ATCC2001
AID45503	In vivo Evaluation of minimum inhibitory concentration against Candida albicans 60	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID1076024	Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1783062	Antifungal activity against fluconazole-resistant Candida tropicalis 5008 assessed as inhibition of fungal growth incubated for 48 hrs by two-fold serial microdilution method	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID547563	Antifungal activity against Candida albicans after 24 to 72 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
AID584594	Antifungal activity against 43 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1157290	Antifungal activity against Candida albicans Y0109 assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID555805	Antimicrobial activity against Lecythophora hoffmannii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID541565	AUC (0 to 24 hrs) in healthy human plasma at 200 mg, po every 12 hrs for 5 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID531462	Antifungal activity against Candida glabrata assessed as susceptible dose-dependent isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID531468	Antimicrobial activity against azole-susceptible Aspergillus fumigatus after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID555631	Antimicrobial activity against Chrysonilia sitophila by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID581860	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID322545	Antifungal activity against Trichophyton soudanense after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID1392808	Antifungal activity against Candida albicans CPCC 400523 after 24 hrs by serial dilution method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
AID518593	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, L358L, E427K and C454C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID285864	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.03 ug/ml by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID1392811	Antifungal activity against Aspergillus fumigatus cgmcc 3.7795 after 7 days by serial dilution method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
AID527142	Antifungal activity against Candida parapsilosis LMGO 05 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID249344	Minimum inhibitory concentration against Trichophyton mentagrophytes (n=20)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID54923	Inhibition of human cytochrome P450 3A4	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID532321	Antifungal activity against Candida lusitaniae by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID322860	Antifungal activity against azole-resistant Aspergillus fumigatus V34/78-CM3279 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID405058	Antifungal activity against Sporothrix schenckii P14036 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID624622	Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID532551	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 8 ug/ml (Rvb = 0.157%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID1904361	Antifungal activity against Candida glabrata clinical isolate assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID283230	Prolongation of survival in po dosed CD1 mouse infected with Coccidioides immitis Silveira administered after 3 days of infection after 12 days relative to control	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID584390	Antifungal activity against 14 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID420663	Antifungal activity against Candida tropicalis by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1157296	Antifungal activity against Trichophyton rubrum Cmccftla assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID622011	Ratio of itraconazole IC50 to compound IC50 for antiangiogenic activity in human HUVEC cells assessed as inhibition of cell proliferation	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.
AID624623	Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1557080	Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID768345	Antifungal activity against Candida parapsilosis ATCC 22019 after 24 hrs	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID341556	Apparent volume of distribution in human at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1525382	Inhibition of mouse Smo A1 mutant expressed in mouse Shh Light2 cells assessed as reduction in hedgehog pathway activation incubated for 30 hrs by luminescence assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies.
AID467285	Antifungal activity against Candida albicans by serial dilution method after 24 hrs	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Discovery of highly potent novel antifungal azoles by structure-based rational design.
AID510820	Antifungal activity against Fusarium oxysporum ATCC 48112 after 24 hrs by AFSTEUCAST assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID1898160	Antifungal activity against Candida albicans 25#
AID1770942	Antifungal activity against Candida glabrata assessed as fungal growth inhibition by CLSI protocol based method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID532131	Antifungal activity against Candida guilliermondii	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID519284	Antifungal activity against Candida parapsilosis ATCC 22019 by AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID405103	Antimicrobial activity against Rhizopus sp. assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID563409	Antifungal activity against Aspergillus tubingensis isolate CM-3125 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID575749	Antimicrobial activity against sterol 14-alpha demethylase isoenzyme A-deficient Aspergillus fumigatus CEA10	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID323072	Antifungal activity against Cryptococcus neoformans IM 972751 by microbroth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID341571	Cmax in children of >2-6 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID564265	Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as obtusifoliol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID249330	Minimum inhibitory concentration against Aspergillus species (n=8)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID1820641	Antifungal activity against Aspergillus fumigatus CGMCC 3.7795 assessed as inhibition of fungal growth by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents.
AID508314	Antifungal activity against Aspergillus fumigatus isolate V59-73 harboring G54W mutation in Cyp51A protein by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID554723	Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Candida albicans ERG11A to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID609893	Antifungal activity against Candida kefyr by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID525596	Antibacterial activity against Fluconazole resistant Candida albicans DSY3608 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-1) genotype by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID425157	Antimicrobial activity against azole-resistant Candida albicans isolate CA10 assessed as log reduction in colony count at 1 ug/ml co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by XTT assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1770937	Antifungal activity against Candida albicans ATCC SC5314 assessed as fungal growth inhibition by CLSI protocol based method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID341568	Tmax in human at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID606213	Antifungal activity against Candida parapsilosis ATCC 0306392 by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID634078	Fungistatic activity against Saccharomyces cerevisiae ATCC 24657 assessed as cell growth at 90.7 uM after 48 hrs by spectrophotometric bioassay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID1265821	Antifungal activity against Aspergillus nidulans ATCC 38163 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID50156	In vitro evaluation of minimum inhibitory concentration against Candida krusei 70	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID584408	Antifungal activity against 10 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 37 days after 9 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID283227	Effect on fungal burdens in Coccidioides immitis Silveira infected CD1 mouse spinal cord administered after 3 days of infection at 50 mg/kg, po bid after 12 days	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID1658281	Effect on VEGFR2 localization in human HUVEC cells assessed as accumulation of VEGFR2 in perinuclear region at 2 uM by DAPI staining based confocal micrscopy
AID29423	HPLC capacity factor (k')	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1877305	Antibiofilm activity against FLC-resistant Candida albicans CPCC400616 assessed as assessed as inhibition of biofilm formation measured at 6 hrs by XTT reduction assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID532953	Antifungal activity against Candida albicans isolate V3 with CAI genotype by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
AID1877316	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID289591	Antifungal activity against Aspergillus flavus by serial plate dilution method	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis of some bioactive 2-bromo-5-methoxy-N'-[4-(aryl)-1,3-thiazol-2-yl]benzohydrazide derivatives.
AID532565	Antifungal activity against wild-type Saccharomyces cerevisiae BY4741 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID340960	Antifungal activity against Candida rugosa isolates from feeding stuff by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID584415	Antifungal activity against 31 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 31 days after 28 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1557076	Antifungal activity against Candida albicans P-87 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID323067	Antifungal activity against Cryptococcus neoformans IM 983040 by micro-broth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID584388	Antifungal activity against 42 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool after 48 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID559693	Antimicrobial activity against Mucor circinelloides after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID609319	Half life in rat at 10 mg/kg, iv administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID294852	Antifungal activity against Aspergillus fumigatus after 7 days by micro-broth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID1872519	Antifungal activity against Candida albicans SANK 51486 by 96-well microplate method	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID566879	Antifungal activity against Candida glabrata by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID554707	Antimicrobial activity against Candida krusei NZCDC 89.021 after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID725874	Antifungal activity against Aspergillus fumigatus ASFU20 after 48 hrs by M38 method	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID563614	Effect on sterol composition in Candida albicans isolate 14 expressing wild type erg11 and erg5 assessed as lanosterol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID648417	Antifungal activity against Aspergillus flavus NCIM 524 at MIC after 3 to 4 days	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID1325032	Displacement of BODIPY-cyclopamine from human Smo expressed in HEK293 cells at 5 uM measured after 10 hrs by FACS analysis	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
AID736600	Antifungal activity against anidulafungin-resistant Candida parapsilosis ANF8 assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID1589582	Inhibition of CYP3A4 (unknown origin) using midazolam as substrate by UPLC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
AID555819	Antifungal activity against cdr1/cdr1/cdr2/cdr2 deficient Candida albicans STY31 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID1783772	Antifungal activity against Candida albicans CPCC400523 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID322864	Antifungal activity against azole-resistant Aspergillus fumigatus V49/09-CM4023 isolate from patient with chronic obstructive pulmonary disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID371236	Antimicrobial activity against Aspergillus fumigatus SANK 10569 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID249267	Minimum inhibitory concentration against Trichophyton rubrum (n=14)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID119042	Tested in vivo for anti-candida activity in mice model 1 (dose: 0.5 mg/kg, untreated group).	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID220226	In vitro for antifungal activity against 10 yeasts	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1589580	Half life in human liver microsomes at 1 uM by UPLC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
AID405013	Antifungal activity against Sporothrix schenckii PSSA81 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID283225	Prolongation of survival in CD1 mouse infected with Coccidioides immitis Silveira administered after 3 days of infection at 50 mg/kg, po bid after 12 days relative to control	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID1534782	Intrinsic clearance in human liver microsomes at 1 uM by LC-MS/MS analysis	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID584398	Antifungal activity against 14 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool after 12 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405046	Antifungal activity against Sporothrix schenckii SSA29 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID566881	Antifungal activity against Candida guilliermondii by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1223572	Inhibition of CYP3A4.2 (unknown origin)-mediated testosterone 6beta-hydroxylation incubated for 10 mins prior to NADPH addition measured after 20 mins by HPLC-UV analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID405070	Antifungal activity against Candida parapsilosis ATCC 22019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID575466	Antifungal activity against 5 x 10'6 CFU/ml Candida krusei B68404 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID1674369	Volume of distribution at steady state in human	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID442520	Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by microbroth dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.
AID1301912	Inhibition of hedgehog pathway in mouse C3H10T1/2 cells assessed as downregulation of Gli1 mRNA expression after 24 hrs by qPCR method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID1474171	Antifungal activity against Aspergillus fumigatus cgmcc 3.7795 by broth microdilution assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents.
AID520620	Antifungal activity against Candida metapsilosis by microdilution AFST-EUCAST method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID532345	Antifungal activity against Penicillium marneffei by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID325035	Antimicrobial activity against Candida albicans SC5314 after 24 hrs by broth macrodilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID406958	Antifungal activity against fluconazole-sensitive Candida albicans Fe40 at 35 degC after 48 hrs by broth microdilution test	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID1917563	Induction of intracellular reactive oxygen species production in human A549 cells assessed as increase in number ROS positive cells at 30 uM and measured after 24 hrs by H2DCFH-DA staining based flow cytometric analysis (Rvb=1.10%)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID319750	Antimicrobial activity against Candida albicans ATCC 76615	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID531469	Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring G54V, G54E, G54R and G54W mutation in cyp51A gene after 48 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
AID532325	Antifungal activity against Cryptococcus neoformans var. neoformans by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1833887	Inhibition of Naegleria fowleri CYP51 catalytic activity using [3-3H]sterol substrate measured after 1 hr by RP-HPLC analysis	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Relaxed Substrate Requirements of Sterol 14α-Demethylase from
AID554725	Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Candida krusei ERG11g to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID262551	Antifungal activity against Fonsecaea pedrosoi	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID582244	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1743172	Antifungal activity against Microsporum canis	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID484281	Colloidal aggregation in fed state simulated intestinal fluid at 100 uM by transmission electron microscopy in presence of 1% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID141791	Minimum concentration required to inhibit the growth of Mucosporum canis	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID1059365	Antifungal activity against Candida tropicalis after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID405072	Antifungal activity against Aspergillus flavus ATCC 204304 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1557078	Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID637165	Antifungal activity against Saccharomyces cerevisiae ATCC 9763 at 12.5 mg/ml after 72 hrs by agar diffusion test	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and in vitro antimycobacterial activity of compounds derived from (R)- and (S)-2-amino-1-butanol - The crucial role of the configuration.
AID533025	Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as biofilm on 16HBE cell after 24 to 48 hrs by XTT assay	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1223580	Ratio of Ki for CYP3A4.2 (unknown origin) to Ki for CYP3A4.1 (unknown origin)	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID532129	Antifungal activity against Candida lusitaniae	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID581885	Antifungal activity against Candida glabrata isolated from HSCT recipient 270 with acute or chronic GVHD mouth receiving antifungal drug after 108 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405033	Antifungal activity against Sporothrix schenckii PSCC1 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID532142	Antifungal activity against Rhizomucor species	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1204545	Antifungal activity against Candida albicans Strain 15 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1743170	Antifungal activity against Trichophyton mentagrophytes var. interdigitale	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID606215	Antifungal activity against Cryptococcus neoformans ATCC BLS108 after 72 hrs by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID582236	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID322862	Antifungal activity against azole-resistant Aspergillus fumigatus V45/07-CM3819 isolate from patient with chronic granulomatous disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID575195	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 50 mg/kg, po bid administered 1 day after infection for 7 days relative to untreated control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID701453	Antifungal activity against Aspergillus fumigatus	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	The biology and chemistry of antifungal agents: a review.
AID681122	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID545672	Ratio of intracellular to extracellular drug uptake in alveolar macrophages of New Zealand white rabbit infected with Mycobacterium bovis at 1 ug/ml in presence of 5% serum	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID405015	Antifungal activity against Sporothrix schenckii P25013 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1872521	Antifungal activity against Aspergillus fumigatus SANK 10569 by 96-well microplate method	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID405071	Antifungal activity against Candida parapsilosis ATCC 22019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID284103	Antifungal activity against Candida neoformans IM 983036 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID524739	Antimicrobial activity against Fusarium oxysporum after 48 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID584417	Antifungal activity against 12 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID549320	Antifungal activity against Rhizomucor pusillus after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID440325	Antifungal activity against Aspergillus terreus isolated from patient bronchoalveolar lavage fluid after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID575374	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 25 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated contr	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID442522	Antifungal activity against Microsporum gypseum NCPF 580 after 7 days by microbroth dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.
AID555138	Antimicrobial activity against Candida parapsilosis ATCC 22019 by EUCAST broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID1783770	Antifungal activity against Cryptococcus neoformans GIM2.209 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID1059353	Antifungal activity against Candida parapsilosis clinical isolate after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID665068	Antifungal activity against Candida tropicalis after 24 hrs by serial dilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.
AID1743168	Antifungal activity against Trichophyton tonsurans	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID527146	Antifungal activity against Trichophyton mentagrophytes LMGO 09 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID549322	Antifungal activity against Rhizomucor variabilis after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID575461	Antifungal activity against 5 x 10'6 CFU/ml Trichophyton quinckeanum B68683 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID1674367	Clearance in human	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID555606	Antimicrobial activity against Aspergillus niger by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1301911	Inhibition of hedgehog pathway in mouse C3H10T1/2 cells assessed as Gli1 mRNA expression at 1 uM after 24 hrs by qPCR method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID584399	Antifungal activity against 59 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID283201	Susceptibility of Candida glabrata 21231 isolate at 8 ug by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
AID555808	Antimicrobial activity against Mucor spp.by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1265817	Antifungal activity against azole-resistant Candida albicans ATCC 90819 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID1493830	Antifungal activity against Cryptococcus neoformans 32609 after 24 hrs by spectrophotometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.
AID549314	Antifungal activity against Mycocladus corymbifer after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1770961	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID563407	Antifungal activity against Aspergillus tubingensis isolate CM-4688 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID341575	Cmax in children of >6-12 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID420664	Antifungal activity against Trichophyton rubrum by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID519425	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3537 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID745593	Antifungal activity against Trichophyton rubrum SNB-TR1 assessed as growth inhibition after 5 days by CLSI microdilution method	2013	Journal of natural products, May-24, Volume: 76, Issue:5	Antifungal agents from Pseudallescheria boydii SNB-CN73 isolated from a Nasutitermes sp. termite.
AID28233	Fraction ionized (pH 7.4)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1557086	Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1265814	Antifungal activity against azole-resistant Candida albicans ATCC 10231 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID1493831	Antifungal activity against Aspergillus fumigatus 07544 after 24 hrs by spectrophotometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.
AID1898166	Antifungal activity against Candida parapsilosis 660
AID1689822	Antifungal activity against Aspergillus fumigatus ASFU76 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID405044	Antifungal activity against Sporothrix schenckii P1621 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1511962	Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in recombinant mouse sonic hedgehog/oxysterol-induced Gli1 mRNA expression by q-PCR analysis	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties.
AID564268	Effect on sterol composition in Candida albicans isolate 108 harboring erg11 and erg5 double mutant eburicol level after 2 hrs by gas chromatography	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID176374	Efficacy against Aspergillosis fumigatus CF924390 on day 14th after peroral administration in rat	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.
AID424629	Antimicrobial activity against azole-susceptible Candida albicans isolate CA8 co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID532144	Antifungal activity against Absidia species	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID531243	Antifungal activity against Candida parapsilosis assessed as susceptible isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID284109	Antifungal activity against Candida neoformans IM 052470 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID725873	Antifungal activity against Aspergillus fumigatus ASFU19 after 48 hrs by M38 method	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID341544	Apparent volume of distribution in children of >2-6 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID563389	Antifungal activity against Aspergillus niger isolate CM-3506 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID39835	Minimum inhibitory concentration of compound for antifungal activity against Aspergillus fumigatus	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID609307	Antifungal activity against Aspergillus fumigatus JLC 30883 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID559695	Antimicrobial activity against Rhizomucor pusillus after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID572709	Selectivity ratio of Kd for Mycobacterium smegmatis ATCC 700084 CYP164A2 in presence of 0.5 M NaCl to Kd for Mycobacterium smegmatis ATCC 700084 CYP164A2	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID1754265	Antifungal activity against clinical strain Candida parapsilosis by microplate reader assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	A new sulfated triterpene glycoside from the sea cucumber Colochirus quadrangularis, and evaluation of its antifungal, antitumor and immunomodulatory activities.
AID49982	Minimum inhibitory concentration of compound for antifungal activity against Candida glabrata	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID584395	Antifungal activity against 8 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool after 12 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID681128	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID575499	Antifungal activity against Aspergillus fumigatus isolates harboring Cyp51A TR/L98H mutation by EUCAST method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID1157294	Antifungal activity against Cryptococcus neoformans 32609 assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID150755	Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID341574	Half life in children of >2-6 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID323068	Antifungal activity against Cryptococcus neoformans IM 972724 by micro-broth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID1309058	Antifungal activity against Aspergillus terreus ATCC MYA3633 after 48 hrs by CLSI M38-A2 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID555814	Antifungal activity against azole-susceptible Candida albicans 5457 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID543971	AUC (0 to 72 hrs) in human at 15 mg, po pretreated with itraconazole at 200 mg, po qd for 4 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID509099	Antifungal activity against Fonsecaea monophora CBS 117236	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID555816	Antifungal activity against azole-resistant Candida albicans 5674 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID575460	Antifungal activity against 5 x 10'6 CFU/ml Trichophyton rubrum J941704 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID532132	Antifungal activity against Saccharomyces cerevisiae	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID341539	Clearance in infants of 0.6-2 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID602927	Antifungal activity against Candida albicans Y0109 after 24 hrs by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID581892	Antifungal activity against Candida albicans isolated from HSCT recipient 042 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID603348	Antifungal activity against Aspergillus fumigatus clinical isolate by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID551210	Antifungal activity against Fusarium by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID419081	Antifungal activity against Candida krusei ATCC 6258	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID518405	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220K mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID551206	Antifungal activity against Cryptococcus neoformans ATCC BLS108 after 72 hrs by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID563405	Antifungal activity against Aspergillus tubingensis isolate CM-4003 after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID284108	Antifungal activity against Candida neoformans IM 961951 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID1067044	Antifungal activity against Candida glabrata by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID665069	Antifungal activity against Candida parapsilosis after 24 hrs by serial dilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.
AID549315	Antifungal activity against Mycocladus corymbifer after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1330317	Antagonist activity at Cav2.2 in human SH-SY5Y cells assessed as inhibition of KCl/CaCl2-stimulated Ca2+ flux up to 100 uM after 30 mins in presence of nifedipine by Fuo-4 dye based FLIPR assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID582245	Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID531240	Antifungal activity against Candida albicans assessed as susceptible isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID285858	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 1 ug/ml by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID1783065	Antifungal activity against fluconazole-sensitive Candida albicans SC5314 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID509123	Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in lung at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID1059358	Fungicidal activity against Candida parapsilosis by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID565403	Antifungal activity against Rhizopus microsporus IHEM 4770 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID420662	Antifungal activity against Candida parapsilosis by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID531465	Antifungal activity against Candida guilliermondii assessed as susceptible dose-dependent isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID440322	Antifungal activity against Aspergillus fumigatus isolated from patient bronchoalveolar lavage fluid after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID532950	Antifungal activity against Candida albicans isolate O with CAI genotype by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
AID581863	Antifungal activity against Candida albicans isolated from HSCT recipient 262 with acute or chronic GVHD mouth after 115 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID620354	Antifungal activity against Aspergillus fumigatus RCMB 002003 at 30 ug/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID419077	Antifungal activity against Aspergillus flavus SANK 18497	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID480479	Antifungal activity against Trichophyton rubrum after 7 days by serial dilution method	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
AID681127	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID340957	Antifungal activity against Candida lambica isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID405039	Antifungal activity against Sporothrix schenckii P10012 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID575498	Antifungal activity against Aspergillus lentulus isolate	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID424622	Antimicrobial activity against azole-susceptible Candida albicans isolate CA129 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID584387	Antifungal activity against 36 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS pharynx after 48 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405024	Antifungal activity against Sporothrix schenckii P14954 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1904356	Antifungal activity against Candida albicans ATCC SC5314 assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID610069	Antifungal activity against Candida parapsilosis JLC 30365 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID406957	Antifungal activity against fluconazole-resistant Candida albicans isolated from oropharyngeal or vaginal disease patient after 48 hrs by broth microdilution test	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID584599	Antifungal activity against 6 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID609310	Solubility of the compound in water at pH 1.2	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID566882	Antifungal activity against Cryptococcus neoformans by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID285856	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.25 ug/ml by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID532151	Antifungal activity against Scedosporium prolificans	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1595050	Antifungal activity against Aspergillus niger assessed as reduction in fungal cell growth incubated for 72 hrs by broth microdilution method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID405028	Antifungal activity against Sporothrix schenckii MRSS4 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1301915	Antiproliferative activity against mouse MERP MB cells assessed as cell growth inhibition using methyl-[3H]thymidine after 48 hrs by liquid scintillation spectrophotometry	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
AID1770962	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID1223575	Inhibition of CYP3A4.18 (unknown origin)-mediated testosterone 6beta-hydroxylation incubated for 10 mins prior to NADPH addition measured after 20 mins by HPLC-UV analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID467290	Antifungal activity against Microsporum gypseum by serial dilution method after 24 hrs	2009	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20	Discovery of highly potent novel antifungal azoles by structure-based rational design.
AID619765	Antifungal activity against Geotrichum candidum RCMB 052006 at 30 mg/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents.
AID150751	Inhibition of P-glycoprotein using ATPase in MDR1 membranes	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1392809	Antifungal activity against Cryptococcus neoformans cgmcc 2.3161 after 72 hrs by serial dilution method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.
AID341552	Apparent volume of distribution in adolescents of >12-16 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1059345	Antifungal activity against Candida glabrata after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID1204529	Antifungal activity against Trichosporon cutaneum ATCC 28592 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1419504	Antifungal activity against Aspergillus nidulans ATCC 38163 incubated for 48 hrs by CLSI M38-A2 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID532155	Antifungal activity against Fusarium solani	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID584391	Antifungal activity against 16 days cultured Candida glabrata isolated from invasive fungal infected subject blood after 17 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532951	Antifungal activity against Candida albicans isolate V1 with CAI genotype by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
AID565398	Antifungal activity against Rhizopus microsporus CBS 102277 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID531466	Antifungal activity against Candida krusei assessed as susceptible dose-dependent isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID48233	In vitro evaluation of minimum inhibitory concentration against Candida pseudotropicalis 13	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID519448	Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-3147 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1473927	Ratio of drug concentration at steady state in human at 200 mg, po QD for 1 to 2 weeks after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1556209	Antifungal activity against Candida albicans ATCC SC5314 assessed as inhibition of visible microbial growth by NCCLS protocol based method	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents.
AID1877285	Antifungal activity against Candida krusei GIM2.1 assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID655583	Antifungal activity against Candida parapsilosis by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID1783774	Antifungal activity against Aspergillus fumigatus CGMCC3.7795 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID283223	Prolongation of survival in CD1 mouse infected with Coccidioides immitis Silveira administered after 3 days of infection at 10 mg/kg, po bid after 12 days relative to control	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID283228	Effect on fungal burdens in Coccidioides immitis Silveira infected CD1 mouse lung administered after 3 days of infection at 50 mg/kg, po bid after 12 days	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID575208	Antifungal activity against Cunninghamella echinulata UTHSC 01-2298 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID405026	Antifungal activity against Sporothrix schenckii P14954 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID563396	Antifungal activity against Aspergillus niger isolate CM-4004 obtained from after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID584404	Antifungal activity against 3 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID39829	Minimum concentration required to inhibit the growth of Aspergillus fumigatus	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID285874	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID1689829	Antifungal activity against Scedosporium apiospermum SCAP1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID532135	Antifungal activity against Trichosporon inkin	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1059361	Fungicidal activity against Candida albicans by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID1609925	Antifungal activity against Candida albicans SC5314 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID747170	Antimicrobial activity against Candida albicans ATCC 22019 by broth dilution method	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Synthesis and antimicrobial activity of novel amphiphilic aromatic amino alcohols.
AID531467	Antifungal activity against Candida lusitaniae assessed as susceptible dose-dependent isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID541559	Cmax in healthy human plasma at 200 mg, po every 12 hrs for 5 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1770935	Anti-biofilm activity in Candida albicans CPCC400616 assessed as inhibition of biofilm formation incubated for 6 hrs by XTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID1849824	Antifungal activity against Sporothrix schenckii assessed as fungal growth inhibition incubated for 48 hrs by CLSI-based broth microdilution assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID419080	Antifungal activity against Candida parapsilosis ATCC 90018	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID532348	Antifungal activity against Fusarium oxysporum by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID582220	Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1204546	Antifungal activity against Candida albicans Strain 16 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID551208	Antifungal activity against Candida tropicalis by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID118897	In vivo antifungal activity against murine candidosis model after peroral administration with 1 mg/kg for 5 days.(percent protection for 100% mortality with fluconazole-treated group.); not tested	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID319753	Antimicrobial activity against Cryptococcus neoformans ATCC 32609	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID262548	Antifungal activity against Candida tropicalis	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID555573	Antimicrobial activity against Candida kefyr by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID532136	Antifungal activity against Trichosporon asahii	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID246892	Effective dose was measured in mice infected with Trichophyton mentagrophytes	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID565551	Antifungal activity against Rhizopus microsporus IHEM 15210 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID440323	Antifungal activity against Aspergillus versicolor isolated from patient sputum after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID566889	Antifungal activity against Exophiala spinifera by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID245420	Minimum inhibitory concentration against Candida albicans A261 evaluated by in vitro agar diffusion and micro-broth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID1770963	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID555626	Antimicrobial activity against Phialemonium curvatum by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID325038	Antimicrobial activity against Candida albicans P5 after 48 hrs by broth macrodilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID1898172	Antifungal activity against Candida krusei 629
AID405276	Antifungal activity against Sporothrix schenckii P3287 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID249263	Minimum inhibitory concentration against Candida species (n=24)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID1646827	Inhibition of Hedgehog signaling pathway in mouse ASZ001 cells assessed as decrease in Gli1 mRNA expression after 48 hrs by qRT-PCR analysis	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Inhibition of hedgehog signaling by stereochemically defined des-triazole itraconazole analogues.
AID527131	Antifungal activity against Microsporum gypseum LMGO 10 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID415949	Antimicrobial activity against Candida albicans by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID405036	Antifungal activity against Sporothrix schenckii P24255 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID549048	Antifungal activity against Candida albicans CA127 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID519286	Antifungal activity against Candida parapsilosis ATCC 22019 by WIDERYST method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID522130	Antimicrobial activity against Candida glabrata TG162 containing calcineurin deltacnb1 mutant by colorimetric microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata.
AID519444	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3769 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID549050	Antifungal activity against Candida albicans CA10 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID680505	TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 0.1 uM, Itraconazole: 100 uM) in MDR1-expressing LLC-PK1 cells	1999	Biological & pharmaceutical bulletin, Dec, Volume: 22, Issue:12	Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
AID519428	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3599 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID340958	Antifungal activity against Candida norvegensis isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID48961	Tested in vitro for the minimum inhibitory concentration (MIC) against Candida albicans SANK51486	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Synthesis of Sordaricin analogues as potent antifungal agents against Candida albicans.
AID1917557	Induction of apoptosis in human A549 cells assessed as necrotic cells at 30 uM incubated for 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 0.084%)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID1155873	Antifungal activity against Aspergillus fumigatus assessed as growth inhibition after 7 days by serial dilution method	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.
AID1609930	Antifungal activity against fluconazole-resistant Candida albicans 17 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID609894	Antifungal activity against Cryptococcus neoformans BLS108 by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID285867	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.25 ug/ml by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID1689825	Antifungal activity against Rhizopus oryzae RHPOR1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID284102	Antifungal activity against Candida neoformans IM 042074 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID1557088	Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID442523	Antifungal activity against Trichophyton tonsurans NCPF 245 after 7 days by microbroth dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.
AID559691	Antimicrobial activity against Rhizopus oryzae after 24 hrs by broth microdilution checkerboard procedure	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
AID545330	Antimicrobial activity against Candida albicans isolate C after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID341549	Half life in children of >6-12 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID285857	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.5 ug/ml by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID565553	Antifungal activity against Rhizopus microsporus UTHSC 03-1802 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID554950	Inhibition of Candida krusei B2399 Abc1p assessed as fractional inhibitory concentration index at 2.5 ug/ml after 48 hrs by checkerboard susceptibility assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID1689239	Antifungal activity against Candida albicans SS5314 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID519424	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3364 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID555136	Antimicrobial activity against Candida albicans by CLSI M27-A2 broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID415952	Antimicrobial activity against Candida tropicalis by micro-broth dilution method	2009	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6	Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.
AID729314	Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID302123	Antifungal activity against fluconazole-resistant Candida albicans 01010 after 24 hrs	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and antifungal activities of novel 2-aminotetralin derivatives.
AID1557081	Antifungal activity against Candida parapsilosis ATCC 90018 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1334848	Anti-fungal activity against Candida albicans CPCC 400523 by broth microdilution method	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.
AID1898163	Antifungal activity against Candida albicans 305
AID1898173	Antifungal activity against Candida krusei 397
AID1204537	Antifungal activity against Candida albicans Strain 7 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID515015	Antifungal activity against Aspergillus fumigatus by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID555589	Antimicrobial activity against Cryptococcus neoformans var. neoformans by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID322854	Antifungal activity against azole-resistant Aspergillus fumigatus V13/03-CM3272 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1534783	Kinetic solubility of compound in pH 7.4 PBS by LC-MS/MS analysis	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID48801	Minimum concentration required to inhibit the growth of Candida tropicalis	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID531242	Antifungal activity against Candida tropicalis assessed as susceptible isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID581902	Antifungal activity against Candida glabrata isolated from HSCT recipient 807 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1493828	Antifungal activity against Candida parapsilosis 22019 after 24 hrs by spectrophotometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.
AID670446	Antifungal activity against Trichophyton rubrum incubated at 35 degC for 72 hrs by NCCLS based microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of vinyl ether-containing azole derivatives as inhibitors of Trichophyton rubrum.
AID1067042	Antifungal activity against Microsporum gypseum by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID581868	Antifungal activity against Candida glabrata isolated from neutropenic subject 1102 with AML or MDS stool after 26 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID141790	Minimum inhibitory concentration of compound for antifungal activity against Mucosporam canis	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID420667	Antifungal activity against Aspergillus fumigatus by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID285853	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.03 ug/ml by CLSI method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID1204541	Antifungal activity against Candida albicans Strain 11 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1889406	Hepatotoxicity in zebrafish embryos assessed as liver failure by measuring necrotic and decreased liver with non-resorbed yolk at 0.25 uM treated at 6 hpf and measured at 120 hpf by stereomicroscopic analysis	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Unraveling the anti-virulence potential and antifungal efficacy of 5-aminotetrazoles using the zebrafish model of disseminated candidiasis.
AID283224	Prolongation of survival in CD1 mouse infected with Coccidioides immitis Silveira administered after 3 days of infection at 25 mg/kg, po bid after 12 days relative to control	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID1164091	Antifungal activity against Candida tropicalis ATCC 750 by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Synthesis and biological evaluation of a new series of N-acyldiamines as potential antibacterial and antifungal agents.
AID197814	In vitro evaluation of minimum inhibitory concentration against Rhodotorula rubra 16	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID49637	Minimum inhibitory concentration of compound for antifungal activity against Candida albicans 4	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID442521	Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by microbroth dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.
AID340955	Antifungal activity against Candida krusei isolates from grapes and feeding stuffs by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID527143	Antifungal activity against Candida glabrata LMGO 44 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID405014	Antifungal activity against Sporothrix schenckii PSSA81 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID584413	Antifungal activity against 9 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575462	Antifungal activity against 5 x 10'6 CFU/ml Candida albicans B59163 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1204532	Antifungal activity against Candida albicans Strain 2 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID249269	Minimum inhibitory concentration against Trichophyton species (n=80)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID1589576	Inhibition of human ERG	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
AID1474168	Antifungal activity against Candida albicans ATCC SC5314 by broth microdilution assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents.
AID582252	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID341543	Clearance in children of >2-6 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID214279	Minimum inhibitory concentration of compound for antifungal activity against Trichophyton mentagrophytes	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID245450	Minimum inhibitory concentration against Candida tropicalis ATCC750 evaluated by in vitro agar diffusion and microbroth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID341541	Half life in infants of 0.6-2 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID609305	Antifungal activity against Cryptococcus neoformans JLC 50123 by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID424634	Antimicrobial activity against azole-resistant Candida albicans isolate CA15 cotreated with calcineurin signaling inhibitor Tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID405052	Antifungal activity against Sporothrix schenckii PGAC0016 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID584406	Antifungal activity against 25 days cultured Candida glabrata isolated from invasive fungal infected subject blood receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID49630	Minimum concentration required to inhibit the growth of Candida albicans 1	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID1770939	Antifungal activity against Candida tropicalis CGMCC 2.3739 assessed as fungal growth inhibition by CLSI protocol based method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID582999	Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51B gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID1689826	Antifungal activity against Rhizopus oryzae RHPOR2 assessed as reduction in microbial growth after 24 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID551205	Antifungal activity against Candida albicans ATCC Y0109 after 24 hrs by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID49634	Minimum inhibitory concentration of compound for antifungal activity against Candida albicans 2	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID1155871	Antifungal activity against Cryptococcus neoformans assessed as growth inhibition after 72 hrs by serial dilution method	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.
AID575465	Antifungal activity against 5 x 10'6 CFU/ml Candida kefyr B46120 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID537734	Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1204555	Antifungal activity against Candida albicans Strain 25 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID480474	Antifungal activity against Candida albicans after 24 hrs by serial dilution method	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
AID518600	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, A284A mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1877307	Antibiofilm activity against FLC-resistant Candida albicans CPCC400616 assessed as assessed as inhibition of biofilm formation measured at 24 hrs by XTT reduction assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID405042	Antifungal activity against Sporothrix schenckii P1621 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID572696	Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP164A2 in presence of 0.5 M NaCl at pH7.5	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID582241	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1589579	Kinetic solubility of the compound in PBS at pH 7.4 by by UPLC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1204556	Antifungal activity against Candida albicans Strain 26 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID245494	Minimum inhibitory concentration against Candida parapsilosis ATCC 22019 evaluated by in vitro agar diffusion and micro-broth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID1419499	Antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-1003 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID582248	Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID745594	Antifungal activity against Aspergillus fumigatus SNB-AF1 assessed as growth inhibition after 24 hrs by CLSI microdilution method	2013	Journal of natural products, May-24, Volume: 76, Issue:5	Antifungal agents from Pseudallescheria boydii SNB-CN73 isolated from a Nasutitermes sp. termite.
AID519061	Antifungal activity against Candida albicans assessed as resistant isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1743173	Antifungal activity against Candida albicans	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID549045	Antifungal activity against Candida albicans CA2 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID1309046	Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1413324	Antifungal activity against Cryptococcus neoformans H99	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID606216	Antifungal activity against Aspergillus fumigatus after 7 days by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID1689216	Antifungal activity against Candida glabrata ATCC MYA-2950 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID245429	Minimum inhibitory concentration against Candida krusei ATCC 6528 evaluated by in vitro agar diffusion and micro-broth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID519435	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4428 obtained from skin of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1059359	Fungicidal activity against Candida glabrata by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID518615	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing wild type cyp51A gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID701448	Antifungal activity against Microsporum lauosum	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	The biology and chemistry of antifungal agents: a review.
AID584602	Antifungal activity against 19 days cultured Candida krusei isolated from invasive fungal infected subject blood receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1265820	Antifungal activity against azole-resistant Candida albicans MYA-1003 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID545329	Antimicrobial activity against Candida albicans isolate R after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID582247	Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID509121	Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in kidney at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID565402	Antifungal activity against Rhizopus microsporus IHEM 10123 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID609312	Cmax in rat at 10 mg/kg, po administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID531248	Antifungal activity against Candida glabrata assessed as resistant isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID563416	Antifungal activity against Aspergillus niger isolate CM-4262 after 48 hrs by EUCAST broth dilution method Ophthalmic	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1546101	Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs by agar disk diffusion method	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Current scenario of tetrazole hybrids for antibacterial activity.
AID532346	Antifungal activity against Penicillium species by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID546081	Antifungal activity against Candida intermedia isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID582223	Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID436744	Antifungal activity against Microsporum gypseum after 7 days by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID1254076	Antifungal activity against Candida albicans 7535 by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID584409	Antifungal activity against -3 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1872500	Antifungal activity against Candida glabrata	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1877306	Antibiofilm activity against FLC-resistant Candida albicans CPCC400616 assessed as assessed as inhibition of biofilm formation measured at 18 hrs by XTT reduction assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID581897	Antifungal activity against Candida glabrata isolated from neutropenic subject 1331 with AML or MDS pharynx receiving antifungal drug after 21 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575206	Antifungal activity against Cunninghamella echinulata FMR 10974 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID655582	Antifungal activity against Cryptococcus neoformans after 72 hrs by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID118765	In vivo antifungal activity against murine candidosis model after peroral administration with 0.5 mg/kg at various time intervals. (percent protection for 100% mortality with untreated group)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID563408	Antifungal activity against Aspergillus foetidus isolate CM-5264 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1549136	Antifungal activity against azole-sensitive Candida albicans SC5314 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID545675	Ratio of cellular uptake in alveolar macrophages to plasma of healthy human at 14 doses of 400 mg/kg, twice daily	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID519447	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3914 obtained from nail of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1067049	Antifungal activity against Candida albicans Y0109 after 24 hrs by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID1493832	Antifungal activity against Trichophyton rubrum Cmccftla after 24 hrs by spectrophotometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.
AID1783064	Antifungal activity against Cryptococcus neoformans H99 assessed as inhibition of fungal growth incubated for 72 hrs by two-fold serial microdilution method	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID1357633	Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by microbroth dilution assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID322753	Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID1557077	Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1309053	Antifungal activity against Candida glabrata ATCC 2001 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID532150	Antifungal activity against Cunninghamella species	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID283205	Antimicrobial activity against Candida glabrata 21231 isolate by E-test	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
AID48793	In vitro evaluation of minimum inhibitory concentration against Candida tropicalis 2.11	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532559	Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 2 ug/ml (Rvb = 0.144%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID515011	Antifungal activity against Candida parapsilosis by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID564269	Antifungal activity against Candida albicans isolate 6 after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
AID531245	Antifungal activity against Candida krusei assessed as susceptible isolates after 48 hrs by CLSI method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
AID1783773	Antifungal activity against Cryptococcus neoformans CGMCC2.3161 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID322856	Antifungal activity against azole-resistant Aspergillus fumigatus V28/78-CM3275 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID575477	Antifungal activity against 10'7 CFU/ml Candida albicans B2630 infected in vulvovaginitis rat model assessed as fungal burden at 5 mg/kg, po SID	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID1265819	Antifungal activity against azole-resistant Candida albicans MYA-1237 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID633996	Antifungal activity against Saccharomyces cerevisiae ATCC 24657 assessed as growth inhibition at 90.7 uM after 24 hrs by agar plate bioassay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID436743	Antifungal activity against Aspergillus fumigatus after 7 days by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID150752	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID581861	Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID522126	Antimicrobial activity against deltacrz1 mutant containing Candida glabrata TG173 complemented with CRZ1 gene by colorimetric microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata.
AID405097	Antimicrobial activity against Absidia sp. after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID563402	Antifungal activity against Aspergillus niger isolate CM-5095 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1157295	Antifungal activity against Aspergillus fumigatus 07544 assessed as growth inhibition by automatic microplate reader analysis	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Polyhydroxy cyclohexanols from a Dendrodochium sp. fungus associated with the sea cucumber Holothuria nobilis Selenka.
AID1419500	Antifungal activity against Candida glabrata ATCC 2001 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID519445	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-2270 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1204525	Antifungal activity against Candida parapsilosis by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID584597	Antifungal activity against 1 day cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1309050	Antifungal activity against Candida albicans ATCC MYA-2310 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID525142	Antifungal activity against Fusarium thapsinum by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID1877286	Antifungal activity against Aspergillus fumigatus CGMCC3.7795 assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID1491244	Antifungal activity against Candida tropicalis cgmcc 2.3739 by broth microdilution method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.
AID49631	Minimum inhibitory concentration of compound for antifungal activity against Candida albicans 1	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID1770931	Ratio of MFC for fungicidal activity against Candida albicans ATCC SC5314 to MIC for Antifungal activity against Candida albicans ATCC SC5314	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID405094	Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID545151	Antimicrobial activity against Candida albicans isolate R after 48 hrs by EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID341555	Clearance in human at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID518401	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G138C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1474170	Antifungal activity against Cryptococcus neoformans cgmcc 2.3161 by broth microdilution assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents.
AID1917559	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 30 uM incubated for 24 hrs by Annexin V-FITC/PI staining based flow cytometric analysis (Rvb = 1.40%)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Design, synthesis and activity evaluation of Hedgehog inhibitor Itraconazole derivatives in A549 cells.
AID575456	Cytotoxicity against human MRC5 cells	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID509389	Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in brain at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID285865	Antimicrobial susceptibility of Pichia anomala from nosocomial fungemia patient assessed as percent susceptible isolates at 0.06 ug/ml by EUCAST method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
AID525595	Antibacterial activity against Fluconazole resistant Candida albicans DSY3606 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-5) genotype by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID405110	Antimicrobial activity against Absidia sp. assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID575377	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 50 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated contr	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID572695	Binding affinity to Mycobacterium smegmatis ATCC 700084 CYP164A2 at pH7.5	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.
AID518599	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, Q141H mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID341576	Tmax in children of >6-12 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID440324	Antifungal activity against Aspergillus versicolor isolated from patient skin after 48 hrs by broth microdilution method	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp.
AID584411	Antifungal activity against 2 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID729310	Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID532141	Antifungal activity against Aspergillus niger	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID484287	Aggregation-based binding affinity to beta-lactamase AmpC at 200 uM in fed state simulated intestinal fluid after 30 mins by silver staining in presence of 2% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1597996	Antifungal activity against Candida albicans after 24 hrs by NCCLS protocol based method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.
AID419071	Antifungal activity against Candida albicans SANK 51486	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID405061	Antifungal activity against Sporothrix schenckii P30915 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID48051	Minimum inhibitory concentration of compound for antifungal activity against Candida parapsilosis	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID554705	Antimicrobial activity against Candida krusei B2399 after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID563392	Antifungal activity against Aspergillus niger isolate CM-3586 obtained from catheter of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID532557	Antifungal activity against Saccharomyces cerevisiae BY4741 assessed as growth rate at 16 ug/ml (Rvb = 0.144%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID554710	Antimicrobial activity against Candida krusei NZCDC 90.147 after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID518607	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, L358L, C454C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID563418	Antifungal activity against Aspergillus tubingensis isolate CM-4897 obtained from blood culture after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID1849833	Antifungal activity against Sporothrix brasiliensis assessed as fungal growth inhibition incubated for 48 hrs by CLSI-based broth microdilution assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID1534781	Half life in human liver microsomes at 1 uM by LC-MS/MS analysis	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID575365	Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in brain at 50 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID554713	Antimicrobial activity against Candida krusei NZCDC 89.021 after 48 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID1557087	Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID546077	Antifungal activity against Candida pelliculosa isolated from candidemia patient by AFST-EUCAST microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID555822	Ratio of MIC50 for Candida albicans 5674 to MIC50 for cdr2/cdr2 deficient Candida albicans STY7	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance.
AID575478	Antifungal activity against 10'7 CFU/ml Candida albicans B2630 infected in vulvovaginitis rat model assessed as fungal burden at 10 mg/kg administered tropically twice daily measured after 3 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID575457	Antifungal activity against 5 x 10'6 CFU/ml Microsporum canis B68128 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID575201	Antifungal activity against Cunninghamella bertholletiae FMR-9598 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1589584	Substrate activity at P-glycoprotein in human Caco2 cells assessed as efflux ratio by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
AID1309052	Antifungal activity against Candida albicans ATCC MYA-1003 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1658277	Inhibition of NPC1 in HUVEC cells assessed as accumulation of cholesterol in perinuclear structure at 0.2 uM incubated for 24 hrs by filipin staining based confocal microscopy analysis
AID284107	Antifungal activity against Candida neoformans IM 031706 after 48 hrs	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID1524625	Antifungal activity against Candida albicans 7535 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID665070	Antifungal activity against Cryptococcus neoformans after 72 hrs by serial dilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.
AID581881	Antifungal activity against Candida glabrata isolated from HSCT recipient 474 with acute or chronic GVHD mouth receiving antifungal drug after 124 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405035	Antifungal activity against Sporothrix schenckii PSCC1 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1223576	Ratio of Ki for CYP3A4.7 (unknown origin) to Ki for CYP3A4.1 (unknown origin)	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
AID29925	Volume of distribution in man (IV dose)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID249273	Minimum inhibitory concentration against Trichophyton mentagrophytes (n=20)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID519059	Antifungal activity against Candida parapsilosis assessed as susceptible isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID575754	Antimicrobial activity against Aspergillus fumigatus AF293	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID1204538	Antifungal activity against Candida albicans Strain 8 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID532331	Antifungal activity against Aspergillus terreus by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID549317	Antifungal activity against Cunninghamella bertholletiae after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID405112	Antimicrobial activity against Cunninghamella sp. assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1334864	Inhibition of CYP3A4 in human liver microsomes assessed as reduction in nifedipine oxidation incubated for 10 mins	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID405060	Antifungal activity against Sporothrix schenckii P30915 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID554706	Antimicrobial activity against Candida krusei IFO0011 after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID405062	Antifungal activity against Sporothrix schenckii P30915 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID565399	Antifungal activity against Rhizopus microsporus IHEM 18821 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID405017	Antifungal activity against Sporothrix schenckii P25013 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1674376	AUC at steady state in human administered as single dose	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID563403	Antifungal activity against Aspergillus tubingensis isolate CM-3123 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID340950	Antifungal activity against Candida albicans isolates from HIV infected patient during fluconazole therapy by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID518594	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, S297T, F495 mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1067046	Antifungal activity against Candida parapsilosis by micro-broth dilution method	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.
AID1180168	Antifungal activity against Candida albicans by broth macrodilution method	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Design and optimization of highly-selective fungal CYP51 inhibitors.
AID1059355	Antifungal activity against Candida albicans clinical isolate after 20 hrs by agar dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID768327	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID1254072	Antibacterial activity against Escherichia coli CCARM 1356 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID405041	Antifungal activity against Sporothrix schenckii P10012 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID648419	Antifungal activity against Aspergillus fumigatus NCIM 902 at MIC after 3 to 4 days	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID581884	Antifungal activity against Candida glabrata isolated from HSCT recipient 270 with acute or chronic GVHD mouth after 108 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID545152	Antimicrobial activity against Candida albicans isolate R after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID405054	Antifungal activity against Sporothrix schenckii PJRC002 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1474169	Antifungal activity against Candida albicans CPCC 400523 by broth microdilution assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents.
AID56597	Compound was tested for inherent antifungal geometric minimum inhibitory concentration (GMMIC) against Dermatophytes in serial dilution from 64 to 0.0313 ug/mL	2002	Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13	Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.
AID725875	Antifungal activity against Aspergillus fumigatus ASFU17 after 48 hrs by M38 method	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID714985	Antifungal activity against Saccharomyces cerevisiae MYH 500 assessed as growth inhibition in presence of 30 mM sodium fluoride after 9 hrs	2012	Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9	Fluoride enhances the activity of fungicides that destabilize cell membranes.
AID249272	Minimum inhibitory concentration against Epidermophyton floccosum (n=12)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID246926	Effective dose was measured in guinea pig infected with Microsporum canis on 7th day	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID341564	Tmax in infants of 0.6-2 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1689213	Antifungal activity against fluconazole-resistant Candida auris 383 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID249271	Minimum inhibitory concentration against Trichophyton tonsurans (n=18)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID655587	Antifungal activity against Aspergillus fumigatus by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID405063	Antifungal activity against Sporothrix schenckii P3287 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID753512	Antidermatophytic activity against Microsporum gypseum isolate after 7 days by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID575454	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 50 mg/kg, po bid administered 1 day post infection measured after 4 to 5 days relative to untreated cont	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID341538	Cmax in infants of 0.6-2 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID532531	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as accumulation of 14-alpha-methylergosta-8,24(28)-dien-3beta-6alpha-diol at 8 ug/ml	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID575497	Antifungal activity against Aspergillus nidulans isolate	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID1071690	Antifungal activity against Candida parapsilosis ATCC 22019 assessed as growth inhibition by microdliution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Antifungal ether diglycosides from Matayba guianensis Aublet.
AID1076033	Antifungal activity against Candida parapsilosis ATCC 22019 by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID50296	Minimum inhibitory concentration of compound for antifungal activity against Candida krusei	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID575203	Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID176378	Efficacy against Candida albicans CY1002 on day 14th after peroral administration in rat	2003	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2	Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole.
AID1609929	Antifungal activity against Candida parapsilosis GIM 2.190 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID519441	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3764 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID371232	Antimicrobial activity against Candida krusei ATCC 6258 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID584589	Antifungal activity against 15 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1413335	Antifungal activity against resistant Candida parapsilosis	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID581874	Antifungal activity against Candida glabrata isolated from neutropenic subject 1497 with AML or MDS pharynx after 61 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1155875	Antifungal activity against Microsporum gypseum assessed as growth inhibition by serial dilution method	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.
AID432802	Antifungal activity against Sporothrix mexicana after 72 hrs by microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro antifungal susceptibilities of five species of sporothrix.
AID1334847	Anti-fungal activity against Candida albicans SC5314 by broth microdilution method	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies.
AID1309049	Antifungal activity against Candida albicans ATCC MYA-90819 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID563401	Antifungal activity against Aspergillus tubingensis isolate CM-5094 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID575066	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 25 mg/kg, po bid administered 1 day after infection for 7 days relative to untreated control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID322852	Antifungal activity against azole-resistant Aspergillus fumigatus M03/669-CM2627 isolate from patient by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID584590	Antifungal activity against 43 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID405032	Antifungal activity against Sporothrix schenckii P24223 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1556212	Antifungal activity against Aspergillus fumigatus CGMCC 3.7795 assessed as inhibition of visible microbial growth by NCCLS protocol based method	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents.
AID519058	Antifungal activity against Candida krusei assessed as susceptible isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID768337	Antifungal activity against Aspergillus fumigatus ATCC 204305 after 48 hrs	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID1204536	Antifungal activity against Candida albicans Strain 6 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1586469	Antifungal activity against Histoplasma capsulatum G217B after 10 to 14 days by microscopic method	2018	Journal of natural products, 12-28, Volume: 81, Issue:12	Onydecalins, Fungal Polyketides with Anti- Histoplasma and Anti-TRP Activity.
AID1511951	Inhibition of Hedgehog signaling pathway in mouse ASZ001 cells assessed as decrease in Gli1 mRNA expression after 48 hrs by qRT-PCR analysis	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties.
AID584596	Antifungal activity against 177 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID532534	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as accumulation of lanosterol at 8 ug/ml (Rvb = 23+/- 1.08 %)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID1491245	Antifungal activity against Aspergillus fumigatus GIM 3.524 by broth microdilution method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.
AID584587	Antifungal activity against 111 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID541566	AUC (0 to 24 hrs) in healthy human lung epithelial lining fluid at 200 mg, po every 12 hrs for 5 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1872501	Antifungal activity against Candida krusei	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID45494	In vitro evaluation of minimum inhibitory concentration against Candida albicans 76	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID405047	Antifungal activity against Sporothrix schenckii SSA29 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID322550	Antifungal activity against Microsporum gypseum after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID1524624	Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID1283997	Antifungal activity against Candida albicans ATCC 10231 by M27-A3 protocol-based broth microdilution method	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.
AID1283998	Antifungal activity against Candida tropicalis ATCC 13803 by M27-A3 protocol-based broth microdilution method	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.
AID1061738	Antimicrobial activity against Trichophyton rubrum by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID1164093	Antifungal activity against Candida parapsilosis ATCC 22019 by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19	Synthesis and biological evaluation of a new series of N-acyldiamines as potential antibacterial and antifungal agents.
AID518601	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, L339L mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID747168	Antimicrobial activity against Candida parapsilosis ATCC 90030 by broth dilution method	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Synthesis and antimicrobial activity of novel amphiphilic aromatic amino alcohols.
AID537736	Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1898178	Antifungal activity against Candida auris 887
AID294855	Antifungal activity against Microsporum gypseum after 7 days by micro-broth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID714984	Antifungal activity against Saccharomyces cerevisiae MYH 500 assessed as growth inhibition in presence of 80 mM sodium fluoride after 9 hrs	2012	Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9	Fluoride enhances the activity of fungicides that destabilize cell membranes.
AID584592	Antifungal activity against -2 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525594	Antibacterial activity against Fluconazole resistant Candida albicans DSY3706 containing tac1delta/delta ERG11-1/ERG11-1 genotype by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID1770933	Anti-biofilm activity in Candida albicans CPCC400616 assessed as inhibition of biofilm formation incubated for 24 hrs by XTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID584598	Antifungal activity against 6 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1557084	Antifungal activity against Candida dubliniensis T-99 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1783069	Antifungal activity against fluconazole-sensitive Candida albicans 10061 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID405040	Antifungal activity against Sporothrix schenckii P10012 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID581876	Antifungal activity against Candida glabrata isolated from neutropenic subject 1491 with AML or MDS pharynx after 23 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID554717	Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID582235	Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving posaconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1076026	Antifungal activity against Candida sp. clinical isolate 12485 derived from urine by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1597997	Antifungal activity against Candida tropicalis after 24 hrs by NCCLS protocol based method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.
AID609892	Antifungal activity against Candida parapsilosis by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID50295	Minimum concentration required to inhibit the growth of Candida krusei	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID1549139	Antifungal activity against azole-resistant Candida albicans 4108 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID532161	Antifungal activity against Candida albicans by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID655580	Antifungal activity against Candida albicans SC5314 after 24 hrs by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID1689827	Antifungal activity against Mucor circinelloides MURI1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID341567	Cmax in human at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID524740	Antimicrobial activity against Fusarium subglutinans after 48 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID1898169	Antifungal activity against Candida tropicalis 112936
AID518595	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, F495I mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1076021	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID1689227	Antifungal activity against Aspergillus fumigatus NR 35304 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID532130	Antifungal activity against Candida tropicalis	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1059348	Fungicidal activity against Candida parapsilosis clinical isolate by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID606212	Antifungal activity against Candida albicans ATCC Y0109 after 24 hrs by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
AID1595045	Antifungal activity against Candida glabrata assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID532045	Antifungal activity against Lichtheimia ornata clinical isolate after 24 hrs by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
AID725877	Antifungal activity against Aspergillus fumigatus ASFU13 after 48 hrs by M38 method	2013	ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2	Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.
AID565400	Antifungal activity against Rhizopus microsporus IHEM 13267 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID602928	Antifungal activity against Candida tropicalis by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID1254073	Antibacterial activity against Pseudomonas aeruginosa 2742 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID509388	Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in kidney at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID1413315	Antifungal activity against Cryptococcus neoformans 90-26	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID307628	Antifungal activity against Aspergillus fumigatus AF980003 by alamar blue assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety.
AID575459	Antifungal activity against 5 x 10'6 CFU/ml Trichophyton rubrum B68183 by resazurin based fluorimetry assay	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID581894	Antifungal activity against Candida albicans isolated from HSCT recipient 928 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1180174	Selectivity index, ratio of IC50 for human hepatocytes CYP3A4 to MIC for Trichophyton rubrum	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Design and optimization of highly-selective fungal CYP51 inhibitors.
AID420666	Antifungal activity against Microsporum gypseum by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1911627	Antifungal activity against Aspergillus fumigatus shjt40 assessed as fungal growth inhibition by broth microdilution assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Development of Lipo-γ-AA Peptides as Potent Antifungal Agents.
AID768339	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Candida krusei ATCC 6258	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID581883	Antifungal activity against Candida glabrata isolated from HSCT recipient 975 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1330316	Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID424619	Antimicrobial activity against azole-susceptible Candida albicans isolate CA8 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1595074	Antifungal activity against Trichophyton mentagrophytes assessed as reduction in fungal cell growth incubated for 3 to 4 days by disk diffusion method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID549327	Antifungal activity against Actinomucor spp. after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID1689223	Antifungal activity against Cryptococcus neoformans NR48770 assessed as reduction in fungal growth incubated for 48 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID584405	Antifungal activity against 23 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID323075	Antifungal activity against Cryptococcus neoformans IM 961951 by micro-broth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID555137	Antimicrobial activity against Candida parapsilosis ATCC 22019 by CLSI M27-A2 broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID532329	Antifungal activity against Geotrichum candidum by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID609325	Oral bioavailability in rat at 10 mg/kg, administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID736605	Antifungal activity against azole-resistant Candida albicans clinical isolate 7.O.A assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID1419497	Antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2310 incubated for 48 hrs by modified CLSI M27-A3 protocol based method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Novel alkylated azoles as potent antifungals.
AID532553	Antifungal activity against Saccharomyces cerevisiae BY4741 harboring human CYP51 assessed as growth rate at 0.5 ug/ml (Rvb = 0.157%)	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID341551	Clearance in adolescents of >12-16 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID679463	TP_TRANSPORTER: inhibition of Daunorubicin transport in G185 cells	2002	Antimicrobial agents and chemotherapy, Jan, Volume: 46, Issue:1	Interaction of common azole antifungals with P glycoprotein.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID543972	Cmax in human at 15 mg, po pretreated with itraconazole at 200 mg, po qd for 4 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID537733	Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID648413	Antifungal activity against recultured Penicillium marneffei at MIC after 3 to 4 days	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID371237	Antimicrobial activity against Aspergillus fumigatus SANK 18497 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID246929	Effective dose was measured in guinea pig infected with Microsporum canis on 14th day	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID532351	Antifungal activity against Bipolaris australiensis by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1609933	Antifungal activity against fluconazole-resistant Candida albicans 904 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID1901374	Toxicity in Galleria mellonella larvae assessed as melanization of larvae at 0.23 ug/ml measured every 24 hrs upto 5 days relative to control	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Tetrazole derivatives bearing benzodiazepine moiety-synthesis and action mode against virulence of Candida albicans.
AID341133	Antifungal activity against sSaccharomyces cerevisiae isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID1204558	Antifungal activity against Candida albicans Strain 28 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID340952	Antifungal activity against Candida albicans isolates by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID73613	The compound was tested in vitro for antifungal activity against 6 filamentous fungi.	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
AID522128	Antimicrobial activity against calcineurin deltacnb1 mutant containing Candida glabrata TG163 complemented with CNB1 gene by colorimetric microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Roles of calcineurin and Crz1 in antifungal susceptibility and virulence of Candida glabrata.
AID341540	Apparent volume of distribution in infants of 0.6-2 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID575752	Antimicrobial activity against Aspergillus fumigatus CEA10	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID1549140	Antifungal activity against azole-resistant Candida tropicalis 5008 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID341542	Cmax in children of >2-6 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID518616	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G54E mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID262552	Antifungal activity against Trichophyton rubrum	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID1413333	Antifungal activity against Candida albicans B-311	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID1415220	Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 5 uM after 24 hrs by matrigel assay relative to control	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition.
AID519426	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3538 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID428913	Antifungal activity against Cryptococcus neoformans ATCC 24067 after 72 hrs by NCCLS M27A method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Voriconazole inhibits melanization in Cryptococcus neoformans.
AID1770940	Antifungal activity against Cryptococcus neoformans CGMCC2.3161 assessed as fungal growth inhibition by CLSI protocol based method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID519446	Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-4060 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1595072	Antifungal activity against Aspergillus fumigatus NCIM 902 assessed as reduction in fungal cell growth incubated for 3 to 4 days by disk diffusion method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID554711	Antimicrobial activity against Candida krusei B2399 after 48 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID551207	Antifungal activity against Candida parapsilosis by broth microdilution method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New azoles with antifungal activity: Design, synthesis, and molecular docking.
AID1204530	Antifungal activity against Rhizopus oryzae ATCC 10329 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID575487	Antifungal activity against azole-susceptible Aspergillus fumigatus isolate CM-237 assessed as fungal growth at 4 mg/l relative to control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
AID1254069	Antibacterial activity against Staphylococcus aureus 503 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID405057	Antifungal activity against Sporothrix schenckii P14036 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID655586	Antifungal activity against Trichophyton rubrum by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID519442	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3740 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID1904363	Antifungal activity against Aspergillus fumigatus CGMCC 3.7795 assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID39390	In vitro evaluation of minimum inhibitory concentration against Aspergillus flavus 19	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID581889	Antifungal activity against Candida albicans isolated from HSCT recipient 031 with acute or chronic GVHD mouth receiving antifungal drug after 109 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1265818	Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2310 after 48 hrs by microbroth dilution method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.
AID603345	Antifungal activity against Trichophyton rubrum clinical isolate by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID563393	Antifungal activity against Aspergillus niger isolate CM-3636 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID294848	Antifungal activity against Candida albicans ATCC Y0109 after 24 hrs by micro-broth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID1204524	Antifungal activity against Candida krusei by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID549324	Antifungal activity against Cunninghamella spp. after 24 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
AID581896	Antifungal activity against Candida glabrata isolated from neutropenic subject 1331 with AML or MDS pharynx after 21 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID371227	Antimicrobial activity against Candida albicans SANK 51486 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID519062	Antifungal activity against Candida glabrata assessed as resistant isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID603261	Antifungal activity against Candida tropicalis clinical isolate by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID768324	Antifungal activity against Candida parapsilosis ATCC 22019 at > MIC up to 24 hrs by time kill study	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID1059360	Fungicidal activity against Candida tropicalis by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID566878	Antifungal activity against Candida parapsilosis by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID681120	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID545673	Ratio of intracellular to extracellular drug uptake in alveolar macrophages of New Zealand white rabbit infected with Mycobacterium bovis at 1 ug/ml in presence of 100% serum	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Intracellular concentrations of posaconazole in different compartments of peripheral blood.
AID554724	Fold resistant, ratio of MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Candida krusei ERG11C to MIC for Saccharomyces cerevisiae isolate ADdelta overexpressing Abc1p	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID609889	Antifungal activity against Candida albicans SC5314 by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.
AID1904359	Antifungal activity against Cryptococcus neoformans CGMCC 2.3161 assessed as fungal growth inhibition by CLSI based serial microbroth dilution method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.
AID581887	Antifungal activity against Saccharomyces cerevisiae isolated from HSCT recipient 513 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1674375	Oral bioavailability in human	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID371228	Antimicrobial activity against Candida albicans TIMM 3164 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID648412	Antifungal activity against recultured Penicillium marneffei by serial plate dilution method	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID1413334	Antifungal activity against Candida albicans 94-2181	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID581871	Antifungal activity against Candida glabrata isolated from neutropenic subject 1318 with AML or MDS stool receiving antifungal drug after 36 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID549053	Antifungal activity against Candida albicans CA138 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID262547	Antifungal activity against Candida parapsilosis	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
AID1076032	Antifungal activity against Candida sp. clinical isolate 13184 derived from high vaginal swabs by microbroth dilution method	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	Synthesis and anti-Candidal activity of N-(4-aryl/cyclohexyl)-2-(pyridine-4-yl carbonyl) hydrazinecarbothioamide.
AID655585	Antifungal activity against Candida kefyr by microbroth dilution method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.
AID1689218	Antifungal activity against Candida parapsilosis CAB 502638 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID519432	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4415 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID519434	Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4426 obtained from sputum of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID563420	Antifungal activity against Aspergillus foetidus isolate CM-4995 obtained from prosthesis after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID508313	Antifungal activity against Aspergillus fumigatus isolate V52-35 harboring TR L98H mutation in Cyp51A protein by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
AID1658273	Inhibition of NPC1/VDAC1 in HUVEC cells assessed as reduction in cell proliferation pretreated for 24 hrs followed by [3H]thymidine incorporation by scintillation counter method
AID119038	Tested in vivo for anti-candida activity in mice model 1 (dose:0.5 mg/kg, fluconazole-treated group)	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
AID582237	Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving posaconazole assessed as maximum MIC by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1674368	Unbound clearance in human	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID634087	Antifungal activity against Candida albicans assessed as morphogenetic transformation after 3 hrs by phase-contrast microscopy	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID555139	Antimicrobial activity against Candida krusei ATCC 6258 by CLSI M27-A2 broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
AID436745	Antifungal activity against Candida parapsilosis after 24 hrs by serial dilution method	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	New azoles with potent antifungal activity: design, synthesis and molecular docking.
AID340949	Antifungal activity against Candida albicans isolates from HIV infected patient before fluconazole therapy by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID584595	Antifungal activity against 176 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID566887	Antifungal activity against Aspergillus terreus by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID532148	Antifungal activity against Mucor hiemalis	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1491241	Antifungal activity against Candida albicans CPCC 400523 by broth microdilution method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.
AID424636	Antimicrobial activity against azole-resistant Candida albicans isolate CA135 cotreated with calcineurin signaling inhibitor Tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID768342	Antifungal activity against Candida krusei ATCC 6258 after 24 hrs	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antifungal activity of terpenyl-1,4-naphthoquinone and 1,4-anthracenedione derivatives.
AID545166	Antimicrobial activity against Candida albicans isolate C after 48 hrs by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
AID323071	Antifungal activity against Cryptococcus neoformans IM 00319 by microbroth dilution method	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID1689215	Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal growth incubated for 24 hrs by CLSI based broth microdilution method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Oxadiazolylthiazoles as novel and selective antifungal agents.
AID325037	Antimicrobial activity against Candida albicans SC5314 after 48 hrs by broth macrodilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID405029	Antifungal activity against Sporothrix schenckii MRSS4 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID603344	Antifungal activity against Cryptococcus neoformans ATCC BLS108 after 72 hrs by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and molecular docking studies of novel triazole as antifungal agent.
AID701451	Antifungal activity against Candida tropicalis	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	The biology and chemistry of antifungal agents: a review.
AID1898162	Antifungal activity against Candida albicans 14#
AID602926	Antifungal activity against Candida albicans SC5314 after 24 hrs by micro-broth dilution method	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
AID1254067	Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID405056	Antifungal activity against Sporothrix schenckii PJRC002 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1595049	Antifungal activity against Candida tropicalis assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method	2019	European journal of medicinal chemistry, May-15, Volume: 170	Tetrazole hybrids and their antifungal activities.
AID47895	Minimum concentration required to inhibit the growth of Candida parapsilosis	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity.
AID1634357	Antifungal activity against Candida albicans ATCC SC5314 assessed as inhibition of visible microbe growth by broth microdilution method	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents.
AID519443	Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-4328 obtained from cornea of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID532133	Antifungal activity against Cryptococcus neoformans var. neoformans	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID584396	Antifungal activity against 13 days cultured Candida krusei isolated from invasive fungal infected subject blood after 12 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID575747	Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme A expressed in Escherichia coli	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID294849	Antifungal activity against Candida parapsilosis ATCC 0306392 after 7 days by micro-broth dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).
AID575202	Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID527134	Antifungal activity against Microsporum canis LMGO 02 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID525590	Antibacterial activity against azole-susceptible Candida albicans DSY294 by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID665071	Antifungal activity against Candida krusei after 24 hrs by serial dilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.
AID419075	Antifungal activity against Cryptococcus neoformans TIMM 1855	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID484389	Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 20 uM by dynamic light scattering assay in presence of 1% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID420661	Antifungal activity against Cryptococcus neoformans ATCC 32609 after 72 hrs by micro-broth dilution method	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID1204528	Antifungal activity against Aspergillus fumigatus 16907 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID582801	Antifungal activity against Candida albicans isolate 490 harboring ERG3 D147G, T330A, A351V and ERG11 F72S, T229A, E266D, N440S, V488I, R523G mutant genes by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID1674370	Unbound volume of distribution at steady state in human	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
AID582796	Antifungal activity against Candida albicans isolate 6 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID510817	Antifungal activity against Aspergillus fumigatus ATCC 204305 after 24 hrs by AFSTEUCAST assay	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID1634360	Antifungal activity against Candida tropicalis cgmcc 2.3739 assessed as inhibition of visible microbe growth by broth microdilution method	2019	Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17	Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents.
AID319752	Antimicrobial activity against Candida tropicalis isolates	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
AID419074	Antifungal activity against Candida tropicalis ATCC 750	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID1357635	Antifungal activity against Cryptococcus gattii ATCC 32608 after 72 hrs by microbroth dilution assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID1783068	Antifungal activity against fluconazole-sensitive Candida albicans 4108 assessed as inhibition of fungal growth	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
AID575200	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1898161	Antifungal activity against Candida albicans 162
AID581890	Antifungal activity against Candida albicans isolated from HSCT recipient 462 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID1309055	Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID1877281	Antifungal activity against Candida tropicalis CGMCC 2.3739 assessed as fungal growth inhibition by NCCLS protocol based method	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.
AID419078	Antifungal activity against Candida albicans ATCC 24433	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID341546	Cmax in children of >6-12 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID563579	Cmin in healthy human plasma before initiation of 3 mg/kg QD	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.
AID289593	Antifungal activity against Aspergillus fumigatus by serial plate dilution method	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis of some bioactive 2-bromo-5-methoxy-N'-[4-(aryl)-1,3-thiazol-2-yl]benzohydrazide derivatives.
AID521970	Antibacterial activity against Fluconazole resistant Candida albicans DSY3752 containing (TAC1-5/TAC1-5 ERG11-1/ERG11-1) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID519285	Antifungal activity against Candida parapsilosis ATCC 22019 by CLSI M27-A2 microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID532149	Antifungal activity against Mucor species	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID283229	Effect on Coccidioides immitis Silveira infection in CD1 mouse brain, spinal cord and lungs administered after 3 days of infection at 50 mg/kg, po bid after 10 days	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.
AID424637	Antimicrobial activity against azole-resistant Candida albicans isolate CA137 cotreated with calcineurin signaling inhibitor Tacrolimus after 48 hrs by microdilution checkerboard technique	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1873196	Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by liquid scintillation counter analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1770941	Antifungal activity against Candida parapsilosis GIM2.190 assessed as fungal growth inhibition by CLSI protocol based method	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.
AID575067	Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 50 mg/kg, po bid administered 1 day after infection for 7 days relative to untreated control	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
AID1061742	Antimicrobial activity against Candida albicans SC5314 after 24 hrs by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID1283999	Antifungal activity against Aspergillus fumigatus ATCC 16907 by M38-A protocol-based broth microdilution method	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.
AID1061736	Antimicrobial activity against Microsporum gypseum by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID584407	Antifungal activity against 7 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 37 days after 9 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID371230	Antimicrobial activity against Candida parapsilosis ATCC 90018 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID581900	Antifungal activity against Candida glabrata isolated from HSCT recipient 497 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID736602	Antifungal activity against voriconazole-resistant Candida glabrata clinical isolate 730 assessed as growth inhibition after 24 to 48 hrs by CLSI microbroth dilution method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives.
AID249264	Minimum inhibitory concentration against Aspergillus species (n=8)	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
AID648416	Antifungal activity against Aspergillus flavus NCIM 524 by serial plate dilution method	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID214425	In vitro evaluation of minimum inhibitory concentration against Trichophyton rubrum 90	1995	Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20	Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring.
AID484390	Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering-based beads autocorrelation assay in presence of 1% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1534784	Inhibition of human ERG expressed in CHO cells at 25 uM by electrophysiology assay relative to control	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
AID518402	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220R mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1557085	Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.
AID1059356	Fungicidal activity against Candida dubliniensis by micro dilution method	2013	European journal of medicinal chemistry, , Volume: 70	Designing and synthesis of novel antimicrobial heterocyclic analogs of fatty acids.
AID584393	Antifungal activity against 1 day cultured Candida albicans isolated from HSCT recipient with acute or chronic GVHD mouth after 2 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID325036	Antimicrobial activity against Candida albicans P5 after 24 hrs by broth macrodilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.
AID1546103	Antimicrobial activity against Proteus mirabilis after 24 hrs by agar disk diffusion method	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Current scenario of tetrazole hybrids for antibacterial activity.
AID1175556	Antimicrobial activity against Trichophyton rubrum SNB-TR1 after 5 days	2015	Journal of natural products, Jan-23, Volume: 78, Issue:1	Antibacterial ilicicolinic acids C and D and ilicicolinal from Neonectria discophora SNB-CN63 isolated from a termite nest.
AID519438	Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-3227 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.
AID566885	Antifungal activity against Aspergillus niger by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID322853	Antifungal activity against azole-resistant Aspergillus fumigatus V13/02-CM3271 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.
AID1357639	Cytotoxicity against human HEK293 cells assessed as cell viability at 250 uM after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.
AID405104	Antimicrobial activity against Rhizopus arrhizus assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID340954	Antifungal activity against Candida glabrata ATCC 90030 by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID424620	Antimicrobial activity against azole-susceptible Candida albicans isolate CA12 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID532324	Antifungal activity against Saccharomyces cerevisiae by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID341545	Half life in children of >2-6 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID541561	Cmax in healthy human alveolar cell at 200 mg, po every 12 hrs for 5 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.
AID1128928	Antifungal activity against Cryptococcus gattii assessed as total growth inhibition by micro-broth dilution method	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Imidazolylchromanones containing non-benzylic oxime ethers: synthesis and molecular modeling study of new azole antifungals selective against Cryptococcus gattii.
AID1204521	Antifungal activity against Candida utilis ATCC 9226 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID1155874	Antifungal activity against Trichophyton rubrum assessed as growth inhibition by serial dilution method	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.
AID341559	AUC (0 to 24 hrs) in children of >2-6 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID648415	Antifungal activity against recultured Trichophyton mentagrophytes at MIC after 3 to 4 days	2012	European journal of medicinal chemistry, May, Volume: 51	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID1549137	Antifungal activity against azole-resistant Candida albicans 0304103 after 48 hrs by spectrophotometry-based serial microdilution method	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
AID424624	Antimicrobial activity against azole-resistant Candida albicans isolate CA15 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1309048	Antifungal activity against Candida albicans ATCC MYA-2876 after 48 hrs by CLSI M27-A3 method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
AID519282	Antifungal activity against Candida krusei ATCC 6258 by CLSI M27-A2 microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID515013	Antifungal activity against Trichophyton rubrum by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID405106	Antimicrobial activity against Rhizopus microsporus var. microsporus assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID1411892	Antifungal activity against Aspergillus fumigatus ATCC 16907 by M38-A guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID529667	Antimicrobial activity against Paecilomyces variotii by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Susceptibility testing and molecular classification of Paecilomyces spp.
AID532541	Antifungal activity against wild-type Saccharomyces cerevisiae BY4741 assessed as accumulation of 14-alpha-methylergosta-8,24(28)-dien-3beta-6alpha-diol at 8 ug/ml	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.
AID581877	Antifungal activity against Candida glabrata isolated from neutropenic subject 1491 with AML or MDS pharynx receiving antifungal drug after 23 days prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID525593	Antibacterial activity against Fluconazole resistant Candida albicans DSY3604 containing tac1delta/delta ERG11-1/ERG11-5 genotype by EUCAST standards based broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.
AID575472	Half life in guinea pig infected with 10'6 CFU Microsporum canis B68128 at 20 mg/kg, po administered 2 hrs before infection for 5 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models.
AID371233	Antimicrobial activity against Candida tropicalis ATCC 750 by broth microdilution method	2008	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24	Carbon analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID515012	Antifungal activity against Candida tropicalis by micro-broth dilution method	2010	European journal of medicinal chemistry, Oct, Volume: 45, Issue:10	Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase.
AID543975	Fraction unbound in human at 15 mg, po pretreated with itraconazole at 200 mg, po qd for 4 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
AID1330315	Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-stimulated Ca2+ flux up to 100 uM after 30 mins by calcium-4 dye based FLIPR assay	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca
AID554718	Antimicrobial activity against Saccharomyces cerevisiae isolate ADdelta overexpressing Saccharomyces cerevisiae ERG11 after 48 hrs by liquid microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID518611	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID405069	Antifungal activity against Candida parapsilosis ATCC 22019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID341550	Cmax in adolescents of >12-16 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID532319	Antifungal activity against Candida parapsilosis by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1061737	Antimicrobial activity against Aspergillus fumigatus by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and evaluation of novel azoles as potent antifungal agents.
AID582998	Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.
AID419082	Antifungal activity against Aspergillus fumigatus ATCC 26430	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID527139	Antifungal activity against Candida albicans ATCC 10231 after 5 days microdilution technique	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Search for antifungal compounds from the wood of durable tropical trees.
AID1491243	Antifungal activity against Cryptococcus neoformans cgmcc 2.3161 by broth microdilution method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents.
AID405043	Antifungal activity against Sporothrix schenckii P1621 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1283996	Antifungal activity against Candida utilis ATCC 9226 by M27-A3 protocol-based broth microdilution method	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.
AID340956	Antifungal activity against Candida krusei ATCC 6258 by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID425135	Antimicrobial activity against azole-susceptible Candida albicans isolate CA14 assessed as log reduction in colony count at 1 ug/ml co-treated with calcineurin signaling inhibitor tacrolimus after 48 hrs by time killing test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1473926	Drug concentration at steady state in human at 200 mg, po QD for 1 to 2 weeks after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID620356	Antifungal activity against Candida albicans RCMB 005002 at 30 ug/ml after 3 to 4 days by agar well diffusion method	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Synthesis and anti-microbial activity of some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.
AID405073	Antifungal activity against Aspergillus flavus ATCC 204304 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1325030	Displacement of BODIPY-cyclopamine from human Smo expressed in HEK293 cells at 5 uM measured after 10 hrs by DAPI staining based fluorescence microscopic assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
AID1155869	Antifungal activity against Candida parapsilosis assessed as growth inhibition after 24 hrs by serial dilution method	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.
AID1783776	Antifungal activity against Candida krusei GIM2.1 assessed as inhibition of fungal growth by NCCLS protocol based method	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.
AID1609932	Antifungal activity against fluconazole-resistant Candida albicans 901 assessed as reduction in fungal growth incubated for 24 hrs by serial dilution method
AID509401	Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse brain at 50 mg/kg, po bid administered 1 day after infection measured on day 6 after 4 hrs of last treatment	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID1743169	Antifungal activity against Trichophyton violaceum	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID532326	Antifungal activity against Cryptococcus neoformans var. gattii by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID1204552	Antifungal activity against Candida albicans Strain 22 by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID341573	AUC (0 to 24 hrs) in children of >2-6 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.
AID1413339	Antifungal activity against Aspergillus flavus	2018	MedChemComm, Jun-01, Volume: 9, Issue:6	Antifungal amphiphilic kanamycins: new life for an old drug.
AID729298	Inverse agonist activity at CCR4 in human HTLA cells assessed as depression of basal activity incubated for 20 mins by beta arrestin-recruitment mediated luciferase reporter gene assay in absence of CCL22	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Colloidal aggregation causes inhibition of G protein-coupled receptors.
AID519056	Antifungal activity against Candida albicans assessed as susceptible isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID524738	Antimicrobial activity against Fusarium proliferatum after 48 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
AID532344	Antifungal activity against Scedosporium apiospermum by EUCAST method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID509387	Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in spleen at 25 mg/kg, po bid administered 1 day after infection for 7 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.
AID609318	Half life in rat at 10 mg/kg, po administered as single dose	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
AID549051	Antifungal activity against Candida albicans CA135 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.
AID1411886	Antifungal activity against Candida tropicalis ATCC 13803 by M27-A3 guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID582798	Antifungal activity against Candida albicans isolate 177 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
AID424618	Antimicrobial activity against azole-susceptible Candida albicans isolate CA5 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID518612	Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A E130D mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID1155870	Antifungal activity against Candida glabrata assessed as growth inhibition after 24 hrs by serial dilution method	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.
AID1128927	Antifungal activity against Candida albicans assessed as total growth inhibition by micro-broth dilution method	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Imidazolylchromanones containing non-benzylic oxime ethers: synthesis and molecular modeling study of new azole antifungals selective against Cryptococcus gattii.
AID405108	Antimicrobial activity against Mucor circinelloides assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID322546	Antifungal activity against Trichophyton violaceum after 7 days by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.
AID405030	Antifungal activity against Sporothrix schenckii P24223 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1689823	Antifungal activity against Aspergillus fumigatus ASFU7 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	New azole antifungals with a fused triazinone scaffold.
AID405105	Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis assessed as percent of susceptible isolates after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID1204526	Antifungal activity against Candida glabrata by broth microdilution method	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	A facile synthesis of novel miconazole analogues and the evaluation of their antifungal activity.
AID340961	Antifungal activity against Candida albidus isolates from grapes by NCCLS M27-A2 method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
AID584412	Antifungal activity against 2 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
AID50137	Minimum inhibitory concentration of compound for antifungal activity against Candida kefyr	2000	Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19	Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization.
AID405034	Antifungal activity against Sporothrix schenckii PSCC1 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1411885	Antifungal activity against Candida albicans ATCC 10231 by M27-A3 guideline based method	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Synthesis and antifungal activity of novel oxazolidin-2-one-linked 1,2,3-triazole derivatives.
AID753513	Antidermatophytic activity against Microsporum gypseum NCPF 580 after 7 days by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID442525	Antifungal activity against Trichophyton mentagrophytes var. erinacei NCPF 375 after 7 days by microbroth dilution method	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.
AID245421	Minimum inhibitory concentration against Candida krusei 1766-1 evaluated by in vitro agar diffusion and micro-broth dilution assay	2005	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15	Synthesis of some diguanidino 1-methyl-2,5-diaryl-1H-pyrroles as antifungal agents.
AID518403	Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220I mutant gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
AID563404	Antifungal activity against Aspergillus tubingensis isolate CM-3810 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.
AID525139	Antifungal activity against Fusarium moniliforme clade 1 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
AID519063	Antifungal activity against Candida krusei assessed as resistant isolates after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID424623	Antimicrobial activity against azole-resistant Candida albicans isolate CA10 after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	150 (2.47)	18.7374
1990's	1328 (21.88)	18.2507
2000's	1907 (31.42)	29.6817
2010's	1973 (32.51)	24.3611
2020's	711 (11.72)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	653 (10.14%)	5.53%
Trials	4 (1.61%)	5.53%
Reviews	748 (11.61%)	6.00%
Reviews	15 (6.02%)	6.00%
Case Studies	2,181 (33.87%)	4.05%
Case Studies	2 (0.80%)	4.05%
Observational	18 (0.28%)	0.25%
Observational	0 (0.00%)	0.25%
Other	2,840 (44.10%)	84.16%
Other	228 (91.57%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (352)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail. [NCT00356915]	Phase 3	1,381 participants (Actual)	Interventional	2006-07-31	Completed
A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986209 in Healthy Participants [NCT04154800]	Phase 1	114 participants (Actual)	Interventional	2019-12-06	Completed
A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS [NCT01259336]	Phase 4	31 participants (Actual)	Interventional	2010-07-31	Completed
Prospective, Open-Label, Comparative, Multi-Center Study Of Voriconazole Compared To Itraconazole For The Primary Prophylaxis Of Invasive Fungal Infection (IFI) With Allogeneic Hematopoietic Stem Cell Transplants (HSCT) [NCT00289991]	Phase 3	489 participants (Actual)	Interventional	2006-03-31	Completed
An Open-label, Single Group Study to Evaluate the Effect of Repeated Oral Administration of Itraconazole (ITZ) on the Single Oral Dose Pharmacokinetics of BAY1902607 in Healthy Male Participants [NCT03789890]	Phase 1	14 participants (Actual)	Interventional	2019-01-08	Completed
An Open-label Phase II (Proof of Concept (POC)) Trial of PKC412 Monotherapy in Participants With Acute Myeloid Leukemia (AML) and Participants With High Risk Myelodysplastic Syndrome (MDS) (CPKC412A2104 Core); An Open-label, Randomized Phase II POC Trial [NCT00045942]	Phase 1/Phase 2	144 participants (Actual)	Interventional	2002-01-30	Completed
A Open-Label, Two-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid in Healthy Participants [NCT05954624]	Phase 1	48 participants (Anticipated)	Interventional	2023-07-10	Recruiting
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer [NCT05563766]	Phase 2	78 participants (Anticipated)	Interventional	2024-01-15	Not yet recruiting
Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients With Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single B [NCT03656081]	Phase 3	224 participants (Anticipated)	Interventional	2018-12-19	Recruiting
A Non-Randomized, Open Label, One Sequence, Two-Period Cross-Over Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants [NCT03774576]	Phase 1	14 participants (Actual)	Interventional	2018-12-17	Completed
Itraconazole in the Management of Superficial Fungal Infections in India. A Pilot Study [NCT03923010]	Phase 4	40 participants (Actual)	Interventional	2019-08-06	Terminated(stopped due to Further recruitment not possible due to COVID 19 impact. Hence a decision to close study was taken by the sponsor in Aug 2020)
Relative Bioavailability of a Single Oral Dose of BI 730357 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, One-way Crossover Study) [NCT03782987]	Phase 1	14 participants (Actual)	Interventional	2019-01-10	Completed
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation [NCT01160952]	Phase 2	120 participants (Anticipated)	Interventional	2009-05-31	Recruiting
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection [NCT01198236]	Phase 4	150 participants (Actual)	Interventional	2008-07-31	Completed
A Phase 1 Single Center Open-label, Non-randomized, Fixed Sequence Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of AZD9977 When Administered Alone and With Itraconazole [NCT03843060]	Phase 1	14 participants (Actual)	Interventional	2019-02-22	Completed
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects [NCT03755778]	Phase 1	72 participants (Actual)	Interventional	2018-11-29	Completed
An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications [NCT06004947]	Phase 1	32 participants (Actual)	Interventional	2016-01-14	Completed
a Single-center, Open-label, Fixed Sequence Study in Healthy Chinese Subjects to Evaluate the Pharmacokinetic Effects of Itraconazole and Rifampicin on Oral Administration of a Single Dose of ABSK021 [NCT06089733]	Phase 1	32 participants (Anticipated)	Interventional	2023-04-11	Enrolling by invitation
A Randomized Phase II, Multi-center, Non-inferiority Clinical Trial for Efficacy and Safety of Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases [NCT01344681]	Phase 2	153 participants (Actual)	Interventional	2011-06-30	Completed
Effect of a Potent CYP3A and P-gp Inhibitor (Itraconazole) on Ipatasertib Pharmacokinetics in Healthy Subjects [NCT03222310]	Phase 1	15 participants (Actual)	Interventional	2017-07-18	Completed
A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6282 in Healthy Nonelderly and Elderly Male and Female Subjects, Including a Food Effect Cohort and Drug-drug [NCT02420782]	Phase 1	116 participants (Actual)	Interventional	2015-05-31	Completed
A Single-Center, Non-Randomized, Open-Label, One-Sequence, Two-Period Within-Subject Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Multiple Doses of Balovaptan in Healthy Volunteers [NCT03579719]	Phase 1	15 participants (Actual)	Interventional	2018-07-10	Completed
A Phase 1, 2-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Itraconazole, Food, and pH, on the Single Dose Pharmacokinetics of BMS-986368 in Healthy Participants [NCT06170723]	Phase 1	32 participants (Anticipated)	Interventional	2024-01-12	Not yet recruiting
A Phase 1, Open-Label, Fixed-sequence, 5-part, Drug-drug Interaction Study of Tucatinib to Evaluate the Effects of CYP3A4 and CYP2C8 Inhibition and Induction on the Pharmacokinetics of Tucatinib and to Evaluate the Effects of Tucatinib on the Pharmacokine [NCT03723395]	Phase 1	116 participants (Actual)	Interventional	2018-09-17	Completed
A PHASE 1 OPEN-LABEL, TWO-ARM,DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON THE PHARMACOKINETICS OF TALAZOPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS [NCT03077607]	Phase 1	36 participants (Actual)	Interventional	2016-11-07	Completed
A Single-Sequence, Open-Label, 2-Period, Crossover Trial to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult Subjects [NCT03161405]	Phase 1	12 participants (Actual)	Interventional	2017-06-05	Completed
A PHASE 1, OPEN-LABEL, FIXED SEQUENCE 2-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSES OF ITRACONAZOLE ON THE PHARMACOKINETICS OF A SINGLE DOSE OF PF-06651600 IN HEALTHY PARTICIPANTS [NCT03821493]	Phase 1	12 participants (Actual)	Interventional	2019-02-21	Completed
[NCT01321827]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2011-04-30	Completed
A Phase I, Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy [NCT02093728]	Phase 1	26 participants (Actual)	Interventional	2014-04-30	Completed
Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1584862 in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Design Study) [NCT06041438]	Phase 1	14 participants (Actual)	Interventional	2023-09-29	Completed
Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With ABPA [NCT05667662]	Phase 2	30 participants (Anticipated)	Interventional	2023-02-01	Recruiting
A Phase 1, Open-Label, Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Itraconazole On The Single Dose Pharmacokinetics of Palbociclib (PD-0332991) In Healthy Volunteers [NCT02131298]	Phase 1	12 participants (Actual)	Interventional	2014-05-31	Completed
Open-Label, Single-Center, Single-arm, Fixed Sequence Study on the Effect of Itraconazole on the Pharmacokinetics of SHR1459 in Health Subjects [NCT04455100]	Phase 1	20 participants (Actual)	Interventional	2020-07-17	Completed
A Phase 1, Open-Label, 2-Period, Fixed Sequence Study to Estimate the Effect of Itraconazole on the Pharmacokinetics of PF-07817883 in Healthy Adults [NCT05822440]	Phase 1	12 participants (Actual)	Interventional	2023-04-13	Completed
A Phase 1, Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211 [NCT01568411]	Phase 1	20 participants (Actual)	Interventional	2012-04-30	Completed
A Phase I, Open-label, Fixed Sequence, Two-period, Crossover, Drug-drug Interaction Study to Investigate the Interaction Potential of Itraconazole on the Pharmacokinetics of Ganaplacide and Lumefantrine Combination in Healthy Participants [NCT05084651]	Phase 1	19 participants (Actual)	Interventional	2021-11-18	Completed
An Adaptive, Part Open-label, Part Randomised Phase 1 Clinical Trial in Healthy Volunteers to Study Drug Interactions With RV521 Including Those Mediated by CYP3A4 and P-glycoprotein [NCT03782662]	Phase 1	82 participants (Actual)	Interventional	2018-11-06	Completed
An Open-label, Single-Sequence, 2-Treatment Period Study to Investigate the Effects of Cytochrome P450 3A4 Inhibition by Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants [NCT03950960]	Phase 1	15 participants (Actual)	Interventional	2019-05-02	Completed
A Phase 1, Open-label, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Steady-state Pharmacokinetics Of Pf-06649751 In Healthy Adult Subjects [NCT03121664]	Phase 1	11 participants (Actual)	Interventional	2017-04-07	Completed
A Phase 1, Single-Center, Open-Label, 2-Cohort, Fixed-Sequence, Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healt [NCT05994807]	Phase 1	33 participants (Actual)	Interventional	2023-08-08	Completed
A Non-randomized, Open-label, Fixed-sequence Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD5305 in Patients With Advanced Solid Malignancies [NCT05573724]	Phase 1	16 participants (Actual)	Interventional	2022-11-07	Active, not recruiting
A Phase 1, Open-Label, Fixed Sequence Study to Investigate the Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 in Healthy Adult Subjects [NCT05437094]	Phase 1	20 participants (Actual)	Interventional	2022-06-27	Completed
A Phase 1, Open-label, Two-period, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Single-dose Pharmacokinetics Of Pf-06372865 In Healthy Adult Subjects [NCT02475746]	Phase 1	0 participants (Actual)	Interventional	2015-07-31	Withdrawn
A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer [NCT03513211]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2018-08-23	Completed
[NCT02470832]	Phase 1	12 participants (Actual)	Interventional	2015-05-31	Completed
A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42847922 in Healthy Male Subjects [NCT02455856]	Phase 1	16 participants (Actual)	Interventional	2015-05-18	Completed
A Phase 1, Open-Label, Fixed Sequence Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects [NCT03209648]	Phase 1	20 participants (Actual)	Interventional	2017-06-14	Completed
Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis [NCT03171584]	Phase 3	60 participants (Anticipated)	Interventional	2017-07-01	Not yet recruiting
A Phase 1, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effect of the Modulators of the Cytochrome P450 (CYP) 2C8 and/or 3A on the Single-Dose Pharmacokinetics of Ozanimod and CC112273 in Healthy Adult Subjects [NCT03624959]	Phase 1	100 participants (Actual)	Interventional	2018-06-20	Completed
Phase I, Open-label, Single-sequence, Cross-over Study of the Effect of Multiple Doses of Itraconazole on Single-dose Tepotinib Pharmacokinetics in Healthy Participants [NCT05203822]	Phase 1	18 participants (Actual)	Interventional	2022-01-21	Completed
A Phase 1, Single-center, Open-label, 2-part, 2-treatment Period, 1-sequence, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Erythromycin on SAR443820 (Part A) and the Effect of Itraconazole on SAR443820 (Part B) in Healthy Adult Par [NCT05797753]	Phase 1	16 participants (Actual)	Interventional	2022-02-18	Completed
The Effect of Itraconazole on the Clinical Outcomes of Patients With Advanced Non Small Cell Lung Cancer Receiving Platinum Based Chemotherapy [NCT03664115]	Phase 2	60 participants (Anticipated)	Interventional	2018-07-02	Recruiting
An Open-label, Fixed-sequence, Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of Itraconazole, a Strong CYP3A4 Inhibitor and Potent P-gp Inhibitor on the Pharmacokinetics of GLPG3667 [NCT05272683]	Phase 1	14 participants (Actual)	Interventional	2022-02-28	Completed
An Open Labe Study to Evaluate the Drug-Drug Interaction of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Adult Chinese Participants [NCT05665647]	Phase 1	36 participants (Actual)	Interventional	2022-12-29	Completed
An Open-label, Randomized, 2-period, 2-sequence Study to Evaluate the Single-dose Pharmacokinetics of Milademetan When Administered Alone or Concomitantly With Itraconazole or Posaconazole in Healthy Subjects [NCT03614455]	Early Phase 1	36 participants (Actual)	Interventional	2018-07-13	Completed
Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital [NCT02068170]		178 participants (Actual)	Observational	2014-02-28	Completed
Comparison of Efficacy of Double Dose Oral Terbinafine Versus Itraconazole in Treatment of Dermatophyte Infections of Skin - A Prospective, Randomized Controlled Trial [NCT04880980]	Phase 3	120 participants (Actual)	Interventional	2021-03-15	Completed
A Phase 1,Parallel Assignment,Fixed-Sequence Study to Assess the Effect of Itraconazole, Rifampicin on the Pharmacokinetics of TPN171H in Healthy Subjects [NCT06090123]	Phase 1	24 participants (Actual)	Interventional	2020-01-01	Completed
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors [NCT05150691]	Phase 1/Phase 2	631 participants (Anticipated)	Interventional	2022-01-31	Recruiting
Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects [NCT02989389]	Phase 1	42 participants (Actual)	Interventional	2016-12-12	Completed
Interventional, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects [NCT02122692]	Phase 1	20 participants (Actual)	Interventional	2014-03-31	Completed
An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and No [NCT02253420]	Phase 1	51 participants (Actual)	Interventional	2014-10-08	Completed
An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants [NCT03498170]	Phase 1	16 participants (Actual)	Interventional	2018-03-19	Completed
An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973 [NCT03499106]	Phase 1	24 participants (Actual)	Interventional	2018-04-12	Completed
A Study to Evaluate the Relative Bioavailability of Different Strengths of STI-1558 Capsules and the Effect of Strong CYP3A4 Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics of STI-1558 in Healthy Volunteers [NCT05685719]	Phase 1	37 participants (Actual)	Interventional	2023-01-04	Completed
A Two Cohort, Open-Label, Fixed Sequence Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam [NCT04411030]	Phase 1	36 participants (Actual)	Interventional	2020-05-20	Completed
A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Male Participants to Determine the Effect of an Inhibitor of Cytochrome P450 3A and P Glycoprotein on Exposure to Orvepitant [NCT03535662]	Phase 1	16 participants (Actual)	Interventional	2018-06-08	Completed
An Open-Label, Fixed-Sequence Study to Assess Effects of Clarithromycin on the Single-Dose Pharmacokinetics of JNJ-54861911 in Healthy Male Subjects [NCT02197884]	Phase 1	13 participants (Actual)	Interventional	2014-07-31	Completed
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) [NCT02054793]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to This study was never able to open due to lack of funding from the pharmaceutical company.)
Phase I Open Label, Drug-Drug Interaction, Study to Evaluate the Effect of Itraconazole and Phenytoin on the Pharmacokinetics of ASC41 in Healthy Volunteers and A Study to Evaluate the PK, Safety and Tolerability in Subjects With Non-alcoholic Fatty Liver [NCT04845646]	Phase 1	24 participants (Actual)	Interventional	2021-03-16	Completed
A Phase 1, Single-Center, Nonrandomized, Open-Label, 2-Part, Fixed-Sequence, Drug-Drug Interaction Study to Assess the Pharmacokinetics and Safety of AZD4205 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered Wi [NCT05486949]	Phase 1	32 participants (Actual)	Interventional	2022-07-27	Completed
An Open-Label, Pharmacokinetic Study to Evaluate the Pharmacokinetics and Relative Bioavailability of BIIB091 Formulations and to Assess the Impact of Food, a Proton Pump Inhibitor and CYP3A4 Inhibitor on BIIB091 Exposure Using the Selected Formulation in [NCT04564612]	Phase 1	59 participants (Actual)	Interventional	2020-09-28	Completed
A Two-Part Study to Evaluate the Effect of CYP3A4 Inhibition (Itraconazole-Part 1) and CYP1A2 Inhibition (Ciprofloxacin - Part 2) on the Single-Dose Pharmacokinetics of Pracinostat in Healthy Nonsmoking Subjects [NCT02118909]	Phase 1	32 participants (Actual)	Interventional	2014-05-31	Completed
The Possible Effect of Itraconazole as add-on Therapy to Paclitaxel and Carboplatin on the Treatment Outcome in Patients With Advanced Ovarian Cancer [NCT05591560]		66 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
A Phase I, Open-Label, Randomized, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole and Voriconazole on the Single-Dose Pharmacokinetics of GLPG1690 in Healthy Male Subjects [NCT03515382]	Phase 1	18 participants (Actual)	Interventional	2018-03-16	Completed
A Randomized, Open-Label, Parallel Group, Drug-drug Interaction Study to Evaluate the Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adult Subjects [NCT03135106]	Phase 1	54 participants (Actual)	Interventional	2017-04-14	Completed
An Open-label, 2-cycle Clinical Study to Evaluate the Drug Interaction Between Itraconazole or Dextromethorphan and IBI351 in Healthy Subjects [NCT05699993]	Phase 1	24 participants (Actual)	Interventional	2023-03-10	Completed
[NCT01214941]	Phase 4	12 participants (Actual)	Interventional	2010-09-30	Completed
A Phase 1 Single Center Open-label, Non-randomized, Fixed Sequence Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of BV100 When Administered Alone and With Itraconazole [NCT05684718]	Phase 1	16 participants (Actual)	Interventional	2023-02-01	Completed
A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of an Inhibitor of Cytochrome P450 3A on Exposure to Relacorilant and Its Main Metabolites [NCT03512548]	Phase 1	52 participants (Actual)	Interventional	2018-04-10	Completed
Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation [NCT01282879]	Phase 4	36 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to In interim analysis, this study met the primary hypothesis.)
An Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of JNJ-56136379 in Healthy Adult Participants [NCT03945539]	Phase 1	16 participants (Actual)	Interventional	2019-05-15	Completed
A Phase 1, 3-arm, Open-label, Sequential Design Study to Investigate the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on Single-dose Pharmacokinetics of BMS-986278 in Healthy Participants [NCT05932303]	Phase 1	47 participants (Actual)	Interventional	2023-07-12	Completed
A Phase 1 First in Human, Single and Multiple Ascending Dose and Food Effect and Drug-Drug Interaction in Healthy Subjects to Evaluate the Safety, Tolerability and Assessment of Pharmacokinetics of ABBV-903 [NCT05691699]	Phase 1	104 participants (Actual)	Interventional	2023-01-03	Completed
Effects of CYP3A4 Inhibition by Itraconazole on the Pharmacokinetics of LY3200882 in Healthy Subjects [NCT03792139]	Phase 1	23 participants (Actual)	Interventional	2019-01-08	Completed
A Phase 1, Two-part, Open-label, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole and Carbamazepine on the Single-dose Pharmacokinetics of LY3410738 in Healthy Adult Subjects [NCT05205447]	Phase 1	27 participants (Actual)	Interventional	2022-01-05	Terminated(stopped due to Data from part 2 no longer deemed necessary for this program.)
A Single-center, Open-label, Fixed-sequence Study to Investigate the Effect of Multiple-dose Itraconazole on the Pharmacokinetics of a Single Dose of 10 mg ACT-1004-1239 in Healthy Male Subjects [NCT05549531]	Phase 1	16 participants (Actual)	Interventional	2022-10-01	Completed
An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of Olinciguat (IW-1701) [NCT03892499]	Phase 1	24 participants (Actual)	Interventional	2019-05-03	Completed
A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole and Mefenamic Acid on the Single-Dose Pharmacokinetic Profile of Soticlestat in Healthy Participants [NCT05064449]	Phase 1	28 participants (Actual)	Interventional	2021-10-14	Completed
A Phase 1, Open-label, Fixed-sequence, 2-Panel Study to Assess the Effects of Itraconazole and Etravirine on the Single-dose Pharmacokinetics of JNJ-64417184 in Healthy Adult Subjects [NCT04208373]	Phase 1	32 participants (Actual)	Interventional	2019-12-20	Completed
An Open-Label, Fixed Sequence Study in Healthy Post Menopausal Female Subjects to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole [NCT05551897]	Phase 1	14 participants (Actual)	Interventional	2022-10-04	Completed
A Randomized Double-blind (Sponsor Unblind) Placebo Controlled Study in Healthy Subjects to Evaluate: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Repeat Doses of GSK2881078, the Selective Androgen Receptor Modulator With an Open La [NCT02567773]	Phase 1	108 participants (Actual)	Interventional	2015-09-30	Completed
A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the [NCT02633709]	Phase 1	33 participants (Actual)	Interventional	2016-01-07	Completed
A NON-RANDOMIZED, OPEN-LABEL, THREE-PART, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF ITRACONAZOLE, CARBAMAZEPINE, AND QUINIDINE ON THE PHARMACOKINETICS AND SAFETY OF EDP-235 IN HEALTHY PARTICIPANTS [NCT05594602]	Phase 1	36 participants (Actual)	Interventional	2022-10-06	Completed
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711 in Chinese Healthy Volunteers [NCT04135833]	Phase 1	31 participants (Actual)	Interventional	2019-12-12	Completed
A First-in-Human, Phase I, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects, Including Food-Effect and Drug-drug Interaction With Itr [NCT04908800]	Phase 1	99 participants (Actual)	Interventional	2021-05-27	Completed
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies [NCT04537715]	Phase 1	42 participants (Actual)	Interventional	2020-04-23	Completed
Phase 1, Open-label, Fixed Sequence, 2-period Study To Investigate The Effect Of Multiple Doses Of Itraconazole On The Pharmacokinetics Of Single Dose Pf-06463922 In Healthy Volunteers In The Fasted Condition [NCT02838264]	Phase 1	16 participants (Actual)	Interventional	2016-08-16	Completed
A Phase I Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets [NCT06165822]	Phase 1	40 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
An Open-Label, Randomized, Parallel-Group Drug-Drug Interaction Study to Assess the Effect of Multiple Doses of Itraconazole or Gemfibrozil on the Pharmacokinetics of a Single Dose of JNJ-56021927 in Healthy Male Subjects [NCT02230033]	Phase 1	45 participants (Actual)	Interventional	2014-09-30	Completed
The Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine (an Open-label, Randomised, Single-dose, Two-way Crossover Study) [NCT02264041]	Phase 1	25 participants (Actual)	Interventional	2004-01-31	Completed
A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer [NCT05156892]	Phase 1	44 participants (Anticipated)	Interventional	2022-09-04	Recruiting
A Single-centre, Open, Single-dose, Self-control Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects [NCT04479891]	Phase 1	18 participants (Actual)	Interventional	2019-09-18	Completed
A Phase 1, One Sequence, Cross-over Pharmacokinetic Study to Assess the Interaction Between ASP1707 and Itraconazole, a CYP3A and P-gp Inhibitor in Healthy Female Subjects [NCT02175407]	Phase 1	14 participants (Actual)	Interventional	2014-04-30	Completed
A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, Drug Interaction Study Between AVP-923 and Itraconazole, and Between AVP-786 and Itraconazole in Healthy Adult Subjects [NCT02402595]	Phase 1	24 participants (Actual)	Interventional	2015-03-31	Completed
A Randomized, Placebo Controlled, Double Blind, Single and Repeat Dose Escalation Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and Open Label Assessment of Coadministration of GSK3915393 With G [NCT04604795]	Phase 1	65 participants (Actual)	Interventional	2020-11-04	Completed
A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of Pamiparib (BGB-290) in Cancer Patients [NCT03994211]	Phase 1	25 participants (Actual)	Interventional	2019-05-29	Completed
[NCT02055703]	Phase 1	195 participants (Actual)	Interventional	2014-01-31	Completed
Interventional, Open-label, One-sequence Crossover Study Evaluating the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics, Safety and Tolerability of Lu AF35700 in Healthy Young Men and Women [NCT03103646]	Phase 1	22 participants (Actual)	Interventional	2017-03-28	Completed
A Three-part, Single-center, Open-label, Phase I Drug-drug Interaction Clinical Study to Investigate the Effect of Itraconazole, Gemfibrozil or Rifampicin on Pharmacokinetics of SKLB1028 in Healthy Subjects [NCT05069870]	Phase 1	42 participants (Actual)	Interventional	2021-06-07	Active, not recruiting
A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-drug Interactions (DDIs) Between GP681 and Rosuvastatin/Digoxin/Itraconazole/Oseltamivir in Chinese Healthy Volunteers [NCT05789342]	Phase 1	54 participants (Actual)	Interventional	2023-02-15	Completed
[NCT02085967]	Phase 1	106 participants (Actual)	Interventional	2014-02-28	Completed
A Phase 1, Open Label, Two Period, Fixed Sequence, Parallel Group Study To Estimate The Effects Of Multiple Dose Administration Of Itraconazole On The Single Dose Pharmacokinetics Of Conjugated Estrogens/Bazedoxifene In Non Obese (Bmi <30 Kg/m2) And Obese [NCT02100553]	Phase 1	24 participants (Actual)	Interventional	2014-04-30	Completed
An Open-Label, Multicenter Study to Assess the Potential Effects of Itraconazole (a Strong CYP3A4 Inhibitor) on the Pharmacokinetics of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors [NCT05063318]	Phase 1	11 participants (Anticipated)	Interventional	2020-10-07	Recruiting
A Pilot Study Investigating Antitumorigenic Potential of Topical Itraconazole in the Treatment of Basal Cell Carcinoma [NCT02120677]	Early Phase 1	5 participants (Actual)	Interventional	2014-05-31	Completed
An Open-label, Non-randomized, Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Roniciclib in Patients With Advanced Solid Tumors [NCT02457351]	Phase 1	14 participants (Actual)	Interventional	2015-07-31	Completed
A Phase I, Two-part, Open-label Study to Evaluate the Pharmacokinetics of Rilapladib (SB-659032) and Its Metabolites, and to Determine the Effect of Repeat Dose Itraconazole on the Pharmacokinetics of Rilapladib in Healthy Volunteers [NCT02130661]	Phase 1	0 participants (Actual)	Interventional	2017-10-31	Withdrawn
SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial [NCT03572049]	Phase 2/Phase 3	88 participants (Actual)	Interventional	2018-09-17	Completed
A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects [NCT02065739]	Phase 1	16 participants (Actual)	Interventional	2014-01-31	Completed
An Open-label, Three-period, One-sequence Crossover Clinical Trial to Evaluate the Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers [NCT04942652]	Phase 1	13 participants (Actual)	Interventional	2021-07-13	Completed
A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of a Probe CYP3A4 Inhibitor and Inducer on the Pharmacokinetics of BAY1841788 (ODM 201) in Healthy Male Volunteers [NCT03048110]	Phase 1	15 participants (Actual)	Interventional	2017-02-15	Completed
A Phase 1, Open-Label, 2-Cohort Study to Assess the Single Dose Pharmacokinetics of Two Formulations of TD-1473 and to Assess the Effect of a High-Fat Meal and Itraconazole on the Pharmacokinetics of TD-1473 in Healthy Subjects [NCT03555617]	Phase 1	36 participants (Actual)	Interventional	2018-06-13	Completed
A Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole, and Carbamazepine in Healthy Adult Participants [NCT06173596]	Phase 1	60 participants (Anticipated)	Interventional	2023-12-21	Not yet recruiting
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia [NCT02675452]	Phase 1	142 participants (Actual)	Interventional	2016-06-13	Active, not recruiting
A Single-center, Open-label, Drug-drug Interaction Study of SH-1028 Tablets in Healthy Subjects [NCT04808648]	Phase 1	40 participants (Anticipated)	Interventional	2021-04-06	Not yet recruiting
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1323495 Versus Placebo in Healthy Male Japanese Subjects Genotyped as Poor and Extensive Metabolizers of UGT2B17 (Single-blind, Randomised, Placebo-control [NCT04619251]	Phase 1	74 participants (Actual)	Interventional	2020-11-13	Completed
A Phase 1 Study of the Effects of Itraconazole on the Pharmacokinetics of ALKS 5461 in Healthy Volunteers [NCT02272764]	Phase 1	24 participants (Actual)	Interventional	2014-10-31	Completed
A Phase I, Single-center, Open-label, Fixed-sequence Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 Pharmacokinetics [NCT05357820]	Phase 1	56 participants (Actual)	Interventional	2021-07-19	Completed
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-708 in Healthy Subjects [NCT05518734]	Phase 1	64 participants (Actual)	Interventional	2022-09-17	Completed
Interventional, Open-label, Interaction Study Investigating the Effects of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics and Safety and Tolerability of Lu AF11167 in Healthy Young Subjects [NCT02199431]	Phase 1	20 participants (Actual)	Interventional	2014-07-31	Completed
An Open-Label, 2-Period, Fixed Sequence Study to Determine the Effect of Multiple Oral Doses of Itraconazole on the Single Dose Pharmacokinetics of AG 120 in Healthy Adult Subjects [NCT02831972]	Phase 1	22 participants (Actual)	Interventional	2016-06-30	Completed
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-828 [NCT06154447]	Phase 1	157 participants (Anticipated)	Interventional	2023-12-12	Recruiting
Single- and Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study With LY3154885 in Healthy Subjects [NCT04014361]	Phase 1	36 participants (Actual)	Interventional	2019-08-09	Terminated(stopped due to HUAA study is terminated early due to a business decision.)
A PHASE 1, OPEN-LABEL, FIXED SEQUENCE 2-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSES OF ITRACONAZOLE ON THE PHARMACOKINETICS OF A SINGLE DOSE OF PF-06700841 IN HEALTHY PARTICIPANTS [NCT04090047]	Phase 1	12 participants (Actual)	Interventional	2019-09-24	Completed
A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study With Omaveloxolone in Healthy Subjects [NCT04008186]	Phase 1	61 participants (Actual)	Interventional	2019-06-14	Completed
A Phase I Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets [NCT06024915]	Phase 1	40 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
A Phase 1, Open-label, Single-center Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects [NCT02820935]	Phase 1	36 participants (Actual)	Interventional	2016-07-31	Completed
An Open-Label Single-Sequence Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-Dose Pharmacokinetics of BMS-986177 in Healthy Subjects [NCT02807909]	Phase 1	28 participants (Actual)	Interventional	2016-07-31	Completed
Relative Bioavailability of a Single Oral Dose of BI 1323495 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, One-way Crossover Study) [NCT04011241]	Phase 1	14 participants (Actual)	Interventional	2019-07-24	Completed
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach [NCT04577378]	Phase 2	45 participants (Anticipated)	Interventional	2020-10-20	Not yet recruiting
An Open-Label, One-Sequence, Two-Period Study to Evaluate the Effects of Itraconazole on the Pharmacokinetics of DS-8500a in Healthy Subjects [NCT02790671]	Phase 1	26 participants (Actual)	Interventional	2016-05-31	Completed
A 3-Part, Phase 1 Study to Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects [NCT04138836]	Phase 1	48 participants (Actual)	Interventional	2019-09-17	Completed
Efficacy and Safety of Terbinafine and Itraconazole Monotherapy in Conventional and Increased Doses and in Combination in Dermatophytosis [NCT05881980]	Phase 2/Phase 3	150 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
A Two-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Subjects [NCT03991312]	Phase 1	28 participants (Actual)	Interventional	2019-06-20	Completed
A Phase 1, Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects, Including a Drug-drug Interaction Part With Itraconazole [NCT02155504]	Phase 1	44 participants (Actual)	Interventional	2014-05-31	Completed
A Randomized Controlled Trial to Compare Oral Itraconazole and Standard Care Versus Standard Care Alone in Patients With Non-cystic Fibrosis Related Bronchiectasis With Chronic Aspergillus Infection in Reducing Bronchiectasis Exacerbations [NCT06160713]	Phase 3	80 participants (Anticipated)	Interventional	2023-12-01	Recruiting
A Phase I, Open Label Study in Healthy Subjects to Evaluate the Effect of Itraconazole and Rifampicin Upon the Pharmacokinetics of a Single Oral Dose of Olorofim. [NCT04171739]	Phase 1	24 participants (Actual)	Interventional	2019-11-18	Completed
A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State [NCT02608034]	Phase 1	32 participants (Anticipated)	Interventional	2016-05-26	Completed
Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor [NCT05862714]	Phase 1	164 participants (Actual)	Interventional	2022-03-01	Completed
An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) [NCT00787917]	Phase 4	14 participants (Actual)	Interventional	2008-11-30	Terminated
An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of DIC075V in Subjects With Mild or Moderate Chronic Renal Insufficiency and in Subjects With Mild Chronic Hepatic Impairment Compared to Healthy Adult Volunteers and a Randomize [NCT00805090]	Phase 1	37 participants (Actual)	Interventional	2008-12-31	Completed
Clinical Evaluation of a Formulated Nanoemulsion for Topical Application [NCT04110834]	Phase 2	30 participants (Actual)	Interventional	2018-02-15	Completed
Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors [NCT00336531]	Phase 4	100 participants (Anticipated)	Interventional	2006-04-30	Completed
A Phase 1, Open-label, Two-period, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Single-dose Pharmacokinetics Of Pf-06648671 In Healthy Adults [NCT02883114]	Phase 1	12 participants (Actual)	Interventional	2016-09-30	Completed
A Multi-center, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of Mycamine® vs Itraconazole Oral Solution for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant [NCT00794703]	Phase 3	288 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis [NCT04824417]	Phase 3	100 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Not Responding Adequately to Current Therapy [NCT05049525]	Phase 2	68 participants (Anticipated)	Interventional	2022-02-22	Recruiting
Study on the Pharmacokinetic Effects of Single-centered, Open, Single-arm, Fixed-sequence Itraconazole on SHR0302 Tablets in Healthy Subjects [NCT05404724]	Phase 1	14 participants (Actual)	Interventional	2022-06-25	Completed
An Open Label, Phase I Study to Assess the Effect of Itraconazole (CYP3A4 and P-gp Inhibitor) on the Pharmacokinetics of Anetumab Ravtansine and to Assess the ECG Effects, Safety and Immunogenicity of Anetumab Ravtansine Given as a Single Agent and Togeth [NCT02824042]	Phase 1	63 participants (Actual)	Interventional	2016-09-07	Completed
Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses (10 - 1500 mg, Tablets) of BAY1817080 Including the Effect of Food and Itraconazole on the Rela [NCT02817100]	Phase 1	88 participants (Actual)	Interventional	2016-07-22	Completed
A 3-Part, Open-Label Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole (Moderate Inhibitor of CYP2C9 and CYP3A), Itraconazole (Strong CYP3A Inhibitor), or Rifampin (Strong CYP3A and Moderate C [NCT02809768]	Phase 1	48 participants (Actual)	Interventional	2016-04-30	Completed
A Case Study of the Effects of Topical Itraconazole on Pharmacodynamic Modulation of Hedgehog Target Gene Expression in Basal Cell Carcinomas in Patients [NCT02735356]	Early Phase 1	9 participants (Actual)	Interventional	2016-05-05	Completed
An Open-Label Study of the Effect of a Strong CYP3A4 Inhibitor (Itraconazole) on the Pharmacokinetics of Bardoxolone Methyl in Healthy Volunteers [NCT03264079]	Phase 1	16 participants (Actual)	Interventional	2017-10-16	Completed
Pharmacokinetics of Itraconazole in Pediatric Cancer Patients [NCT01409018]	Phase 1	6 participants (Actual)	Interventional	2009-06-30	Completed
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas [NCT01108094]	Phase 2	29 participants (Actual)	Interventional	2010-04-30	Completed
A Phase 1, Open-label Study in Healthy Adult Subjects to Evaluate Effects of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-99677 and the Effects of CC-99677 on the Pharmacokinetics of Digoxin, Metformin, Methotrexate, Midazolam, R [NCT04268394]	Phase 1	48 participants (Actual)	Interventional	2020-03-13	Completed
A Single-arm, Multiple-Dose, Steady-State, Bioavailability Study With Twice Daily Dosing of Lozanoc™ (65 mg Itraconazole Capsules, Mayne) Taken Regardless of Food [NCT02755857]	Phase 2	20 participants (Actual)	Interventional	2016-07-31	Completed
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer [NCT00798135]		13 participants (Actual)	Interventional	2008-11-30	Completed
A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigator the Effect of P-glycoprotien Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Health Subjects [NCT05255276]	Phase 1	36 participants (Actual)	Interventional	2022-01-29	Completed
Evaluation of the Effect of Food, Omeprazole, Itraconazole, and Carbamazepine on the Pharmacokinetics of LY3484356 in Healthy Females of Non-Child-Bearing Potential [NCT04840888]	Phase 1	82 participants (Actual)	Interventional	2021-04-26	Completed
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, and Quinidine on the Pharmacokinetics and Safety of EDP-514 in Healthy Subjects [NCT04783753]	Phase 1	72 participants (Actual)	Interventional	2020-11-05	Completed
A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction With Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, [NCT02045849]	Phase 1	46 participants (Actual)	Interventional	2014-01-28	Completed
Pilot Study To Determine the Feasibility of Itraconazole for Primary Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome [NCT00000975]	Phase 2	30 participants	Interventional		Completed
Evaluation Of The Treatment With Oral Itraconazole In Patients With Basocellular Carcinoma Of Skin, Locally Limited Disease. [NCT03972748]		28 participants (Anticipated)	Interventional	2018-01-05	Recruiting
A Non-randomised, Open-label, Sequential, Three-part, Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation, and to Provide Data on the Effect of Olaparib [NCT01900028]	Phase 1	85 participants (Actual)	Interventional	2013-10-31	Completed
A Phase I Randomized, Open-label, 3-arm Parallel-design Study to Determine the Effect of Multiple-dose Gemfibrozil or Itraconazole on the Pharmacokinetics, Safety and Tolerability of Single-dose MDV3100 (ASP9785) in Healthy Male Subjects [NCT01913379]	Phase 1	41 participants (Actual)	Interventional	2011-08-31	Completed
A Phase Ib Study of Extending Relugolix Dosing Intervals Through Addition of the CYP3A4 and Pg-P Inhibitor Itraconazole or Ritonavir in Prostate Cancer Patients [NCT05679388]	Phase 1	100 participants (Anticipated)	Interventional	2023-02-13	Recruiting
Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors. [NCT01951430]		229 participants (Actual)	Observational	2014-03-31	Completed
A Single-Center, Open-Label, One-Sequence, 2-Period, Within-Subject Study in 2 Cohorts to Investigate the Effect of Multiple Doses of Itraconazole (Cohort 1) and Fluoxetine (Cohort 2) on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjec [NCT01967979]	Phase 1	28 participants (Actual)	Interventional	2013-10-31	Completed
Phase 1, Open-label, Parallel, 2-arm, Fixed-sequence Study to Investigate the Effect of Coadministration of CYP3A4 Inhibitor and CYP3A4 Inducer on the Pharmacokinetics, Safety, and Tolerability of KBP-5074 in Healthy Subjects [NCT04606537]	Phase 1	24 participants (Actual)	Interventional	2020-10-24	Completed
Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients [NCT00673309]	Phase 2/Phase 3	644 participants (Actual)	Interventional	2000-07-31	Completed
A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacoki [NCT02010970]	Phase 1	56 participants (Actual)	Interventional	2013-12-31	Completed
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis [NCT00000639]		400 participants	Interventional		Completed
A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK (Pharmacokinetics) Profiles of IMP4297 Capsules in Healthy Subjects [NCT04584515]	Phase 1	32 participants (Actual)	Interventional	2020-11-02	Completed
An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors [NCT04312282]	Phase 1	93 participants (Actual)	Interventional	2020-03-06	Terminated(stopped due to The Sponsor has discontinued the development of tesetaxel)
The Relationship of Defeverscence and Itraconazole Plasma Level Using Sporanox IV as an Empiric Therapy in Immunocompromised Patients Who Have Been Treated With Sporanox Oral Solution as Prophylaxis [NCT01021683]		203 participants (Actual)	Observational	2009-07-31	Completed
A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents [NCT01686607]		40,110 participants (Actual)	Observational	2012-10-01	Completed
A Phase 1, Single-Center, Parallel-Group, Open-Label, Randomized, Drug-Drug Interaction Study to Assess the Effect of Itraconazole, Phenytoin, and Gemfibrozil on the Pharmacokinetics of a Single Oral Dose of BMS-986166 in Healthy Participants [NCT04956627]	Phase 1	15 participants (Actual)	Interventional	2021-07-28	Completed
Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation [NCT00675714]	Phase 2/Phase 3	1,126 participants (Actual)	Interventional	2004-01-31	Terminated(stopped due to At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.)
Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules [NCT00871728]	Phase 4	132 participants (Actual)	Interventional	2007-01-31	Completed
Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma [NCT02699723]	Early Phase 1	0 participants (Actual)	Interventional	2020-12-31	Withdrawn(stopped due to Logistics)
An Open-Label Fixed-Sequence Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adult Subjects [NCT02729467]	Phase 1	33 participants (Actual)	Interventional	2016-03-31	Completed
A Single Center, Two Part, Randomized, Open Label Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential [NCT02706535]	Phase 1	29 participants (Actual)	Interventional	2016-05-05	Completed
An Open-label, Fixed-sequence, Phase 1 Study of the Effect of CYP3A4 Inhibition by Itraconazole on the Pharmacokinetics of BIIB074 in Healthy Subjects [NCT02698267]	Phase 1	16 participants (Actual)	Interventional	2016-02-29	Completed
Assessment of the Steady State Pharmacokinetics of Itraconazole and Hydroxy-Itraconazole in Healthy Subjects After Administration of a New Itraconazole 200 mg Film Coated Tablet Once Daily for Fourteen Days in Fed Condition [NCT00695071]	Phase 1	16 participants (Actual)	Interventional	2008-06-30	Completed
Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions [NCT02621905]	Phase 4	40 participants (Actual)	Interventional	2015-11-30	Completed
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma [NCT02770378]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2016-11-30	Completed
A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese [NCT04586920]	Phase 1	104 participants (Actual)	Interventional	2020-10-20	Terminated(stopped due to Terminated due to safety findings)
A Drug-Drug Interaction Study to Evaluate the Effects of Strong CYP3A Induction and Inhibition on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol From the Annovera™ Contraceptive Vaginal System [NCT04290390]	Phase 1	67 participants (Actual)	Interventional	2020-02-12	Completed
A Randomized Controlled Trial to Compare Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in Chronic Pulmonary and Allergic Bronchopulmonary Aspergillosis Overlap Syndrome [NCT05444946]		104 participants (Anticipated)	Interventional	2022-06-15	Recruiting
Monthly Itraconazole Versus Classic Homeopathy for the Treatment of Recurrent Vulvovaginal Candidiasis: a Randomised Trial [NCT00895453]		144 participants (Actual)	Interventional	2000-05-31	Completed
A 2-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects [NCT05338489]	Phase 1	24 participants (Actual)	Interventional	2018-05-11	Completed
Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients Who Had CD4+ Cell Count <200 Cells/mm3 But Undetectable Plasma HIV-1 RNA [NCT01392430]		74 participants (Actual)	Interventional	2009-06-30	Completed
A Multicenter, Randomized Trial Comparing The Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Subjects With Hematological Malignancy [NCT02895529]	Phase 4	61 participants (Actual)	Interventional	2016-11-30	Terminated(stopped due to Study is a commitment for license renew, we target on Apr19 submission, considering timeline, a cut off should be scheduled in Apr18.)
An Open-label, 3-Arm, Parallel Design Pharmacokinetic Interaction Study Between MYK-224 and Cytochrome P450 3A4 Inhibitors Itraconazole and Verapamil in Healthy Participants [NCT05304533]	Phase 1	45 participants (Actual)	Interventional	2022-04-21	Completed
Concentration of Itraconazole Solution in Nasal Secretions [NCT00588016]	Phase 1	6 participants (Actual)	Interventional	2007-04-30	Completed
Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1815368 in Healthy Male Subjects (an Open-label, Two-period Fixed-sequence Design Study) [NCT05965583]	Phase 1	14 participants (Actual)	Interventional	2023-08-02	Completed
A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 [NCT05840952]	Phase 1	144 participants (Anticipated)	Interventional	2023-07-04	Recruiting
Phase 1, First-in-human, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses of XEN1101 and Preliminary Open-label Pharmacodynamic Assessment in Healthy Subjects Addendum: Phase 1 [NCT03340220]	Phase 1	130 participants (Actual)	Interventional	2017-11-13	Completed
An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours [NCT01772563]	Phase 1	28 participants (Actual)	Interventional	2013-02-04	Completed
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate CYP3A4-Mediated, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adult Subjects [NCT04142762]	Phase 1	80 participants (Actual)	Interventional	2019-10-18	Completed
A Phase 1, Open-Label, 4-Part, Fixed-Sequence Study to Assess the Effect of Itraconazole, a Strong CYP3A Inhibitor, the Effect of Fluconazole, a Moderate CYP3A/2C9 Inhibitor, the Effect of Rifampin, a Strong CYP3A Inducer, and the Effect of Rabeprazole, a [NCT05602597]	Phase 1	59 participants (Actual)	Interventional	2022-06-01	Completed
A Phase 1, Two Period Fixed-sequence Crossover Study to Assess the Effects of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Surufatinib in Healthy Subjects [NCT04372407]	Phase 1	13 participants (Actual)	Interventional	2020-07-09	Completed
A Single-Sequence, Open-Label, 2-Period Crossover Trial to Evaluate the Effect of the Potent Cytochrome P-450 3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK-954 in Healthy Adult Subjects [NCT03173170]	Phase 1	10 participants (Actual)	Interventional	2017-05-31	Completed
A Crossover, Phase 1, Open-label, One-arm Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Male and Female Participants [NCT06106334]	Phase 1	14 participants (Anticipated)	Interventional	2023-11-15	Recruiting
Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis [NCT05578950]	Phase 1	100 participants (Actual)	Interventional	2022-03-01	Completed
An Open Labe Study to Evaluate the Drug-Drug Interaction of Itraconazole With GST-HG171/Ritonavir in Healthy Adult Chinese Participants [NCT06087055]	Phase 1	12 participants (Actual)	Interventional	2023-05-12	Completed
A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction With Itraconazole and Rifampin in Healthy Adult Subjects [NCT03928327]	Phase 1	24 participants (Actual)	Interventional	2019-05-02	Completed
A Three-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Subjects [NCT04981704]	Phase 1	74 participants (Actual)	Interventional	2021-04-08	Completed
Pharmacokinetics Study of Intravenous Itraconazole Followed by Oral Dosing at 200 Mg Twice Daily in Patients With Advanced HIV Infection [NCT00002370]		36 participants	Interventional		Completed
A Phase 1, Fixed-Sequence, Open-Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD-9855 in Healthy Subjects [NCT03432793]	Phase 1	41 participants (Actual)	Interventional	2018-02-28	Completed
A Phase 1 Study to Evaluate the Effects of Multiple Doses of Itraconazole or Carbamazepine on the Single-Dose Pharmacokinetics of LY3537982 in Healthy Adult Subjects [NCT05860933]	Phase 1	30 participants (Anticipated)	Interventional	2023-05-08	Recruiting
Effect of Cold Atmospheric Plasma on Malassezia Folliculitis: a Randomized Controlled Trial [NCT04886323]		50 participants (Actual)	Interventional	2022-08-03	Completed
A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects [NCT01814709]	Phase 1	32 participants (Actual)	Interventional	2013-04-30	Completed
A Single-center, Open, Single Does, Drug-drug Interaction Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of Healthy Chinese Adult Subjects After Oral Administration of SHR2554 Tablets [NCT04627129]	Phase 1	18 participants (Actual)	Interventional	2020-06-01	Completed
Effect of Itraconazole on the Pharmacokinetics of Apatinib in Chinese Healthy Volunteers [NCT02836171]	Phase 1	20 participants (Actual)	Interventional	2016-07-31	Completed
A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subjects in China [NCT05949385]	Phase 1	16 participants (Anticipated)	Interventional	2023-07-12	Not yet recruiting
A Phase 1, Single-center, Open-label, Sequential Dose-Escalation Study of ACP-196 in Healthy Subjects to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-Drug Interactions [NCT04901923]	Phase 1	59 participants (Actual)	Interventional	2014-03-15	Completed
SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole [NCT04809649]	Phase 2	0 participants (Actual)	Interventional	2021-05-15	Withdrawn(stopped due to Sponsor is not proceeding with study due to budget cuts as a result of COVID-19.)
Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection [NCT00002438]		0 participants	Interventional		Completed
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, and the Effect of Rifampin on the Pharmacokinetics of HMPL-523 in Healthy Volunteers [NCT05720767]	Phase 1	28 participants (Actual)	Interventional	2022-11-04	Completed
An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Capivasertib When Administered Alone and In Combination With Itraconazole [NCT04712396]	Phase 1	11 participants (Actual)	Interventional	2021-02-01	Completed
Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease [NCT00001280]	Phase 2	100 participants	Interventional	1991-01-31	Completed
Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study) [NCT02044393]	Phase 1	20 participants (Actual)	Interventional	2014-01-31	Completed
Randomized Trial Of Safety And Tolerability Of Intravenous/Oral Voriconazole Versus Intravenous/Oral Itraconazole For Long-Term Antifungal Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplant Recipients [NCT00079222]		0 participants	Interventional	2003-11-30	Completed
An Open-label Study to Evaluate the Drug-drug Interaction Effect of Itraconazole, a CYP3A4 Inhibitor, on the Pharmacokinetics of AMG 510 in Healthy Subjects [NCT05568082]	Phase 1	14 participants (Actual)	Interventional	2019-12-03	Completed
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Men [NCT00012467]	Phase 2	60 participants	Interventional	2000-01-31	Completed
Randomized, Double-blind, Placebo-controlled, Escalating Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered BAY1161116 in Healthy Postmenopausal Women Including Food-effect and Drug-drug-interaction With Itraconazol [NCT03119077]	Phase 1	32 participants (Actual)	Interventional	2017-04-27	Terminated(stopped due to Study early terminated due to lower drug exposure)
Comparative Study Between Pulsed and Continuous Itraconazole for the Treatment of Onychomychosis [NCT05567484]	Phase 1	60 participants (Actual)	Interventional	2021-05-01	Completed
An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole [NCT05236543]	Phase 1	21 participants (Actual)	Interventional	2022-02-18	Completed
Prediction of Itraconazole Oral Absorption From In Vitro Dissolution [NCT04035187]	Phase 4	17 participants (Actual)	Interventional	2020-02-10	Completed
Relative Bioavailability of a Single Oral Dose of BI 894416 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, One-way Crossover Study) [NCT03722173]	Phase 1	14 participants (Actual)	Interventional	2018-11-13	Completed
Randomized Double-Blinded Controlled Trial of Oral Antifungal for the Treatment of Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps [NCT02285283]	Phase 2/Phase 3	58 participants (Actual)	Interventional	2014-11-30	Terminated(stopped due to Recruitment failure.)
A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects [NCT01974687]	Phase 1/Phase 2	178 participants (Actual)	Interventional	2013-10-31	Completed
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study) [NCT02513446]	Phase 1	16 participants (Actual)	Interventional	2015-09-29	Completed
An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid Tumours [NCT05372367]	Phase 1	32 participants (Anticipated)	Interventional	2022-06-30	Recruiting
An Open-label, Non-randomized, Fixed Sequence Study Assessing the Pharmacokinetics of AZD7986 When Administered Alone and With Multiple Doses of Verapamil and Itraconazole or Diltiazem in Healthy Subjects [NCT02653872]	Phase 1	15 participants (Actual)	Interventional	2016-01-22	Completed
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER [NCT03458221]	Phase 2/Phase 3	148 participants (Anticipated)	Interventional	2023-01-31	Recruiting
A Phase 1 Open-label 2-Part 2-Period Fixed-sequence Crossover Study To Assess The Effect Of Itraconazole, A Strong CYP3A Inhibitor, And The Effect Of Rifampin, A Strong CYP3A Inducer, On Pharmacokinetics Of Fruquintinib In Healthy Subjects [NCT04557397]	Phase 1	28 participants (Actual)	Interventional	2020-09-02	Completed
A Two-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0145228 and Midazolam, Digoxin, and Itraconazole in Healthy Adult Subjects [NCT04709081]	Phase 1	38 participants (Actual)	Interventional	2019-12-22	Completed
A Randomized, Double Blind, Multiple-site, Placebo-Controlled Study, Comparing the Efficacy and Safety of SUBA™-Itraconazole Capsules Compared to SPORANOX® (Itraconazole) Capsules in the Treatment of Onychomycosis of the Toenail [NCT00791219]	Phase 2	175 participants (Actual)	Interventional	2008-11-30	Completed
Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 474121 in Healthy Male Subjects (an Open-label, Two-period Fixed Sequence Design Study) [NCT04716894]	Phase 1	14 participants (Actual)	Interventional	2021-02-01	Completed
Relative Bioavailability of a Single Oral Dose of BI 1291583 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Two-period, Fixed Sequence Study) [NCT03890887]	Phase 1	14 participants (Actual)	Interventional	2019-04-12	Completed
A Single-center, Non-randomized, Open-lable, Self-controlled Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects [NCT06162169]	Phase 1	66 participants (Anticipated)	Interventional	2023-11-25	Recruiting
Open-label, Randomised, Two-way Crossover Study to Assess the Effect of Once Daily Itraconazole on the Pharmacokinetics of BI 409306 After a Single Oral Dose in Healthy Male Volunteers Genotyped as Poor and Extensive Metabolizers of CYP2C19 [NCT02248259]	Phase 1	25 participants (Actual)	Interventional	2014-10-31	Completed
A Single-center, Open, Self-controlled Design Clinical Study to Evaluate the Pharmacokinetic Effects of Rifampicin or Itraconazole on Single-dose Laolotinib Mesylate Capsules in Healthy Subjects [NCT05057949]	Phase 1	32 participants (Anticipated)	Interventional	2021-11-24	Active, not recruiting
Evaluation and Validation of Metabolic Markers for the Prediction of Drug-drug Interaction of Various CYP3A4 Substrates and Inhibitors in Healthy Male Subjects [NCT02975037]	Phase 1	32 participants (Actual)	Interventional	2017-02-06	Completed
A Phase 1, Open-label, Fixed-sequence Study to Estimate the Effects of Multiple-dose Administration of Itraconazole on the Pharmacokinetics of SHR8554 in Healthy Adult Subjects [NCT05928988]	Phase 1	17 participants (Actual)	Interventional	2022-01-04	Completed
A Phase 1, Open-label Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Pharmacokinetics and Safety of BMS-986235 [NCT04464577]	Phase 1	0 participants (Actual)	Interventional	2021-04-01	Withdrawn(stopped due to Business objectives have changed.)
Retrospective Observation of Empirical Antifungal Therapy With Itraconazole [NCT01706562]		138 participants (Actual)	Observational	2011-05-31	Completed
A Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects [NCT01768663]	Phase 1	80 participants (Actual)	Interventional	2013-01-31	Completed
A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib [NCT01772290]	Phase 1	92 participants (Actual)	Interventional	2013-02-28	Completed
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma [NCT02259010]	Phase 1	24 participants (Actual)	Interventional	2014-10-22	Completed
A Phase I, Single-center, Open-label, Fixed-sequence Clinical Study to Evaluate the Effects of Multiple Administrations of Rifampin or Itraconazole on the Pharmacokinetic Characteristics of a Single Administration of Orelabrutinib Tablets in Healthy Subje [NCT05316857]	Phase 1	36 participants (Actual)	Interventional	2021-12-16	Completed
A Phase 1, Open-label, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Pharmacokinetics Of Pf 04958242 In Healthy Adult Subjects [NCT02341482]	Phase 1	13 participants (Actual)	Interventional	2015-02-05	Completed
A Single Centre, Open Label, One Sequence, Cross-over Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Single Inhaled Doses of Nemiralisib in Healthy Subjects [NCT03398421]	Phase 1	20 participants (Actual)	Interventional	2018-01-17	Completed
Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial) [NCT02342717]	Phase 1	16 participants (Actual)	Interventional	2015-01-31	Completed
Effect of P-gp Inhibition, OATP-inhibition and Food on the Kinetics of a Single Oral Dose BI 685509 in Healthy Male Subjects [NCT03116893]	Phase 1	15 participants (Actual)	Interventional	2017-04-19	Completed
An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects. [NCT00002133]		0 participants	Interventional		Completed
A Prospective, Two-center, Clinical Study to Optimize the Treatment for Allergic Bronchopulmonary Aspergillosis (ABPA) [NCT05129033]		100 participants (Anticipated)	Interventional	2021-11-15	Not yet recruiting
An Open-lable, Two- Period, Single-sequence, Self-controlled Study to Evaluate the Effect of Oral Rifampicin or Itraconazole on the Pharmacokinetics of ASK120067 Tablets [NCT05631678]	Phase 1	48 participants (Actual)	Interventional	2022-06-06	Completed
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis [NCT02440009]	Phase 2/Phase 3	191 participants (Actual)	Interventional	2014-05-31	Completed
A Phase 1, Randomized, Open-label, 3-sequence, 4-treatment, Incomplete Block Design To Estimate The Effect Of Steady State Cyp3a4 Inhibitors (Itraconazole, Diltiazem Or Verapamil) On The Pharmacokinetics Of Singe Dose Pf-00489791 In Healthy Volunteers [NCT02319148]	Phase 1	22 participants (Actual)	Interventional	2014-07-31	Completed
An Open-label, Randomized, 2-Period Crossover Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose Pharmacokinetics of Danicamtiv in Healthy Participants [NCT05162222]	Phase 1	30 participants (Actual)	Interventional	2021-12-15	Completed
A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma [NCT00005668]	Phase 2	96 participants	Interventional		Completed
A Phase 1, Open-Label, Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inhibitor (Itraconazole) of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites [NCT03259542]	Phase 1	33 participants (Actual)	Interventional	2017-08-09	Completed
Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole) [NCT04557163]	Phase 1	10 participants (Actual)	Interventional	2020-10-13	Completed
Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects [NCT05902728]	Phase 1	52 participants (Anticipated)	Interventional	2023-07-04	Not yet recruiting
Efficacy of Itraconazole and of Voriconazole in Patients With Cystic Fibrosis and Presenting With Persistent Positive Sputums for Aspergillus. [NCT01576315]	Phase 2	11 participants (Actual)	Interventional	2014-06-30	Completed
A Randomized Phase II Clinical Trial of Two Dose-levels of Itraconazole in Patients With Metastatic Castration-resistant Prostate Cancer [NCT00887458]	Phase 2	46 participants (Actual)	Interventional	2009-07-31	Completed
Phase II Study of Concurrent Chemoradiotherapy With Itraconazole in Treating Patients With Locally Advanced Esophageal Squamous Cancer [NCT04481100]	Phase 2	38 participants (Anticipated)	Interventional	2020-10-01	Recruiting
Efficacy and Safety of Ambulatory Low-dose Venetoclax and Azacitidne as First Line Therapy in Newly Diagnosed AML: a Pilot Study [NCT05048615]	Phase 2	15 participants (Actual)	Interventional	2021-07-26	Completed
A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of TAK-272 and the Effect of TAK-272 on the Pharmacokinetics of Digoxin or Midazolam In the Healthy Adult Participants [NCT02370615]	Phase 1	34 participants (Actual)	Interventional	2015-02-28	Completed
Relative Bioavailability of a Single Oral Dose of BI 1015550 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects [NCT03403439]	Phase 1	16 participants (Actual)	Interventional	2018-05-03	Completed
A Phase 1, Open-Label, 2-period Drug-Drug Interaction Study to Investigate the Effect of Multiple Doses of Itraconazole on the Single-Dose Pharmacokinetic Profile of AB928 in Healthy Adult Participants [NCT05154136]	Phase 1	20 participants (Actual)	Interventional	2021-10-20	Completed
A Randomized, Double Blind Phase II Proof-of-Concept Superiority Trial of Fosravuconazole 200 mg or 300 mg Weekly Dose Versus Itraconazole 400 mg Daily, All Three Arms in Combination With Surgery, in Patients With Eumycetoma in Sudan [NCT03086226]	Phase 2	138 participants (Anticipated)	Interventional	2017-04-30	Recruiting
A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Hydroxychloroquine and Itraconazole in Patients With Advanced Platinum-resistant Epithelial Ovarian Cancer (EOC) (HYDRA-1 Study) [NCT03081702]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2017-07-25	Completed
Phase 0 Pharmacodynamic Study of the Effects of Itraconazole on Tumor Angiogenesis and the Hedgehog Pathway in Early-stage Non-small Cell Lung Cancer [NCT02357836]	Early Phase 1	13 participants (Actual)	Interventional	2015-06-30	Completed
An Open-label, 3-period Fixed-sequence Study in Healthy Subjects to Assess the Pharmacokinetics (PK) of Savolitinib When Administered Alone and in Combination With Itraconazole [NCT04121910]	Phase 1	16 participants (Actual)	Interventional	2019-11-07	Completed
A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors [NCT03383692]	Phase 1	40 participants (Actual)	Interventional	2018-01-12	Completed
A Study to Determine the Effect of CYP3A Inhibition on the Pharmacokinetics of LY2623091 and the Effect of LY2623091 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects [NCT02300259]	Phase 1	48 participants (Actual)	Interventional	2014-11-30	Completed
Pilot Study to Determine the Feasibility of Itraconazole for Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome [NCT00000992]	Phase 1	30 participants	Interventional		Completed
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. [NCT00002132]		0 participants	Interventional		Completed
An Open-Label Extension Study of Maintenance Therapy in HIV-Positive Subjects With Fluconazole-Refractory Oropharyngeal Candidiasis Who Have Responded to Itraconazole Oral Solution [NCT00002341]		0 participants	Interventional		Completed
An Open-label, Fixed Sequence Study to Evaluate the Effects of Multi-dose of Itraconazole or Rifampin on the Pharmacokinetic Profiles of Single Dose of SPH3127 in Healthy Volunteers [NCT05359055]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2021-12-13	Completed
A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients [NCT00003883]	Phase 3	578 participants (Anticipated)	Interventional	1998-10-31	Completed
A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors [NCT02122770]	Phase 1	51 participants (Actual)	Interventional	2014-04-01	Completed
A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Subjects [NCT01929876]	Phase 1	16 participants (Actual)	Interventional	2013-07-31	Completed
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis [NCT00002159]	Phase 3	60 participants	Interventional		Completed
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI [NCT02157883]	Phase 1	39 participants (Actual)	Interventional	2014-11-06	Completed
Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 706321 in Healthy Male Subjects (an Open-label, Two-period Fixed Sequence Design Study) [NCT04714073]	Phase 1	14 participants (Actual)	Interventional	2021-02-11	Completed
Open-label, Non-randomized, One Sequence Cross-over Study to Investigate the Effect of Inhibition of CYP3A4/5 by Itraconazole on the Pharmacokinetics of CHF6001 in Healthy Subjects [NCT04739774]	Phase 1	24 participants (Actual)	Interventional	2021-02-22	Completed
Randomized, Double-Blinded, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects [NCT02341638]	Phase 1	148 participants (Actual)	Interventional	2014-09-30	Completed
A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects [NCT03301181]	Phase 1	40 participants (Actual)	Interventional	2017-09-18	Completed
An Open-label Study to Evaluate the Effect of Repeated Oral Administration of 200 mg Itraconazole(ITZ) Given Once Daily Over 14 Days on the Single Oral Dose Pharmacokinetics of Vilaprisan (BAY1002670) as Well as Assessment of Absolute Bioavailability Usin [NCT02456129]	Phase 1	14 participants (Actual)	Interventional	2015-07-31	Completed
A Phase I, Open Label, Drug-drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects [NCT04843449]	Phase 1	24 participants (Actual)	Interventional	2021-04-04	Completed
Single Center, Open-Label, Single-Sequence, Within-Subject Study In Two Cohorts Of Healthy Male Subjects Comparing Single-Dose Pharmacokinetics Of Fedovapagon Alone And In Combination With A CYP3A4 Inhibitor, Itraconazole, Or A CYP3A4 Inducer, Rifampicin [NCT02440841]	Phase 1	29 participants (Actual)	Interventional	2015-05-31	Completed
A 4-Part Phase 1 Study to Evaluate the Effect of GDC-0853 on the Pharmacokinetics of Midazolam, Rosuvastatin, and Simvastatin and the Effect of Itraconazole on the Pharmacokinetics of GDC-0853 [NCT03174041]	Phase 1	63 participants (Actual)	Interventional	2017-04-18	Completed
An Open-Label Phase I Trial to Evaluate the Safety and Tolerability of ATRA, Celecoxib, and Itraconazole Administered As Maintenance Treatment Post-Autologous Transplantation in Relapsed Multiple Myeloma [NCT02401295]	Phase 1	1 participants (Actual)	Interventional	2015-05-31	Completed
Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Cytochrome P450 Interaction Study of LY3154207 in Healthy Subjects [NCT02365571]	Phase 1	64 participants (Actual)	Interventional	2015-02-28	Completed
Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) [NCT02354261]	Phase 2	38 participants (Actual)	Interventional	2015-08-07	Completed
Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of Drug-drug Interaction in Korean Healthy Subjects [NCT02328443]	Phase 1	24 participants (Actual)	Interventional	2014-01-31	Completed
A Single-centre, Open, Single-dose, Self-control Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Chinese Adult Subjects. [NCT04423601]	Phase 1	18 participants (Actual)	Interventional	2020-06-10	Completed
UVX as an Adjuvant in the Treatment of Fungal Keratitis [NCT03138785]		20 participants (Actual)	Interventional	2015-01-01	Active, not recruiting
A Phase 1, Open Label, Two-part, Fixed-sequence Drug Interaction Study to Investigate the Effect of Strong CYP3A4 Inhibitor (Itraconazole) and CYP3A4 Inducer (Rifampin) on the Pharmacokinetics of LOXO 305 in Healthy Adult Subjects [NCT05134337]	Phase 1	24 participants (Actual)	Interventional	2020-02-12	Completed
AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSES OF ITRACONAZOLE ON THE PHARMACOKINETICS OF SINGLE DOSE ARV-471 IN THE FED CONDITION IN HEALTHY ADULT MALES, AND FEMALES OF NONCHILDBEARING POTE [NCT05538312]	Phase 1	12 participants (Actual)	Interventional	2023-02-23	Completed
Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation [NCT05076955]	Early Phase 1	100 participants (Anticipated)	Interventional	2021-03-31	Recruiting
PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER [NCT00585195]	Phase 1	596 participants (Actual)	Interventional	2006-04-19	Completed
Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin B Sequential Itraconazole Therapy [NCT03827278]		200 participants (Anticipated)	Interventional	2018-12-30	Recruiting
A Drug-drug Interaction Study Evaluating the Pharmacokinetic Effects of Itraconazole or Rifampin or Esomeprazole on XZP-3621 Tablets in Healthy Subjects [NCT05586568]	Phase 1	72 participants (Anticipated)	Interventional	2022-11-15	Not yet recruiting
A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis [NCT03471455]	Phase 2	100 participants (Anticipated)	Interventional	2018-04-30	Not yet recruiting
A Phase 1, Parallel-group, 3-part, 2-period, Fixed-sequence, Crossover, Open-label, Nonrandomized, Drug-drug Interaction Study to Assess the Pharmacokinetics of CC-92480 (BMS-986348) After Coadministration With Rifampin and Itraconazole, and Pharmacokinet [NCT05389722]	Phase 1	24 participants (Actual)	Interventional	2022-06-09	Completed
Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial [NCT00528190]	Phase 4	35 participants (Actual)	Interventional	2007-10-31	Completed
A Phase 2 Study of Itraconazole in Castrate-resistant Prostate Cancer Post-chemotherapy [NCT01450683]	Phase 2	4 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Low accrual)
A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer [NCT00769600]	Phase 2	23 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Low accrual.)
Interventional, Open-label, Randomized, Two-sequence Study Evaluating the Effect of CYP3A4 Inhibition on the Pharmacokinetics, Safety and Tolerability of Lu AG06466 in Healthy Men and Women [NCT04405323]	Phase 1	16 participants (Actual)	Interventional	2020-05-20	Completed
Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections [NCT01823289]	Phase 4	71 participants (Actual)	Interventional	2007-06-30	Completed
Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer [NCT02749513]	Early Phase 1	18 participants (Actual)	Interventional	2016-01-31	Active, not recruiting
Relative Bioavailability of a Single Oral Dose of BI 1358894 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Fixed Sequence Study) [NCT03843151]	Phase 1	16 participants (Actual)	Interventional	2019-03-19	Completed
A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas [NCT02875223]	Phase 1	91 participants (Anticipated)	Interventional	2016-08-31	Active, not recruiting
[NCT00004811]	Phase 1/Phase 2	7 participants	Interventional	1985-03-31	Completed
The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1810631 in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial) [NCT05833139]	Phase 1	16 participants (Actual)	Interventional	2023-04-14	Completed
Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse [NCT01787331]	Phase 2	21 participants (Actual)	Interventional	2013-10-29	Completed
Itraconazole Repurposing to Reduce Residual Cancer Risk in Patients With High-risk Barrett's Esophagus After Ablation [NCT05609253]	Phase 1	10 participants (Anticipated)	Interventional	2022-09-14	Recruiting
Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin in Healthy Male and Female Subjects (Open-label, Fixed-sequence) [NCT01795937]	Phase 1	51 participants (Actual)	Interventional	2013-02-28	Completed
A Phase 1, Open-Label, 4-Part Study to Evaluate the Effect of Food, Cytochrome P 450 Inhibition and Induction on the Pharmacokinetics of CC 122 in Healthy Adult Subjects [NCT03340662]	Phase 1	81 participants (Actual)	Interventional	2017-11-09	Completed
A Phase 1, Open-label, Three-Part, Fixed-Sequence Trial in Healthy Adult Participants to Evaluate the Effects of Itraconazole and Carbamazepine on the Single-Dose Pharmacokinetics of Emraclidine, and the Effect of Emraclidine on the Single-Dose Pharmacoki [NCT05965219]	Phase 1	60 participants (Anticipated)	Interventional	2023-08-15	Recruiting
A Phase I Single-Center, Randomized, Open-label, Single Dose, Crossover Study in Korean Healthy Male Volunteers to Evaluate Pharmacokinetics of Lozanoc and Sporanox [NCT02493738]	Phase 1	24 participants (Actual)	Interventional	2015-07-31	Completed
A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer. [NCT01752023]	Phase 2	3 participants (Actual)	Interventional	2013-03-31	Terminated(stopped due to Low Accrual)
A Randomized Trial Comparing the Role of Prednisolone, Itraconazole, or Their Combination in Patients With Acute Stage of Allergic Bronchopulmonary Aspergillosis [NCT06174922]	Phase 3	300 participants (Anticipated)	Interventional	2023-12-31	Recruiting
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor), Rifampicin (a CYP3A4 Inducer), and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients With Ad [NCT04959266]	Phase 1	5 participants (Actual)	Interventional	2021-06-28	Terminated(stopped due to The study terminated because the clinical development programme for Adavosertib has been discontinued)
COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS [NCT04962022]	Phase 1	12 participants (Actual)	Interventional	2021-07-20	Completed
A 2-Part, Non-randomized, Open-label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of Belumosudil (KD025) [NCT03530995]	Phase 1	73 participants (Actual)	Interventional	2018-04-09	Completed
Phase 1, 3-Part, Open-Label Study to Assess Safety, Tolerability and PK of Single and Multiple Doses of PUR1900 in Healthy Subjects and Crossover Study of Single Doses of PUR1900 and Sporanox in Adult Subjects With Mild to Moderate Asthma [NCT03479411]	Phase 1	58 participants (Actual)	Interventional	2018-02-09	Completed
A Randomized, Open-Label, Four-Cohort, Parallel Design Study to Evaluate the Effect of Itraconazole or Rifampin on the Single-Dose Pharmacokinetics of BMS-986205 in Normal Healthy Participants [NCT03346837]	Phase 1	53 participants (Actual)	Interventional	2017-11-22	Completed
A Phase II Trial Evaluating the Effectiveness of Itraconazole in Improving Pathologic Complete Response Rates in Patients With Esophageal Cancer Through Inhibition of the Hedgehog and AKT Signaling Pathways [NCT04018872]	Phase 2	78 participants (Anticipated)	Interventional	2019-06-24	Recruiting
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS [NCT05745701]	Phase 1	16 participants (Actual)	Interventional	2023-02-22	Completed
A Randomized Controlled Trial to Compare the Clinical Outcomes of Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis [NCT03920527]	Phase 3	164 participants (Actual)	Interventional	2019-07-01	Completed
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of APX001 to Evaluate the Effects of CYP3A4 Inhibition and Pan-CYP Induction in Two Parallel Groups of Healthy Male and Female Subjects [NCT04166669]	Phase 1	36 participants (Actual)	Interventional	2019-11-12	Completed
Pilot Study on the Evaluation of the Efficacy, Tolerability and Safety of Topical and Oral Antifungals in the Treatment of Onychomycosis and Creation of a Library of Dermatological Clinical Isolates [NCT05482763]		200 participants (Anticipated)	Observational [Patient Registry]	2022-07-20	Recruiting
Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626 [NCT02323334]	Phase 1	94 participants (Actual)	Interventional	2014-12-31	Completed
A Phase 1 Open-Label, Fixed-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Steady-state Itraconazole and Rifampin on the Single-dose Pharmacokinetics of Lazertinib Tablets in Healthy Adult Participants [NCT04410094]	Phase 1	32 participants (Actual)	Interventional	2020-09-14	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00045942 (36) [back to overview]	Summary of CGP62221 Plasma Concentration for 100 mg Bid Arm (E1)
NCT00045942 (36) [back to overview]	Summary of CGP52421 Plasma Concentration for 50 mg Bid Arm (E1)
NCT00045942 (36) [back to overview]	Summary of CGP62221 Concentration (E2)
NCT00045942 (36) [back to overview]	Summary of CGP62221 Plasma Concentration (Core)
NCT00045942 (36) [back to overview]	Summary of CGP62221 Plasma Concentration for 50 mg Bid Arm (E1)
NCT00045942 (36) [back to overview]	Summary of Midostaurin Concentration in the PKC412 Dose Escalation Arms(E2)
NCT00045942 (36) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for CGP52421 in the PKC412 + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Summary of Midostaurin Plasma Concentration (Core)
NCT00045942 (36) [back to overview]	Summary of PKC412 Plasma Concentration for 50 mg Twice Daily (Bid) Arm (E1)
NCT00045942 (36) [back to overview]	Terminal Elimination Half-life (T1/2) for PKC412 in the PKC + Itrconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Time to Reach the Maximum Concentration After Drug Administration (Tmax) for CGP52421 in the PKC412 + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Time to Reach the Maximum Concentration After Drug Administration (Tmax) for CGP62221 in the PKC412 + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Time to Reach the Maximum Concentration After Drug Administration (Tmax) for PKC412 in the PKC412 + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Duration of Best Clinical Response (E1)
NCT00045942 (36) [back to overview]	Event-free Survival (E1)
NCT00045942 (36) [back to overview]	Number of Participants With Best Clinical Response (Core)
NCT00045942 (36) [back to overview]	Overall Survival (E2)
NCT00045942 (36) [back to overview]	Overall Survival (OS) (E1)
NCT00045942 (36) [back to overview]	Terminal Elimination Half-life (T1/2) for CGP62221 in the PKC + Itrconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Time to Disease Progression (E1)
NCT00045942 (36) [back to overview]	Time to Disease Progression (E2)
NCT00045942 (36) [back to overview]	Time to Disease Progression (TTP) (Core)
NCT00045942 (36) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for CGP52421 Plasma in the PKC + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for CGP62221 Plasma in the PKC + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for PKC412 Plasma in the PKC + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Summary of PKC412 Plasma Concentration for 100 mg Bid Arm (E1)
NCT00045942 (36) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for CGP622221 in the PKC412 + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for PKC412 in the PKC412 + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Best Clinical Response (E2)
NCT00045942 (36) [back to overview]	Number of Participants With Overall Clinical Response (E1)
NCT00045942 (36) [back to overview]	Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for CGP52421 in the PKC + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for CGP62221 in the PKC + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for PKC412 in the PKC + Itraconazole Combination Arm (E2)
NCT00045942 (36) [back to overview]	Summary of CGP52421 Concentration (E2)
NCT00045942 (36) [back to overview]	Summary of CGP52421 Plasma Concentration (Core)
NCT00045942 (36) [back to overview]	Summary of CGP52421 Plasma Concentration for 100 mg Bid Arm (E1)
NCT00289991 (9) [back to overview]	Duration of Treatment
NCT00289991 (9) [back to overview]	Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment
NCT00289991 (9) [back to overview]	Survival: Percent of Subjects Who Died Within 1 Year
NCT00289991 (9) [back to overview]	Time to Breakthrough Invasive Fungal Infection (IFI)
NCT00289991 (9) [back to overview]	Time to Discontinuation of Study Treatment
NCT00289991 (9) [back to overview]	Percent of Subjects With Occurrence of Breakthrough IFI
NCT00289991 (9) [back to overview]	Success at Day 100: Percent of Responders (Randomization Strata)
NCT00289991 (9) [back to overview]	Success at Day 180: Percent of Responders (Randomization Strata)
NCT00289991 (9) [back to overview]	Survival: Percent of Subjects Who Died at or Before Day 180
NCT00356915 (4) [back to overview]	Clinical Improvement Compared to Placebo
NCT00356915 (4) [back to overview]	Clinical Improvement of the Target Toenail
NCT00356915 (4) [back to overview]	Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules
NCT00356915 (4) [back to overview]	Clinical and Mycological Cure of Target Toenail
NCT00528190 (1) [back to overview]	The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over the 24 Week Trial Treatment Period.
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)
NCT00585195 (53) [back to overview]	Probability of Participant Survival at Month 6
NCT00585195 (53) [back to overview]	Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole
NCT00585195 (53) [back to overview]	Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole
NCT00585195 (53) [back to overview]	Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole
NCT00585195 (53) [back to overview]	Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib
NCT00585195 (53) [back to overview]	Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)
NCT00585195 (53) [back to overview]	Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 24 Day 1
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1
NCT00585195 (53) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib
NCT00585195 (53) [back to overview]	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at End of Treatment
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 9 Day 1
NCT00585195 (53) [back to overview]	Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 6 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 4 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 30 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 27 Day 1
NCT00585195 (53) [back to overview]	Probability of Participant Survival at Month 12
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 21 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 2 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 18 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 15 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1
NCT00585195 (53) [back to overview]	Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 1 Day 15
NCT00585195 (53) [back to overview]	Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)
NCT00585195 (53) [back to overview]	RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food
NCT00585195 (53) [back to overview]	RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food
NCT00585195 (53) [back to overview]	Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin
NCT00585195 (53) [back to overview]	Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8
NCT00585195 (53) [back to overview]	Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16
NCT00769600 (3) [back to overview]	Progression Free Survival as Measured by Number of Days Without Disease Progression
NCT00769600 (3) [back to overview]	RECIST Response
NCT00769600 (3) [back to overview]	Overall Survival
NCT00791219 (7) [back to overview]	"The Proportion of Patients in Each Treatment Group Who Are Considered a Therapeutic Cure at the End of Treatment Visit (Week 12) 12)."
NCT00791219 (7) [back to overview]	Superiority of Test Treatment Over Placebo for Mycological Cure
NCT00791219 (7) [back to overview]	"Non-inferiority Will be Determined by Evaluating the Difference Between the Proportion of Patients in the Test and Reference Treatment Groups Who Are Considered a Clinical Cure at the End of Study Visit (Week 24)"
NCT00791219 (7) [back to overview]	"Non-inferiority Will be Determined by Evaluating the Difference Between the Proportion of Patients in the Test and Reference Treatment Groups Who Are Considered a Mycological Cure at the End of Study Visit (Week 12)"
NCT00791219 (7) [back to overview]	"Non-inferiority Will be Determined by Evaluating the Difference Between the Proportion of Patients in the Test and Reference Treatment Groups Who Are Considered a Mycological Cure at the End of Study Visit (Week 24)"
NCT00791219 (7) [back to overview]	"Non-inferiority Will be Determined by Evaluating the Difference Between the Proportion of Patients in the Test and Reference Treatment Groups Who Are Considered a Therapeutic Cure at the End of Study Visit (Week 24)"
NCT00791219 (7) [back to overview]	"Non-inferiority Will be Determined by Evaluating the Difference Between the Proportion of Patients in the Test and Reference Treatment Groups Who Are Considered a Clinical Cure at the End of Study Visit (Week 12)"
NCT00798135 (3) [back to overview]	Pharmacokinetics (PK) of Oral Itraconazole
NCT00798135 (3) [back to overview]	Time to Progression.
NCT00798135 (3) [back to overview]	Number of Patients With Adverse Events Grade 3 or 4 That Are Related to Study Treatment
NCT00871728 (7) [back to overview]	Percentage of Participants Showing Mycological Cure
NCT00871728 (7) [back to overview]	Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 9
NCT00871728 (7) [back to overview]	Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 5
NCT00871728 (7) [back to overview]	Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 49
NCT00871728 (7) [back to overview]	Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 25
NCT00871728 (7) [back to overview]	Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 13
NCT00871728 (7) [back to overview]	Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 37
NCT00887458 (2) [back to overview]	To Determine the Proportion of Men With ≥ 50% PSA Reduction From Baseline.
NCT00887458 (2) [back to overview]	To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy With One of Two Dose-levels of Itraconazole: 200 mg or 600 mg Daily.
NCT00895453 (1) [back to overview]	Candida Culture Free After Maintenance Therapy
NCT01021683 (9) [back to overview]	Plasma Concentration of Itraconazole by Overall Success Rate (OSR) in Participants Who Received the Study Treatment
NCT01021683 (9) [back to overview]	Percentage of Participants Achieving Plasma Level of Itraconazole at 1000 Nanogram Per Milliliter (ng/mL) or Higher After Administration of Study Treatment
NCT01021683 (9) [back to overview]	Duration of Neutropenia
NCT01021683 (9) [back to overview]	Percentage of Participants With Baseline Fungal Infection
NCT01021683 (9) [back to overview]	Absolute Neutrophil Count (ANC)
NCT01021683 (9) [back to overview]	Percentage of Participants With Deferevescence After Administration of Study Treatment
NCT01021683 (9) [back to overview]	Percentage of Participants With Defervescence by Plasma Level of Itraconazole
NCT01021683 (9) [back to overview]	Plasma Concentration of Itraconazole by Breakthrough Fungal Infection
NCT01021683 (9) [back to overview]	Mean Time to Defervescence in Participants Who Received the Study Treatment
NCT01108094 (3) [back to overview]	Change of GLI1 Tumor Biomarker
NCT01108094 (3) [back to overview]	Ki67 Tumor Proliferation Biomarker
NCT01108094 (3) [back to overview]	Tumor Size
NCT01450683 (1) [back to overview]	Reduction in Serum PSA
NCT01772563 (3) [back to overview]	Maximum Measured Concentration of Volasertib and Its Metabolite CD 10899 in Plasma (Cmax)
NCT01772563 (3) [back to overview]	Area Under the Plasma Concentration-time Curve Over the Time Interval From 0 to Infinity (AUC0-∞) of Volasertib and Its Metabolite CD 10899
NCT01772563 (3) [back to overview]	Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to the Last Quantifiable Drug Plasma Concentration After Dose Administration (AUC0-tz) of Volasertib and Its Metabolite CD 10899
NCT01787331 (6) [back to overview]	Mean Percent Change in PSA Doubling Time
NCT01787331 (6) [back to overview]	Median Time to Clinical Progression
NCT01787331 (6) [back to overview]	Median Time to PSA Progression
NCT01787331 (6) [back to overview]	Percentage of Participants With Treatment-related, Adverse Changes in Vital Signs
NCT01787331 (6) [back to overview]	Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA)
NCT01787331 (6) [back to overview]	Percentage of Participants With Treatment-related, Clinical Laboratory Adverse Events
NCT01795937 (10) [back to overview]	AUC0-∞ of Atorvastatin (Statins Part)
NCT01795937 (10) [back to overview]	AUC0-∞ of Rosuvastatin (Statins Part)
NCT01795937 (10) [back to overview]	AUC0-tz of Atorvastatin
NCT01795937 (10) [back to overview]	AUC0-tz of Rosuvastatin
NCT01795937 (10) [back to overview]	AUCτ,ss (Itraconazole Part)
NCT01795937 (10) [back to overview]	AUCτ,ss of Faldaprevir (Statins Part)
NCT01795937 (10) [back to overview]	Cmax of Atorvastatin (Statins Part)
NCT01795937 (10) [back to overview]	Cmax of Rosuvastatin
NCT01795937 (10) [back to overview]	Cmax,ss (Itraconazole Part)
NCT01795937 (10) [back to overview]	Cmax,ss of Faldaprevir (Statins Part)
NCT01823289 (3) [back to overview]	Number of Participants With Clinical Efficacy
NCT01823289 (3) [back to overview]	Number of Participants With Comprehensive Efficacy
NCT01823289 (3) [back to overview]	Number of Participants With Mycological Efficacy
NCT01929876 (10) [back to overview]	Tmax of Itraconazole and Hydroxy-Itraconazole
NCT01929876 (10) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Cobimetinib With and Without Itraconazole
NCT01929876 (10) [back to overview]	Plasma Half-Life (t1/2) of Cobimetinib With and Without Itraconazole
NCT01929876 (10) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Cobimetinib With and Without Itraconazole
NCT01929876 (10) [back to overview]	Cmax of Itraconazole and Hydroxy-Itraconazole
NCT01929876 (10) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Cobimetinib With and Without Itraconazole
NCT01929876 (10) [back to overview]	Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] of Itraconazole and Hydroxy-Itraconazole
NCT01929876 (10) [back to overview]	Apparent Volume of Distribution (Vz/F) of Cobimetinib With and Without Itraconazole
NCT01929876 (10) [back to overview]	Apparent Clearance (CL/F) of Cobimetinib With and Without Itraconazole
NCT01929876 (10) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - Inf)] of Cobimetinib With and Without Itraconazole
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)
NCT01974687 (81) [back to overview]	Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)
NCT01974687 (81) [back to overview]	Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)
NCT01974687 (81) [back to overview]	Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	Tmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1,HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	Reduction in HCV RNA From Baseline on Day 8 Following Uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	Percentage of Participants Who Experienced at Least One Treatment-emergent Grade 1, 2, 3, 4 or 5 Laboratory Abnormality
NCT01974687 (81) [back to overview]	Maximum Reduction in log10 HCV RNA From Baseline - Normal Participants (From Groups B and C) vs. Mild Hepatic Impairment Participants (Group E)
NCT01974687 (81) [back to overview]	Maximum Reduction in log10 HCV RNA From Baseline - Normal Participants (From Groups B and C) vs. Mild Hepatic Impairment Participants (Group E)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)
NCT01974687 (81) [back to overview]	Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)
NCT01974687 (81) [back to overview]	Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	Cmax of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	Area Under the Plasma Drug Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	AUC0-t of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)
NCT01974687 (81) [back to overview]	Cmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	Cmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	Cmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)
NCT01974687 (81) [back to overview]	Cumulative Urine Excretion of Unchanged M6 in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	Cumulative Urine Excretion of Unchanged Uprifosbuvir in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	Maximum (Peak) Observed Plasma Drug Concentration (Cmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	Observed Terminal Half-Life (t1/2) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to a Treatment-emergent AE
NCT01974687 (81) [back to overview]	Percentage of Participants Who Experienced a Treatment-emergent Dose-limiting Toxicity (DLT)
NCT01974687 (81) [back to overview]	Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (AE)
NCT01974687 (81) [back to overview]	Percentage of Participants Who Experienced at Least One Treatment-emergent Serious AE (SAE)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)
NCT01974687 (81) [back to overview]	t1/2 of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)
NCT01974687 (81) [back to overview]	t1/2 of Uprifosbuvir After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, With Itraconazole (Group F)
NCT01974687 (81) [back to overview]	t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	t1/2 of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)
NCT01974687 (81) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	Tmax of M6 After Single Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)
NCT01974687 (81) [back to overview]	Tmax of M6 After Single Dose of Uprifosbuvir as the Capsule Formulation in Healthy Participants (Group A)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Singe Dose of Uprifosbuvir as Capsule Formulation in Genotype 1, HCV-infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)
NCT01974687 (81) [back to overview]	Tmax of Uprifosbuvir After Single Dose of Uprifosbuvir as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants With Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A - Cohort 6a)
NCT01974687 (81) [back to overview]	AUC0-inf of M6 After Multiple Doses of Uprifosbuvir Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)
NCT02044393 (3) [back to overview]	AUC0-infinity (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 Extrapolated to Infinity)
NCT02044393 (3) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 up to the Last Quantifiable Concentration)
NCT02044393 (3) [back to overview]	Cmax (Maximum Measured Concentration of BI 691751 in Plasma and Whole Blood)
NCT02122770 (17) [back to overview]	Part A: Terminal Phase Elimination Half-life (T1/2) for MLN4924
NCT02122770 (17) [back to overview]	Number of Participants With TEAEs Related to Clinically Significant Laboratory Evaluation Findings
NCT02122770 (17) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements
NCT02122770 (17) [back to overview]	Number of Participants With TEAEs Related to Clinically Significant Vital Sign Findings
NCT02122770 (17) [back to overview]	Part A AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN4924 and MLN4924 + Fluconazole
NCT02122770 (17) [back to overview]	Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
NCT02122770 (17) [back to overview]	Part B: Percentage of Participants With Objective Response
NCT02122770 (17) [back to overview]	Part B: Duration of Response
NCT02122770 (17) [back to overview]	Part A AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN4924 and MLN4924 + Itraconazole
NCT02122770 (17) [back to overview]	Part A Cmax: Maximum Observed Plasma Concentration for MLN4924 and MLN4924 + Itraconazole
NCT02122770 (17) [back to overview]	Part A Cmax: Maximum Observed Plasma Concentration for MLN4924 and MLN4924 + Fluconazole
NCT02122770 (17) [back to overview]	Part A AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN4924 and MLN4924 + Itraconazole
NCT02122770 (17) [back to overview]	Part A: Volume of Distribution (Vz) for MLN4924
NCT02122770 (17) [back to overview]	Part A AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN4924 and MLN4924 + Fluconazole
NCT02122770 (17) [back to overview]	Part A Tmax: Time to Reach the Cmax for MLN4924
NCT02122770 (17) [back to overview]	Part A: Blood to Plasma (B/P) Concentration Ratio for MLN4924
NCT02122770 (17) [back to overview]	Part A: Plasma Clearance (CLp) for MLN4924
NCT02157883 (12) [back to overview]	AUC(0-t) of AZD9291
NCT02157883 (12) [back to overview]	CL/F of AZD9291
NCT02157883 (12) [back to overview]	AUC of AZ5104
NCT02157883 (12) [back to overview]	AUC of AZ7550
NCT02157883 (12) [back to overview]	AUC of AZD9291
NCT02157883 (12) [back to overview]	AUC(0-120) of AZD9291
NCT02157883 (12) [back to overview]	Cmax of AZ5104
NCT02157883 (12) [back to overview]	Cmax of AZ7550
NCT02157883 (12) [back to overview]	Cmax of AZD9291
NCT02157883 (12) [back to overview]	t1/2 of AZD9291
NCT02157883 (12) [back to overview]	Tmax of AZD9291
NCT02157883 (12) [back to overview]	Vz/F of AZD9291
NCT02259010 (13) [back to overview]	Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs
NCT02259010 (13) [back to overview]	Number of Participants With Abnormal Laboratory Values Reported as AEs
NCT02259010 (13) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	Tmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	Number of Participants With Clinically Significant Change in Weight Reported as AEs
NCT02259010 (13) [back to overview]	Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	CL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	Terminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A
NCT02259010 (13) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02259010 (13) [back to overview]	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
NCT02285283 (2) [back to overview]	Number of Participants With Adverse Events During Time Frame of Taking Medication/Placebo
NCT02285283 (2) [back to overview]	Number of Participants With Recurrence of Nasal Polyps Requiring Intervention
NCT02300259 (6) [back to overview]	Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091
NCT02300259 (6) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of LY2623091
NCT02300259 (6) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY2623091
NCT02300259 (6) [back to overview]	Pharmacokinetics: Maximum Drug Concentration (Cmax) of Simvastatin and Simvastatin Acid
NCT02300259 (6) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of Simvastatin and Simvastatin Acid
NCT02300259 (6) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Simvastatin and Simvastatin Acid
NCT02319148 (12) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
NCT02319148 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Vital Signs Findings
NCT02319148 (12) [back to overview]	Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
NCT02319148 (12) [back to overview]	Number of Participants Who Used at Least 1 Concomitant Medication
NCT02319148 (12) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-00489791
NCT02319148 (12) [back to overview]	Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern
NCT02319148 (12) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of PF-00489791
NCT02319148 (12) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-00489791
NCT02319148 (12) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-00489791
NCT02319148 (12) [back to overview]	Apparent Volume of Distribution (Vz/F) of PF-00489791
NCT02319148 (12) [back to overview]	Apparent Oral Clearance (CL/F) of PF-00489791
NCT02319148 (12) [back to overview]	Terminal Elimination Half-Life (t1/2) of PF-00489791
NCT02323334 (7) [back to overview]	PD Biomarker: Cerebral Spinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration
NCT02323334 (7) [back to overview]	PD Biomarker: Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid-beta Peptide (A-beta) 1-40 Concentration
NCT02323334 (7) [back to overview]	Pharmacodynamic(PD) Biomarker: Plasma Minimum Amyloid-Beta Peptide (A-beta) 1-40 Concentration
NCT02323334 (7) [back to overview]	Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3202626
NCT02323334 (7) [back to overview]	PK: Area Under the Concentration Time Curve (AUC) of LY3202626
NCT02323334 (7) [back to overview]	PK: CSF Concentration of LY3202626
NCT02323334 (7) [back to overview]	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
NCT02341482 (13) [back to overview]	Number of Participants With Significant Change in Physical Examination From Previous Examination
NCT02341482 (13) [back to overview]	Area Under the Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval, Where Tau = 12 Hours (AUCtau) of PF-04958242
NCT02341482 (13) [back to overview]	Apparent Oral Clearance (CL/F) of PF-04958242
NCT02341482 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of PF-04958242
NCT02341482 (13) [back to overview]	Number of Participants With Significant Change in Neurological Examination From Previous Examination
NCT02341482 (13) [back to overview]	Predose Concentration (Ctrough) of PF-04958242
NCT02341482 (13) [back to overview]	Number of Participants With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT02341482 (13) [back to overview]	Number of Participants With Electrocardiogram Data Meeting Criteria of Potential Clinical Concern
NCT02341482 (13) [back to overview]	Number of Participants With Abnormal Clinical Laboratory Measurements
NCT02341482 (13) [back to overview]	Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-04958242
NCT02341482 (13) [back to overview]	Time for Cmax (Tmax) of PF-04958242
NCT02341482 (13) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02341482 (13) [back to overview]	Number of Participants With Vital Signs Data Meeting Criteria of Potential Clinical Concern
NCT02357836 (8) [back to overview]	Mean Percent Change in Angiogenic Cytokines From Baseline
NCT02357836 (8) [back to overview]	Mean Percent Change in Other Plasma Cytokine From Baseline to Post-Treatment
NCT02357836 (8) [back to overview]	Change in Skin Biopsy PTCH1 Levels From Baseline
NCT02357836 (8) [back to overview]	Itraconazole Levels in Post-treatment Serum
NCT02357836 (8) [back to overview]	Changes in Tumor Tissue Microvessel Density [MVD] From Baseline
NCT02357836 (8) [back to overview]	Changes in Perfusion (Ktrans)
NCT02357836 (8) [back to overview]	Itraconazole Levels in Tumor Tissue
NCT02357836 (8) [back to overview]	Change in Skin Biopsy GLI1 Levels From Baseline
NCT02370615 (17) [back to overview]	Cumulative Urinary Excretion Ratio of TAK 272F and TAK 272-M-I From 0 to 72 Hours Postdose in Cohort 1
NCT02370615 (17) [back to overview]	Cmax: Maximum Observed Plasma Concentration for TAK 272F and TAK 272-Metabolite (M-I) in Cohort 1
NCT02370615 (17) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Midazolam and 1'Hydroxymidazolam in Cohort 2
NCT02370615 (17) [back to overview]	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK 272F and TAK 272-M-I in Cohort 1
NCT02370615 (17) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Continuous Pulse Oximetry (SpO2) in Cohort 2
NCT02370615 (17) [back to overview]	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Midazolam and 1'Hydroxymidazolam in Cohort 2
NCT02370615 (17) [back to overview]	Urinary Excretion Ratio of Digoxin From 0 to 48 Hours Postdose in Cohort 2
NCT02370615 (17) [back to overview]	Number of Participants With TEAEs Related to Vital Signs
NCT02370615 (17) [back to overview]	AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK 272F and TAK 272-M-I in Cohort 1
NCT02370615 (17) [back to overview]	AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam and 1'Hydroxymidazolam in Cohort 2
NCT02370615 (17) [back to overview]	Number of Participants With TEAEs Related to Body Weight
NCT02370615 (17) [back to overview]	Number of Participants Who Had Clinically Significant Changes From Baseline in 12-lead Electrocardiograms
NCT02370615 (17) [back to overview]	Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
NCT02370615 (17) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Digoxin in Cohort 2
NCT02370615 (17) [back to overview]	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Digoxin in Cohort 2
NCT02370615 (17) [back to overview]	AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Digoxin in Cohort 2
NCT02370615 (17) [back to overview]	Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis
NCT02513446 (3) [back to overview]	Maximum Concentration of BI 1026706 (Cmax)
NCT02513446 (3) [back to overview]	Area Under the Curve of BI 1026706 From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT02513446 (3) [back to overview]	Area Under the Curve of BI 1026706 From 0 Extrapolated to Infinity (AUC0-inf)
NCT02653872 (9) [back to overview]	Assessment of the Tmax of Verapamil, Itraconazole and OH-itraconazole Following Co-administration of AZD7986 With Verapamil or Itraconazole.
NCT02653872 (9) [back to overview]	Effect of Verapamil and the Effect of Itraconazole on the PK of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC).
NCT02653872 (9) [back to overview]	Effect of Verapamil and the Effect of Itraconazole on the PK of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax).
NCT02653872 (9) [back to overview]	Pharmacokinetics (PK) of AZD7986 by Assessment of Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz).
NCT02653872 (9) [back to overview]	Pharmacokinetics (PK) of AZD7986 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F).
NCT02653872 (9) [back to overview]	Pharmacokinetics (PK) of AZD7986 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F).
NCT02653872 (9) [back to overview]	Pharmacokinetics (PK) of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC [0-t]).
NCT02653872 (9) [back to overview]	Pharmacokinetics (PK) of AZD7986 by Assessment of the Time to Reach Maximum Plasma Concentration (Tmax)
NCT02653872 (9) [back to overview]	Assessment of the Area Under the Plasma Concentration-curve Over the Dosing Interval (AUC [0 - τ]) of Verapamil, Itraconazole and OH-itraconazole Following Co-administration of AZD7986 With Verapamil or Itraconazole.
NCT02989389 (7) [back to overview]	Part B Pharmacodynamics (PD): Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)₁-₄₀ and Aβ₁-₄₂
NCT02989389 (7) [back to overview]	Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3323795 in Plasma
NCT02989389 (7) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Tlast (AUC[0-tlast]) of LY3323795 in Plasma
NCT02989389 (7) [back to overview]	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
NCT02989389 (7) [back to overview]	Part B Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Tlast (AUC[0-tlast]) of LY3323795 in Cerebrospinal Fluid (CSF)
NCT02989389 (7) [back to overview]	Pharmacodynamics (PD): Change From Baseline in Plasma Amyloid Beta (Aβ)₁-₄₀ and Aβ₁-₄₂
NCT02989389 (7) [back to overview]	Part B Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3323795 in Cerebrospinal Fluid (CSF)
NCT03077607 (19) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Talazoparib: Alone and in Combination With Itraconazole
NCT03077607 (19) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of Talazoparib: Alone and in Combination With Rifampin
NCT03077607 (19) [back to overview]	Apparent Volume of Distribution During Terminal Phase (Vz/F) of Talazoparib: Alone and in Combination With Rifampin
NCT03077607 (19) [back to overview]	Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
NCT03077607 (19) [back to overview]	Apparent Clearance (CL/F) of Talazoparib: Alone and in Combination With Rifampin
NCT03077607 (19) [back to overview]	Apparent Clearance (CL/F) of Talazoparib: Alone and in Combination With Itraconazole
NCT03077607 (19) [back to overview]	Number of Participants With Clinically Significant Abnormalities in Vital Signs
NCT03077607 (19) [back to overview]	Number of Participants With Clinically Significant Physical Examination Findings
NCT03077607 (19) [back to overview]	Terminal Elimination Half-Life (t1/2) of Talazoparib: Alone and in Combination With Itraconazole
NCT03077607 (19) [back to overview]	Terminal Elimination Half-Life (t1/2) of Talazoparib: Alone and in Combination With Rifampin
NCT03077607 (19) [back to overview]	Time to Attain Maximum Observed Plasma Concentration (Tmax) of Talazoparib: Alone and in Combination With Itraconazole
NCT03077607 (19) [back to overview]	Apparent Volume of Distribution During Terminal Phase (Vz/F) of Talazoparib: Alone and in Combination With Itraconazole
NCT03077607 (19) [back to overview]	Time to Attain Maximum Observed Plasma Concentration (Tmax) of Talazoparib: Alone and in Combination With Rifampin
NCT03077607 (19) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT03077607 (19) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Talazoparib: Alone and in Combination With Rifampin
NCT03077607 (19) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Talazoparib: Alone and in Combination With Itraconazole
NCT03077607 (19) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinity (AUC0-inf) of Talazoparib: Alone and in Combination With Itraconazole
NCT03077607 (19) [back to overview]	Number of Participants With Clinical Significance Abnormalities in Laboratory Parameters
NCT03077607 (19) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Talazoparib: Alone and in Combination With Rifampin
NCT03161405 (3) [back to overview]	AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906
NCT03161405 (3) [back to overview]	AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906
NCT03161405 (3) [back to overview]	Cmax: Maximum Observed Plasma Concentration for TAK-906
NCT03173170 (2) [back to overview]	AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954
NCT03173170 (2) [back to overview]	Cmax: Maximum Observed Plasma Concentration for TAK-954
NCT03383692 (11) [back to overview]	Best Objective Response as Confirmed By The Investigator's Assessment in Participants With HER2-Expressing Advanced Solid Malignant Tumors
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve Following Treatment With DS-8201a and Ritonavir - Cohort 1
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve Following Treatment With DS-8201a and Itraconazole - Cohort 2
NCT03383692 (11) [back to overview]	Objective Response Rate as Confirmed By The Investigator's Assessment in Participants With HER2-Expressing Advanced Solid Malignant Tumors
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Ritonavir - Cohort 1
NCT03383692 (11) [back to overview]	Objective Response Ratio (ORR) as Confirmed By The Investigator's Assessment in Participants With HER2-Expressing Advanced Solid Malignant Tumors
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) of MAAA-1181a Following Treatment With DS-8201a and Itraconazole - Cohort 2
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) For MAAA-1181a Following Treatment With DS-8201a and Ritonavir - Cohort 1
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Itraconazole - Cohort 2
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve of MAAA-1181a Following Treatment With DS-8201a and Ritonavir - Cohort 1
NCT03383692 (11) [back to overview]	Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve of MAAA-1181a Following Treatment With DS-8201a and Itraconazole - Cohort 2
NCT03398421 (52) [back to overview]	Change From Baseline of Clinical Chemistry Parameters When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered: Alkaline Phosphate, Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
NCT03398421 (52) [back to overview]	Change From Baseline in Temperature When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in Respiratory Rate When Single Inhaled Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg Repeated Dose
NCT03398421 (52) [back to overview]	Change From Baseline in SBP and DBP When Single Inhaled Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg Repeated Dose
NCT03398421 (52) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in Temperature When Single Inhaled Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg Repeated Dose
NCT03398421 (52) [back to overview]	Change From Baseline of Clinical Chemistry Parameters When Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg Repeated Dose: Bilirubin, Direct Bilirubin and Creatinine
NCT03398421 (52) [back to overview]	Change From Baseline of Clinical Chemistry Parameters When Nemiralisib 100 mcg When Co-administered With Itraconazole 200 mg Repeated Dose: Alkaline Phosphate, ALT and AST
NCT03398421 (52) [back to overview]	Change From Baseline of Clinical Chemistry Parameters When Nemiralisib 100 mcg When Co-administered With Itraconazole 200 mg Repeated Dose: Calcium, Glucose, Potassium and Sodium
NCT03398421 (52) [back to overview]	Number of Participants With Abnormal Urinalysis Parameter
NCT03398421 (52) [back to overview]	Change From Baseline of Clinical Chemistry Parameters When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered: Calcium, Glucose, Potassium and Sodium
NCT03398421 (52) [back to overview]	Change From Baseline of Clinical Chemistry Parameters When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered:Bilirubin, Direct Bilirubin and Creatinine
NCT03398421 (52) [back to overview]	Change From Baseline of Total Protein When Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg Repeated Dose
NCT03398421 (52) [back to overview]	Cmax of Itraconazole and Hydroxy Itraconazole When Co-administered With Nemiralisib in Treatment Period 2
NCT03398421 (52) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Number of Participants With Abnormal Microscopic Examinations: Casts, Epithelial Cells, Erythrocytes and Leukocytes
NCT03398421 (52) [back to overview]	Number of Participants With Abnormal Urinalysis Parameter
NCT03398421 (52) [back to overview]	Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT03398421 (52) [back to overview]	Number of Participants With Urine Potential of Hydrogen (pH) at Indicated Time Points
NCT03398421 (52) [back to overview]	Number of Participants With Urine Potential of Hydrogen (pH) at Indicated Time Points
NCT03398421 (52) [back to overview]	Specific Gravity at Indicated Time Points
NCT03398421 (52) [back to overview]	Specific Gravity at Indicated Time Points
NCT03398421 (52) [back to overview]	T1/2 of Itraconazole and Hydroxy Itraconazole When Co-administered With Nemiralisib in Treatment Period 2
NCT03398421 (52) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Tmax of Itraconazole and Hydroxy Itraconazole When Co-administered With Nemiralisib in Treatment Period 2
NCT03398421 (52) [back to overview]	Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Apparent Terminal Half-life (t1/2) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Apparent Terminal Half-life (t1/2) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG) Findings
NCT03398421 (52) [back to overview]	Change From Baseline of Total Protein When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in Reticulocyte Percentage When Single Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg
NCT03398421 (52) [back to overview]	Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Nemiralisib in Plasma
NCT03398421 (52) [back to overview]	Change From Baseline in Reticulocyte Percentage When Single Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	AUC(0-inf) of Itraconazole and Hydroxy Itraconazole When Co-administered With Nemiralisib in Treatment Period 2
NCT03398421 (52) [back to overview]	AUC(0-t) of Itraconazole and Hydroxy Itraconazole When Co-administered With Nemiralisib in Treatment Period 2
NCT03398421 (52) [back to overview]	Change From Baseline in Hematology Parameters When Single Oral Dose of Nemiralisib 100 mcg Administered: Lymphocytes, Neutrophils, Platelets, Basophils, Eosinophils, Monocytes, Erythrocytes and White Blood Cells (WBC)
NCT03398421 (52) [back to overview]	Change From Baseline in Hematology Parameters When Single Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg Repeated Dose: Lymphocytes, Neutrophils, Platelets, Basophils, Eosinophils, Monocytes, Erythrocytes and WBC
NCT03398421 (52) [back to overview]	Change From Baseline in Pulse Rate When Single Inhaled Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg Repeated Dose
NCT03398421 (52) [back to overview]	Change From Baseline in Respiratory Rate When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in Pulse Rate When Single Inhaled Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in MCV When Single Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg
NCT03398421 (52) [back to overview]	Change From Baseline in MCH When Single Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg
NCT03398421 (52) [back to overview]	Change From Baseline in Hemoglobin When Single Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg
NCT03398421 (52) [back to overview]	Change From Baseline in Hemoglobin When Single Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in Hematocrit When Single Oral Dose of Nemiralisib 100 mcg Co-administered With Itraconazole 200 mg
NCT03398421 (52) [back to overview]	Change From Baseline in Hematocrit When Single Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) When Single Oral Dose of Nemiralisib 100 mcg Administered
NCT03398421 (52) [back to overview]	Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (MCH) When Single Oral Dose of Nemiralisib 100 mcg Administered
NCT03530995 (5) [back to overview]	Pharmacokinetics: AUC(0-24) of KD025m1 for Part 1 and for Part 2
NCT03530995 (5) [back to overview]	Pharmacokinetics: Cmax of KD025m1 in Part 1
NCT03530995 (5) [back to overview]	Pharmacokinetics: AUC(0-inf) and AUC(0-24) of KD025 and KD025 m2 for Subject in Part 1 and Part 2
NCT03530995 (5) [back to overview]	Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1
NCT03530995 (5) [back to overview]	Pharmacokinetics: Cmax of KD025, KD025m1, and KD025m2 in Part 2
NCT03572049 (5) [back to overview]	Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole Levels at Day 14
NCT03572049 (5) [back to overview]	Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole Levels at Day 42
NCT03572049 (5) [back to overview]	Frequency of Treatment Related Adverse Events Days 1-42
NCT03572049 (5) [back to overview]	Resolution of Signs and Symptoms of Invasive Fungal Infection on Day 42
NCT03572049 (5) [back to overview]	The Number of Days of Hospitalization at Day 180
NCT03579719 (14) [back to overview]	Maximum Plasma Concentration (Cmax) for M3 Metabolite
NCT03579719 (14) [back to overview]	Maximum Plasma Concentration (Cmax) for M2 Metabolite (as Applicable)
NCT03579719 (14) [back to overview]	Trough Plasma Concentration (Ctrough) for M3 Metabolite
NCT03579719 (14) [back to overview]	Trough Plasma Concentration (Ctrough) for M2 Metabolite (as Applicable)
NCT03579719 (14) [back to overview]	Trough Plasma Concentration (Ctrough) for Balovaptan
NCT03579719 (14) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) for M3 Metabolite
NCT03579719 (14) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) for M2 Metabolite (as Applicable)
NCT03579719 (14) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) for Balovaptan
NCT03579719 (14) [back to overview]	Maximum Plasma Concentration (Cmax) for Balovaptan
NCT03579719 (14) [back to overview]	Area Under the Concentration Vs Time Curve Over the Dosing Interval (AUC0-tau) for M3 Metabolite
NCT03579719 (14) [back to overview]	Area Under the Concentration Vs Time Curve Over the Dosing Interval (AUC0-tau) for M2 Metabolite (as Applicable)
NCT03579719 (14) [back to overview]	Area Under the Concentration Vs Time Curve Over the Dosing Interval (AUC0-tau) for Balovaptan
NCT03579719 (14) [back to overview]	Percentage of Participants With Adverse Events
NCT03579719 (14) [back to overview]	Time to Steady State for Balovaptan
NCT03722173 (3) [back to overview]	Maximum Measured Concentration of BI 894416 in Plasma (Cmax)
NCT03722173 (3) [back to overview]	Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03722173 (3) [back to overview]	Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03774576 (4) [back to overview]	Change in Suicide Risk as Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)
NCT03774576 (4) [back to overview]	Cmax of Itraconazole in Plasma
NCT03774576 (4) [back to overview]	Maximum Concentration (Cmax) of RO7017773 in Plasma
NCT03774576 (4) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT03782987 (3) [back to overview]	Area Under the Concentration-time Curve of the BI 730357 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03782987 (3) [back to overview]	Maximum Measured Concentration of the BI 730357 in Plasma (Cmax)
NCT03782987 (3) [back to overview]	Area Under the Concentration-time Curve of the BI 730357 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03928327 (7) [back to overview]	Tmax - Time to Reach the Maximum Plasma Concentration (Cmax) of AP32914
NCT03928327 (7) [back to overview]	Tmax - Time to Reach the Maximum Plasma Concentration (Cmax) of AP32960
NCT03928327 (7) [back to overview]	Tmax - Time to Reach the Maximum Plasma Concentration (Cmax) of TAK-788
NCT03928327 (7) [back to overview]	Treatment B Vs Treatment A (Part 1), Combined Molar Exposure for AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-788, AP32960, and AP32914
NCT03928327 (7) [back to overview]	Treatment B vs Treatment A (Part 1), Combined Molar Exposure for Cmax: Maximum Observed Plasma Concentration of TAK-788, AP32960, and AP32914
NCT03928327 (7) [back to overview]	Treatment D Vs Treatment C (Part 2), Combined Molar Exposure for AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-788, AP32960, and AP32914
NCT03928327 (7) [back to overview]	Treatment D Vs Treatment C (Part 2), Combined Molar Exposure for Cmax: Maximum Observed Plasma Concentration of TAK-788, AP32960, and AP32914
NCT03994211 (20) [back to overview]	Apparent Volume of Distribution (Vz/F) of Pamiparib in Plasma for Part B
NCT03994211 (20) [back to overview]	Apparent Volume of Distribution (Vz/F) of Pamiparib in Plasma for Part A
NCT03994211 (20) [back to overview]	AUC From Time Zero to Time of Last Quantifiable Concentration Post-dose (AUC0-tlast) in Plasma for Part B
NCT03994211 (20) [back to overview]	Apparent Terminal Elimination Half-life (t1/2) of Pamiparib in Plasma for Part B
NCT03994211 (20) [back to overview]	Apparent Terminal Elimination Half-life (t1/2) of Pamiparib in Plasma for Part A
NCT03994211 (20) [back to overview]	Apparent Oral Clearance (CL/F) of Pamiparib in Plasma for Part B
NCT03994211 (20) [back to overview]	Apparent Oral Clearance (CL/F) of Pamiparib in Plasma for Part A
NCT03994211 (20) [back to overview]	AUC From Zero to Infinity (AUC0-inf) of Pamiparib in Plasma for Part A
NCT03994211 (20) [back to overview]	AUC From Zero to 9 Hours (AUC0-9) of Pamiparib in Plasma for Part B
NCT03994211 (20) [back to overview]	AUC From Zero to 9 Hours (AUC0-9) of Pamiparib in Plasma for Part A
NCT03994211 (20) [back to overview]	AUC From Zero to 12 Hours (AUC0-12) of Pamiparib in Plasma for Part A
NCT03994211 (20) [back to overview]	AUC From Time Zero to Time of Last Quantifiable Concentration Post-dose (AUC0-tlast) in Plasma for Part A
NCT03994211 (20) [back to overview]	AUC From Zero to 12 Hours (AUC0-12) of Pamiparib in Plasma for Part B
NCT03994211 (20) [back to overview]	AUC From Zero to Infinity (AUC0-inf) of Pamiparib in Plasma for Part B
NCT03994211 (20) [back to overview]	Maximum Observed Concentration (Cmax) of Pamiparib in Plasma for Part A
NCT03994211 (20) [back to overview]	Maximum Observed Concentration (Cmax) of Pamiparib in Plasma for Part B
NCT03994211 (20) [back to overview]	Time of the Maximum Observed Concentration (Tmax) of Pamiparib for Part A
NCT03994211 (20) [back to overview]	Time of the Maximum Observed Concentration (Tmax) of Pamiparib for Part B
NCT03994211 (20) [back to overview]	Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments, Vital Signs, ECG Parameters and Physical Examinations
NCT03994211 (20) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT04035187 (2) [back to overview]	Cmax
NCT04035187 (2) [back to overview]	AUC
NCT04604795 (84) [back to overview]	Part C: Time to Maximum Observed Plasma Drug Concentration (Tmax) Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part C: t1/2 of GSK3915393 Following Oral Dose of GSK3915393 in Combination With Water, GFJ and ITZ
NCT04604795 (84) [back to overview]	Part C: t1/2 of GSK3915393 Following IV Dose of GSK3915393+ITZ
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Treatment-related AEs Following Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Abnormal Physical Examination Findings Following Administration of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Maximum Observed Plasma Drug Concentration (Cmax) Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Fraction of Drug Escaping Hepatic Metabolism (FH) Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Fraction of Drug Escaping Gut Metabolism (FG) Following Oral Administration of GSK3915393+Water
NCT04604795 (84) [back to overview]	Part C: Fraction of Drug Absorbed (FA) Following Oral Administration of GSK3915393+Water
NCT04604795 (84) [back to overview]	Part C: FH Following IV Administration of GSK3915393+ITZ
NCT04604795 (84) [back to overview]	Part C: Cmax of GSK3915393 Following IV Dose of GSK3915393+ITZ
NCT04604795 (84) [back to overview]	Part C: Cmax Following Oral Dose of GSK3915393 in Combination With Water, GFJ and ITZ
NCT04604795 (84) [back to overview]	Part C: AUCLST(0-24) of GSK3915393 Following Oral Dose of GSK3915393 in Combination With Water, GFJ and ITZ
NCT04604795 (84) [back to overview]	Part C: AUCLST(0-24) of GSK3915393 Following IV Dose of GSK3915393+ITZ
NCT04604795 (84) [back to overview]	Part C: AUC(0-inf) of GSK3915393 Following Oral Dose of GSK3915393 in Combination With Water, GFJ and ITZ
NCT04604795 (84) [back to overview]	Part C: AUC(0-inf) of GSK3915393 Following IV Dose of GSK3915393+ITZ
NCT04604795 (84) [back to overview]	Part C: AUC From Time Zero to Infinity (AUC[0-inf]) Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Area Under Curve up to the Last Measurable Concentration (AUCLST[0-10]) Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Apparent Terminal Half-life (t1/2) of GSK3915393 Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Trough Concentration (Ctau) Following Dose of 20 mg BID and 80 mg BID of GSK3915393 on Day 14
NCT04604795 (84) [back to overview]	Part B: Trough Concentration (Ctau) Following Dose of 160 mg of GSK3915393 on Day 14
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Treatment-related AEs
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Abnormal Physical Examination Findings Following Administration of Repeat Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Volume of Distribution (Vd) Following Single IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Tmax Following Single Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Tmax Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: t1/2 Following Single IV Dose of GSK3915393 100 mcg IV
NCT04604795 (84) [back to overview]	Part A: Product of Fraction of Drug Absorbed and Fraction of Drug Escaping Gut Metabolism (FA*FG) Following Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Treatment-related AEs Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Abnormal Physical Examination Findings Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Abnormal Physical Examination Findings Following Administration of IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Fraction of Drug Escaping Hepatic Metabolism (FH) Following Single Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Cmax Following Single Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Cmax Following Single IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Clearance (CL) Following Single IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: AUCLST(0-24) Following Single Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: AUC(0-inf) Following Single Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: AUC(0-inf) Following Single IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Absolute Bioavailability (F) Following Single Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Tmax(0-10) Following Dosing of GSK3915393 on Days 1 and 14
NCT04604795 (84) [back to overview]	Part A: AUCLST(0-6) Following Single IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Tmax(0-10) Following First Dosing of GSK3915393 on Days 3, 5 and 7 (for Food-effect Assessment)
NCT04604795 (84) [back to overview]	Part B: Tmax(10-24) Following Dose 160 mg (QD) of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Tmax(10-24) Following Repeat Dose 20 mg BID and 80 mg BID of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Number of Participants With All Non-serious AEs and SAEs
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Worst Case Chemistry Results: Creatinine by PCI Criteria Post-Baseline Relative to Baseline Following Dose Administration of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Worst Case Chemistry Results: Urea by PCI Criteria Post-Baseline Relative to Baseline Following Dose Administration of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline Following Dose Administration of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Worst Case Post-Baseline Abnormal ECG Findings Following Administration of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline Following Dose Administration of GSK3915393
NCT04604795 (84) [back to overview]	Part B: AUCLST(0-10) Following Dosing of GSK3915393
NCT04604795 (84) [back to overview]	Part B: AUC(10-24) Following Repeat Dose of GSK3915393 160 mg (QD)
NCT04604795 (84) [back to overview]	Part B: AUC(10-24) Following Repeat Dose 20 mg BID and 80 mg BID of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline Following IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Post-Baseline Abnormal ECG Findings Following Administration of IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline Following Administration of IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part C: Number of Participants With Worst Case Chemistry Results by PCI Criteria Post-Baseline Relative to Baseline Following Dose Administration of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Chemistry Results-urea by PCI Criteria Post-Baseline Relative to Baseline Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Chemistry Results-urea by PCI Criteria Post-Baseline Relative to Baseline Following Administration of IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Chemistry Results-creatinine by PCI Criteria Post-Baseline Relative to Baseline Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Chemistry Results-creatinine by PCI Criteria Post-Baseline Relative to Baseline Following Administration Administration of IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part B: Cmax(10-24) Following Dose 160 mg (QD) of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Cmax(10-24) Following Repeat Dose 20 mg and 80 mg of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Number of Participants With All Non-serious AEs and SAEs
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Worst Case Chemistry Results by PCI Criteria Post-Baseline Relative to Baseline Following Administration of Repeat Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Worst Case Chemistry Results-creatinine by PCI Criteria Post-Baseline Relative to Baseline Following Administration of Repeat Oral Dose
NCT04604795 (84) [back to overview]	Part A: Number of Participants With Worst Case Chemistry Results by PCI Criteria Post-Baseline Relative to Baseline Following Administration Administration of IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part A: Number of Participants With All Non-serious AEs and SAEs Following Administration Administration of IV Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: AUCLST(0-10) Following First Dosing of GSK3915393 on Days 3, 5 and 7 (for Food-effect Assessment)
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Worst Case Chemistry Results-urea by PCI Criteria Post-Baseline Relative to Baseline Following Administration of Repeat Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline Following Repeat Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Worst Case Post-Baseline Abnormal ECG Findings Following Repeat Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline Following Repeat Oral Dose of GSK3915393
NCT04604795 (84) [back to overview]	Part B: Cmax(0-10) Following First Dosing of GSK3915393 on Days 3, 5 and 7 (for Food-effect Assessment)
NCT04604795 (84) [back to overview]	Part B: Cmax(0-10) Following Dosing of GSK3915393 on Days 1 and 14
NCT04604795 (84) [back to overview]	Part B: AUCLST(0-24) Following Repeat Dose 20 mg BID and 80 mg BID of GSK3915393
NCT04604795 (84) [back to overview]	Part B: AUCLST(0-24) Following Dose of GSK3915393 160 mg (QD)
NCT04604795 (84) [back to overview]	Part A: Number of Participants With All Non-serious Adverse Events (AEs) and Serious AEs (SAEs) Following Administration of Oral Dose
NCT04604795 (84) [back to overview]	Part C: Tmax of GSK3915393 Following Oral Dose of GSK3915393 in Combination With Water, GFJ and ITZ
NCT04604795 (84) [back to overview]	Part C: Tmax of GSK3915393 Following IV Dose of GSK3915393+ITZ
NCT04962022 (16) [back to overview]	Apparent Clearance(CL/F) of PF-07321332
NCT04962022 (16) [back to overview]	Apparent Volume of Distribution (Vz/F) of PF-07321332
NCT04962022 (16) [back to overview]	Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration(AUClast) of PF-07321332
NCT04962022 (16) [back to overview]	Area Under the Plasma Concentration-time Profile From Time Zero to Time Tau (τ), Where Tau=12-hour Dosing Interval(AUCtau) for PF-07321332
NCT04962022 (16) [back to overview]	Maximum Observed Concentration (Cmax) of PF-07321332
NCT04962022 (16) [back to overview]	Terminal Half-life(t1/2) of PF-07321332
NCT04962022 (16) [back to overview]	Time for Cmax (Tmax) for PF-07321332
NCT04962022 (16) [back to overview]	Change From Baseline in Vital Signs Data - Supine Diastolic Blood Pressure
NCT04962022 (16) [back to overview]	Change From Baseline in Vital Signs Data - Supine Diastolic Blood Pressure
NCT04962022 (16) [back to overview]	Change From Baseline in Vital Signs Data - Supine Pulse Rate
NCT04962022 (16) [back to overview]	Change From Baseline in Vital Signs Data - Supine Systolic Blood Pressure
NCT04962022 (16) [back to overview]	Change From Baseline in Vital Signs Data - Supine Systolic Blood Pressure
NCT04962022 (16) [back to overview]	Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings
NCT04962022 (16) [back to overview]	Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
NCT04962022 (16) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT04962022 (16) [back to overview]	Change From Baseline in Vital Signs Data - Supine Pulse Rate
NCT05064449 (13) [back to overview]	Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]	Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG)
NCT05064449 (13) [back to overview]	Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Laboratory Evaluations
NCT05064449 (13) [back to overview]	Parts 1 and 2: Number of Participants With Clinically Significant Abnormal Values for Vital Signs
NCT05064449 (13) [back to overview]	Parts 1 and 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT05064449 (13) [back to overview]	Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]	Part 1, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]	Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Itraconazole
NCT05064449 (13) [back to overview]	Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]	Part 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]	Part 2, Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]	Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat When Administered Alone and With Mefenamic Acid
NCT05064449 (13) [back to overview]	Parts 1 and 2: Number of Participants Reported One or More Treatment-emergent Adverse Event (TEAE)

Summary of CGP62221 Plasma Concentration for 100 mg Bid Arm (E1)

Blood samples were collected for analysis. (NCT00045942)
Timeframe: Cycle 1: days 1 (0h, 4h, 24 h), 3 (0h), 8 (0h); cycle 2: days 1 (0h); cycle 3: day 1 (0h); cycle 4: day 1 (0h); cycle 5: day 1 (0h) and cycle 6: day 1 (0h)

Intervention	ng/ml (Mean)
	Cycle 1, day 1 (0h) (n=39)	Cycle 1, day 1 (4h) (n=34)	Cycle 1, day 1 (24h) (n=36)	Cycle 1, day 3 (0h) (n=29)	Cycle 1, day 8 (0h) (n=24)	Cycle 2, day 1 (0h) (n=15)	Cycle 3, day 2 (0h) (n=6)	Cycle 4, day 1 (0h) (n=6)	Cycle 5, day 1 (0h) (n4)	Cycle 6, day 1 (0h) (n=4)
FLT3 Mutated and Wild Type PKC412 200 mg/Day	0.000	471.635	1134.764	1944.069	2898.708	1828.667	1258.333	1602.950	1111.250	1662.500

Intervention	ng/ml (Mean)
	Cycle 1, day 1 (0h) (n=41)	Cycle 1, day 1 (4h) (n=38)	Cycle 1, day 1 (24h) (n=39)	Day 1, day 3 (0h) (n=34)	Cycle 1, day 8 (0h) (n=30)	Cycle 2, day 1 (0h) (n=22)	Cycle 3, day 1 (0h) (n=12)	Cycle 4, day 1 (0h) (n=4)
FLT3 Mutated and Wild Type PKC412 100 mg/Day Arms Combined	0.000	203.013	436.282	1188.359	2840.833	6467.591	8175.000	6205.000

Intervention	ng/ml (Median)
	Cycle 1, day 1 (n=7)	Cycle 1, day 2 (24 hr post day 1) (n=12)	Cycle 1, day 3 (n=12)	Cycle 1, day 8 (n=8)	Cycle 1, day 15 (n=6)	Cycle 1, day 16 (24 hr post day 15) (n=6)	Cycle 1, day 17 (n=5)	Cycle 1, day 22 (n=5)	Cycle 2, day 1 (n=4)	Cycle 2, day 2 (24 hr post day 1) (n=4)	Cycle 2, day 3 (n=4)	Cycle 2, day 8 (n=4)	Cycle 2, day 15 (n=3)
FLT3 Mutated and Wild Type PKC412 Dose Escalation Combined	0	1320.0	2750.0	2380.0	1505.0	1425.0	1480.0	1520.0	1545.0	1945.0	2070.0	2030.0	1740.0

Intervention	ng/ml (Mean)
	Cycle 1, day 1 (24 hour) (n=10)	Cycle 1, day 3 (n=7)	Cycle 1, day 8 (n=9)	Cycle 2, day 1 (n=6)
PKC412 in FLT3 Mutated Participants (Core)	1636.00	3143.71	4873.33	2816.67

Intervention	ng/ml (Mean)
	Cycle 1, day 1 (0h) (n=44)	Cycle 1, day 1 (4h) (n=38)	Cycle 1, day 1 (24h) (n=39)	Cycle 1, day 3 (0h) (n=34)	Cycle 1, day 8 (0h) (n=30)	Cycle 2, day 1 (0h) (n=22)	Cycle 3, day 1 (0h) (n=12)	Cycle 4, day 1 (0h) (n=4)
FLT3 Mutated and Wild Type PKC412 100 mg/Day Arms Combined	0.000	367.079	808.182	1400.476	2868.933	1930.000	1971.500	1207.500

Intervention	ng/ml (Median)
	Cycle 1, day 1 (=7)	Cycle 1, day 2 (24 hours post day 1) (n=12)	Cycle 1, day 3 (n=12)	Cycle 1, day 8 (n=8)	Cycle 1, day 15 (n=6)	Cycle 1, day 16 (24 hr post day 15) (n=6)	Cycle 1, day 17 (n=5)	Cycle 1, day 22 (n=5)	Cycle 2, day 1 (n=4)	Cycle 2, day 2 (24 hr post day 1) (n=4)	Cycle 2, day3 (n=4)	Cycle 2, day 8 (n=4)	Cycle 2, day 15 (n=3)
FLT3 Mutated and Wild Type PKC412 Dose Escalation Combined	0	2565.0	3100.0	1640.0	744.5	836.0	800.0	1410.0	772.0	1141.0	1295.0	1210.0	834.0

Intervention	h*ng/ml (Mean)
	Cycle 1, day 21 (n=10)	Cycle 1, day 22 (n=10)	Cycle 1, day 28 (n=8)
FLT3 Mutated and FLT3 Wild Type PKC + Itraconazole Combined	38899.84	41035.50	44447.05

Intervention	ng/ml (Mean)
	Cycle 1, day 1(24 hour) (n=10)	Cycle 1, day 3 (n=7)	Cycle 1, day 8 (n=9)	Cycle 2, day 1 (n=6)
PKC412 in FLT3 Mutated Participants (Core)	3801.0	7152.86	5154.44	1873.17

Intervention	ng/ml (Mean)
	Cycle 1, day 1 (0h) (n=43)	Cycle 1, day 1 (4h) (n=38)	Cycle 1, day 1 (24h) (n=39)	Cycle 1, day 3 (0h) (n=34)	Cycle 1, day 8 (0h) (n=30)	Cycle 2, day 1 (0h) (n=22)	Cycle 3, day 1 (0h) (n=12)	Cycle 4, day 1 (0h) (n=4)
FLT3 Mutated and Wild Type PKC412 100 mg/Day Arms Combined	0.000	1198.000	1735.974	2585.471	3576.467	1756.500	2038.417	820.750

Intervention	hour (Mean)
	Cycle 1, day 21 (n=6)	Cycle 1, day 22 (n=8)
FLT3 Mutated and FLT3 Wild Type PKC + Itraconazole Combined	18.13	13.23

Intervention	days (Median)
FLT3 Mutated PKC412 100 mg/Day (E1)	57.0
FLT3 Mutated PKC412 200 mg/Day (E1)	29.0
FLT3 Wild Type PKC412 100 mg/Day (E1)	56.0
FLT3 Wild Type PKC412 200 mg/Day (E1)	58.0

Intervention	days (Median)
FLT3 Mutated PKC412 100 mg/Day (E1)	60.0
FLT3 Mutated PKC412 200 mg/Day (E1)	50.0
FLT3 Wild Type PKC412 100 mg/Day (E1)	58.0
FLT3 Wild Type PKC412 200 mg/Day (E1)	1.0

Intervention	days (Median)
FLT3 Mutated PKC412 Dose Escalation (E2)	116.0
FLT3 Mutated PKC+Itraconazole (E2)	75.0
FLT3 Wild Type PKC412 Dose Escalation (E2)	372.0
FLT3 Wild Type PKC+Itraconazole (E2)	220.0

Intervention	days (Median)
FLT3 Mutated PKC412 100 mg/Day (E1)	99.0
FLT3 Mutated PKC412 200 mg/Day (E1)	93.0
FLT3 Wild Type PKC412 100 mg/Day (E1)	145.0
FLT3 Wild Type PKC412 200 mg/Day (E1)	159.0

Intervention	days (Median)
FLT3 Mutated PKC412 100 mg/Day (E1)	77.0
FLT3 Mutated PKC412 200 mg/Day (E1)	50.0
FLT3 Wild Type PKC412 100 mg/Day (E1)	62.0
FLT3 Wild Type PKC412 200 mg/Day (E1)	54.0

Intervention	days (Median)
FLT3 Mutated PKC412 Dose Escalation (E2)	49.0
FLT3 Mutated PKC+Itraconazole (E2)	26.0
FLT3 Wild Type PKC412 Dose Escalation (E2)	169.0
FLT3 Wild Type PKC+Itraconazole (E2)	78.0

Intervention	h*ng/ml (Mean)
	Cycle 1, day 21 (n=9)	Cycle 1, day 22 (n=7)	Cycle 1, day 28 (n=7)
FLT3 Mutated and FLT3 Wild Type PKC + Itraconazole Combined	40258.65	42950.76	49758.77

Intervention	h*ng/ml (Mean)
	Cycle 1, day 21 (n=8)	Cycle 1, day 22 (n=7)	Cycle 1, day 28 (n=7)
FLT3 Mutated and FLT3 Wild Type PKC + Itraconazole Combined	30217.82	23824.69	31545.54

Intervention	ng/ml (Mean)
	Cycle 1, day 1 (0h) (n=38)	Cycle 1, day 1 (4h) (n=34)	Cycle 1, day 1 (24h) (n=36)	Cycle 1, day 3 (0h) (n=29)	Cycle 1, day 8 (0h) (n=24)	Cycle 2, day 1 (0h) (n=15)	Cycle 3, day 2 (0h) (n=6)	Cycle 4, day 1 (0h) (n=6)	Cycle 5, day 1 (0h) (n=4)	Cycle 6, day 1 (0h) (n=4)
FLT3 Mutated and Wild Type PKC412 200 mg/Day	0.000	2087.088	2849.731	3756.483	4447.583	1226.333	754.500	1187.167	572.250	1433.250

Intervention	h*ng/ml (Mean)
	Cycle 1, day 21 (n=10)	Cycle 1, day 22 (n=10)	Cycle 1, day 28, (n=8)
FLT3 Mutated and FLT3 Wild Type PKC + Itraconazole Combined	32120.58	34684.6	33020.17

Intervention	Participants (Number)
	Complete response	Partial response	Minor response	Minor response and blast response	Blast response	Best clinical response
FLT3 Mutated PKC+Itraconazole (E2)	0	0	0	0	0	0
FLT3 Mutated PKC412 Dose Escalation (E2)	0	0	0	1	4	5
FLT3 Wild Type PKC+Itraconazole (E2)	1	0	1	1	1	4
FLT3 Wild Type PKC412 Dose Escalation (E2)	0	0	0	2	0	2

itraconazole

Description

Cross-References

Synonyms (188)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (9)

Protein Targets (75)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (450)

Molecular Functions (158)

Ceullar Components (84)

Bioassays (2253)

Research

Studies (6,069)

Market Indicators

Research Demand Index: 110.55

Study Types

Clinical Trials (352)

Trial Overview

Trial Outcomes

Summary of CGP62221 Plasma Concentration for 100 mg Bid Arm (E1)

Summary of CGP52421 Plasma Concentration for 50 mg Bid Arm (E1)

Summary of CGP62221 Concentration (E2)

Summary of CGP62221 Plasma Concentration (Core)

Summary of CGP62221 Plasma Concentration for 50 mg Bid Arm (E1)

Summary of Midostaurin Concentration in the PKC412 Dose Escalation Arms(E2)

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for CGP52421 in the PKC412 + Itraconazole Combination Arm (E2)

Summary of Midostaurin Plasma Concentration (Core)

Summary of PKC412 Plasma Concentration for 50 mg Twice Daily (Bid) Arm (E1)

Terminal Elimination Half-life (T1/2) for PKC412 in the PKC + Itrconazole Combination Arm (E2)

Time to Reach the Maximum Concentration After Drug Administration (Tmax) for CGP52421 in the PKC412 + Itraconazole Combination Arm (E2)

Time to Reach the Maximum Concentration After Drug Administration (Tmax) for CGP62221 in the PKC412 + Itraconazole Combination Arm (E2)

Time to Reach the Maximum Concentration After Drug Administration (Tmax) for PKC412 in the PKC412 + Itraconazole Combination Arm (E2)

Duration of Best Clinical Response (E1)

Event-free Survival (E1)

Number of Participants With Best Clinical Response (Core)

Overall Survival (E2)

Overall Survival (OS) (E1)

Terminal Elimination Half-life (T1/2) for CGP62221 in the PKC + Itrconazole Combination Arm (E2)

Time to Disease Progression (E1)

Time to Disease Progression (E2)

Time to Disease Progression (TTP) (Core)

Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for CGP52421 Plasma in the PKC + Itraconazole Combination Arm (E2)

Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for CGP62221 Plasma in the PKC + Itraconazole Combination Arm (E2)

Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) for PKC412 Plasma in the PKC + Itraconazole Combination Arm (E2)

Summary of PKC412 Plasma Concentration for 100 mg Bid Arm (E1)

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for CGP622221 in the PKC412 + Itraconazole Combination Arm (E2)

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) for PKC412 in the PKC412 + Itraconazole Combination Arm (E2)

Best Clinical Response (E2)

Number of Participants With Overall Clinical Response (E1)

Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for CGP52421 in the PKC + Itraconazole Combination Arm (E2)

Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for CGP62221 in the PKC + Itraconazole Combination Arm (E2)

Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax) for PKC412 in the PKC + Itraconazole Combination Arm (E2)

Summary of CGP52421 Concentration (E2)

Summary of CGP52421 Plasma Concentration (Core)

Summary of CGP52421 Plasma Concentration for 100 mg Bid Arm (E1)

Duration of Treatment

Percent of Subjects With Use of Other Systemic Antifungal Agents as Empirical or Therapeutic Treatment

Survival: Percent of Subjects Who Died Within 1 Year

Time to Breakthrough Invasive Fungal Infection (IFI)

Time to Discontinuation of Study Treatment

Percent of Subjects With Occurrence of Breakthrough IFI

Success at Day 100: Percent of Responders (Randomization Strata)

Success at Day 180: Percent of Responders (Randomization Strata)

Survival: Percent of Subjects Who Died at or Before Day 180

Clinical Improvement Compared to Placebo

Clinical Improvement of the Target Toenail

Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules

Clinical and Mycological Cure of Target Toenail

The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over the 24 Week Trial Treatment Period.

Intervention	ng/ml (Mean)
	Cycle 1 , day 21 (n=10)	Cycle 1, day 22 (n=10)	Cycle 1, day 28 (n=8)
FLT3 Mutated and FLT3 Wild Type PKC + Itraconazole Combined	3945.00	3968.70	3931.25

Intervention	percent of participants (Number)
	Myeloablative/matched related (n=66, 85)	Myeloablative/mismatched unrelated (n=59, 58)	Non-myeloablative/matched related (n=58, 57)	Non-myeloablative/mismatched unrelated (n=41, 41)
Itraconazole	50.6	27.6	38.6	36.6
Voriconazole	65.2	55.9	43.1	48.8

Intervention	Percentage of participants (Number)
Itraconazole Tablets	22.3
Itraconazole Capsules	21.7
Placebo Tablets	1.0

Intervention	Months (Median)
RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg	51.4
RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg	20.0
RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg	10.1
RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg	NA

Intervention	Weeks (Median)
RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg	14.5
RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg	6.8
RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg	5.2
RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg	26.2

Intervention	Probability of participants survival (Number)
RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg	90.5
RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg	86.7
RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg	67.8
RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg	90.0

Intervention	nanogram per milliliter (Geometric Mean)
RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone	136.0
RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg With Itraconazole	214.0

Intervention	nanogram per milliliter (Geometric Mean)
RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone	259.9
RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg With Itraconazole	353.2

Intervention	nanogram*hour per milliliter (Geometric Mean)
RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone	4102
Itraconazole Interaction Cohort: Crizotinib 250 mg + Itraconazole	6665

Intervention	milligram (Number)
Low Dose Escalation Cohort: Crizotinib 50 mg QD	250
Low Dose Escalation Cohort: Crizotinib 100 mg QD	250
Low Dose Escalation Cohort: Crizotinib 200 mg QD	250
Low Dose Escalation Cohort: Crizotinib 200 mg BID	250
Low Dose Escalation Cohort: Crizotinib 250 mg BID	250
Low Dose Escalation Cohort: Crizotinib 300 mg BID	250
High Dose Escalation Cohort: Crizotinib 300 mg QD	250
High Dose Escalation Cohort: Crizotinib 400 mg QD	250
High Dose Escalation Cohort: Crizotinib 500 mg QD	250
High Dose Escalation Cohort: Crizotinib 650 mg QD	250
High Dose Escalation Cohort: Crizotinib 800 mg QD	250